Add files using upload-large-folder tool
Browse filesThis view is limited to 50 files because it contains too many changes. See raw diff
- .gitattributes +31 -0
- medical/md/PMC10514600.md +306 -0
- medical/md/PMC2193773.md +422 -0
- medical/md/PMC4789817.md +387 -0
- medical/md/PMC5038876.md +234 -0
- medical/md/PMC5228319.md +161 -0
- medical/md/PMC5945097.md +180 -0
- medical/md/PMC6438152.md +291 -0
- medical/md/PMC6764476.md +28 -0
- medical/md/PMC6910871.md +133 -0
- medical/md/PMC6917096.md +363 -0
- medical/md/PMC7308133.md +235 -0
- medical/md/PMC7776074.md +48 -0
- medical/md/PMC8562246.md +410 -0
- medical/md/PMC8873605.md +485 -0
- medical/md_images/PMC10559360/0_image_4.png +3 -0
- medical/md_images/PMC10559360/0_image_6.png +3 -0
- medical/md_images/PMC10559360/15_image_0.png +3 -0
- medical/md_images/PMC10645190/PMC10645190_meta.json +27 -0
- medical/md_images/PMC10756843/0_image_0.png +3 -0
- medical/md_images/PMC10756843/5_image_0.png +3 -0
- medical/md_images/PMC10767772/2_image_1.png +3 -0
- medical/md_images/PMC10772648/10_image_0.png +3 -0
- medical/md_images/PMC10772648/7_image_0.png +3 -0
- medical/md_images/PMC10790005/7_image_1.png +3 -0
- medical/md_images/PMC10850403/0_image_0.png +3 -0
- medical/md_images/PMC10850403/2_image_0.png +3 -0
- medical/md_images/PMC10850403/5_image_0.png +3 -0
- medical/md_images/PMC2190190/12_image_0.png +3 -0
- medical/md_images/PMC2212278/2_image_0.png +3 -0
- medical/md_images/PMC2212278/4_image_0.png +3 -0
- medical/md_images/PMC2212278/5_image_0.png +3 -0
- medical/md_images/PMC2212278/6_image_0.png +3 -0
- medical/md_images/PMC2886898/6_image_7.png +3 -0
- medical/md_images/PMC2886898/7_image_7.png +3 -0
- medical/md_images/PMC3276052/1_image_0.png +3 -0
- medical/md_images/PMC3321272/2_image_0.png +3 -0
- medical/md_images/PMC3321272/2_image_1.png +3 -0
- medical/md_images/PMC3341158/0_image_0.png +3 -0
- medical/md_images/PMC3341158/1_image_0.png +3 -0
- medical/md_images/PMC3341158/1_image_1.png +3 -0
- medical/md_images/PMC3378941/PMC3378941.md +313 -0
- medical/md_images/PMC3378941/PMC3378941_meta.json +27 -0
- medical/md_images/PMC3426374/1_image_0.png +3 -0
- medical/md_images/PMC3426374/PMC3426374_meta.json +27 -0
- medical/md_images/PMC3777673/0_image_3.png +3 -0
- medical/md_images/PMC3920570/0_image_0.png +3 -0
- medical/md_images/PMC3920570/0_image_4.png +3 -0
- medical/md_images/PMC3942506/2_image_0.png +3 -0
- medical/md_images/PMC4144211/0_image_0.png +3 -0
.gitattributes
CHANGED
|
@@ -1884,3 +1884,34 @@ medical/pdf/PMC9084288.pdf filter=lfs diff=lfs merge=lfs -text
|
|
| 1884 |
medical/pdf/PMC5171726.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1885 |
medical/pdf/PMC10017293.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1886 |
medical/pdf/PMC5125953.pdf filter=lfs diff=lfs merge=lfs -text
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1884 |
medical/pdf/PMC5171726.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1885 |
medical/pdf/PMC10017293.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1886 |
medical/pdf/PMC5125953.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1887 |
+
medical/pdf/PMC5186468.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1888 |
+
medical/pdf/PMC7499863.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1889 |
+
medical/pdf/PMC6781791.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1890 |
+
medical/pdf/PMC10167448.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1891 |
+
medical/pdf/PMC2172580.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1892 |
+
medical/pdf/PMC10793757.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1893 |
+
medical/pdf/PMC10168322.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1894 |
+
medical/pdf/PMC5164359.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1895 |
+
medical/pdf/PMC10230885.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1896 |
+
medical/pdf/PMC10131533.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1897 |
+
medical/pdf/PMC5163773.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1898 |
+
medical/pdf/PMC8799306.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1899 |
+
medical/pdf/PMC7489482.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1900 |
+
medical/pdf/PMC6115620.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1901 |
+
medical/pdf/PMC3845578.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1902 |
+
medical/pdf/PMC10776058.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1903 |
+
medical/pdf/PMC9524408.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1904 |
+
medical/pdf/PMC7315235.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1905 |
+
medical/pdf/PMC2954121.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1906 |
+
medical/pdf/PMC7229763.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1907 |
+
medical/pdf/PMC8913981.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1908 |
+
medical/pdf/PMC8645609.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1909 |
+
medical/pdf/PMC5559925.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1910 |
+
medical/pdf/PMC5398048.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1911 |
+
medical/pdf/PMC8600993.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1912 |
+
medical/pdf/PMC6851248.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1913 |
+
medical/pdf/PMC2113571.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1914 |
+
medical/pdf/PMC5186372.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1915 |
+
medical/pdf/PMC6896399.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1916 |
+
medical/pdf/PMC8982173.pdf filter=lfs diff=lfs merge=lfs -text
|
| 1917 |
+
medical/pdf/PMC8610360.pdf filter=lfs diff=lfs merge=lfs -text
|
medical/md/PMC10514600.md
ADDED
|
@@ -0,0 +1,306 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
Efficacy of transcutaneous auricular vagus nerve stimulation on radiotherapy-related neuropathic pain in patients with head and neck cancers
|
| 2 |
+
(RELAX): protocol for a multicentre, randomised, double-blind, shamcontrolled **trial**
|
| 3 |
+
Xuzheng Zuo,1 Yi Li,1 Xiaoming Rong,1 Xinguang Yang,1 Yingying Zhu,1,2 Dong Pan,3 Honghong Li,1 Qing-Yu Shen,1 Yamei Tang 1,4 To cite: Zuo X, Li Y, Rong X,
|
| 4 |
+
et al. Efficacy of transcutaneous auricular vagus nerve stimulation on radiotherapyrelated neuropathic pain in patients with head and neck cancers (RELAX): protocol for a multicentre, randomised, double-blind, shamcontrolled trial. *BMJ Open* 2023;13:e072724. doi:10.1136/ bmjopen-2023-072724
|
| 5 |
+
► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2023-072724). XZ and YL contributed equally. Received 27 March 2023 Accepted 20 August 2023 © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. For numbered affiliations see end of article. Correspondence to Dr Yamei Tang; tangym@mail.sysu.edu.cn and Dr Qing-Yu Shen; shenqy@mail.sysu.edu.cn
|
| 6 |
+
|
| 7 |
+
## Abstract
|
| 8 |
+
|
| 9 |
+
Introduction Radiotherapy-related neuropathic pain
|
| 10 |
+
(RRNP) is one of the most distressing complications after radiotherapy for head and neck cancers. Drug therapy is not sufficiently effective and has limitations in terms of dose titration period and side effects. Transcutaneous auricular vagus nerve stimulation (taVNS), which stimulates the auricular branches of the vagus nerve through electrical impulses, has been proven to have analgesic effects in certain diseases. However, it is unknown whether taVNS can relieve RRNP.
|
| 11 |
+
|
| 12 |
+
Methods and analysis This is a multicentre, randomised, double-blind, parallel, sham-controlled trial. We will include adult patients newly diagnosed with neuropathic pain after radiotherapy for head and neck cancers. One hundred and sixteen individuals will be recruited and randomly assigned in a 1:1 ratio to receive taVNS or sham stimulation. The interventions will last for 7 days, twice daily for 30min each. The primary efficacy outcome is pain reduction on day 7. The secondary outcomes are changes in functional interference, psychological distress, fatigue, quality of life and serum inflammatory factors. The study may provide a new early intervention strategy for RRNP among patients with head and neck cancers. Ethics and dissemination This study has been approved by the Medical Research Ethics Committee of Sun Yat-sen University (SYSKY-2022-109-01) and will be conducted in strict accordance with the Declaration of Helsinki. Ethical approvals will be obtained separately for all centres involved in the study. Study results will be published in peer-reviewed academic journals. The database of the study will be available from the corresponding author on reasonable request. Trial registration number NCT05543239
|
| 13 |
+
|
| 14 |
+
## Introduction
|
| 15 |
+
|
| 16 |
+
Pain is a common adverse event after radiotherapy for head and neck cancers1 and can
|
| 17 |
+
|
| 18 |
+
## Strengths And Limitations Of This Study
|
| 19 |
+
|
| 20 |
+
⇒ This is the first trial to test the efficacy of transcutaneous auricular vagus nerve stimulation (taVNS)
|
| 21 |
+
on radiotherapy-related neuropathic pain (RRNP) in patients with head and neck cancers.
|
| 22 |
+
|
| 23 |
+
⇒ The trial will examine the potential impact of taVNS
|
| 24 |
+
on emotion, psychology and quality of life of patients with RRNP.
|
| 25 |
+
|
| 26 |
+
⇒ Since the trial will be conducted in southern China, where the population is mainly Chinese, it may limit the generalisability of the study results for Western countries.
|
| 27 |
+
|
| 28 |
+
⇒ Given the long follow-up period, this may result in more data loss and may influence some secondary results.
|
| 29 |
+
|
| 30 |
+
be divided into acute nociceptive pain and chronic neuropathic pain.2 Previous studies have mostly focused on treatment for acute nociceptive pain which is mainly caused by mucositis3 4 while there has been a lack of high-quality studies about chronic neuropathic pain that is difficult to relieve in clinical practice.5 Radiotherapy-related neuropathic pain
|
| 31 |
+
(RRNP) is a severe, long-lasting chronic pain and it is one of the most distressing postcomplications from radiotherapy for head and neck cancers. It is a late-onset adverse effect with an onset time ranging from 6 months to 20 years after radiotherapy,6 7 which mainly results from cranial neuralgias, brachial plexopathy and cervical plexopathy.8 Studies have shown that the prevalence of neuropathic pain in patients with cancer pain
|
| 32 |
+
|
| 33 |
+
##
|
| 34 |
+
|
| 35 |
+
is as high as 31–45%.9 In addition to the painful feelings, RRNP produces psychological and emotional disturbances that jeopardise quality of life.10 There are few effective treatments for RRNP. Previous studies have shown that some analgesics such as amitriptyline, carbamazepine, and non-steroidal antiinflammatory drugs (NSAIDs) are ineffective for RRNP.11 Our previous study of pregabalin versus placebo in the treatment of RRNP showed that patients in the pregabalin group have better pain intensity reduction than those in the placebo group,12 which is the only randomised controlled trial currently available for the treatment of RRNP for head and neck cancers.5 However, 41.6% of patients still failed to achieve at least 30% pain relief even with standard doses of pregabalin, and the use of pregabalin requires a dose titration process and some side effects such as dizziness, limb oedema and obesity may also follow.12 Moreover, previous studies have shown that more than 60% of chronic pain patients report inadequate pain control with drug therapy.13 Therefore, the ideal management strategy for RRNP should not rely solely on medication but should employ a biopsychosocial approach using pharmacological and nonpharmacological interventions.14 Vagus nerve stimulation (VNS) has been proven to attenuate systemic inflammatory responses via a unique
|
| 36 |
+
'parasympathetic anti-inflammatory pathway'. Acetylcholine, the principal vagal neurotransmitter, significantly attenuated the release of proinflammatory cytokines
|
| 37 |
+
(tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6) in lipopolysaccharide-stimulated human macrophage cultures.15 Inflammatory responses, especially inflammatory factors such as TNF-α, IL-1β and IL-6 are proven to be involved in nerve injury and central sensitisation which play an important role in pathological processes of neuropathic pain.16–18 It is suggested that VNS may improve chronic neuropathic pain by inhibiting the inflammatory response.
|
| 38 |
+
|
| 39 |
+
Transcutaneous auricular VNS (taVNS) works by stimulating the auricular branches of the vagus nerve (mainly located in the concha cavity and conchae) through electrical impulses.19 Previous studies have shown that taVNS
|
| 40 |
+
can increase the pain threshold in healthy individuals20 and relieve a variety of pains including migraine,21 22 cluster headache23 and musculoskeletal pain in patients with systemic lupus erythematosus.24 The taVNS can also improve psychological disorders and fatigue.25 In addition, it is well tolerated with few adverse events (AE).26 Existing evidence has suggested a potential application of taVNS in the treatment of RRNP, but a randomised study is still needed to validate it.
|
| 41 |
+
|
| 42 |
+
Accordingly, we designed this multicentre, randomised, double-blind, parallel-group, sham-controlled trial to evaluate the efficacy of taVNS on RRNP in patients with head and neck cancers.
|
| 43 |
+
|
| 44 |
+
## Methods
|
| 45 |
+
|
| 46 |
+
Design The efficacy of taVNS on RRNP in patients with head and neck cancers (RELAX) study is a multicentre, randomised, double-blind, parallel-group, sham-controlled trial, which will be conducted at four centres of China: Sun Yat-sen Memorial Hospital, Sun Yat-sen University Cancer Center, The Affiliated Brain Hospital of Guangzhou Medical University and The Zhongshan City People's Hospital. The trial flow chart and the follow-up schedule are shown in figure 1 and table 1, respectively. This protocol follows the Recommendations for Interventional Trials guidelines.27 A Standard Protocol Items: Recommendations for Interventional Trials checklist is provided in the online supplemental file 1. This trial has been started on 16 September 2022 and is scheduled to end in December 2024.
|
| 47 |
+
|
| 48 |
+
## Participants
|
| 49 |
+
|
| 50 |
+
Patients with head and neck cancers who meet the following eligible criteria will be recruited:
|
| 51 |
+
Inclusion criteria
|
| 52 |
+
► Male or female patients aged ≥18 years with an estimated survival of at least 5 months.
|
| 53 |
+
|
| 54 |
+
► Prior radiotherapy for histologically confirmed head and neck cancers ≥6 months prior to study entry (the head and neck cancer is defined as soft tissue tumours or cancer arising from the mucosal surfaces of the lip, oral cavity, pharynx, larynx and cervical oesophagus; the nose, paranasal sinuses, salivary glands, thyroid gland and parathyroid glands).
|
| 55 |
+
|
| 56 |
+
► Pain for at least 4 weeks with an average intensity of 4 or more on an 11-point Numeric Rating Scale (NRS)
|
| 57 |
+
in the screening period, and pain locations in accordance with radiated innervated areas, for example, head, face, neck and arms.
|
| 58 |
+
|
| 59 |
+
► Neuropathic pain is defined according to clinical history, symptoms, physical signs and a score ≥12 in the Chinese version of the Leeds Assessment of Neuropathic Symptoms and Signs questionnaire28 by two trained and experienced neurology specialists.
|
| 60 |
+
|
| 61 |
+
► With informed consent.
|
| 62 |
+
|
| 63 |
+
Exclusion criteria
|
| 64 |
+
► Current diagnosis of tumour recurrence or metastasis and evidence of tumour-associated pain.
|
| 65 |
+
|
| 66 |
+
► Patients with non-radiotherapy induced neuropathic pain; for example, postherpetic neuralgia, diabetes mellitus, HIV infection, spinal cord injury and other neurological disease.
|
| 67 |
+
|
| 68 |
+
► Use of carbamazepine, gabapentin, pregabalin, taVNS
|
| 69 |
+
or transcranial magnetic stimulation within the last 30 days prior to study entry.
|
| 70 |
+
|
| 71 |
+
► Other ongoing treatments for neuropathic pain including antidepressants with norepinephrine and serotonin reuptake inhibition, calcium channel α2-δ ligands and other anticonvulsant medications, and topical lidocaine.
|
| 72 |
+
|
| 73 |
+

|
| 74 |
+
|
| 75 |
+
Figure 1 Study flow chart. AE, adverse events; BPI-SF, Brief Pain Inventory-Short Form; CGIC, Clinical Global Impression of Change; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue Scale; NRS, Numeric Rating Scale; PGIC, Patient Global Impression of Change; POMS-SF, Profile of Mood States-Short Form; taVNS, transcutaneous auricular vagus nerve stimulation; WHOQOL-BREF, brief version of The WHO Quality of Life.
|
| 76 |
+
|
| 77 |
+
► Concomitant medication that may cause an adverse interaction with pregabalin, including sedatives (eg, benzodiazepines).
|
| 78 |
+
|
| 79 |
+
► Significant renal impairment: plasma creatinine
|
| 80 |
+
>1.5mg/mL and creatinine clearance <60mL/min.
|
| 81 |
+
|
| 82 |
+
► History of anaphylactic response to pregabalin. ► Ulceration of the auricle skin.
|
| 83 |
+
|
| 84 |
+
► Diagnosis of mental illness, peptic ulcer, atrioventricular III degree block, heart rate <50/min, heart rate corrected QT interval >450ms.
|
| 85 |
+
|
| 86 |
+
► Patients with cardiac pacemakers or implanted ECG
|
| 87 |
+
monitoring equipment.
|
| 88 |
+
|
| 89 |
+
► Evidence of severe systemic diseases.
|
| 90 |
+
|
| 91 |
+
► Subjects with any other condition which, in the investigator's judgement, might interfere the outcome of the study.
|
| 92 |
+
|
| 93 |
+
► Cognitive function and language skills are insufficient to complete study questionnaires.
|
| 94 |
+
|
| 95 |
+
► Pregnant or lactating women. Withdrawal or drop-out criteria Any patient can withdraw at any time for any reason in conditions that they wish to do so without any consequences, and the investigator will ensure that the patient's
|
| 96 |
+
|
| 97 |
+
| Table 1 | Schedule of events and examinations | BPI-SF/ POMS-SF/ | Drugs and | |
|
| 98 |
+
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|--------------------|----------------|----|
|
| 99 |
+
| WHOQOL-BREF/ | PGIC/ | TNF-α/IL-1β/ | rehabilitation | |
|
| 100 |
+
| FACIT-F | CGIC | IL-6/IL-10 | treatment | |
|
| 101 |
+
| Baseline (day 0) | × | × | × | × |
|
| 102 |
+
| Day 7 | × | × | × | × |
|
| 103 |
+
| Telephone review | × | × | | |
|
| 104 |
+
| (week 2, 4, 8 and 12±1 day) Haemoglobin WBC counting Platelet counting/AST/ALT/ BUN/Cr/ Na+/K+ | NRS | | | |
|
| 105 |
+
| Week 16±1 day | × | × | × | × |
|
| 106 |
+
| ALT, alanine aminotransferase; AST, aspartate aminotransferase; BPI-SF, Brief Pain Inventory-Short Form; BUN, blood urea nitrogen; CGIC, Clinical Global Impression of Change; CR, creatinine; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; IL-6, interleukin-6 level; IL-10, interleukin-10 level; IL-1β, interleukin-1 beta level; K+, potassium level; Na+, natrium level; NRS, Numeric Rating Scale; PGIC, Patient Global Impression of Change; POMS-SF, Profile of Mood States-Short Form; TNF-α, tumour necrosis factor-α level; WBC, white blood cell; WHOQOL-BREF, brief version of The WHO Quality of Life. | | | | |
|
| 107 |
+
|
| 108 |
+
care continues and that any reason for withdrawal is documented. The investigator can decide to withdraw a subject from the study due to abnormal function of important organs, poor compliance or serious AE (SAE).
|
| 109 |
+
|
| 110 |
+
## Recruitment And Screening
|
| 111 |
+
|
| 112 |
+
Recruitment advertising will be via posters on the bulletin board of the neurology department. Potential subjects will be identified by two certified and trained neurologists according to inclusion and exclusion criteria. The mean value of NRS pain scores in two consecutive days is used as the patient's baseline pain intensity score. Eligible patients will receive detailed information about the trial by a trained research assistant. Patients who decide to participate will then be asked to sign written informed consent. Randomisation allocation and blinding Randomisation is done centrally by using the block randomisation method (block size=4or 6) to generate the allocation sequence with the pseudorandom code produced by the computer. Multicentre competition enrolment was used to randomise eligible participants to receive either taVNS or sham stimulation at a ratio of 1:1. The allocation sequence will be kept for another copy and conserved in a locked filing cabinet. Non-transparent envelopes with the allotted sequences inside are prepared by independent statisticians who are not involved in subsequent recruitment.
|
| 113 |
+
|
| 114 |
+
Investigators (physicians), patients, outcome assessors and statistical analysts will remain unaware of patient study allocation. An independent physiotherapist performs VNS or sham stimulation according to the group envelope; non-transparent envelopes with the allotted sequences inside are delivered and distributed by the clinical research coordinator and kept sealed to avoid revealing the sequences during the trial. Investigators (physicians) are only responsible for administering medications other than VNS. The control strategy used 'transient sham stimulation', which allows for subjects to be blinded while delivering a true placebo treatment.29 Before treatment, all participants will be informed that the intensity of this treatment method may not be felt and the therapeutic device is placed in an opaque airtight pouch that is invisible to both the clinician and the patient during use. To provide additional assurance that the outcome assessors would not inadvertently uncover a subject's treatment allocation, all participants were reminded not to mention any aspects of the stimulation procedures to the assessors. Case Report Forms containing data relevant to the stimulation were maintained in a separate location. Data analysts will be blinded to the allocated treatment group. Unless emergencies happen, which the investigator considers necessary to conceal the unblinding codes, the randomisation code will be unblinded after the completion of data analysis. Blinding will be monitored by asking participants 'Do you believe that the taVNS device was functioning properly?' through a telephone review after the treatment period.
|
| 115 |
+
|
| 116 |
+
## Intervention
|
| 117 |
+
|
| 118 |
+
For all participants, after cleaning the skin of the concha with an alcohol pad, electrodes will be placed on the concha of the left ear (figure 2). Stimulation pulses (frequency 30Hz, pulse width 300 µs) will be generated by a commercial transcutaneous ear VNS device (tVNS 501, Jiangsu, China) (figure 2).
|
| 119 |
+
|
| 120 |
+
For the taVNS group (Arm A), the amplitude will increase within 30s until the participant develops a tingling sensation and then decrease to the maximum tolerable amount without pain within 15s.
|
| 121 |
+
|
| 122 |
+
For the sham taVNS group (Arm B), the amplitude will also increase within 30s until the participant develops a tingling sensation, but then decrease to zero stimuli within 15s.
|
| 123 |
+
|
| 124 |
+
All participants will be informed that the target stimulus has been reached and they may or may not experience any sensations from the stimulation. All patients receive intervention for 30min, twice a day (between 9:00 to 10:00 and 15:00 to 16:00), for seven consecutive days. The device is housed in an opaque bag throughout the treatment.
|
| 125 |
+
|
| 126 |
+
All enrolled patients will receive a basal dose of pregabalin (75mg two times per day) for analgesia, which was maintained constant during the study intervention
|
| 127 |
+
|
| 128 |
+

|
| 129 |
+
|
| 130 |
+
period (7days). Other treatments for radiation-induced brain injury are allowed and prescribed by trial clinicians after evaluation. Certain medicines are forbidden during the intervention period (eg, antiepileptic medications, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine and benzodiazepines). During the study, participants are permitted to take rescue drugs (eg, NSAIDs, cyclo-oxygenase-2 inhibitors, acetaminophen and opioids) to alleviate unbearable breakthrough pain.
|
| 131 |
+
|
| 132 |
+
## Treatment Adherence
|
| 133 |
+
|
| 134 |
+
To enhance intervention adherence, researchers will provide free clinical evaluation and taVNS treatment. Telephone interviews will be conducted in the weeks 2, 4, 8 and 12 after the treatment. If the patient missed more than two times (20%) of stimulation, they will be excluded from the per-protocol (PP) analysis.
|
| 135 |
+
|
| 136 |
+
## Outcome Assessment Primary Outcome
|
| 137 |
+
|
| 138 |
+
The primary efficacy outcome is the pain reduction at day 7, measured by the NRS, with which patients evaluated the average pain in the last 24 hours from 0, indicating no pain, to 10, indicating 'pain as bad as you can imagine'. The use of NRS complies with the recommendations of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials guidelines.14 Secondary outcomes All secondary endpoints will be assessed at baseline, day 7 and week 16 by the trained assessors who does not know the group allocation.
|
| 139 |
+
|
| 140 |
+
The Chinese version of the Brief Pain Inventory-Short Form (BPI-SF)30 is used to assess pain severity and inference, which has been widely used in neuropathic pain.14 31 The pain severity score is assessed as the mean of the four pain items (ie, pain at its worst, least, average and now).32 The functional inference is measured by the BPI Interference in seven items, which include general activity, mood, walking ability, work, social relations, sleep and life enjoyment.
|
| 141 |
+
|
| 142 |
+
The Chinese version of the short form of the Profile of Mood States (POMS-SF)33 has been recommended as a core outcome measure of emotional functioning in chronic pain clinical trials.14 It is a 30-item scale to evaluate patients' mood states.
|
| 143 |
+
|
| 144 |
+
The Chinese version of WHOQOL-BREF34 is a brief version of The WHO quality of life (WHOQOL), which has been widely used in clinical studies on cancer and neuropathic pain.35 36 In the questionnaire, a total of 26 items assess four domains of quality of life.
|
| 145 |
+
|
| 146 |
+
The Chinese version of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)37 is widely used to assess various chronic disease-related fatigue states.38 It is a self-report scale, with a higher total score representing less fatigue.38 The Patient Global Impression of Change (PGIC)39 is a self-evaluation of the patient's overall change on a 7-point scale (1=verymuch improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=verymuch worse). Treatment success is defined as 'much' or 'very much' improved.
|
| 147 |
+
|
| 148 |
+
The Clinical Global Impression of Change (CGIC)40 is a single-item questionnaire that asks the investigator to evaluate the subject's overall symptom change on a 7-point scale (1=verymuch improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=verymuch worse). Treatment success is defined as 'much' or 'very much' improved.
|
| 149 |
+
|
| 150 |
+
## Exploratory Outcome
|
| 151 |
+
|
| 152 |
+
The serum inflammatory factors include TNF-α, IL-1β, IL-6 and IL-10. Whole blood was centrifuged and serum was then stored at −80°C. The inflammatory factors were detected by ELISA in the laboratory. The change in these factors from baseline to day 7 will be calculated to evaluate the potential inflammatory response mechanism of taVNS on RRNP.
|
| 153 |
+
|
| 154 |
+
## Safety Evaluation
|
| 155 |
+
|
| 156 |
+
The record of AE will be conducted from the first electrical stimulation to the end of the trial and then be used to evaluate their potential associations with taVNS by a trained neurologist. The investigator is responsible for the detection and documentation of events meeting the criteria and definitions detailed below. A treatmentemergent AE is defined as any undesirable event that takes place after the first electrical stimulation of the taVNS and prior to the last protocol-arranged contact with the patient. Open-ended and non-leading verbal questioning of the participant will be used to enquire about AE/SAE occurrence. If there is any doubt as to whether a clinical observation is an AE, the event should be recorded. All AE reported by the participants or observed by the investigator or his staff will be recorded in detail. Data on the use of concomitant medications and rescue medications, as well as adherence to the study treatment, defined as taking 80% or more of the full course of taVNS treatment were also collected.
|
| 157 |
+
|
| 158 |
+
## Study Procedures
|
| 159 |
+
|
| 160 |
+
The face-to-face interview will be conducted by an assessor blinded to the intervention at days 0, 7 and week 16 of the regimen. There are three stages for this trial: ► Stage 1. Day 0.
|
| 161 |
+
|
| 162 |
+
This stage refers to the day between the signing of the consent form and the first taVNS (or sham) treatment. BPI-SF, POMS-SF, FACIT-F, WHOQOL-BERF and serum inflammatory factors will be assessed as the baseline data.
|
| 163 |
+
|
| 164 |
+
► Stage 2. Treatment period.
|
| 165 |
+
|
| 166 |
+
This stage will start from day 1 of this trial, and last for 7days. At the beginning of this stage, 1:1 randomisation will be carried out to divide patients into taVNS or sham taVNS groups. Patients will receive taVNS or sham taVNS treatment for seven consecutive days. After the last treatment, NRS, BPI-SF, POMS-SF, FACIT-F, WHOQOLBERF, PGIC, CGIC and serum inflammatory factors will be assessed. ► Stage 3. Follow-up period.
|
| 167 |
+
|
| 168 |
+
This stage will start from day 8 and continue to week 16 of this trial. During this stage, patients will stop stimulation and perform pregabalin dosage adjustments based on the pain relief with a maximum dosage of four capsules two times per day. The pain and drugs or rehabilitation treatment information during this stage were obtained through telephone review (week 2, 4, 8 and 12).
|
| 169 |
+
|
| 170 |
+
BPI-SF, POMS-SF, FACIT-F, and WHOQOL-BERF, will be assessed on week 16 by face-to-face interview.
|
| 171 |
+
|
| 172 |
+
## Data Management And Monitoring
|
| 173 |
+
|
| 174 |
+
The study data will be stored in the researcher's department at Sun Yat-sen University, which will be responsible for research data monitoring and auditing. The auditing will be conducted annually and independent of investigators and the sponsor. The paper data will be stored in a locked cabinet in the office which is locked when no research personnel is present and the database will be stored in Sun Yat-sen University and be passwordprotected. Data will be coded once entered into the computer and the file will be password-protected and accessible only by investigators. All private participant data will be coded and protected. When disseminating the results, no individuals will be identified or identifiable.
|
| 175 |
+
|
| 176 |
+
## Sample Size
|
| 177 |
+
|
| 178 |
+
Sample size calculation was based on the primary outcome: the change of score in pain at day 7 assessed by an 11-point NRS. According to our preliminary study of taVNS for RRNP and the previous trial12 of pregabalin for the treatment of RRNP in patients with head and neck cancers, 52 participants per group will be recruited to have 90% power to detect a between-group difference of 0.9 in the change of score in pain, SD of 1.4 and a onesided type I error rate of 2.5%. Taking into account an estimated 10% dropout rate, this trial plans to include 116 participants, with 58 participants in each group.
|
| 179 |
+
|
| 180 |
+
## Statistical Analysis Plan
|
| 181 |
+
|
| 182 |
+
The data will be presented as mean and SD or median and IQR for continuous variables according to its distribution and numbers with percentages for categorical variables.
|
| 183 |
+
|
| 184 |
+
The primary analysis will be conducted according to the intention-to-treat (ITT) principle, which will include all patients who were randomised. After the normality test, the Student's t-test or the Mann-Whitney U test will be used to compare the difference in primary outcome between the two groups. Missing data for the primary outcome will be imputed with a Markov chain Monte-Carlo multiply imputation approach41 with the assumption of missingat-random. Sensitivity analyses using a last observation carried forward imputation as well as the complete case of the ITT population will be performed to evaluate the primary outcome. The PP analysis will also be applied to the primary outcome as another sensitivity analysis. The PP set is defined as ITT patients who completed the study with evidence of receiving ≥80% course of taVNS treatment and no other significant protocol violations.
|
| 185 |
+
|
| 186 |
+
For secondary outcomes, the absolute rate differences with 95% CIs are calculated for responder status (≥30%
|
| 187 |
+
and 50% pain relief) and treatment success rates for PGIC
|
| 188 |
+
and CGIC using the Newcombe-Wilson score method,42 and comparison between groups will be performed with the Cochran-Mantel-Haenszel test. For other continuous secondary endpoints, the Student's t-test or the Mann-Whitney U test will be applied in the ITT and PP
|
| 189 |
+
set without imputation of missing data. The safety set includes all patients who received at least one electrical stimulation of the taVNS and will be used to compare the safety of treatment. Adverse effects, use of concomitant drugs and rescue drugs are compared between groups using χ2 or Fisher's exact tests.
|
| 190 |
+
|
| 191 |
+
Furthermore, subgroup analyses will be performed to evaluate the potential relationship between some clinical factors with the outcomes, including the different cancer types, and the use of chemotherapy and corticosteroids, based on the analysis of our previous research. Analysis of variance or linear mixed-effect model will also be used for repeated measurements to evaluate the potential longitudinal trend of efficacy.
|
| 192 |
+
|
| 193 |
+
Several factors associated with RRNP that might also have an impact, such as radiation-induced brain necrosis, seizure symptoms and dysphagia, these will be reported with the appropriate descriptive methods. Meanwhile, multivariable analyses or subgroup analyses will be conducted to control or identify the potential influence of these variables on the efficacy of the intervention.
|
| 194 |
+
|
| 195 |
+
Statistical analyses will be performed by independent statisticians who are blinded to the allocation information. All the statistical analyses will be performed using R
|
| 196 |
+
Project for Statistical Computing V.3.4.2. Patient and public involvement No patients or the public are involved in the design, conduct, reporting and dissemination plans of this research.
|
| 197 |
+
|
| 198 |
+
## Discussion
|
| 199 |
+
|
| 200 |
+
The RELAX study will be the first randomised controlled trial to evaluate the efficacy of taVNS on RRNP among patients with head and neck cancers. In addition, we will explore the potential impact of taVNS on mood, psychology and quality of life in these populations.
|
| 201 |
+
|
| 202 |
+
Despite the increasing number of studies, there is no clear consensus regarding the optimal parameters that need to be adopted for taVNS research.25 Moreover, the effects of taVNS in RRNP have yet to be assessed. Our stimulation parameters are based on a published study showing that taVNS can help reduce pain in patients with systemic lupus erythematosus,24 in which taVNS
|
| 203 |
+
on concha of the left ear at 30Hz and 300 µs showed a good analgesic effect. The amplitude was increased to the maximum amount tolerated by the participant without pain and taVNS was well tolerated with few AE attributed to the stimulation.
|
| 204 |
+
|
| 205 |
+
The duration of taVNS treatment has varied across studies, from 4days to several weeks,25 and there has been no research on the effect of taVNS on RRNP treatment so far. According to our previous trial of pregabalin in the treatment of RRNP,12 pregabalin requires a titration period of 7days, while the NRS pain score of the experimental group in this period only decreases by 0.62 points, which is far from satisfactory, while rapid dosage increase will bring more side effects. How to reduce the pain intensity within 1week is a key problem in clinical practice. Therefore, we set 7days as the trial course and the pain reduction at day 7 as the primary endpoint. Furthermore, previous studies have shown that VNS can reduce inflammation18 and may have long-term analgesic effects.25 Therefore, we design 16 weeks as the follow-up endpoint.
|
| 206 |
+
|
| 207 |
+
For the sham taVNS group, we use the same stimulation pulses as the taVNS group, the amplitude is also increased within 30s until the participant develops a tingling sensation, but then decreases to zero stimuli over 15s. This control strategy is called 'transient sham stimulation', based on the previous study showing that the method could facilitate the blinding of both participants and investigators to avoid expectation bias and determine the true efficacy of transcutaneous electrical nerve stimulation for use in clinical populations.29 Considering the temporal difference in vagal excitability, we give stimuli at 9:00 to 10:00 and 15:00 to 16:00 to minimise the differences in stimulus periods. All stimulation processes are carried out by trained physiotherapists according to the operation protocols to ensure that the patients complete the prescribed course of treatment and that possible side effects are detected timely to improve treatment compliance.
|
| 208 |
+
|
| 209 |
+
The RELAX trial will be carried out in four centres in China to explore the efficacy of taVNS in the treatment of RRNP among patients with head and neck cancers and may provide a new early intervention strategy for this high-incidence and serious disease.
|
| 210 |
+
|
| 211 |
+
## Limitations
|
| 212 |
+
|
| 213 |
+
There are some possible study limitations. First, this trial will be conducted only in southern China, where the population is mainly Chinese, due to differences in race, there may be differences in sensitivity to electrical stimulation, which may limit the generalisability of the study results for Western countries. Second, we have set a follow-up period of 16 weeks. A longer follow-up period may result in more data loss, which increases the difficulty in the medication management and rehabilitation during the follow-up and may affect some secondary results. However, our team has accumulated experience in follow-up and patient management in our previous study of pregabalin,12 which will effectively promote participant retention and complete follow-up.
|
| 214 |
+
|
| 215 |
+
Author affiliations 1Department of Neurology, Sun Yat-sen Memorial Hospital, Guangzhou, China 2Division of Clinical Research Design, Sun Yat-sen University, Guangzhou, China 3Department of Neurology, The Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, China 4Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Guangzhou, China Acknowledgements We are grateful for support from the Sun Yat-sen Memorial Hospital, the Guangzhou Clinical Characteristic Technology Research Project, the National Natural Science Foundation of China. The authors thank in advance all the patients, investigators, caregivers and institutions involved in this study. Contributors YT and Q-YS conceived and designed the study. XZ and YL drafted the manuscript. XR, XY, YZ, DP and HL contributed to the revision of the manuscript. All authors approved the submission of this manuscript. Funding This work is supported by Sun Yat-sen Memorial Hospital Clinical Research 5010 Program (grant number: N/A), the Guangzhou Clinical Characteristic Technology Research Project (grant number: N/A), the National Natural Science Foundation of China (grant number: 82003389) and Sun Yat-sen Clinical Research Cultivating Program (grant number: SYS-Q-202208). Competing interests None declared. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Patient consent for publication Informed consent was obtained from all subjects involved in the study. Provenance and peer review Not commissioned; externally peer reviewed. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise. Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. ORCID iD Yamei Tang http://orcid.org/0000-0002-6353-6107
|
| 216 |
+
|
| 217 |
+
## References
|
| 218 |
+
|
| 219 |
+
1 Astrup GL, Rustøen T, Miaskowski C, *et al*. Changes in and predictors of pain characteristics in patients with head and neck cancer undergoing radiotherapy. *Pain* 2015;156:967–79.
|
| 220 |
+
|
| 221 |
+
2 Epstein JB, Wilkie DJ, Fischer DJ, *et al*. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol 2009;1:26.
|
| 222 |
+
|
| 223 |
+
3 Leenstra JL, Miller RC, Qin R, *et al*. Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [alliance]). *J Clin* Oncol 2014;32:1571–7.
|
| 224 |
+
|
| 225 |
+
4 Bar Ad V, Weinstein G, Dutta PR, *et al*. Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. *Cancer* 2010;116:4206–13.
|
| 226 |
+
|
| 227 |
+
5 Lefebvre T, Tack L, Lycke M, *et al*. Effectiveness of adjunctive analgesics in head and neck cancer patients receiving curative (chemo-) radiotherapy: a systematic review. *Pain Med* 2021;22:152–64.
|
| 228 |
+
|
| 229 |
+
6 Glare PA, Davies PS, Finlay E, *et al*. Pain in cancer survivors. J Clin Oncol 2014;32:1739–47.
|
| 230 |
+
|
| 231 |
+
7 Fathers E, Thrush D, Huson SM, *et al*. Radiation-induced brachial plexopathy in women treated for carcinoma of the breast. *Clin* Rehabil 2002;16:160–5.
|
| 232 |
+
|
| 233 |
+
8 Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. *Lancet Neurol* 2010;9:807–19.
|
| 234 |
+
|
| 235 |
+
9 Cramer JD, Johnson JT, Nilsen ML. Pain in head and neck cancer survivors: prevalence, predictors, and quality-of-life impact. Otolaryngol Head Neck Surg 2018;159:853–8.
|
| 236 |
+
|
| 237 |
+
10 Fallon MT. Neuropathic pain in cancer. *British Journal of Anaesthesia* 2013;111:105–11.
|
| 238 |
+
|
| 239 |
+
11 Brown M, Farquhar-Smith P. Pain in cancer survivors; filling in the gaps. *Br J Anaesth* 2017;119:723–36.
|
| 240 |
+
|
| 241 |
+
12 Jiang J, Li Y, Shen Q, *et al*. Effect of pregabalin on radiotherapyrelated neuropathic pain in patients with head and neck cancer: a randomized controlled trial. *J Clin Oncol* 2019;37:135–43.
|
| 242 |
+
|
| 243 |
+
13 Breivik H, Collett B, Ventafridda V, *et al*. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. *Eur J Pain* 2006;10:287–333.
|
| 244 |
+
|
| 245 |
+
14 Dworkin RH, Turk DC, Farrar JT, *et al*. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. *Pain* 2005;113:9–19.
|
| 246 |
+
|
| 247 |
+
15 Borovikova LV, Ivanova S, Zhang M, *et al*. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 2000;405:458–62.
|
| 248 |
+
|
| 249 |
+
16 Maguire AD, Bethea JR, Kerr BJ. TNFalpha in MS and its animal models: implications for chronic pain in the disease. *Front Neurol* 2021;12:780876.
|
| 250 |
+
|
| 251 |
+
17 Cavalcanti MRM, Passos FRS, Monteiro BS, *et al*. HPLC-DADUV analysis, anti-inflammatory and anti-neuropathic effects of methanolic extract of sideritis bilgeriana (lamiaceae) by NF-ΚB, TNF-Α, IL-1Β and IL-6 involvement. *J Ethnopharmacol* 2021;265:113338.
|
| 252 |
+
|
| 253 |
+
18 Kummer KK, Zeidler M, Kalpachidou T, *et al*. Role of IL-6 in the regulation of neuronal development, survival and function. *Cytokine* 2021;144.
|
| 254 |
+
|
| 255 |
+
19 De Couck M, Cserjesi R, Caers R, *et al*. Effects of short and prolonged transcutaneous vagus nerve stimulation on heart rate variability in healthy subjects. *Auton Neurosci* 2017;203:88–96.
|
| 256 |
+
|
| 257 |
+
20 Busch V, Zeman F, Heckel A, *et al*. The effect of transcutaneous vagus nerve stimulation on pain perception--an experimental study. Brain Stimulation 2013;6:202–9.
|
| 258 |
+
|
| 259 |
+
21 Tassorelli C, Grazzi L, de Tommaso M, *et al*. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. *Neurology* 2018;91:e364–73.
|
| 260 |
+
|
| 261 |
+
22 Straube A, Eren O. tVNS in the management of headache and pain.
|
| 262 |
+
|
| 263 |
+
Auton Neurosci 2021;236:102875.
|
| 264 |
+
|
| 265 |
+
23 Diener H-C, Goadsby PJ, Ashina M, *et al*. Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: the multicenter, double-blind, randomized, sham-controlled PREMIUM trial. *Cephalalgia* 2019;39:1475–87.
|
| 266 |
+
|
| 267 |
+
24 Aranow C, Atish-Fregoso Y, Lesser M, *et al*. Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomized, double-blind, shamcontrolled pilot trial. *Ann Rheum Dis* 2021;80:203–8.
|
| 268 |
+
|
| 269 |
+
25 Farmer AD, Strzelczyk A, Finisguerra A, *et al*. International consensus based review and recommendations for minimum reporting standards in research on transcutaneous vagus nerve stimulation (version 2020). *Front Hum Neurosci* 2020;14:568051.
|
| 270 |
+
|
| 271 |
+
26 Redgrave J, Day D, Leung H, *et al*. Safety and tolerability of transcutaneous vagus nerve stimulation in humans; a systematic review. *Brain Stimul* 2018;11:1225–38.
|
| 272 |
+
|
| 273 |
+
27 Chan A-W, Tetzlaff JM, Gøtzsche PC, *et al*. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
|
| 274 |
+
|
| 275 |
+
28 Li J, Feng Y, Han J, *et al*. Linguistic adaptation, validation and comparison of 3 routinely used neuropathic pain questionnaires. Pain Physician 2012;15:179–86.
|
| 276 |
+
|
| 277 |
+
29 Rakel B, Cooper N, Adams HJ, *et al*. A new transient sham TENS
|
| 278 |
+
device allows for investigator blinding while delivering a true placebo treatment. *J Pain* 2010;11:230–8.
|
| 279 |
+
|
| 280 |
+
30 Wang XS, Mendoza TR, Gao SZ, *et al*. The Chinese version of the brief pain inventory (BPI-C): its development and use in a study of cancer pain. *Pain* 1996;67:407–16.
|
| 281 |
+
|
| 282 |
+
31 Gilron I, Bailey JM, Tu D, *et al*. Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomized controlled crossover trial. *Lancet* 2009;374:1252–61.
|
| 283 |
+
|
| 284 |
+
32 Irwin ML, Cartmel B, Gross CP, *et al*. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015;33:1104–11.
|
| 285 |
+
|
| 286 |
+
33 Chen KM, Snyder M, Krichbaum K. Translation and equivalence: the profile of mood states short form in English and Chinese. Int J Nurs Stud 2002;39:619–24.
|
| 287 |
+
|
| 288 |
+
34 Xia P, Li N, Hau K-T, *et al*. Quality of life of Chinese urban community residents: a Psychometric study of the Mainland Chinese version of the WHOQOL-BREF. *BMC Med Res Methodol* 2012;12:37.
|
| 289 |
+
|
| 290 |
+
35 Hanna EY, Mendoza TR, Rosenthal DI, *et al*. The symptom burden of treatment-naive patients with head and neck cancer. *Cancer* 2015;121:766–73.
|
| 291 |
+
|
| 292 |
+
36 Han Z-A, Song DH, Oh H-M, *et al*. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. *Ann Neurol* 2016;79:569–78.
|
| 293 |
+
|
| 294 |
+
##
|
| 295 |
+
|
| 296 |
+
37 Wang S-Y, Zang X-Y, Liu J-D, *et al*. Psychometric properties of the functional assessment of chronic illness therapy-fatigue (FACITfatigue) in Chinese patients receiving maintenance dialysis. *J Pain* Symptom Manage 2015;49:135–43.
|
| 297 |
+
|
| 298 |
+
38 Webster K, Cella D, Yost K. The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. *Health Qual Life Outcomes* 2003;1:79.
|
| 299 |
+
|
| 300 |
+
39 Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther 2004;27:26–35.
|
| 301 |
+
|
| 302 |
+
40 Schneider LS, Olin JT, Doody RS, *et al*. Validity and reliability of the alzheimer's disease cooperative study-clinical global impression of change. The alzheimer's disease cooperative study. Alzheimer Dis Assoc Disord 1997;11:S22–32.
|
| 303 |
+
|
| 304 |
+
41 Kenward MG, Carpenter J. Multiple imputation: current perspectives. *Stat Methods Med Res* 2007;16:199–218.
|
| 305 |
+
|
| 306 |
+
42 Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. *Stat Med* 1998;17:873–90.
|
medical/md/PMC2193773.md
ADDED
|
@@ -0,0 +1,422 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
Jens Hennecke1 and Don C. Wiley1, 2 1Department of Molecular and Cellular Biology, Harvard University, and 2Howard Hughes Medical Institute, Cambridge, MA 02138
|
| 2 |
+
|
| 3 |
+
## Abstract
|
| 4 |
+
|
| 5 |
+
J. Exp. Med. The Rockefeller University Press - 0022-1007/2002/03/571/11 $5.00 Volume 195, Number 5, March 4, 2002 571–581 http://www.jem.org/cgi/content/full/195/5/571 571 Structure of a Complex of the Human - **T Cell Receptor**
|
| 6 |
+
(TCR) HA1.7, Influenza Hemagglutinin Peptide, and Major Histocompatibility Complex Class II Molecule, HLA-DR4 (DRA*0101 and DRB1***0401): Insight into TCR**
|
| 7 |
+
Cross-Restriction and Alloreactivity The T cell receptor (TCR) HA1.7 specific for the hemagglutinin (HA) antigen peptide from influenza A virus is HLA-DR1 restricted but cross-reactive for the HA peptide presented by the allo-major histocompatibility complex (MHC) class II molecule HLA-DR4. We report here the structure of the HA1.7/DR4/HA complex, determined by X-ray crystallography at a resolution of 2.4 Å. The overall structure of this complex is very similar to the previously reported structure of the HA1.7/DR1/HA complex. Amino acid sequence differences between DR1 and DR4, which are located deep in the peptide binding groove and out of reach for direct contact by the TCR, are able to indirectly influence the antigenicity of the pMHC surface by changing the conformation of HA peptide residues at position P5 and P6. Although TCR HA1.7 is cross-reactive for HA presented by DR1 and DR4 and tolerates these conformational differences, other HA-specific TCRs are sensitive to these changes. We also find a dependence of the width of the MHC class II peptide-binding groove on the sequence of the bound peptide by comparing the HA1.7/DR4/HA complex with the structure of DR4 presenting a collagen peptide. This structural study of TCR cross-reactivity emphasizes how MHC sequence differences can affect TCR binding indirectly by moving peptide atoms. Key words: T cell receptor - MHC class II - cross-reactivity - antigen recognition - X-ray crystallography
|
| 8 |
+
|
| 9 |
+
## Introduction
|
| 10 |
+
|
| 11 |
+
The MHC-restricted recognition of antigen peptides by TCRs is a central event in the cellular immunity against pathogens and in the immune surveillance of cancer cells. It is also directly involved in immunological diseases, such as autoimmune diseases, hypersensitive reactions, and alloreactive responses after organ transplantations. The recent crystal structures of TCRs in complex with peptide antigen presented by MHC class I and class II molecules identify atomic contacts between the TCR on one side and the antigen peptide and the MHC molecule on the other side and give a detailed picture of the structural diversity of this interaction (1–7). Although the different structures represent different biological situations (immune response against pathogens, positive selection in the thymus, alloreaction)
|
| 12 |
+
no characteristic structural features attributable to the particular biological situation are obvious. The overall mode of TCR binding to pMHC is rather similar for all these structures. The extremely variable CDR3s are located over the center of the pMHC surface and make contacts with the antigen peptide as well as with the MHC --helices, whereas the less variable CDR loops contact the termini of the antigen peptide and residues of the MHC helices adjacent to it (CDR1s) or exclusively contact the central parts of the MHC helices (CDR2s). Although in all these complexes TCRs bind to pMHC in a similar overall orientation and topology, the shapes and chemical properties of the interacting surfaces in these complexes are highly diverse and no conserved contacts between the CDR loops of the TCR and the pMHC exist that could determine this orientation (for a review, see references 8 and 9).
|
| 13 |
+
|
| 14 |
+
Based on the structures of the TCR–pMHCI complexes, recent mutational studies addressed the functional Address correspondence to Jens Hennecke, Micromet AG, Am Klopferspitz 19, D-82152 Martinsried, Germany. Phone: 49-89-895-277-93; Fax: 49-89-895-277-22; E-mail: jens.hennecke@Micromet.de importance of the atomic contacts between the TCR and the pMHCI systematically by mutating residues of the TCR, antigen peptide, and MHC molecule involved in intermolecular contacts and correlating changes in protein conformation and thermodynamic and kinetic stability of the interaction with the outcome of the biological response
|
| 15 |
+
(e.g., phosphorylation patterns of TCR and ZAP-70, cytolytic activity, cytokine production). These studies showed that (i) the outcome of the biological response correlated fairly well with kinetic properties of the TCR–
|
| 16 |
+
pMHC interaction (for example, references 10–12; for a review, see references 13 and 14), (ii) the response does not correlate with structural changes at the interface (minor structural changes can have a dramatic effect on the biological response) (10, 15), and (iii) the importance of atomic contacts for functional binding can be similar for all contacts at the interface in some cases but vary strongly in others (16–18). Similar systematic experiments for TCRs bound to antigen peptide presented by MHC class II molecules have not been reported.
|
| 17 |
+
|
| 18 |
+
We recently solved the crystal structure of the human
|
| 19 |
+
- TCR HA1.7 in complex with an immunodominant peptide epitope of hemagglutinin *(HA) (HA306–318:
|
| 20 |
+
PKYVKQNTLKLAT) from influenza A virus H3N2 presented by the MHC class II molecule DR1 (4). HA is bound in an extended conformation deep in the binding groove of DR1 by a dozen hydrogen bonds between conserved DR1 residues of the --helices and peptide main chain carbonyl and amide groups (19). Burying of the HA peptide side chains of Y308 (P1) in a deep pocket and of Q311 (P4), T313 (P6), L314 (P7), and L316 (P9) in more shallow pockets of DR1 establishes peptide binding specificity (20, 21). However, the HA peptide binds promiscuously and can be presented by most of the frequently occurring DR alleles. Due to differences in shape and chemical properties of the P4, P6, P7, and P9 pockets, HA
|
| 21 |
+
residues at the corresponding positions are of varying importance for HA binding to these DR alleles, whereas Tyr308 at position P1 is always the dominant anchor residue (20, 22–24).
|
| 22 |
+
|
| 23 |
+
The interaction between the HA antigen peptide and TCR HA1.7 is dominated by charged interactions between the three lysine residues of HA at position P-1, P3, and P8 and glutamate and aspartate residues in CDR3and CDR1 of TCR HA1.7 (4, 25). These charged interactions are conserved in the recognition of the HA peptide by other TCRs (21, 25–27). Contacts by TCR
|
| 24 |
+
HA1.7 to these three lysines and to other residues that point upward from the DR1/HA surface (Val309 (P2), Asn312 (P5), and Leu314 (P7) are important for functional binding (21, 27–30).
|
| 25 |
+
|
| 26 |
+
Although TCR HA1.7 is DR1-restricted (DRA1, DRB1*0101), it is cross-reactive with HA peptide presented by the allo-MHC class II molecule HLA-DR4 (DRA1, DRB1*0401) (26, 31–33). However, other HAspecific TCRs are known that do not show this cross-reac-
|
| 27 |
+
|
| 28 |
+
## Materials And Methods
|
| 29 |
+
|
| 30 |
+
Protein Expression, Purification, and Crystallization. Empty HLA-DR4 (DRA*0101, DRB1*0401) and HLA-DM were overexpressed from stable Schneider cell lines (35–37) and TCR HA1.7 with the HA306–318 antigen peptide linked to residue D1 of the TCR -chain via an octapeptide linker was refolded from *Escherichia coli* inclusion bodies (4). The HA-HA1.7/DR4 complex was assembled by loading the HA peptide that is part of the p-TCR HA-HA1.7 onto empty DR4 with the help of the peptide exchange catalyst HLA-DM and purified as described previously (4). The addition of HLA-DM during complex formation increased the yield of the assembled complex by a factor of -4–10.
|
| 31 |
+
|
| 32 |
+
Crystallization, Structure Determination, and Refinement. HAHA1.7/DR4 crystals were obtained by streak seeding sitting drops of 1 l of protein (10 mg/ml) and 1 l of well solution
|
| 33 |
+
(13% PEG 8000, 1 M NaCl, 100 mM Hepes, pH 7.0) with crystals of HA-HA1.7/DR1 after 12 h preequilibration of the drops at 18C (4). Crystals are monoclinic, space group C2, with a 143.8 Å, b 73.3 Å, c 123.0 Å, 108.5 and one complex molecule per asymmetric unit.
|
| 34 |
+
|
| 35 |
+
After briefly soaking the crystals in 20% glycerol, 16% PEG
|
| 36 |
+
8000, 1 M NaCl, 100 mM Hepes, pH 7.0, and flash cooling in liquid nitrogen, X-ray diffraction data were collected from a single cryocooled crystal (100K; 20.0–2.4 Å resolution) (see Table I) at the BIOCARS station 14-BM-C at the APS at Argonne National Laboratory using 1 Å wavelength X-rays and a Quantum4 CCD detector. Data processing was performed with HKL2000 (38).
|
| 37 |
+
|
| 38 |
+
The structure of the complex was determined by molecular replacement using the program AMoRe (39) and the refined coordinates of the HA-HA1.7/DR1 complex (4) as search models.
|
| 39 |
+
|
| 40 |
+
Solutions for the TCR HA1.7 and DR4/HA were found in independent rotation and translation searches (R 31.4, corr. coeff. 74.2). Rigid-body refinement of the individual domains of this model with CNS (40) yielded Rfree 31.1% (Rwork 29.5%) used all the data between 20 and 2.4 Å resolution.
|
| 41 |
+
|
| 42 |
+
To avoid model bias, sigma-A-weighted (2mFo-DFc) simulated annealing omit maps (composite omit maps) and (mFo-DFc)
|
| 43 |
+
electron density maps (41) were used for model building and correction in O (42). For all residues that are different between DR4 and DR1 unambiguous electron density could be observed in the initial maps. For the calculation of the Rfree value during refinement the same reflections were set-aside in the test set as during the refinement of the HA-HA1.7/DR1 structure (4).
|
| 44 |
+
|
| 45 |
+
Simulated annealing torsion angle dynamics, positional, and individual B factor refinement was performed in CNS using a maximum likelihood (ML) target. A bulk solvent correction and
|
| 46 |
+
**Abbreviations used in this paper:* HA, hemagglutinin; TT, tetanus toxin. anisotropic B-factor tensor were applied throughout the refinetive behavior (26, 34). To understand the basis of the crossreactivity of HA1.7 and that of other TCRs we determined the X-ray structure of TCR HA1.7 in complex with DR4/HA at a resolution of 2.4 Å. The structure is very similar to the TCR HA1.7/DR1/HA structure. However, local conformational changes of HA peptide residues induced by MHC allelic differences are observed which obviously are tolerated by TCR HA1.7 but sensed by other TCRs. Comparison with the DR4/Col structure indicates a conformational difference in the DR4 molecule that depends on the sequence of the bound antigen peptide.
|
| 47 |
+
|
| 48 |
+
ment. After the Rfree had dropped to 26.4% (Rwork 23.1%) water molecules were added. The final model includes 813 of 855 residues and 305 water molecules. Weak or no electron density was observed for residues 105–113 of DR4, residues 130–132 of the HA1.7 C- domain, the last 10 residues of the C- as well as the C domain, for 0–3 residues at the N- or COOH termini of the different chains and for the octapeptide linker between the HA peptide and the HA1.7 chain (see Table I). Electron density corresponding to the N-linked carbohydrates at Asn78-, Asn118-, and Asn19 was observed, but only one (Asn78-,
|
| 49 |
+
Asn19) or two (Asn118-) monosaccharide units could be reliably modeled at each position.
|
| 50 |
+
|
| 51 |
+
Protein Database Code. The coordinates have been deposited in the PDB under entry code 1J8H.
|
| 52 |
+
|
| 53 |
+
## Results
|
| 54 |
+
|
| 55 |
+
Structural Overview over the Complex. A stable complex between the - TCR HA1.7 and DR4/HA was prepared as described recently for the TCR HA1.7/DR1/HA complex, exploiting the strategy of flexibly linking the HA antigen peptide to the V chain of the TCR (4). Crystals of the complex were of space group C2 and isomorphous to crystals of the TCR HA1.7/DR1/HA complex. The structure was solved by molecular replacement using the TCR HA1.7/DR1/HA complex as the search model and great care was taken to avoid model bias by the search model (Materials and Methods). For all allelic differences between DR4 and DR1 unambiguous electron density could be observed in the initial electron density maps. The structure was refined to a final R value of 0.208 and Rfree value of 0.245 at a resolution of 2.4 Å (Table I).
|
| 56 |
+
|
| 57 |
+
The structures of the TCR HA1.7/DR4/HA complex and the TCR HA1.7/DR1/HA complex (4) are very similar (RMSD for C- atoms is 0.34 Å). The TCR HA1.7 binds similarly to DR4/HA and to DR1/HA with the V-
|
| 58 |
+
domain binding to the NH2-terminal half of the HA peptide and the center and COOH-terminal half of the 1
|
| 59 |
+
--helix and the V domain binding to the COOH-terminal half of the peptide and to the center and COOH-terminal half of the -1 --helix (Fig. 1). Only small conformational differences are observed in the polypeptide mainchain of the HA peptide and the MHC class II molecule around polymorphic residues (see below).
|
| 60 |
+
|
| 61 |
+
Allelic Differences between DR1 and DR4 Determine the HA
|
| 62 |
+
Peptide Conformation. Although the allelic differences between DR1 and DR4 are not accessible for direct contact by the TCR, these residues nevertheless influence the antigenic properties of the pMHC complex by inducing conformational differences in the peptide antigen. There are 15 allelic differences in the DR -chain between DR1
|
| 63 |
+
(DRB1*0101) and DR4 (DRB1*0401) (Fig. 2 A). Nine of the allelic differences are located in the -strands that form the floor of the peptide binding groove and thereby, together with the allelic difference at position 71 in the center of the 1 --helix, determine the differences in size and chemical properties of the P4, P6, P7, and P9 peptide binding pockets (19, 24, 35, 43) (Fig. 2 B). The remaining five polymorphic positions are located in the linker be-
|
| 64 |
+
|
| 65 |
+
| (A) Data Statistics Resolution (Å) | 20.0–2.4 (2.49–2.40) |
|
| 66 |
+
|------------------------------------------------------------------|------------------------|
|
| 67 |
+
| No. unique reflections | 46705 |
|
| 68 |
+
| Multiplicity | 4.5 (4.2) |
|
| 69 |
+
| Completeness | 96.9 (96.7) |
|
| 70 |
+
| Average I/ I | 20.6 (4.3) |
|
| 71 |
+
| Rmerge (%) | 5.8 (33.0) |
|
| 72 |
+
| (B) Refinement statistics (20.0–2.4 Å) No. of reflections (free) | 43905 (2280) |
|
| 73 |
+
| Rwork (Rfree) | 0.208 (0.245) |
|
| 74 |
+
| Rmsd bonds (Å) | 0.007 |
|
| 75 |
+
| Rmsd angles (degree) | 1.38 |
|
| 76 |
+
| (C) Average B factors Protein atoms (Å2) | 45.6 |
|
| 77 |
+
| Sugars (Å2) | 83.7 |
|
| 78 |
+
| Water molecules (Å2) | 48.4 |
|
| 79 |
+
| B11 6.19, B22 1.06, | |
|
| 80 |
+
| Anisotropic B factors (Å2) | B33 7.25 |
|
| 81 |
+
| Bulk solvent correction | B 38.4Å2, k 0.35 e/Å3 |
|
| 82 |
+
|
| 83 |
+
Rrange (hkl|l<l>|)/(hkl<l>), hkl {independent Miller indices}. Rfree (h|FoFc|)/(hFo), h {free set, 5% of reflections}. Rwork (h|FoFc|)/(hFo), h {working set}.
|
| 84 |
+
|
| 85 |
+
tween the 1 and 2 domain and in the 2 domain itself, distant (at least 25 Å) from the interface with the TCR. Despite these allelic differences the HA peptide is bound in the same register in the DR4 peptide binding groove compared with the DR1/HA complex, but with some conformational differences. From residue P4 (Gln311) to P7
|
| 86 |
+
(Leu314) the HA peptide is bound slightly deeper in the groove of DR4 and with conformational differences in the peptide mainchain compared with HA bound to DR1. In addition, conformational differences are seen in the sidechains of residue P5 (Asn312) and P6 (Thr313) (Fig. 3).
|
| 87 |
+
|
| 88 |
+
Polymorphic residues around the P6 pocket influence the conformation of peptide residue P6 Thr (Fig. 3 A). In contrast to HA bound to DR1, the sidechain of P6 Thr points into the P6 pocket of DR4 due to a rotation of –148 degrees about the C--C bond (Chi 1). This rotation leads to the formation of a hydrogen bond between the P6 Thr
|
| 89 |
+
-hydroxyl group and His13 N 2 atom (Fig. 3 A). Since this hydrogen-bonding partner is absent in DR1 (His13 is replaced by Phe) and the P6 pocket is shallower in DR1
|
| 90 |
+
(Val11 at the bottom of the P6 pocket is replaced by Leu), the Thr -hydroxyl group points upward toward the TCR (Fig. 3 A). In DR4, the whole P6 Thr residue is bound slightly deeper in the peptide-binding groove compared with DR1 (C- of P6 Thr in this structure is -0.6 Å
|
| 91 |
+
deeper in the groove compared with the DR1 structure).
|
| 92 |
+
|
| 93 |
+
The TCR HA1.7 does not contact the P6 Thr sidechain in
|
| 94 |
+
|
| 95 |
+
 either case, but other TCR are sensitive to this difference (see below).
|
| 96 |
+
|
| 97 |
+
There is also a conformational difference in peptide residue P5 Asn. In the TCR HA1.7/DR4/HA structure the residue P5 Asn is slightly tipped and moved toward the 1
|
| 98 |
+
--helix compared with the TCR HA1.7/DR1/HA structure (Fig. 3 B). The C-, C, and C atoms of P5 Asn in the TCR HA1.7/DR4/HA structure are moved by 0.7 Å, 1.0 Å, and 1.3 Å, respectively, compared with the TCR HA1.7/DR1/HA structure (coordinate error from Luzzati plot: 0.3 Å). This location of the mainchain residues P4 to P6 (Gln311 to Thr313) of the antigen peptide is identical to the location of the mainchain residues P4 to P6 of the collagen peptide in the DR4/Col structure (35).
|
| 99 |
+
|
| 100 |
+
The difference is caused by residue Lys71 of the DR4
|
| 101 |
+
-chain, which in order to form a hydrogen bond with the mainchain carbonyl group of peptide residue P5 Asn pulls the carbonyl further into the peptide binding groove and thereby tips and moves the whole residue toward the 1 --helix. In DR1, the longer sidechain of Arg 71 can form the same hydrogen bond with the P5 mainchain carbonyl group in a more horizontal orientation (Fig. 3 B). The allelic differences of the DR residues 11 (L and V), 13 (F
|
| 102 |
+
and H), 26 (L and F), and 28 (E and D) are also in the vicinity of this peptide conformational difference.
|
| 103 |
+
|
| 104 |
+
In HA1.7/DR4/HA the HA bound to DR4 lacks one hydrogen bond between N2 of P5 Asn and the carbonyl oxygen of residue Thr97 of the TCR V chain, relative to HA1.7/DR1/HA (Fig. 3 B), but has a new hydrogen bond to O 1 of residue Gln70 of the DR4 1 --helix.
|
| 105 |
+
|
| 106 |
+
Differences in the Conformation of DR4 Bound to HA and Col Peptides. The conformation of the DR4 peptidebinding groove depends on the sequence of the bound peptide. The conformation and location of the polypeptide main chain of the MHC class II peptide-binding groove is very similar for the structures of DR1/HA (19), TCR HA1.7/DR1/HA (4), and the TCR HA1.7/DR4/HA presented here. The RMSD of the MHC peptide binding groove of these structures is 0.5 Å and the largest difference in the C- positions of the polypeptide mainchain is
|
| 107 |
+
-1 Å (RMSD: DR1/HA and TCR HA1.7/DR1/HA: 0.38 Å; DR1/HA and TCR HA1.7/DR4/HA: 0.46 Å; TCR HA1.7/DR1/HA and TCR HA1.7/DR4/HA: 0.29 Å; calculated using residue 5 to 80 of DR1A and 5 to 90 of DR1B). However, the peptide-binding groove of DR4 in the DR4/Col structure (35) is considerably narrower, due to movements of the 1 --helix near residues
|
| 108 |
+
|
| 109 |
+
## Discussion
|
| 110 |
+
|
| 111 |
+
Cross-Reactivity of the HA1.7 TCR with the HA Peptide Bound to DR4 and to DR1. The T cell line HA1.7 recognizes the HA306–318 antigen peptide from influenza A
|
| 112 |
+
presented by HLA-DR1 (DRA*0101, DRB1*0101) and is also cross-reactive with the HA peptide presented by HLA-DR4 (DRA*0101, DRB1*0401) and other DR4 alleles (Table II) (31, 32, 44). We recently solved the structure of the HA1.7-TCR/DR1/HA complex (4) and compare the structure of the same TCR in complex with DR4/HA here. The recognition of a peptide/MHC pair by a TCR usually depends on the sequence of the antigen peptide and the MHC molecule at those positions that are
|
| 113 |
+
|
| 114 |
+
$$100$$
|
| 115 |
+
$\mathbf{m}\mathbf{n}\mathbf{r}\mathbf{n}\mathbf{r}$
|
| 116 |
+
|
| 117 |
+

|
| 118 |
+
|
| 119 |
+
directly contacted by the TCR (34, 45–49). Data also suggest that the antigenic properties of the pMHC surface can be modulated by residues not in direct contact by the TCR (34, 49–55) (for a review, see reference 56). The conformation and antigenicity of the bound peptide is not only strongly influenced by MHC residues that form the peptide binding pockets, but also by the peptide anchors that point into these pockets. Even subtle changes in these anchors can interfere with the T cell response (51). We have seen here how MHC and peptide residues not involved in direct contact by the TCR alter the antigenic properties of a peptide/MHC surface by the mutual influence of the conformation of the bound peptide and the MHC molecule.
|
| 120 |
+
|
| 121 |
+
In the structures of both TCR HA1.7 bound to DR1/
|
| 122 |
+
HA and bound to DR4/HA, the TCR binds virtually identically to the pMHC surface and the low RMSD of the C- atoms (0.32 Å) indicates that the overall structures of both complexes are very similar. However, small structural differences occur locally around MHC residues that differ between the DRB1*0101 and DRB1*0401 alleles.
|
| 123 |
+
|
| 124 |
+
These residues are mainly located at the bottom of the
|
| 125 |
+
|
| 126 |
+

|
| 127 |
+
|
| 128 |
+

|
| 129 |
+
|
| 130 |
+
peptide binding groove or in the 1 --helix with the sidechain pointing into the peptide binding groove so that after binding of the HA peptide they are buried away from the TCR (Fig. 2 B). Despite the similarity at the pMHC surface, HA-specific T cell lines exist that are not cross-reactive for HA presented by DR1 and DR4 (Table II) (26, 34).
|
| 131 |
+
|
| 132 |
+
TCR Recognition of Small Structural Differences near P5 and P6, not Recognized by the HA1.7-TCR. Although the HA peptide binds in the same register to DR1 and DR4, the center and COOH-terminal half of the peptide binds deeper in the groove and closer to the 1 --helix of DR4.
|
| 133 |
+
|
| 134 |
+
These slight differences are caused by allelic differences in the -chain sequence, which are mostly located under peptide residues P5 to P9 (Fig. 3). Published T cell activity and
|
| 135 |
+
|
| 136 |
+
| Table II. | Activation of HA-specific T Cell Lines HA1.7a 3BC6.6b | KM1HA27b | |
|
| 137 |
+
|-------------|---------------------------------------------------------|------------|----|
|
| 138 |
+
| DR1 | | | |
|
| 139 |
+
| DR4 | | | |
|
| 140 |
+
| DR4 H13F | | | |
|
| 141 |
+
| DR4 K71R | | | |
|
| 142 |
+
| DR4 Q70R | | | |
|
| 143 |
+
|
| 144 |
+
aData from Eckels et al. (reference 31). bData from Fu et al. (reference 34).
|
| 145 |
+
|
| 146 |
+
mutagenesis data indicate that the differences in the sidechains of peptide residues P5 and P6, not recognized by the HA1.7-TCR, can be recognized by other TCR. (21, 34) (Fig. 3).
|
| 147 |
+
|
| 148 |
+
His13 is found in all DR4 alleles but is replaced by Phe in all DR1 alleles, resulting in a difference in the conformation of the P6 Thr sidechain (Fig. 3 A). TCR HA1.7 binds both DR4/HA and DR1/HA, tolerating this structural difference in the HA peptide, apparently because it does not make a contact to the P6 Thr sidechain. However, other TCRs are sensitive to this difference (34). 4/5 T cell lines examined by Fu and colleagues (34) were sensitive to changes around the P6 pocket. The HA-specific DR4-restricted TCRs, 3BC6.6, and KM1HA27 (34), are not cross-reactive with HA presented by DR1 (Table II).
|
| 149 |
+
|
| 150 |
+
In these two cases, mutation of His13 at the bottom of the P6 pocket of DR4 to Phe, typically found at this position in DR1, interferes with T cell activation (Table II, and reference 34). This substitution in DR4 probably disrupts the P6 Thr-His13 hydrogen bond and results in a P6 Thr conformation similar to that seen with DR1 (Fig. 3 A). Based on the two HA1.7-TCR/DR/HA structures, we suggest that the lack of cross-reactivity to DR1 and DR4 HA complexes of the 3BC6.6 and KM1HA27 TCRs is based, at least partly, on sensing the conformational difference in the conformation of the P6 Thr sidechain. Tolerance to changes in peptide conformation and peptide sequence at positions that are not contacted by the TCR have been described earlier for other TCR/peptide pairs (6).
|
| 151 |
+
|
| 152 |
+
The additional polymorphism of residue 11, which is located at the bottom of the P6 pocket and determines its depth, seems less likely to influence the conformation of the P6 Thr sidechain (Fig. 3 A). Residue 11 is Val in all DR4 alleles and Leu in DR1 alleles, so that the pocket is deeper in DR4. With a Leu at position 11, as in DR1, the pocket is still deep enough to accommodate a Thr sidechain pointing into the pocket as in DR4.
|
| 153 |
+
|
| 154 |
+
The orientation of the Thr sidechain facing into the P6 pocket of DR4 and the formation of an additional hydrogen bond with His13 that should stabilize peptide binding is supported by experiments with peptide display libraries.
|
| 155 |
+
|
| 156 |
+
These studies show that small sidechains with hydroxyl groups (Ser, Thr), i.e., those that are able to form a hydrogen bond with His13, are preferred at peptide position P6 for binding to DR4, whereas Ala and Gly are preferred for binding to DR1 (24). A Thr at position P6 seems to be the second most important peptide residue for peptide binding to DR4 after the large hydrophobic sidechain at peptide position P1, whereas the P6 position is of less importance for peptide binding to DR1 (23, 57, 58).
|
| 157 |
+
|
| 158 |
+
A conformational difference was also observed in peptide residue P5 Asn (Fig. 3 B). When bound to DR4 the sidechain of P5 Asn is tipped toward and closer to the 1 --helix. This difference is probably caused by the DR polymorphism at position 71. Residue 71 is a Lys in DR4 (DRB1*0401) and an Arg in DR1 (DRB1*0101) and in both cases forms a hydrogen bond with the mainchain carbonyl of P5 Asn. Since in DR4 the Lys sidechain is shorter it apparently "pulls" P5 Asn further into the peptide-binding groove and closer to the 1 --helix in order to form the hydrogen bond. Although this difference disrupts another hydrogen bond between the sidechain of P5 Asn and the TCR HA1.7 in the HA1.7-TCR/DR1/HA complex, the HA1.7-TCR is nevertheless cross-reactive, tolerating one less hydrogen bonded interaction. However, the conservative mutation of residue Lys 71 to Arg in DR4 (Table II) and the substitution seen in DR7 (Lys 71 to Arg) can interfere with the recognition by three out of five DR4- and DR7-restricted HA-specific T cell lines that were examined, (21, 34). With other peptide antigens, the effect of the substitution at position 71 of DR7 (Lys 71 to Arg) is less pronounced (55, 59). The two TCR that bind DR4/HA but not DR1/HA, 3BC6.6 and KM1HA27, both lose recognition of DR4 as the result of mutations in DR4 to DR1-like residues in the P5 pocket (Q70R or K71R)(Table II), suggesting that this small structural difference at P5 Asn is sensed by these TCR but not by the HA1.7-TCR.
|
| 159 |
+
|
| 160 |
+
The positively charged residue Lys/Arg at position 71 plus other residues in its vicinity, Leu67 - — Gln70 Lys/
|
| 161 |
+
Arg71, collectively described as the shared epitope, have been implicated in being responsible for the susceptibility to rheumatoid arthritis in patients that carry the DRB1*0101, DRB1*0401, or DRB1*0404 allele (references 60 and 61; for a review, see reference 62).
|
| 162 |
+
|
| 163 |
+
The promiscuous binding of an antigen peptide to many different MHC class II molecules an their recognition by cross-reactive and cross-restricted T cells is not unique to the HA system. The P2 peptide from tetanus toxin (TT) shows a similar promiscuous binding to many different DR molecules. P2 TT peptide-specific T cells are known that are cross-reactive (less specific) and can recognize P2 TT in the context of many different DR alleles, whereas others are more specific (cross-restricted)
|
| 164 |
+
and can recognize P2 TT only in the context of a particular MHC allele. This includes such T cells that can distinguish between P2 TT presented by DR1 and P2 TT presented by DR4 (59, 63), very similar to the case described above.
|
| 165 |
+
|
| 166 |
+
The Conformation of DR4 Depends on the Sequence of the Bound Antigenic Peptide. In addition to the modulation of the TCR recognition of the HA peptide MHC class II residues in the peptide binding groove, we also observed a conformational change in DR4 that depends on the sequence of the bound peptide. The peptide binding groove of DR4 presenting the collagen peptide (35) is up to 2 Å smaller compared with the groove of DR4 presenting the HA peptide and bound by the TCR HA1.7. It is unlikely that these conformational differences are caused by the binding of the HA1.7 TCR since no structural changes were observed in DR1 upon binding the HA1.7 TCR (4, 19). Instead it appears that the width of the peptide-binding groove is determined by the sequence of the bound peptide. The sidechains of the collagen peptide in the peptide binding pockets in the DR4/Col structure are considerably smaller compared with the sidechains of HA peptide
|
| 167 |
+
(P1: Met versus Tyr; P4: Asp versus Gln; P6: Ala versus Thr; P7: Ala versus Leu; P9: Gly versus Leu). The narrower peptide-binding groove in the DR4/Col structure can therefore be explained by a collapse of DR4 around those peptide binding pockets that are only partially occupied by peptide sidechains (35). The region of residue 62 to 70 which moves the most and the corresponding region in MHC class I molecules (148- to 155-) have been identified earlier as having a degree of conformational freedom (2, 64–68). These effects may also be important for attempts to optimize peptides in vaccines for tighter binding to the MHC
|
| 168 |
+
by changing anchor residues (69 and references cited therein), as those "optimized" peptide vaccines may have different conformations, and hence different antigenic properties when bound to the MHC molecule compared with the actual (original) antigen.
|
| 169 |
+
|
| 170 |
+
Subtle changes in the conformation or sequence of the pMHC molecule even in residues not directly contacted by the TCR can have a large effect on the biological response (34, 49–55, 66) (for a review, see reference 56). The fact that MHC residues that are buried deep in the binding groove can change the conformation of the bound peptide and thereby change the antigenicity of the pMHC surface may also be important in alloreactive T cell responses.
|
| 171 |
+
|
| 172 |
+
T cell alloreactivity, the major cause of organ transplant rejection and graft-versus-host disease, is the reaction of 1–10% of all T cells with nonself pMHC molecules against which they have not been previously negatively selected during development in the thymus (70). Mechanisms for the large T cell response in alloreactivity range from models where the TCR interaction is dominated by contacts with the allo-MHC to models where the TCRs interact mostly with the antigenic peptides (peptides that cannot be presented by self-MHCs but can be presented by the alloMHC) (references 71 and 72; for a review, see references 73 and 74). The observation of different bound peptide conformations resulting from residues of the MHC molecule that are out of reach for the TCR, might also be important in the alloreactive T cell response. T cells that have been negatively selected or are not reactive against selfpeptides presented by self-MHC molecules, may recognize those same peptides bound to an allo-MHC, where they could adopt different conformations, as seen in the HA peptide studied here. If the self- and allo-MHC molecule have identical residues on the part of the surface that is contacted by the TCR, so that contacts used during positive selection may be conserved, and differ mainly in residues buried in the peptide-binding groove, as in the case of DR1 and DR4, presented here, the opportunity for crossreactivity might be enhanced. This structural study of TCR cross-reactivity emphasizes that in addition to the peptide and MHC residues that are contacted by TCRs, the dependence of the conformation of the bound peptide and of the MHC molecule on peptide and MHC residues inaccessible to direct contact by the TCR plays an important role in determining T cell activation.
|
| 173 |
+
|
| 174 |
+
We thank K. Mahan and A. Haykov for excellent technical assistance, the staff at APS at Argonne National Laboratory beamline BIOCARS 14-BM-C for help with data collection, members of the Harrison/Wiley groups for assistance and discussion, R. Gaudet for reading the manuscript, Dr. D. Zaller (Merck) for the gifts of insect cell lines expressing both HLA-DR4 and DM, and Dr. W.C.
|
| 175 |
+
|
| 176 |
+
Stallings (Monsanto) for sharing unpublished data on a DR4/peptide complex.
|
| 177 |
+
|
| 178 |
+
The research was supported by the National Institutes of Health and the Howard Hughes Medical Institute (HHMI). J. Hennecke was supported by fellowships from the Schweizerischer Nationalfonds and the Deutsche Forschungsgemeinschaft. D.C.Wiley was an investigator of the HHMI. Submitted: 11 July 2001 Revised: 3 October 2001 Accepted: 31 October 2001
|
| 179 |
+
|
| 180 |
+
## References
|
| 181 |
+
|
| 182 |
+
1. Ding, Y.H., K.J. Smith, D.N. Garboczi, U. Utz, W.E. Biddison, and D.C. Wiley. 1998. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. *Immunity.* 8:403–
|
| 183 |
+
411.
|
| 184 |
+
|
| 185 |
+
2. Garboczi, D.N., P. Ghosh, U. Utz, Q.R. Fan, W.E. Biddison, and D.C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2.
|
| 186 |
+
|
| 187 |
+
Nature. 384:134–141.
|
| 188 |
+
|
| 189 |
+
3. Garcia, K.C., M. Degano, L.R. Pease, M. Huang, P.A.
|
| 190 |
+
|
| 191 |
+
Peterson, L. Teyton, and I.A. Wilson. 1998. Structural basis of plasticity in T cell receptor recognition of a self peptideMHC antigen. *Science.* 279:1166–1172.
|
| 192 |
+
|
| 193 |
+
4. Hennecke, J., A. Carfi, and D.C. Wiley. 2000. Structure of a covalently stabilized complex of a human - T-cell receptor, influenza HA peptide and MHC class II molecule, HLADR1. *EMBO J.* 19:5611–5624.
|
| 194 |
+
|
| 195 |
+
5. Reinherz, E.L., K. Tan, L. Tang, P. Kern, J. Liu, Y. Xiong, R.E. Hussey, A. Smolyar, B. Hare, R. Zhang, et al. 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. *Science.* 286:1913–1921.
|
| 196 |
+
|
| 197 |
+
6. Reiser, J.-B., C. Darnault, A. Guimezanes, C. Gregoire, T.
|
| 198 |
+
|
| 199 |
+
Mosser, A.-M. Schmitt-Verhulst, J.C. Fontecilla-Camps, B. Malissen, D. Housset, and G. Mazza. 2000. Crystal structure
|
| 200 |
+
578 Structure of TCR HA1.7 in Complex with HLA-DR4 and Influenza HA Peptide of a T cell receptor bound to an allogenic MHC molecule. Nat. Imm. 1:291–297.
|
| 201 |
+
|
| 202 |
+
7. Teng, M.K., A. Smolyar, A.G. Tse, J.H. Liu, J. Liu, R.E.
|
| 203 |
+
|
| 204 |
+
Hussey, S.G. Nathenson, H.C. Chang, E.L. Reinherz, and J.H. Wang. 1998. Identification of a common docking topology with substantial variation among different TCR-peptideMHC complexes. *Curr. Biol.* 8:409–412.
|
| 205 |
+
|
| 206 |
+
8. Garcia, K.C., L. Teyton, and I.A. Wilson. 1999. Structural basis of T cell recognition. *Annu. Rev. Immunol.* 17:369–397.
|
| 207 |
+
|
| 208 |
+
9. Hennecke, J., and D.C. Wiley. 2001. T cell receptor-MHC
|
| 209 |
+
interactions up close. *Cell.* 104:1–4.
|
| 210 |
+
|
| 211 |
+
10. Ding, Y.H., B.M. Baker, D.N. Garboczi, W.E. Biddison, and D.C. Wiley. 1999. Four A6-TCR/peptide/HLA-A2 structures that generate very different T cell signals are nearly identical. *Immunity.* 11:45–56.
|
| 212 |
+
|
| 213 |
+
11. Kalergis, A.M., N. Boucheron, M.A. Doucey, E. Palmieri, E.C. Goyarts, Z. Vegh, I.F. Luescher, and S.G. Nathenson.
|
| 214 |
+
|
| 215 |
+
2001. Efficient T cell activation requires an optimal dwelltime of interaction between the TCR and the pMHC complex. *Nat. Immunol.* 2:229–234.
|
| 216 |
+
|
| 217 |
+
12. Kersh, G.J., E.N. Kersh, D.H. Fremont, and P.M. Allen.
|
| 218 |
+
|
| 219 |
+
1998. High- and low-potency ligands with similar affinities for the TCR: the importance of kinetics in TCR signaling. Immunity. 9:817–826.
|
| 220 |
+
|
| 221 |
+
13. Davis, M.M., J.J. Boniface, Z. Reich, D. Lyons, J. Hampl, B.
|
| 222 |
+
|
| 223 |
+
Arden, and Y.H. Chien. 1998. Ligand recognition by -- T
|
| 224 |
+
cell receptors. *Annu. Rev. Immunol.* 16:523–544.
|
| 225 |
+
|
| 226 |
+
14. Lanzavecchia, A., G. Lezzi, and A. Viola. 1999. From TCR
|
| 227 |
+
engagement to T cell activation: a kinetic view of T cell behavior. *Cell.* 96:1–4.
|
| 228 |
+
|
| 229 |
+
15. Degano, M., K.C. Garcia, V. Apostolopoulos, M.G. Rudolph, L. Teyton, and I.A. Wilson. 2000. A functional hot spot for antigen recognition in a superagonist TCR/MHC complex. *Immunity.* 12:251–261.
|
| 230 |
+
|
| 231 |
+
16. Manning, T.C., C.J. Schlueter, T.C. Brodnicki, E.A. Parke, J.A. Speir, K.C. Garcia, L. Teyton, I.A. Wilson, and D.M.
|
| 232 |
+
|
| 233 |
+
Kranz. 1998. Alanine scanning mutagenesis of an - T cell receptor: mapping the energy of antigen recognition. *Immunity.* 8:413–425.
|
| 234 |
+
|
| 235 |
+
17. Lee, P.U., H.R. Churchill, M. Daniels, S.C. Jameson, and D.M. Kranz. 2000. Role of 2C T cell receptor residues in the binding of self- and allo-major histocompatibility complexes. J. Exp. Med. 191:1355–1364.
|
| 236 |
+
|
| 237 |
+
18. Baker, B.M., R.V. Turner, S.J. Gagnon, D.C. Wiley, and W.E. Biddison. 2001. Identification of a crucial energetic footprint on the -1 helix of human histocompatibility leukocyte antigen (HLA)-A2 that provides functional interactions for recognition by Tax peptide/HLA-A2-specific T cell receptors. *J. Exp. Med.* 193:551–562.
|
| 238 |
+
|
| 239 |
+
19. Stern, L.J., J.H. Brown, T.S. Jardetzky, J.C. Gorga, R.G. Urban, J.L. Strominger, and D.C. Wiley. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. *Nature.* 368:215–221.
|
| 240 |
+
|
| 241 |
+
20. O'Sullivan, D., T. Arrhenius, J. Sidney, M.-F. Del Guercio, M. Albertson, M. Wall, C. Oseroff, S. Southwood, S.M. Colon, F.C. Gaeta, and A. Sette. 1991. On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. *J. Immunol.* 147: 2663–2669.
|
| 242 |
+
|
| 243 |
+
21. Krieger, J.I., R.W. Karr, H.M. Grey, W.Y. Yu, D. O'Sullivan, L. Batovsky, Z.L. Zheng, S.M. Colon, F.C. Gaeta, J.
|
| 244 |
+
|
| 245 |
+
Sidney, M. Albertson, M.-F. Del Guerico, R.W. Chestnut, and A. Sette. 1991. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. *J. Immunol.* 146:2331–2340.
|
| 246 |
+
|
| 247 |
+
22. Jardetzky, T.S., J.C. Gorga, R. Busch, J. Rothbard, J.L.
|
| 248 |
+
|
| 249 |
+
Strominger, and D.C. Wiley. 1990. Peptide binding to HLADR1: a peptide with most residues substituted to alanine retains MHC binding. *EMBO J.* 9:1797–1803.
|
| 250 |
+
|
| 251 |
+
23. Sette, A., J. Sidney, C. Oseroff, M.F. del Guercio, S. Southwood, T. Arrhenius, M.F. Powell, S.M. Colon, F.C. Gaeta, and H.M. Grey. 1993. HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. *J. Immunol.* 151:3163–3170.
|
| 252 |
+
|
| 253 |
+
24. Hammer, J., P. Valsasnini, K. Tolba, D. Bolin, J. Higelin, B.
|
| 254 |
+
|
| 255 |
+
Takacs, and F. Sinigaglia. 1993. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. *Cell.* 74:197–
|
| 256 |
+
203.
|
| 257 |
+
|
| 258 |
+
25. Yassine-Diab, B., P. Carmichael, F.E. L'Faqihi, G. Lombardi, S. Deacock, C. de Preval, H. Coppin, and R.I. Lechler. 1999. Biased T-cell receptor usage is associated with allelic variation in the MHC class II peptide binding groove. *Immunogenetics.* 49:532–540.
|
| 259 |
+
|
| 260 |
+
26. Wedderburn, L.R., S.J.M. Searle, A.R. Rees, J.R. Lamb, and M.J. Owen. 1995. Mapping T cell recognition-the identification of a T cell receptor residue critical to the specific interaction with an influenza hemagglutinin peptide. *Eur. J. Immunol.* 25:1654–1662.
|
| 261 |
+
|
| 262 |
+
27. Ostrov, D., J. Krieger, J. Sidney, A. Sette, and P. Concannon. 1993. T cell receptor antagonism mediated by interaction between T cell receptor junctional residues and peptide antigen analogues. *J. Immunol.* 150:4277–4283.
|
| 263 |
+
|
| 264 |
+
28. De Magistris, M.T., J. Alexander, M. Coggeshall, A. Altman, F.C. Gaeta, H.M. Grey, and A. Sette. 1992. Antigen analogmajor histocompatibility complexes act as antagonists of the T cell receptor. *Cell.* 68:625–634.
|
| 265 |
+
|
| 266 |
+
29. Alexander, J., K. Snoke, J. Ruppert, J. Sidney, M. Wall, S.
|
| 267 |
+
|
| 268 |
+
Southwood, C. Oseroff, T. Arrhenius, F.C. Gaeta, S.M. Colon, et al. 1993. Functional consequences of engagement of the T cell receptor by low affinity ligands. *J. Immunol.* 150: 1–7.
|
| 269 |
+
|
| 270 |
+
30. Snoke, K., J. Alexander, A. Franco, L. Smith, J.V. Brawley, P. Concannon, H.M. Grey, A. Sette, and P. Wentworth. 1993. The inhibition of different T cell lines specific for the same antigen with TCR antagonist peptides. *J. Immunol.* 151: 6815–6821.
|
| 271 |
+
|
| 272 |
+
31. Eckels, D.D., T.W. Sell, S.R. Bronson, A.H. Johnson, R.J.
|
| 273 |
+
|
| 274 |
+
Hartzman, and J.R. Lamb. 1984. Human helper T-cell clones that recognize different influenza hemagglutinin determinants are restricted by different HLA-D region epitopes.
|
| 275 |
+
|
| 276 |
+
Immunogenetics. 19:409–423.
|
| 277 |
+
|
| 278 |
+
32. Lamb, J.R., D.D. Eckels, P. Lake, J.N. Woody, and N.
|
| 279 |
+
|
| 280 |
+
Green. 1982. Human T-cell clones recognize chemically synthesized peptides of influenza haemagglutinin. *Nature.* 300:
|
| 281 |
+
66–69.
|
| 282 |
+
|
| 283 |
+
33. Lamb, J.R., D.D. Eckels, M. Phelan, P. Lake, and J.N.
|
| 284 |
+
|
| 285 |
+
Woody. 1982. Antigen-specific human T lymphocyte clones: viral antigen specificity of influenza virus-immune clones. J. Immunol. 128:1428–1432.
|
| 286 |
+
|
| 287 |
+
34. Fu, X.T., C.P. Bono, S.L. Woulfe, C. Swearingen, N.L.
|
| 288 |
+
|
| 289 |
+
Summers, F. Sinigaglia, A. Sette, B.D. Schwartz, and R.W.
|
| 290 |
+
|
| 291 |
+
Karr. 1995. Pocket 4 of the HLA-DR(-, 1*0401) molecule is a major determinant of T cells recognition of peptide. J. Exp. Med. 181:915–926.
|
| 292 |
+
|
| 293 |
+
35. Dessen, A., C.M. Lawrence, S. Cupo, D.M. Zaller, and D.C. Wiley. 1997. X-ray crystal structure of HLA-DR4
|
| 294 |
+
(DRA*0101, DRB1*0401) complexed with a peptide from human collagen II. *Immunity.* 7:473–481.
|
| 295 |
+
|
| 296 |
+
36. Mosyak, L., D.M. Zaller, and D.C. Wiley. 1998. The structure of HLA-DM, the peptide exchange catalyst that loads antigen onto class II MHC molecules during antigen presentation. *Immunity.* 9:377–383.
|
| 297 |
+
|
| 298 |
+
37. Sloan, V.S., P. Cameron, G. Porter, M. Gammon, M.
|
| 299 |
+
|
| 300 |
+
Amaya, E. Mellins, and D.M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. *Nature.* 375:802–806.
|
| 301 |
+
|
| 302 |
+
38. Otwinowski, Z., and V. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. In Methods Enzymol. C.W. Carter and R.M. Sweet, editors. Academic Press, New York. 307–326.
|
| 303 |
+
|
| 304 |
+
39. Navaza, J., and P. Saludjian. 1997. AMoRe: and automated molecular replacement program package. *Methods Enzymol.* 276:581–594.
|
| 305 |
+
|
| 306 |
+
40. Brunger, A.T., P.D. Adams, G.M. Clore, W.L. Delano, P.
|
| 307 |
+
|
| 308 |
+
Gros, R.W. Grossekunstleve, J.S. Jiang, J. Kuszewski, M. Nilges, N.S. Pannu, et al. 1998. Crystallography and NMR
|
| 309 |
+
system-a new software suite for macromolecular structure determination. *Acta Crystallogr.* D54:905–921.
|
| 310 |
+
|
| 311 |
+
41. Read, R.J. 1986. Improved Fourier coefficients for maps using phases from partial structures with errors. *Acta Crystallogr.*
|
| 312 |
+
A42:140–149.
|
| 313 |
+
|
| 314 |
+
42. Jones, T.A., J.Y. Zou, S.W. Cowan, and M. Kjeldgaard.
|
| 315 |
+
|
| 316 |
+
1991. Improved methods for building protein models in electron density maos and the location of errors in these models.
|
| 317 |
+
|
| 318 |
+
Acta. Crystallogr. A47:110–119.
|
| 319 |
+
|
| 320 |
+
43. Brown, J.H., T.S. Jardetzky, J.C. Gorga, L.J. Stern, R.G. Urban, J.L. Strominger, and D.C. Wiley. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. *Nature.* 364:33–39.
|
| 321 |
+
|
| 322 |
+
44. Rothbard, J.B., R. Busch, V. Bal, J. Trowsdale, R.I. Lechler, and J.R. Lamb. 1989. Reversal of HLA restriction by a point mutation in an antigenic peptide. *Int. Immunol.* 1:487–495.
|
| 323 |
+
|
| 324 |
+
45. Jorgensen, J.L., U. Esser, B. Fazekas de St. Groth, P.A. Reay, and M.M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. *Nature.* 355:224-230.
|
| 325 |
+
|
| 326 |
+
46. Sant'Angelo, D.B., G. Waterbury, P. Preston-Hurlburt, S.T.
|
| 327 |
+
|
| 328 |
+
Yoon, R. Medzhitov, S.C. Hong, and C.A. Janeway, Jr.
|
| 329 |
+
|
| 330 |
+
1996. The specificity and orientation of a TCR to its peptide-MHC class II ligands. *Immunity.* 4:367–376.
|
| 331 |
+
|
| 332 |
+
47. Sun, R., S.E. Shepherd, S.S. Geier, C.T. Thomson, J.M.
|
| 333 |
+
|
| 334 |
+
Sheil, and S.G. Nathenson. 1995. Evidence that the antigen receptors of cytotoxic T lymphocytes interact with a common recognition pattern on the H-2Kb molecule. *Immunity.*
|
| 335 |
+
3:573–582.
|
| 336 |
+
|
| 337 |
+
48. Ehrich, E.W., B. Devaux, E.P. Rock, J.L. Jorgensen, M.M.
|
| 338 |
+
|
| 339 |
+
Davis, and Y.H. Chien. 1993. T cell receptor interaction with peptide/major histocompatibility complex (MHC) and superantigen/MHC ligands is dominated by antigen. *J. Exp.* Med. 178:713–722.
|
| 340 |
+
|
| 341 |
+
49. Fu, X.T., T. Saibara, R.W. Karr, and E. Celis. 1996. Substitutions in the HLA-DR - chain differentially affect DR7restricted T-cell recognition of rabies virus antigen. *Hum. Immunol.* 45:111–116.
|
| 342 |
+
|
| 343 |
+
50. Reid, S.W., S. McAdam, K.J. Smith, P. Klenerman, C.A.
|
| 344 |
+
|
| 345 |
+
O'Callaghan, K. Harlos, B.K. Jakobsen, A.J. McMichael, J.I. Bell, D.I. Stuart, and E.Y. Jones. 1996. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J. Exp. Med. 184:2279–2286.
|
| 346 |
+
|
| 347 |
+
51. Kersh, G.J., M.J. Miley, C.A. Nelson, A. Grakoui, S. Horvath, D.L. Donermeyer, J. Kappler, P.M. Allen, and D.H.
|
| 348 |
+
|
| 349 |
+
Fremont. 2001. Structural and functional consequences of altering a peptide MHC anchor residue. *J. Immunol.* 166:3345–
|
| 350 |
+
3354.
|
| 351 |
+
|
| 352 |
+
52. McMichael, A.J., F.M. Gotch, J. Santos-Aguado, and J.L.
|
| 353 |
+
|
| 354 |
+
Strominger. 1988. Effect of mutations and variations of HLA-A2 on recognition of a virus peptide epitope by cytotoxic T lymphocytes. *Proc. Natl. Acad. Sci. USA.* 85:9194–
|
| 355 |
+
9198.
|
| 356 |
+
|
| 357 |
+
53. Shimojo, N., R.W. Anderson, D.H. Mattson, R.V. Turner, J.E. Coligan, and W.E. Biddison. 1990. The kinetics of peptide binding to HLA-A2 and the conformation of the peptide-A2 complex can be determined by amino acid side chains on the floor of the peptide binding groove. *Int. Immunol.* 2:193–200.
|
| 358 |
+
|
| 359 |
+
54. Brett, S.J., K.B. Cease, C.S. Ouyang, and J.A. Berzofsky.
|
| 360 |
+
|
| 361 |
+
1989. Fine specificity of T cell recognition of the same peptide in association with different I-A molecules. *J. Immunol.*
|
| 362 |
+
143:771–779.
|
| 363 |
+
|
| 364 |
+
55. Karr, R.W., W. Yu, R. Watts, K.S. Evans, and E. Celis.
|
| 365 |
+
|
| 366 |
+
1990. The role of polymorphic HLA-DR chain residues in presentation of viral antigens to T cells. *J. Exp. Med.* 172: 273–283.
|
| 367 |
+
|
| 368 |
+
56. Jorgensen, J.L., P.A. Reay, E.W. Ehrich, and M.M. Davis.
|
| 369 |
+
|
| 370 |
+
1992. Molecular components of T-cell recognition. *Annu.* Rev. Immunol. 10:835–873.
|
| 371 |
+
|
| 372 |
+
57. Hammer, J., C. Belunis, D. Bolin, J. Papadopoulos, R. Walsky, J. Higelin, W. Danho, F. Sinigaglia, and Z.A. Nagy.
|
| 373 |
+
|
| 374 |
+
1994. High-affinity binding of short peptides to major histocompatibility complex class II molecules by anchor combinations. *Proc. Natl. Acad. Sci. USA.* 91:4456–4460.
|
| 375 |
+
|
| 376 |
+
58. Hammer, J., B. Takacs, and F. Sinigaglia. 1992. Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. *J. Exp. Med.* 176:1007–1013.
|
| 377 |
+
|
| 378 |
+
59. Karr, R.W., P. Panina-Bordignon, W.Y. Yu, and A. Lanzavecchia. 1991. Antigen-specific T cells with monogamous or promiscuous restriction patterns are sensitive to different HLA-DR chain substitutions. *J. Immunol.* 146:4242–4247.
|
| 379 |
+
|
| 380 |
+
60. Barber, L.D., V. Bal, J.R. Lamb, R.E. O'Hehir, J. Yendle, R.J. Hancock, and R.I. Lechler. 1991. Contribution of T-cell receptor-contacting and peptide-binding residues of the class II molecule HLA-DR4 Dw10 to serologic and antigen-specific T-cell recognition. *Hum. Immunol.* 32:110–118.
|
| 381 |
+
|
| 382 |
+
61. Hammer, J., F. Gallazzi, E. Bono, R.W. Karr, J. Guenot, P.
|
| 383 |
+
|
| 384 |
+
Valsasnini, Z.A. Nagy, and F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. *J. Exp. Med.* 181:1847– 1855.
|
| 385 |
+
|
| 386 |
+
62. Wucherpfennig, K.W., and J.L. Strominger. 1995. Selective binding of self peptides to disease-associated major histocompatibility complex (MHC) molecules: a mechanism for MHC-linked susceptibility to human autoimmune diseases. J. Exp. Med. 181:1597–1601.
|
| 387 |
+
|
| 388 |
+
63. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. *Eur. J.* Immunol. 19:2237–2242.
|
| 389 |
+
|
| 390 |
+
64. Madden, D.R., D.N. Garboczi, and D.C. Wiley. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. *Cell.* 75:693–708.
|
| 391 |
+
|
| 392 |
+
65. Fremont, D.H., W.A. Hendrickson, P. Marrack, and J. Kappler. 1996. Structures of an MHC class II molecule with covalently bound single peptides. *Science.* 272:1001–1004.
|
| 393 |
+
|
| 394 |
+
66. Rudolph, M.G., J.A. Speir, A. Brunmark, N. Mattsson, M.R. Jackson, P.A. Peterson, L. Teyton, and I.A. Wilson. 2001. The crystal structures of K(bm1) and K(bm8) Reveal that subtle changes in the peptide environment impact thermostability and alloreactivity. *Immunity.* 14:231–242.
|
| 395 |
+
|
| 396 |
+
67. Smith, K.J., S.W. Reid, D.I. Stuart, A.J. McMichael, E.Y.
|
| 397 |
+
|
| 398 |
+
Jones, and J.I. Bell. 1996. An altered position of the -2 helix of MHC class I is revealed by the crystal structure of HLAB*3501. *Immunity.* 4:203–213.
|
| 399 |
+
|
| 400 |
+
68. Fremont, D.H., M. Matsumura, E.A. Stura, P.A. Peterson, and I.A. Wilson. 1992. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. *Science.*
|
| 401 |
+
257:919–927.
|
| 402 |
+
|
| 403 |
+
69. Hagmann, M. 2000. Computers aid vaccine design. *Science.*
|
| 404 |
+
290:80–82.
|
| 405 |
+
|
| 406 |
+
70. Sherman, L.A., and S. Chattopadhyay. 1993. The molecular basis of allorecognition. *Annu. Rev. Immunol.* 11:385–402.
|
| 407 |
+
|
| 408 |
+
71. Elliott, T.J., and H.N. Eisen. 1990. Cytotoxic T lymphocytes recognize a reconstituted class I histocompatibility antigen (HLA-A2) as an allogeneic target molecule. Proc. Natl. Acad. Sci. USA. 87:5213–5217.
|
| 409 |
+
|
| 410 |
+
72. Smith, P.A., A. Brunmark, M.R. Jackson, and T.A. Potter.
|
| 411 |
+
|
| 412 |
+
1997. Peptide-independent recognition by alloreactive cytotoxic T lymphocytes (CTL). *J. Exp. Med.* 185:1023–1033.
|
| 413 |
+
|
| 414 |
+
73. Bevan, M.J. 1984. High determinant density may explain the phenomenon of alloreactivity. *Immunol. Today.* 161:767–775.
|
| 415 |
+
|
| 416 |
+
74. Kranz, D.M. 2000. Incompatible differences: view of an allogeneic pMHC-TCR complex. *Nat. Imm.* 1:277–278.
|
| 417 |
+
|
| 418 |
+
75. Kraulis, P.J. 1991. MOLSCRIPT-a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:946–950.
|
| 419 |
+
|
| 420 |
+
76. Nicholls, A., K.A. Sharp, and B. Honig. 1991. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. *Proteins.* 11:281–296.
|
| 421 |
+
|
| 422 |
+
77. Merritt, E.A., and M.E.P. Murphy. 1994. Raster3d version 2.0-a program for photorealistic molecular graphics. Acta. Crystallogr. D50:869–873.
|
medical/md/PMC4789817.md
ADDED
|
@@ -0,0 +1,387 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
▸ Additional material is published online only. To view please visit the journal online
|
| 2 |
+
(http://dx.doi.org/10.1136/jech2015-205652).
|
| 3 |
+
|
| 4 |
+
Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, Oxfordshire, UK Correspondence to Dr Abiyemi Benita Awoh, Nuffield Department of Medicine, Centre for Tropical Medicine and Global Health, Old Road Campus, University of Oxford, Oxford OX3 7BN, UK; awohbee@yahoo.co.uk Received 18 February 2015 Revised 6 July 2015 Accepted 4 August 2015 Published Online First 7 September 2015
|
| 5 |
+
|
| 6 |
+

|
| 7 |
+
|
| 8 |
+
To cite: Awoh AB,
|
| 9 |
+
|
| 10 |
+
 Plugge E. J Epidemiol Community Health 2016;70:305–311.
|
| 11 |
+
|
| 12 |
+
# Immunisation Coverage In Rural–Urban Migrant Children In Low And Middle-Income Countries (Lmics): A Systematic Review And Meta-Analysis
|
| 13 |
+
|
| 14 |
+
Abiyemi Benita Awoh, Emma Plugge
|
| 15 |
+
|
| 16 |
+
## Abstract
|
| 17 |
+
|
| 18 |
+
Background The majority of children who die from vaccine-preventable diseases (VPDs) live in low-income and-middle-income countries (LMICs). With the rapid urbanisation and rural–urban migration ongoing in LMICs, available research suggests that migration status might be a determinant of immunisation coverage in LMICs, with rural–urban migrant (RUM) children being less likely to be immunised. Objectives To examine and synthesise the data on immunisation coverage in RUM children in LMICs and to compare coverage in these children with non-migrant children. Methods A multiple database search of published and unpublished literature on immunisation coverage for the routine Expanded Programme on Immunisation (EPI) vaccines in RUM children aged 5 years and below was conducted. Following a staged exclusion process, studies that met the inclusion criteria were assessed for quality and data extracted for meta-analysis. Results Eleven studies from three countries (China, India and Nigeria) were included in the review. There was substantial statistical heterogeneity between the studies, thus no summary estimate was reported for the meta-analysis. Data synthesis from the studies showed that the proportion of fully immunised RUM children was lower than the WHO bench-mark of 90% at the national level. RUMs were also less likely to be fully immunised than the urban-non-migrants and general population. For the individual EPI vaccines, all but two studies showed lower immunisation coverage in RUMs compared with the general population using national coverage estimates.
|
| 19 |
+
|
| 20 |
+
Conclusions This review indicates that there is an association between rural–urban migration and immunisation coverage in LMICs with RUMs being less likely to be fully immunised than the urban non-migrants and the general population. Specific efforts to improve immunisation coverage in this subpopulation of urban residents will not only reduce morbidity and mortality from VPDs in migrants but will also reduce health inequity and the risk of infectious disease outbreaks in wider society.
|
| 21 |
+
|
| 22 |
+
## Introduction
|
| 23 |
+
|
| 24 |
+
Migrants are an expanding population of growing global health importance. There are approximately 750 million internal migrants (those who move within their country) and about 214 million international migrants (those who cross national borders)
|
| 25 |
+
worldwide.1 Population expansion in urban areas of low and middle-income countries (LMICs) has largely been driven by internal rural–urban Awoh AB, Plugge E. 2016;70:305–311. doi:10.1136/jech-2015-205652 305 migration.2 3 Between 1995 and 2005, the urban population in LMICs grew by an average of 1.2 million people weekly.4 China in 2010, documented over 221 million rural–urban migrants; a 117%
|
| 26 |
+
increase from the year 2000.5 Such speed of urban growth poses a challenge to the capacity of the health system in LMICs to meet the health needs of the growing urban population3 6 and rural–urban migration might be a determinant of immunisation coverage in LMICs7–11 with evidence of disparities in coverage within urban areas2 3 12 and between recent and long-term migrants. Increased population mobility coupled with low routine vaccine coverage of migrants has been an important factor in recent measles and polio outbreaks in LMICs.13 14 This has been attributed to the characteristics of urban areas (high density, living in close proximity) which provide an environment favourable for outbreaks and rapid spread of diseases.
|
| 27 |
+
|
| 28 |
+
The theories of migrant disruption and migrant adaptation have been used to explain the relationship between rural–urban migration and immunisation coverage.15 16 Migrant disruption proposes that migration disrupts the already established social support networks of migrant families bringing about social isolation and interfering with child immunisation uptake. Migrant adaptation proposes that the observed migrant-native differential can be ascribed to the failure of migrants to adjust to sociocultural norms or utilise health services in the receiving urban area and livelihood insecurity.15 17–19 This underscores the unintended negative effects of rural–urban migration.
|
| 29 |
+
|
| 30 |
+
Following the launching of the Expanded Programme on Immunisation (EPI) in 1974, global immunisation coverage rose from 5% to 84%
|
| 31 |
+
DTP3 coverage in 2013.20 Immunisation is the most cost-effective and successful public health investment for reducing morbidity and mortality in children, averting 2 to 3 million deaths yearly world-wide21 22 and preventing illness, disability from vaccine preventable diseases (VPDs). Despite this, 22.6 million children are still not reached by routine immunisation services.23 WHO uses DTP3 or OPV3 and Measles vaccine coverage as indicators for health system performance and tracking progress towards Millennium Development Goal
|
| 32 |
+
(MDG) 4—to reduce the 1990 mortality rate among children under-5 years old by two-thirds,24 25 respectively.
|
| 33 |
+
|
| 34 |
+
While immunisation is the most cost-effective way to reduce morbidity and mortality in children, there is evidence to suggest that migrant children
|
| 35 |
+
|
| 36 |
+
| Table 1 | Search strategy in MEDLINE | |
|
| 37 |
+
|---------------|------------------------------------------------------------------------|----------------|
|
| 38 |
+
| Search ID | Search terms and filters | Number of hits |
|
| 39 |
+
| #1 | Child terms Filters: Infant (Birth to 23 months) Preschool (2–5 years) | 1 270 466 |
|
| 40 |
+
| #2 | Migration terms | 36 639 |
|
| 41 |
+
| Filter: Human | | |
|
| 42 |
+
| #3 | Immunisation terms | 257 701 |
|
| 43 |
+
| Filter: Human | | |
|
| 44 |
+
| #4 | #1 AND #2 AND #3 | 478 |
|
| 45 |
+
|
| 46 |
+
are less likely to be immunised. However, to date there has been no systematic examination of the data on immunisation coverage in migrant children. The main objectives of this review therefore are to examine immunisation coverage in rural-to-urban migrant (RUM) children and to compare coverage in these children with non-migrant children.
|
| 47 |
+
|
| 48 |
+
## Methods Search For Studies
|
| 49 |
+
|
| 50 |
+
We registered the protocol on PROSPERO and followed PRISMA guidelines. A systematic search for relevant studies was designed and conducted by the authors in consultation with an information specialist. The following databases were searched from inception to 17 May 2014: MEDLINE, EMBASE (1974 to 17 May 2014), Cumulative Index to Nursing and Allied Health Literature, global health library, global health and ProQuest.
|
| 51 |
+
|
| 52 |
+
The search employed a combination of free text, thesaurus terms and MeSH terms in different variations, with explosion of narrow terms to increase the yield of the search (see online supplementary appendix S1 for a full list of search terms). The reference lists of identified studies and papers citing selected articles were also carefully examined for relevant studies. A search for grey literature was also undertaken through the ProQuest database and organisational websites such as WHO.
|
| 53 |
+
|
| 54 |
+
Five authors were contacted for possible clarification of certain items in their studies. No language or time limit was applied and studies were translated if necessary (table 1) .
|
| 55 |
+
|
| 56 |
+
## Inclusion And Exclusion Criteria
|
| 57 |
+
|
| 58 |
+
The inclusion and exclusion criteria are shown in table 2. Included studies were limited to those conducted in LMICs as defined by the World Bank26 and those reporting coverage for routine EPI vaccines.
|
| 59 |
+
|
| 60 |
+
## Extraction And Classification Of Data
|
| 61 |
+
|
| 62 |
+
Data was extracted by the two authors independently. Author names, study date, title, participants, size, outcome, confounders controlled for and findings were extracted. Data was collected on immunisation coverage for individual vaccines. We used WHO definition of full vaccination: a child is considered fully vaccinated when the 'standard six' vaccines—BCG,
|
| 63 |
+
diphtheria-tetanus-pertussis (DTP) (3 doses), polio (3 doses) and measles vaccines are received before reaching 1 year of age. In countries at risk for yellow-fever, hepatitis B, Haemophilus influenzae type b (Hib); these may be added.27 Additional information was requested from authors if data was not reported in a suitable format for data synthesis.
|
| 64 |
+
|
| 65 |
+
## Quality Assessment Of Included Studies
|
| 66 |
+
|
| 67 |
+
The Newcastle-Ottawa Scale (NOS) adapted for cross-sectional studies was used for this review as all the studies that met the inclusion criteria had cross-sectional design. A study can score a maximum of 10.
|
| 68 |
+
|
| 69 |
+
To determine the quality of studies, the selection of study participants, clear definition of migrant status, power calculation, response rates, control for bias and confounding, outcome assessment, study participants' representativeness of the rural–
|
| 70 |
+
urban migrant community and appropriateness of statistical tests were considered.
|
| 71 |
+
|
| 72 |
+
Studies were not excluded from the review on the basis of quality.
|
| 73 |
+
|
| 74 |
+
## Statistical Analysis
|
| 75 |
+
|
| 76 |
+
The proportion of fully immunised RUM and urban nonmigrant (UNM) children and the CIs were calculated using the Wilson's 28 procedure without continuity correction. The effect size (in this case the proportion of fully immunised RUM) and CIs derived for all studies were entered into Stata IC 13(64 bit) for a random-effects meta-analysis.
|
| 77 |
+
|
| 78 |
+
| Table 2 | Inclusion and exclusion criteria Inclusion | Exclusion | |
|
| 79 |
+
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
|
| 80 |
+
| Participants | ▸ | History of Rural-to-Urban migration within low-and-middle-income country (LMIC) | ▸ Non-migrants (rural and urban), rural–rural |
|
| 81 |
+
| ▸ | Children under the age of 5 years | migrants | |
|
| 82 |
+
| ▸ Studies in which migrants' origin is not rural (eg, urban–rural, urban–urban migrants) ▸ Studies with no mention of migration status or the migration status is unclear | | | |
|
| 83 |
+
| Outcome | ▸ | Quantitative coverage of any/all of the WHO recommended routine vaccines under the original Expanded Programme on Immunisation (EPI). These are: BCG, diphtheria-tetanus-pertussis, oral polio, measles and recently added hepatitis B and Haemophilus influenzae type B vaccines. As well vaccines relevant to country-specific EPI schedule. | |
|
| 84 |
+
| ▸ | Immunisation status assessed objectively using child's immunisation records or health facility data and maternal/care-giver recall | ▸ Quantitative coverage of non-routine EPI vaccines ▸ Supplementary immunisation activities (SIAs) and campaigns ▸ Studies assessing Immunity to VPDs | |
|
| 85 |
+
| Other | ▸ | Observational studies | |
|
| 86 |
+
| ▸ | Any publication date | | |
|
| 87 |
+
| ▸ | Any language | | |
|
| 88 |
+
| ▸ | Published and unpublished data | ▸ Qualitative studies ▸ Policy papers without original data | |
|
| 89 |
+
| VPDs, vaccine-preventable diseases. | | | |
|
| 90 |
+
| 306 | Awoh AB, Plugge E. J Epidemiol Community Health 2016;70:305–311. doi:10.1136/jech-2015-205652 | | |
|
| 91 |
+
|
| 92 |
+
Data for the general population was extracted from the demographic health surveys (DHS) for Nigeria,29 India30 and National Health Services Survey (NHSS) for China31 32 matching in date as closely as possible. Coverage data for individual vaccines were compared with the WHO 90% coverage benchmark for each vaccine. Comparison of coverage between RUM
|
| 93 |
+
and UNM/general population were made by meta-analysing the raw data using Stata and the results presented as risk ratios. As a result of the substantial heterogeneity (I2>75%), no overall effect size is reported and studies are presented narratively. Subgroup analysis was attempted as a means of investigating and explaining heterogeneity.
|
| 94 |
+
|
| 95 |
+
## Results
|
| 96 |
+
|
| 97 |
+
The search yielded a total of 1163 studies. Four additional studies were identified from other sources including one conference paper33 obtained from a non-database search and three studies from scanning of reference lists. These were included in the review. After removal of 282 duplicates, 885 abstracts were screened and 835 records were excluded. Fifty full-text articles were assessed for possible inclusion and 39 articles were excluded. A total of 11 studies were included in the review. The summary of the exclusion process is shown in figure 1.
|
| 98 |
+
|
| 99 |
+
A summary of the characteristics and findings of included studies is presented in online supplementary file 1.
|
| 100 |
+
|
| 101 |
+
The quality assessment scores of selected studies ranged from 3 to 10. See table 3.
|
| 102 |
+
|
| 103 |
+
## Description Of Included Studies
|
| 104 |
+
|
| 105 |
+
The 11 included studies2 15 18 33–40 were conducted between 2000 and 2014. Of these, one was from Nigeria15 and five each from China18 34 37 38 40 and India.2 33 35 36 39 All studies were cross-sectional design with varying sampling methods, three of which were based on WHO-advocated cluster sampling technique.41 Supplementary data was obtained for one study after correspondence with the author.33 The number of study participants ranged from 77 to 6029 with a total of 18 912 participants across all studies and 9730 (51%) of these were RUMs.
|
| 106 |
+
|
| 107 |
+
Ten studies had data on full immunisation coverage in RUM,
|
| 108 |
+
four of these compared full immunisation coverage between RUM and the urban non-migrants. Six reported coverage levels for the following EPI vaccines: BCG, OPV, DTP, HBV, Measles
|
| 109 |
+
|
| 110 |
+
 countries.
|
| 111 |
+
|
| 112 |
+
Awoh AB, Plugge E. 2016;70:305–311. doi:10.1136/jech-2015-205652 307
|
| 113 |
+
vaccines. One study assessed coverage for measles containing vaccine alone as its primary outcome.38 Kusuma et al35 and Hu et al18 further divided RUM into recent migrants and settled migrants this was used to assess whether length of stay in a new environment influences the association between rural–urban migration and immunisation coverage. All studies assessed the crude or up-to-date immunisation coverage (all doses were counted not just the valid doses)27 40 and two studies assessed the valid and/or age-appropriate immunisation34 40 in addition.
|
| 114 |
+
|
| 115 |
+
All studies were based on interviewer administered semistructured or structured questionaires. Immunisation coverage was assessed in included studies by using either 'Card plus history' 2 15 18 33 35–37 39 or 'Card only'.
|
| 116 |
+
|
| 117 |
+
34 38 40 Owing to considerable statistical heterogenity between the studies, I2 value of 99.8% from the random-effects meta-analysis of studies for the proportion of fully vaccinated RUM children, summary estimates are not presented.
|
| 118 |
+
|
| 119 |
+
## Proportion Of Fully Vaccinated Rum Children
|
| 120 |
+
|
| 121 |
+
Ten studies provided data on fully immunised RUM children2 15 18 33–37 39 40 and showed a low proportion of RUMs are fully vaccinated according to the EPI schedule. The proportion of fully vaccinated RUM children in each study was lower than the WHO target of 90% coverage at the national level.
|
| 122 |
+
|
| 123 |
+
## Full Vaccination By Migration Status
|
| 124 |
+
|
| 125 |
+
Overall, four studies2 15 33 39 reported comparison of full immunisation coverage between RUMs and urban non-migrants.
|
| 126 |
+
|
| 127 |
+
RUMs were significantly less likely to be fully immunised compared with urban non-migrants in all studies (see figure 2).
|
| 128 |
+
|
| 129 |
+
Antai also found that rural non-migrants were more likely to be immunised than RUMs (OR=1.43 in favour of rural nonmigrants after adjusting for demographic and socioeconomic variables). In Tamoghna's study, no RUM child was fully vaccinated.
|
| 130 |
+
|
| 131 |
+
Kusuma et al35 and Hu et al18 further assessed coverage by recent and settled migrant status. In both studies, settled migrants had higher odds of full immunisation than recent migrants with adjusted OR of 2.41 (95% CI 1.59 to 3.65)35 and 2.19 (1.55 to 5.38)18 respectively (figure 2).
|
| 132 |
+
|
| 133 |
+
Full vaccination in RUM children compared with the general population In all studies, RUM children were significantly less likely to be fully immunised than the general population.
|
| 134 |
+
|
| 135 |
+
## Coverage Estimates For Individual Vaccines
|
| 136 |
+
|
| 137 |
+
Five studies reported data on BCG coverage, six studies reported OPV, DPT, HBV coverage and seven on MCV. Each vaccine is compared with its national coverage estimate for the corresponding year of study (see table 4). WHO benchmark for national coverage for individual vaccines is 90%.
|
| 138 |
+
|
| 139 |
+
In all studies except Kusuma et al35 and Sun et al, 40 coverage estimates for individual vaccines was lower in RUM than the national coverage for the corresponding years.2 15 18 34 In the studies by Kusuma et al35 and Sun et al, 40 DTP3, OPV3, Measles coverage was higher in RUM than the NC.
|
| 140 |
+
|
| 141 |
+
Sun et al's 40 study recorded an estimate in RUM children equal to the national average for that year for HBV3. In Kusuma et al, 35 HBV3 and BCG coverage in RUM was higher than the national estimates.
|
| 142 |
+
|
| 143 |
+
## Discussion
|
| 144 |
+
|
| 145 |
+
The results suggest that rural-to-urban migrants in China, India and Nigeria are less likely to be fully immunised than urban non-migrants and the general population. Within RUM populations, recent migrants had even lower coverage than the settled migrants. The coverage rates for individual vaccines were found to be lower in RUM populations than the national immunisation coverage estimates for each vaccine in all but two studies;35 40 furthermore all coverage estimates for RUM children are below the WHO benchmark of 90% coverage for each vaccine.
|
| 146 |
+
|
| 147 |
+
These findings are consistent with findings from other studies7–9 42–49 including studies by Islam and Azad,46 Chan et al7 and Mathew,49 in Bangladesh, Cambodia and India, respectively, which found associations between RUM status and low childhood immunisation coverage.
|
| 148 |
+
|
| 149 |
+
The lower immunisation rate in recent migrants compared to settled migrants concords with Islam and Azad's 46 study and gives credence to the theory of migrant adaptation as settled migrants have adapted to the culture, norms and living conditions and so utilisation of health services may be better than the
|
| 150 |
+
|
| 151 |
+
| Table 3 | Quality assessment of included studies using the Newcastle-Ottawa Scale adapted for cross-sectional studies Selection Comparability Outcome Clear definition of migration status Comparable participants; control for potential confounders Objective only and/or subjective | Appropriate | | | | | | |
|
| 152 |
+
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|-----|-----|-----|-----|----|----|
|
| 153 |
+
| assessment | statistical test | Total | | | | | | |
|
| 154 |
+
| Sample size calculation reported | Participants representative of | Non-respondents | | | | | | |
|
| 155 |
+
| RUM group | documented | | | | | | | |
|
| 156 |
+
| First author, year Anand, 2014 | X | X | X | X | 4 | | | |
|
| 157 |
+
| Antai, 2010 | X | X X | X | X | X | x | 7 | |
|
| 158 |
+
| Chhabra, 2007 | X | X X | X | X | x | 6 | | |
|
| 159 |
+
| Guo, 2000 | X | X X | X | 4 | | | | |
|
| 160 |
+
| Han, 2014 | X | X | X | X | X X | x | 7 | |
|
| 161 |
+
| Hu, 2013 | X | X | X X | X | X | X | x | 8 |
|
| 162 |
+
| Huang, 2011 | X | X X | 3 | | | | | |
|
| 163 |
+
| Keshri, 2013 | X | X X | X | X | X | x | 7 | |
|
| 164 |
+
| Kusuma, 2010 | X | X | X X | X | X | X | x | 8 |
|
| 165 |
+
| Sun, 2005 | X | X | X X | X X | X | X X | x | 10 |
|
| 166 |
+
| Tamoghna, 2011 | X | X | X | 3 | | | | |
|
| 167 |
+
| Based on an adapted form of the Newcastle-Ottawa scale for cohort studies adapted by Herzog et al for cross-sectional studies http://www.biomedcentral.com/1471–2458/13/154. RUM, rural–urban migrants. | | | | | | | | |
|
| 168 |
+
| 308 | Awoh AB, Plugge E. J Epidemiol Community Health 2016;70:305–311. doi:10.1136/jech-2015-205652 | | | | | | | |
|
| 169 |
+
|
| 170 |
+

|
| 171 |
+
|
| 172 |
+

|
| 173 |
+
|
| 174 |
+

|
| 175 |
+
|
| 176 |
+

|
| 177 |
+
|
| 178 |
+

|
| 179 |
+
|
| 180 |
+

|
| 181 |
+
|
| 182 |
+
recent migrants who are more vulnerable and without social networks. Poorer adaptation also explains lower immunisation coverage in RUM children compared to urban non-migrants and it is significant that regardless of their duration of stay, RUMs do not attain living standards and levels of access to health services equal to that of the urban native population.35 46 The finding of higher immunisation coverage in rural non-migrants documented by Antai could be attributed to the contribution of outreach teams via supplementary immunisation activities and campaigns10 44 50 and better community mobilisation and participation in rural areas.
|
| 183 |
+
|
| 184 |
+
The three countries (India, China and Nigeria) represented in this review have been listed by WHO as countries with very low immunisation coverage23 25 and like other LMICs they have high rates of internal migration. DTP3 and measles coverage rates are indicators of immunisation service delivery and progress towards achieving the MDG4-reducing child mortality, respectively. DTP3, measles, BCG, OPV3 and HBV3 estimates in RUM children were lower than national estimates showing the disparities and inequity in vaccination within the countries that would otherwise remain concealed in national averages alone. This underscores the need for reporting of spatially and socially disaggregated data in order to reveal health inequities which may not be readily apparent.
|
| 185 |
+
|
| 186 |
+
These results have important public health implications for
|
| 187 |
+
|
| 188 |
+

|
| 189 |
+
|
| 190 |
+

|
| 191 |
+
|
| 192 |
+
the eradication of VPDs such as polio and measles. Nigeria for instance, is still polio endemic and measles outbreaks in China have been related to RUM children having lower vaccination rates. According to the United Nation Research Institute for Social Development, RUM children have been at the forefront of China's measles epidemic.51 Targeting RUM children for vaccination should be prioritised in eradication efforts in these countries.
|
| 193 |
+
|
| 194 |
+
The coverage estimates by Kusuma et al35 and Sun et al, 40 though lower than the WHO target for the assessed vaccines (except BCG and OPV3), reported coverage estimates higher than other studies and also higher in RUM children than national averages. This might be explained by immunisation
|
| 195 |
+
'pocketing': these two studies may have been conducted in clusters of relatively higher coverage rates.
|
| 196 |
+
|
| 197 |
+
## Strengths And Limitations
|
| 198 |
+
|
| 199 |
+
This study involved a thorough, systematic search of multiple databases to retrieve all relevant studies without language or time restrictions and it is the first time, to our knowledge, that data on immunisation coverage on the rural–urban migrant children in LMICs has been synthesised. However, the data was only available from three LMICs—China, India and Nigeria and
|
| 200 |
+
|
| 201 |
+
| Table 4 | Summary table for individual vaccine coverage in RUM versus national coverage estimates Immunisation coverage (in per cent) DTP3 OPV3 MEASLES | HBV | BCG | | | | | | | |
|
| 202 |
+
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|----|-----|----|-----|----|-----|----|
|
| 203 |
+
| Study author, year, country | RUM | NC | RUM | NC | RUM | NC | RUM | NC | RUM | NC |
|
| 204 |
+
| Antai 2010, Nigeria | 12 | 54 | 27 | 54 | 21 | 56 | - | - | 30 | 62 |
|
| 205 |
+
| Kusuma 2010, India | 73 | 72 | 72 | 70 | 76 | 74 | 62 | 37 | 91 | 87 |
|
| 206 |
+
| Anand 2014, India | 33 | 72 | 35 | 70 | 30 | 74 | 32 | 67 | 78 | 87 |
|
| 207 |
+
| Sun 2005, China | 88 | 87 | 91 | 87 | 88 | 86 | 84 | 84 | - | - |
|
| 208 |
+
| Hu 2013, China | 53 | 99 | 53 | 99 | 46 | 99 | 55 | 99 | 33 | 99 |
|
| 209 |
+
| Han 2014, China | 74 | 99 | 75 | 99 | 72 | 99 | 72 | 99 | 76 | 99 |
|
| 210 |
+
| DTP3, diphtheria-tetanus-pertussis; OPV3, oral polio vaccine; HBV, hepatitis B vaccine; RUM, rural–urban migrants; NC, national coverage from WHO-UNICEF estimates for corresponding year http://apps.who.int/immunization_monitoring/globalsummary/timeseries/tswucoveragedtp3.html | | | | | | | | | | |
|
| 211 |
+
| Awoh AB, Plugge E. J Epidemiol Community Health 2016;70:305–311. doi:10.1136/jech-2015-205652 | 309 | | | | | | | | | |
|
| 212 |
+
|
| 213 |
+
although all large populous countries, the data from the majority of LMICs is missing. This lack of data from other LMICs is an important global health issue; as most migration occurs within LMICs, these countries host the majority of these vulnerable populations. The consequences of infectious disease outbreaks for these countries, often with fragile health systems, are likely to be considerable. This lack of data therefore not only raises issues of generalisability of the review's findings but more importantly, highlights an important gap in global health research.
|
| 214 |
+
|
| 215 |
+
There was also substantial heterogeneity between studies and though all studies were cross-sectional, they had a range of different sampling methods which may partly account for the observed heterogenity.
|
| 216 |
+
|
| 217 |
+
There is no universally accepted definition of an urban area hence the definitions used in the various studies varied from definitions based on administrative boundaries, population density and/or proportion of population engaged in nonagricultural occupations. Variations existed in the populations from which the samples were drawn. Hence, participants in some studies were not fully representative of the entire RUM population as they were drawn from RUMs in construction sites36 only or schools.37 The use of caregiver recall in the assessment of immunisation coverage in addition to vaccination card can introduce recall bias from the respondents. The use of data from national surveys can also be problematic and means that the risk ratios presented must be interpreted with caution. These national surveys are not designed or conducted in a uniform manner across all countries. Furthermore for some surveys, the year of conduct did not correspond to the same year as the individual studies. The DHS used for Nigeria was conducted in 2008 which was the closest possible for Antai's 2010 study. In India, the most recent UNICEF national coverage survey (2009) was used and for China the only available data for full immunisation coverage was from a 2003 NHSS.
|
| 218 |
+
|
| 219 |
+
Health inequities are an important aspect of migrant health and these findings demonstrate that low vaccination rates are a particular health disadvantage for RUM children. The findings indicate the need for appropriate surveillance and targeted efforts to improve vaccination rates tailored to the specific needs of this heterogeneous population. Evidence has shown improvement in immunisation of highly mobile populations by mass immunisation campaigns and outreach52 53 using communitybased approaches44 and these gains from mass campaigns can be sustained by strengthening health systems for routine immunisation.48 Policymakers should be aware that the provision of immunisation services to RUMs, whether in formal or informal settlements, has a wider beneficial impact on the overall health status of the entire urban population—not only for the RUMs.
|
| 220 |
+
|
| 221 |
+
Thus, the health of RUMs should be prioritised in urban health planning and policy processes.
|
| 222 |
+
|
| 223 |
+
Acknowledgements The authors are very grateful to ExxonMobil for a fully funded scholarship to Awoh Abiyemi Benita to study Global Health Science at the University of Oxford. This work is a product of the Master's degree. Many thanks to Nia Roberts and Paul McGale for their advice on the literature search and use of STATA for meta-analysis respectively. The authors are also grateful for the help of Sharon Xiaodan Cai and Wei Wang in translating the Chinese papers to English; and the following authors Tussnai K, Anand S, Prusty R and Chhabra P for their helpful correspondence. Contributors ABA designed the protocol for this systematic review and meta-analysis and conducted the database searches. ABA screened the abstracts of all the studies identified from the search for eligibility. The full texts of the relevant articles were read by ABA and EP independently for possible inclusion. Data was extracted from the included studies independently by ABA and EP as a means of double-checking. ABA carried out the meta-analysis. The writing of the manuscript was carried out by ABA and EP.
|
| 224 |
+
|
| 225 |
+
Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
|
| 226 |
+
|
| 227 |
+
Competing interests None declared. Provenance and peer review Not commissioned; externally peer reviewed. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/ licenses/by-nc/4.0/
|
| 228 |
+
310 Awoh AB, Plugge E. 2016;70:305–311. doi:10.1136/jech-2015-205652
|
| 229 |
+
|
| 230 |
+
## Conclusion
|
| 231 |
+
|
| 232 |
+
Migration is an issue of growing global health importance and the majority of migrants come from and remain in LMICs. These are the same countries where, despite the increase in the burden of non-communicable diseases, infectious diseases remain an important threat to health and where health systems are most challenged. This systematic review has shown that RUMs are less likely to be fully vaccinated than urban nonmigrants and the general population in Nigeria, China and India. This highlights the urgent need to address inadequacies in the effective delivery of vaccinations to RUMs in order to reduce the risks associated with the spread of communicable diseases in the whole population and to reduce the impact of the existing 'double-burden of disease which stretches the capacity of the health system of most LMICs. Failure to ensure adequate immunisation coverage in RUMs could have far-reaching adverse consequences. It will create clusters of undervaccinated children within populations which may affect herd immunity;34 impede efforts towards control and eradication of polio, measles and other VPDs; increase the vulnerability of the rest of the population to major disease outbreaks and potentially reverse the gains of decreasing child mortality so far achieved in these countries.
|
| 233 |
+
|
| 234 |
+
## What Is Already Known On This Subject
|
| 235 |
+
|
| 236 |
+
▸ Migration may be a determinant of immunisation uptake.
|
| 237 |
+
|
| 238 |
+
Some evidence suggests that rural–urban migration confers an advantage to migrants as better health services are available in urban areas.
|
| 239 |
+
|
| 240 |
+
▸ Very little is known about the role of rural–urban migration on childhood immunisation coverage as the focus has been on international migrants.
|
| 241 |
+
|
| 242 |
+
## What This Study Adds
|
| 243 |
+
|
| 244 |
+
This systematic review and meta-analysis of observational studies has shown that rural–urban migrant children are less likely to be fully immunised compared to their urban non-migrant counterparts and the general population. This has implications for vaccine-preventable disease control and eradication efforts and the risk of disease outbreaks in urban areas.
|
| 245 |
+
|
| 246 |
+
## References
|
| 247 |
+
|
| 248 |
+
1 World Health Organisation (WHO). Humanitarian Health Action: migrant health.
|
| 249 |
+
|
| 250 |
+
2014. http://www.who.int/hac/techguidance/health_of_migrants/en/ (accessed 3 May 2014).
|
| 251 |
+
|
| 252 |
+
2 Anand S, Verma P, Sinha U, et al. Evaluation of primary immunization coverage in migratory versus non-migratory labour population of urban area in Bhopal city. Pediatric Oncall 2014;11. http://www.pediatriconcall.com/Journal/Article/FullText. aspx?artid=841&type=J&tid=&imgid=&reportid=450&tbltype= (accessed 3 May 2014).
|
| 253 |
+
|
| 254 |
+
3 Montgomery MR. The health of urban populations in developing countries. In:
|
| 255 |
+
United Nations Department of Economic and Social Affairs Population Division, Population Distribution, Urbanisation, Internal Migration and Development: an international perspective. United Nations Publications, 2011:264–85. http://www.
|
| 256 |
+
|
| 257 |
+
un.org/esa/population/publications/PopDistribUrbanization/PopulationDistribution Urbanization.pdf 4 World Health Organisation. Urbanization and health. Bull World Health Organ 2010;88:245–6. http://www.who.int/bulletin/volumes/88/4/10–010410/en/
|
| 258 |
+
(accessed 5 May 2014).
|
| 259 |
+
|
| 260 |
+
5 Xiang-jiang Z. Analysis of population movement and distribution based on sixth census. Popul Econ 2011;6:24–7.
|
| 261 |
+
|
| 262 |
+
6 Alirol E, Getaz L, Stoll B, et al. Urbanisation and infectious diseases in a globalised world. Lancet Infect dis 2011;11:131–41.
|
| 263 |
+
|
| 264 |
+
7 Chan Soeung S, Grundy J, Duncan R, et al. From reaching every district to reaching every community: analysis and response to the challenge of equity in immunization in Cambodia. Health Policy Plan 2013;28:526–35.
|
| 265 |
+
|
| 266 |
+
8 Cutts FT, Diallo S, Zell ER, et al. Determinants of vaccination in an urban population in Conakry, Guinea. Int J Epidemiol 1991;20:1099–106.
|
| 267 |
+
|
| 268 |
+
9 Barreto TV, Rodrigues LC. Factors influencing childhood immunisation in an urban area of Brazil. J Epidemiol Commun Health 1992;46:357–61.
|
| 269 |
+
|
| 270 |
+
10 Cutts FT, Rodrigues LC, Colombo S, et al. Evaluation of factors influencing vaccine uptake in Mozambique. Int J Epidemiol 1989;18:427–33.
|
| 271 |
+
|
| 272 |
+
11 Swain BK, Mishra S. Immunization coverage among migrant tribal children in slums of Orissa. Indian Pediatr 2006;43:1011–13.
|
| 273 |
+
|
| 274 |
+
12 Godfrey R, Julien M. Urbanisation and health. Clin Med 2005;5:137–41.
|
| 275 |
+
|
| 276 |
+
13 Yaméogo KR, Perry RT, Yaméogo A, et al. Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002. Int J Epidemiol 2005;34:556–64.
|
| 277 |
+
|
| 278 |
+
14 Hansen P. Long march, bitter fruit: the public health impact of rural-to-urban migration in the People's Republic of China. Stan J East Asian Affairs 2001;1:75–85.
|
| 279 |
+
|
| 280 |
+
15 Antai D. Migration and child immunization in Nigeria: individual- and community-level contexts. BMC Public Health 2010;10:116. http://www.
|
| 281 |
+
|
| 282 |
+
biomedcentral.com/1471–2458/10/116 (accessed 3 May 2014).
|
| 283 |
+
|
| 284 |
+
16 Amankwaa AA, Bavon A, Nkansah PT. Rural-urban migration and its effects on infant and child mortality in Ghana. African Popul Stud 2003;18:1–26.
|
| 285 |
+
|
| 286 |
+
17 Tam L. Rural-to-urban migration in Bolivia and Peru: association with child mortality, breastfeeding cessation, maternal care, and contraception. Demographic and health survey. Macro International Demographic and Health Surveys, 1994.
|
| 287 |
+
|
| 288 |
+
18 Hu Y, Li Q, Chen E, et al. Determinants of childhood immunization uptake among socio-economically disadvantaged migrants in east China. Int J Environ Res Public Health 2013;10:2845–56. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734462/
|
| 289 |
+
(accessed 3 May 2014).
|
| 290 |
+
|
| 291 |
+
19 Oyo-Ita A, Nwachukwu CE, Oringanje C, et al. Interventions for improving coverage of child immunization in low- and middle-income countries. Cochrane Database Syst Rev 2011;(7):Cd008145.
|
| 292 |
+
|
| 293 |
+
20 World Health Organisation (WHO). Global immunization data. 2014. http://www.
|
| 294 |
+
|
| 295 |
+
who.int/immunization/monitoring_surveillance/global_immunization_data.pdf (accessed 3 May 2014).
|
| 296 |
+
|
| 297 |
+
21 World Health Organisation (WHO). Immunisation. 2014. http://www.who.int/topics/
|
| 298 |
+
immunization/en/ (accessed 3 May 2014).
|
| 299 |
+
|
| 300 |
+
22 Mavimbe J, Braa J, Bjune G. Assessing immunization data quality from routine reports in Mozambique. BMC Public Health 2005;5:108.
|
| 301 |
+
|
| 302 |
+
23 World Health Organisation. Immunisation coverage. 2014. http://www.who.int/
|
| 303 |
+
mediacentre/factsheets/fs378/en/ (accessed 30 Apr 2014).
|
| 304 |
+
|
| 305 |
+
24 World Health Organisation. MDG 4: reducing child mortality. 2013. http://www.
|
| 306 |
+
|
| 307 |
+
who.int/topics/millennium_development_goals/child_mortality/en/ (accessed 3 May 2014).
|
| 308 |
+
|
| 309 |
+
25 Burton A, Lautenbach B, Gacic-Dobo M, et al. WHO and UNICEF estimates of national infant immunization coverage: methods and processes. Bull World Health Organ 2009;87:535–41. http://www.who.int/bulletin/volumes/87/7/08–053819/en/
|
| 310 |
+
(accessed 12 May 2014).
|
| 311 |
+
|
| 312 |
+
26 The World Bank. New Country classification. 2014. http://data.worldbank.org/about/
|
| 313 |
+
country-and-lending-groups (accessed 23 Jun 2014).
|
| 314 |
+
|
| 315 |
+
27 World Health Organisation. Training for mid-level managers (MLM) Module 7: the EPI coverage survey. 2008. http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.07_ eng.pdf (accessed 12 May 2014).
|
| 316 |
+
|
| 317 |
+
28 Wilson EB. Probable inference, the law of succession and statistical inference. J Am Statist Assoc 1927;22:209–12.
|
| 318 |
+
|
| 319 |
+
29 National Population Commission (NPC) [Nigeria] and ICF Macro. Nigeria demographic and health survey 2008. Abuja, Nigeria: 2009. http://dhsprogram.com/ pubs/pdf/FR222/FR222.pdf (accessed 12 Jul 2014).
|
| 320 |
+
|
| 321 |
+
30 United Nations Children's Fund (UNICEF). 2009 Coverage Evaluation Survey.
|
| 322 |
+
|
| 323 |
+
Government of India, Ministry of Health & Family Welfare and UNICEF. 2009. http:// www.unicef.org/india/National_Fact_Sheet_CES_2009.pdf (accessed 12 Jul 2014).
|
| 324 |
+
|
| 325 |
+
31 Centre for Health statistics and Information Ministry of Health. An analysis report of national health services in 2003 (Beijing: the Peking Union Medical College Press 2004), cited in Liu Y, Rao K, Wu J, Gakidou E China's health system performance.
|
| 326 |
+
|
| 327 |
+
Lancet 2008;372:1914–23. (accessed 12 Jul 2014).
|
| 328 |
+
|
| 329 |
+
32 Jian W, Chan KY, Reidpath DD, et al. China's rural-urban care gap shrank for chronic disease patients, but inequities persist. Health Affairs 2010;29:
|
| 330 |
+
2189–96.
|
| 331 |
+
|
| 332 |
+
33 Keshri K, Prusty RJ. Migration and child health: exploring disparities in child nutrition and immunisation in urban India. Paper presented at: The XXVII
|
| 333 |
+
International Population Conference of International Union for the Scientific Study of Population; 26–31 August 2013; Busan, Korea. http://iussp.org/sites/default/files/
|
| 334 |
+
event_call_for_papers/Full%20paper.pdf (accessed 17 May 2014).
|
| 335 |
+
|
| 336 |
+
34 Han K, Zheng H, Huang Z, et al. Vaccination coverage and its determinants among migrant children in Guangdong, China. BMC Public Health 2014;14:203. http://
|
| 337 |
+
www.biomedcentral.com/1471–2458/14/203 (accessed 20 May 2014).
|
| 338 |
+
|
| 339 |
+
35 Kusuma YS, Kumari R, Pandav CS, et al. Migration and immunization: determinants of childhood immunization uptake among socioeconomically disadvantaged migrants in Delhi, India. Trop Med Int Health 2010;15:1326–32. http://www.ncbi.
|
| 340 |
+
|
| 341 |
+
nlm.nih.gov/pubmed/20955496 (accessed 17 May 2014).
|
| 342 |
+
|
| 343 |
+
36 Tamoghna B, Mandal PK, Samarendra B. Assessment of health, nutrition and immunisation status amongst under-5 children in migratory brick kiln population of periurban Kolkata, India. Sudanese J Public Health 2011;6:7–13. http://www.sjph.
|
| 344 |
+
|
| 345 |
+
net.sd/files/Vol6N1/Original%20Article1.pdf (accessed 17 May 2014).
|
| 346 |
+
|
| 347 |
+
37 Guo W, Feng Z, Diao L. Investigation of immunization status in children of floating population in Henan Province. Zhonghua yu fang yi xue za zhi [Chin J Prev Med]
|
| 348 |
+
2000;34:287–9. http://www.ncbi.nlm.nih.gov/pubmed/11372398 (accessed 20 May 2014).
|
| 349 |
+
|
| 350 |
+
38 Huang X, Liu L, Chen P, et al. Measles vaccination status and related factors among infants in Ouhai district in Wenzhou city, Zhejiang province. Disease Surveillance 2011;26:815–17. http://www.jbjc.org/EN/abstract/abstract7290.shtml (accessed 17 May 2014).
|
| 351 |
+
|
| 352 |
+
39 Chhabra P, Nair P, Gupta A, et al. Immunization in urbanized villages of Delhi.
|
| 353 |
+
|
| 354 |
+
Indian J Pediatr 2007;74:131–4. http://medind.nic.in/icb/t07/i2/icbt07i2p131.pdf
|
| 355 |
+
(accessed 17 May 2014).
|
| 356 |
+
|
| 357 |
+
40 Sun M, Ma R, Zeng Y, et al. Immunization status and risk factors of migrant children in densely populated areas of Beijing, China. Vaccine 2010;28:1264–74.
|
| 358 |
+
|
| 359 |
+
http://www.ncbi.nlm.nih.gov/pubmed/19941996 (accessed 18 May 2014)
|
| 360 |
+
41 Hoshaw-Woodard S. Description and comparison of the methods of cluster sampling and lot quality assurance sampling to assess immunization coverage. WHO Department of Vaccines and Biologicals, 2001. http://whqlibdoc.who.int/hq/ 2001/WHO_V&B_01.26.pdf [accessed 17 Jun 2014).
|
| 361 |
+
|
| 362 |
+
42 Qian L, Yu H, Yanpeng Z, et al. Using the immunization information system to determine vaccination coverage rates among children aged 1–7 years: a report from Zhejiang Province, China. Int J Environ Res Public Health 2014;11:2713–28.
|
| 363 |
+
|
| 364 |
+
43 Kantayaporn T, Archavanitkul K, Peerapatanapokin W, et al. Expanded program on immunization (EPI) for children of Myanmar migrants living in Bangkok, Thailand.
|
| 365 |
+
|
| 366 |
+
J Popul Soc Stud 2013;21:227–42.
|
| 367 |
+
|
| 368 |
+
44 Itimi K, Dienye P, Ordinioha B. Community participation and childhood immunization coverage: a comparative study of rural and urban communities of Bayelsa State, south-south Nigeria. Niger Med J 2012;53:21–5.
|
| 369 |
+
|
| 370 |
+
45 Canavati S, Plugge E, Suwanjatuporn S, et al. Barriers to immunization among children of migrant workers from Myanmar living in Tak province, Thailand. Bull World Health Organ 2011;89:528–31.
|
| 371 |
+
|
| 372 |
+
46 Islam MM, Azad KM. Rural-urban migration and child survival in urban Bangladesh:
|
| 373 |
+
are the urban migrants and poor disadvantaged? J Biosoc Sci 2008;40:83–96.
|
| 374 |
+
|
| 375 |
+
47 Atkinson SJ, Cheyne J. Immunisation in urban areas: issues and strategies. Bull World Health Organ 1994;72:183–94.
|
| 376 |
+
|
| 377 |
+
48 Cutts FT. Strategies to improve immunization services in urban Africa. Bull World Health Organ 1991;69:407–14.
|
| 378 |
+
|
| 379 |
+
49 Mathew JL. Inequity in childhood immunization in India: a systematic review. Indian Pediatr 2012;49:203–23.
|
| 380 |
+
|
| 381 |
+
50 Amin R, De Oliveira T, Da Cunhab M, et al. Factors limiting immunization coverage in urban Dili, Timor-Leste. Glob Health Sci Pract 2013;1:417–27.
|
| 382 |
+
|
| 383 |
+
51 Tucker JD, Hao C, Zou X, et al. The influence of migration on the burden of & response to infectious disease threats in China. A theoretically informed review. The United Nation Research Institute for social development (UNRISD). 2013–3:1–25.
|
| 384 |
+
|
| 385 |
+
52 Peng ZQ, Chen WS, He Q, et al. Evaluation of the mass measles vaccination campaign in Guangdong Province, China. Int J Infect Dis 2012;16:e99–103.
|
| 386 |
+
|
| 387 |
+
53 Dietz V, Cutts F. The use of mass campaigns in the expanded program on immunization: a review of reported advantages and disadvantages. Int J Health Serv 1997;27:767–90.
|
medical/md/PMC5038876.md
ADDED
|
@@ -0,0 +1,234 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# Hypersplenism: History And Current Status (Review)
|
| 2 |
+
|
| 3 |
+
YUNFU LV1,3, WAN YEE LAU1,2, YEJUAN LI1,3, JIE DENG3, XIAOYU HAN1, XIAOGUANG GONG1, NING LIU1 and HONGFEI WU1 1Department of General Surgery, Hainan Province People's Hospital, Haikou, Hainan 570311; 2Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR;
|
| 4 |
+
3Department of Molecular Biology, Hainan University, Haikou, Hainan 570228, P.R. China Received February 1, 2016; Accepted August 19, 2016 DOI: 10.3892/etm.2016.3683 Abstract. Hypersplenism is a common disorder characterized by an enlarged spleen which causes rapid and premature destruction of blood cells. This review summarizes the history of hypersplenism, discuss its classification and pathogenesis, and examines its diagnosis and treatment options. We performed a comprehensive literature search using PubMed, Web of Knowledge and the China National Knowledge Infrastructure (CNKI) database, reviewed hypersplenism-related articles and summarized the major findings. According to its etiological causes, hypersplenism is characterized by splenomegaly and peripheral cytopenias. It can be classified into three categories: i) primary hypersplenism; ii) secondary hypersplenism; and iii) occult hypersplenism. A number of mechanisms causing hypersplenism have been identified, and mainly involve retention in the spleen, phagocytosis, and autoimmunity. Treatment options for hypersplenism include etiological treatment, non-surgical treatment, total splenectomy and liver transplantation. In any case, treatment should be individualized for each patient.
|
| 5 |
+
|
| 6 |
+
## Contents
|
| 7 |
+
|
| 8 |
+
1. Introduction 2. History 3. Classification of hypersplenism 4. Pathogenesis of hypersplenism 5. Treatment options 6. Conclusion
|
| 9 |
+
Correspondence to: Dr Wan Yee Lau, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, SAR, P.R. China E-mail: josephlau@cuhk.edu.hk Key words: hypersplenism, splenomegaly, classification, historical review, pathogenesis, splenectomy
|
| 10 |
+
|
| 11 |
+
## 1. Introduction
|
| 12 |
+
|
| 13 |
+
Hypersplenism refers to a group of syndromes that involve splenomegaly and peripheral cytopenia of various causes. Hypersplenism can be caused by many diseases which, in turn, affects the prognosis of hypersplenism. Thrombocytopenia may exacerbate liver fibrosis (1,2) and a severe decrease in platelet counts is a major risk factor of hypersplenism (3). Not surprisingly, the more severe the hypersplenism is, the worse is the prognosis (4). Current knowledge regarding hypersplenism is not sufficient, and relatively few studies have been reported. We herein performed a comprehensive literature search on PubMed, Web of Knowledge and the China National Knowledge Infrastructure (CNKI) database, and reviewed 60 hypersplenism-related articles published between 1954 and 2015. Major information and findings in this area were summarized.
|
| 14 |
+
|
| 15 |
+
## 2. History
|
| 16 |
+
|
| 17 |
+
The term 'hypersplenism' first appeared in the thesis of Anatole Chauffard in 1907 (5), and subsequently in the study of Morawitz and Denecked (6).
|
| 18 |
+
|
| 19 |
+
In 1955, Dameshek (7) summarized that hypersplenism should be diagnosed in the presence of four conditions: i) monolineage or mutilineage peripheral cytopenias; ii) compensatory hyperplasia of bone marrow; iii) splenomegaly; and iv) correction of cytopenias after splenectomy. Although these four conditions do not always apply to all cases, they have been commonly cited in the literature, and are important in the diagnosis of hypersplenism.
|
| 20 |
+
|
| 21 |
+
## 3. Classification Of Hypersplenism
|
| 22 |
+
|
| 23 |
+
Hypersplenism can be classified into three categories by its etiological causes as follows. Primary hypersplenism. The cause is not clear. Examples are primary splenic hyperplasia, non-tropical idiopathic splenomegaly, primary splenic granulocytopenia, primary splenic pancytopenia, and splenic anemia or thrombocytopenia. Secondary hypersplenism. The cause is clear. Examples include i) infections such as viral hepatitis, brucellosis, subacute or chronic diseases (7), infectious mononucleosis syndrome and malaria; ii) alcohol use such as long-term or excessive drinking; iii) portal hypertension (PH), such as liver cirrhosis of various causes including post-hepatitic cirrhosis, alcoholic cirrhosis, and biliary cirrhosis, fatty liver cirrhosis, post-hepatitic autoimmune cirrhosis, schistosomiasis-induced cirrhosis, and drug-induced cirrhosis, as well as hemosiderosis and portal vein thrombosis; iv) granulomatous inflammation such as systemic lupus erythematosus, rheumatoid arthritis, chronic syphilis, chronic tuberculosis, Felty's syndrome, and sarcoidosis; v) malignancies such as splenic lymphosarcoma, leukemia, and cancer metastasis; vi) chronic hemolytic diseases such as hereditary spherocytosis, autoimmune hemolytic anemia, and thalassemia; vii) lipidosis such as Gaucher's disease, and Niemann-Pick disease; viii) myeloproliferative disorders such as polycythemia vera, chronic myeloid leukemia, and myelofibrosis; and ix) other diseases such as hemophagocytic syndrome (HPS), relatively benign hamartoma, splenic cyst, splenic artery aneurysm, and cavernous hemangioma. The most common hypersplenism is secondary to post-viral hepatitis cirrhotic PH.
|
| 24 |
+
|
| 25 |
+
Occult hypersplenism. In both primary and secondary hypersplenism, if the underlying disease is not serious, together with benign bone marrow hyperplasia and sufficient bone marrow compensation, peripheral cytopenias may not occur. In this case, hypersplenism becomes occult with no symptoms. However, once the bone marrow hematopoietic function is suppressed by factors such as infection or drugs, monolineage or mutilineage peripheral cytopenia occurs, accompanied by clinical symp-toms, which is not classified as occult hypersplenism.
|
| 26 |
+
|
| 27 |
+
## 4. Pathogenesis Of Hypersplenism
|
| 28 |
+
|
| 29 |
+
Although the exact pathogenesis of hypersplenism-induced peripheral cytopenias is still inconclusive, several mechanisms have been identified (8). Retention in the spleen. In patients with PH, the spleen can increase 8-10 times its normal size (9). Splenic blood volume increases due to the increased venous pressure leading to congestive splenomegaly, or because of the increased splenic arterial blood flow induced by a variety of diseases, resulting in hyperemic splenomegaly. As a consequence, there is retention of a large number of leukocytes, erythrocytes and platelets in the spleen. The number of retained blood cells can be 5.5-20 times higher than the normal level, thus facilitating capture, phagocytosis or destruction of blood cells by phagocytes resulting in peripheral cytopenias.
|
| 30 |
+
|
| 31 |
+
In 1965, Aster (10) found by using 51Cr-labeled platelets that under normal circumstances, approximately one-third of platelets are stored in the spleen, and the remaining two-thirds in the blood circulation. In hypersplenism, 50-90% of platelets are retained in the enlarged spleen resulting in a reduction of platelets in the circulating blood. Furthermore, Aster demonstrated that the distribution of platelets returned to normal after splenectomy, which eliminated the retention of platelets by the splenic blood pool (8). The Wiskott-Aldrich syndrome protein (WASP) is an essential cytoskeleton regulator found in the cells of the hematopoietic lineage that control the motility of leukocytes. The impact of WASP gene deficiency on mobilization of hematopoietic progenitor/stem cells in circulation remains unknown, but previous research has indicated a correlation in the context of autologous gene therapy of Wiskott-Aldrich syndrome. In one study using a murine WASP-knockout model, Charrier et al found the occurrence of B-cell lymphopenia, marked neutrophilia, increased counts of circulating hematopoietic progenitor cells, and splenomegaly in WASP-knockout mice in the steady state, all of which were presumably caused by retention of hematopoietic progenitor cells due to high levels of splenic CXCL12 (11). Phagocytosis. Phagocytes are categorized as mononuclear phagocytes (including macrophages, monocytes, and imma-ture monocytes), and neutrophils. Macrophages (MΦs) have a strong ability for immune phagocytosis, and are the major form of phagocytes in the spleen.
|
| 32 |
+
|
| 33 |
+
Enhanced MΦ phagocytosis. Li et al suggested that in patients with PH, MΦs are overactivated with significantly increased phagocytosis, cytokine secretion, antigen processing and presentation (12). Excessive activation of MΦs is an important cause of hypersplenism. Significantly increased counts of MΦs in the spleen and their enhanced phagocytosis have been reported in patients with PH (13). The number of erythrocytes and platelets phagocytosed was also significantly increased.
|
| 34 |
+
|
| 35 |
+
These findings indicated that MΦs are involved in hypersplenism.
|
| 36 |
+
|
| 37 |
+
In the measurement of splenic size by ultrasonography and radionuclide studies, Shah et al (9) demonstrated that splenic phagocytic activity in cirrhosis increased as the spleen enlarged, which contributed to anemia and leukopenia.
|
| 38 |
+
|
| 39 |
+
Jiang et al (14) found a high expression of miR-615-3p in splenic MΦs in hypersplenism by microarray, and demonstrated its role in enhancing the phagocytic capacity of splenic MΦs. Significantly increased mRNA expression levels of toll‑like receptors 2 and 4 in splenic MΦs were detected in patients with hypersplenism due to PH, consistent with the protein levels measured by immunohistochemistry. This finding further supports the possible mechanism of 'endotoxemia → activation of toll‑like receptor of splenic MΦs → increased destruction of blood cells by macrophages' in hypersplenism due to PH. Cytopenia in hypersplenism may be caused by other factors in addition to excessive destruction of blood cells by MΦs.
|
| 40 |
+
|
| 41 |
+
Upregulation of cytokines. Cytokines are proteins or smallmolecule peptides secreted mainly by immune cells that can regulate cell functions and are involved in inflammation, immune responses, and wound healing.
|
| 42 |
+
|
| 43 |
+
In comparing the spleen in hypersplenism due to PH with a normal spleen, Ma et al (15) found 26 differentially expressed cytokines, 21 of which were significantly upregulated in hypersplenism, including cytokines related to monocyte chemotaxis and MΦ activation, such as macrophage colony‑stimulating factor (M-CSF), tumor necrosis factor (TNF)-β, interferon (IFN)-γ, interleukin (IL)-10, MDC/CCL22, MCP-2/CCL8, and SDF-1/CXCL12. Moreover, M-CSF, TNF-β, and IFN-γ promoted transformation of blood monocytes to MΦs and maintained activation of MΦs (16). IL-10 is mainly produced by macrophages, and plays a role in inhibiting inflammation and activating MΦs (17). MDC is mainly produced by macrophages and monocyte-derived dendritic cells and is a chemokine indicating enhanced phagocytic capacity of MΦs (18,19). In hypersplenism due to PH, significant upregulation of the above cytokines may lead to activation and enhanced phagocytosis of MΦs and other immune cells in the splenic tissues, which eventually results in hypersplenism. Five cytokines have been demonstrated to be significantly downregulated during hypersplenism, including IL-1β, BLC/ CXCL13, MCP-1, EGF, and BDNF.
|
| 44 |
+
|
| 45 |
+
IL-12 activates natural killer (NK) cells and T lymphocytes with secondary synthesis and the release of IFN-γ and other cytokines. IL-12 stimulates differentiation and proliferation of hematopoietic progenitors through synergies with other cytokines in *vitro*, and decreases peripheral blood counts and bone marrow hematopoiesis.
|
| 46 |
+
|
| 47 |
+
IL-18 has pleiotropic immunological competence and is present in multiple organs and tissues throughout the body. It has been demonstrated that the most important biological effect of IL-18 in *vitro* is to induce production of IFN-γ by T cells and NK cells; IL-18 also enhances the cytotoxic activity of NK cells and cytotoxic T lymphocytes (CTLs) in *vivo*. This cytokine is an immune cytokine, and more importantly, it is involved in regulation of humoral immunity and humoral immune responses (20). If bone marrow hematopoietic capacity decreases during long-term liver inflammation and hypersplenism, IL-18 may contribute to progression.
|
| 48 |
+
|
| 49 |
+
TGF-β is a cytokine with a strong biological activity in promoting regeneration of the extracellular matrix, modulating inflammatory reactions, and suppressing immune function.
|
| 50 |
+
|
| 51 |
+
TGF-β and other substances are overexpressed in hypersplenism. Therefore, the spleen may likely regulate various processes during liver cirrhosis via TGF-β (21).
|
| 52 |
+
|
| 53 |
+
Gene dysregulation. Yan et al screened 94 possibly dysregu-lated genes in splenic MΦs in hypersplenism due to PH as compared to normal splenic MΦs, including 21 upregulated genes and 73 downregulated genes (22). One upregulated gene was identified as the activator of S-phase kinase (ASK). By investigating the Dbf4-related Cdc7 kinase activity regulator gene encoded by human ASK, Yamada et al isolated and identified a corresponding promoter of ASK, and demonstrated that this ASK promoter was effective in stimulating cell growth (23). The significantly upregulated ASK in splenic MΦs in hypersplenism due to PH may cause enhanced activity of MΦs, including enhanced phagocytic capacity, which may be an important mechanism leading to hypersplenism due to PH.
|
| 54 |
+
|
| 55 |
+
Under normal circumstances, a mutual restriction and a dynamic balance are present between cytokine or gene upregulation and cytokine or gene downregulation. Significant changes were observed in the expression of cytokines or genes in the spleen of patients with hypersplenism in the context of PH. The differentially expressed cytokines or genes may play an important role in immune cell activation in the spleen and the changes in the immune function in patients with hypersplenism.
|
| 56 |
+
|
| 57 |
+
Autoimmunity. The spleen is the largest lymphoid organ, and is an important site for the production of antibodies. Antigens unprocessed by the liver may enter the periphery of splenic lymphoid follicles (splenic nodules), where reactions of immature lymphocytes and plasma cells occur after antigen stimulation, thus producing antibodies(24), which may destroy blood cells.
|
| 58 |
+
|
| 59 |
+
Significant increases in anti-platelet GPIIb-IIIa antibody and the B-cell-producing GPIIb-IIIa antibody were found in patients with cirrhosis, suggesting that anti-platelet autoantibody-mediated platelet destruction may be an important cause of cirrhotic thrombocytopenia (25). Increased platelet-associated GP antibodies have been detected in 64% of patients with chronic liver diseases of different causes. Such antibodies could lead to decreased platelet counts by themselves or in combination with the GPIIb-IIIa antibody, or by binding to the platelet glycoprotein GPIb-IX complex (26). With progression of hepatitis C, GPAIg levels increase gradually. Consequently, thrombocytopenia often occurs in patients with chronic hepatitis C (27).
|
| 60 |
+
|
| 61 |
+
Granulocyte colony-stimulating factor (G-CSF) is used for hematopoietic progenitor cell mobilization. Platelet counts decrease during G-CSF administration. Platelets entering the spleen are cleared rapidly from the blood stream in the hypersplenic state. Thrombopoietin (TPO) is almost specifically produced by liver cells. Eissa et al found low levels of TPO in patients with cirrhosis (28). The balance between production and destruction of TPO was not maintained. A decrease in TPO secretion from functional hepatocytes was also reported (29). However, Sanjo et al (30) and Rios et al (31) suggested that thrombocytopenia was not directly related to serum TPO levels in patients with hepatitis liver cirrhosis, but with splenic size and certain platelet-associated immunoglobulin hormone (PAIgG).
|
| 62 |
+
|
| 63 |
+
PAIgG is a class of platelet autoantibodies bound to the platelet surface glycoprotein and mainly produced by the spleen. It was shown that significantly higher PAIgG was presented in patients with thrombocytopenic purpura and cirrhotic hypersplenism. PAIgG-bound platelets were easily captured and phagocytized by MΦs while flowing through the spleen with mediation by antibodies. In addition, PAIgG can also bind to and destroy megakaryocytes and their precursors, thus inhibiting their differentiation and platelet formation (32). T helper (Th) cells can be differentiated into Th1, Th2, and Th17 subsets. Th1 cells primarily secrete IL-2, IFN-γ, TNF-α, and other cytokines, and mediate cellular immune responses, such as delayed-type hypersensitivity (DTH) and macrophage activation. Th2 cells primarily secrete IL-4, IL-5, IL-10, IL-13 and other cytokines, promote proliferation and differentia-tion of B cells into plasma cells, secrete specific antibodies, improve mucosal immunity, and mediate humoral immunity and type I hypersensitivity. The balance between Th1 and Th2 cells is an important factor in maintaining immune balance. Immune responses with an increased Th1/Th2 ratio tend to lead to Th1-dominant diseases, and immune responses with a decreased Th1/Th2 ratio tend to lead to Th2-dominant diseases. One previous study demonstrated that autoimmune diseases are Th1-dominant (33).
|
| 64 |
+
|
| 65 |
+
Thrombocytopenia may also be related to excessive consumption of platelets. Accelerated renewal of fibrinogen and plasminogen was found in patients with chronic liver disease, suggesting increased consumption of platelets (34).
|
| 66 |
+
|
| 67 |
+
Liver cirrhosis-related hypercoagulability was considered to be a pathological factor of excessive consumption of platelets (35).
|
| 68 |
+
|
| 69 |
+
## 5. Treatment Options
|
| 70 |
+
|
| 71 |
+
Peripheral cytopenias caused by hypersplenism often affects prognosis, and should therefore be closely monitored during treatment. Non-surgical treatment. This category of treatment primarily includes etiological treatment and treatment of concomitant diseases. Etiological treatment. Hypersplenism has many causes, and treatment should be administered in light of the specific cause.
|
| 72 |
+
|
| 73 |
+
In clinical practice, any deficiencies should be supplemented; for example, transfusion of erythrocytes and platelets should be given for erythropenia and thrombocytopenia, respectively, and transfusion of whole blood should be carried out for leukopenia. After transfusion, treatment including traditional Chinese medication can also be administered to promote restoration of decreased blood cell counts to normal or near normal levels. Kalambokis and Tsianos (36) observed an increased incidence of peripheral cytopenias in patients with liver cirrhosis, which may be related to hypersplenism, and the activation of monocytes and promotion of the release of pro-inflammatory cytokines, such as serum IL-1, leukocyte IL-6, TNF-α, and IFN-γ, by endotoxin produced by intestinal bacteria. In this case, antibiotic therapy should be prescribed for endotoxemia in patients with cirrhosis to increase blood cell counts. Zuchini et al (37) found that electromagnetic hyperthermia was effective in treating thrombocytopenia in a rat model of cirrhotic hypersplenism. Chernykh et al (38) reported satisfactory outcomes achieved by autologous stem cell transplantation in the treatment of peripheral cytopenias due to cirrhotic PH. Zhang et al (39) proposed that phosphatidylinositol 3-kinase regulatory subunit 1 (PIK3R1) may play an important role in the pathogenesis of PH and regulating the inhibition of MΦ activity, and that inhibition of PIK3R1 expression may potentially be useful for the treatment of PH and hypersplenism. External irradiation and ablation. Kenawi et al treated eight patients with liver cirrhosis, splenomegaly and hypersplenism by externally irradiating the spleens using radioactive Co-60. Laboratory data showed that the hemogram returned to completely normal in two patients and partially normal in three patients. Moreover, remission of chronic splenic pain was obtained in all patients and no significant complications were reported (40). Ismail et al (41) also observed increased platelet counts and improved splenic pain in patients treated with splenic irradiation. Feng et al (42) treated patients with hypersplenism using radiofrequency ablation which gave effective symptom relief while maintaining normal blood Tuftsin levels essential for the anti-infective and antitumor functions of the body. Partial splenic artery embolization. In 1979, Spigos et al used partial splenic artery embolization for the first time to treat hypersplenic patients with success (43). Thereafter, it has been applied in the treatment of PH, hypersplenism, and bleeding esophagogastric varices (44). This procedure not only increases platelet and leukocyte counts (38), but also reduces splenic size, improves pancytopenia (45), and stimulates the immune system (46). Despite some clinical success in treating splenomegaly and hypersplenism, the indications for partial splenic artery embolization are limited due to serious complications, such as splenic infarction and abscess, which could result in a high risk of death (47).
|
| 74 |
+
|
| 75 |
+
Total splenectomy. In secondary hypersplenism, the underlying disease must be treated to prevent further sequestration or destruction of blood cells, and possible spleen enlargement. These therapies should be tested prior to splenectomy
|
| 76 |
+
- removal of the target organ of hypersplenism (48). In severe cases of splenomegaly and hypersplenism, splenectomy is performed to correct the effects of low blood cell and platelet counts (49,50). As well, it can effectively improve liver function (51). In particular, laparoscopic splenectomy has several advantages (52) and is superior to partial splenic artery embolization (53). Although splenectomy is commonly used and effective for the treatment of hypersplenism (48), some risk factors and side effects do exist. For instance, the treatment of all future infections in patients who underwent a complete splenectomy became more complicated, as a key component of the body's normal defense system is not longer present (54). These individuals will be more susceptible to sepsis and other infections, and should receive, pre-operatively, proper immunization for pneumococcus, influenza, hepatitis, and meningococcemia. For this reason, total splenectomy should be avoided if possible. Liver transplantation. While liver transplantation for the treatment of hypersplenism has not been reported, hypersplenism is often developed from liver cirrhosis. Severe cirrhosis is often associated with serious hypersplenism. For patients with severe cirrhosis, concurrent early cancer or liver failure, liver transplantation may be suggested. In addition to restoring the liver function, liver transplantation may reduce the splenic size and the portal pressure, decrease the risk factors of bleeding, and eventually eliminate hypersplenism (55). Chu et al (56) reported that liver transplantation plus concurrent splenectomy did not increase the risk and could provide better outcomes in patients with liver cirrhosis and hypersplenism.
|
| 77 |
+
|
| 78 |
+
## 6. Conclusion
|
| 79 |
+
|
| 80 |
+
Hypersplenism, classified as primary, secondary, or occult types, is a common clinical disorder with a long history. The pathogenesis varies considerably from patient to patient. Primary hypersplenism is brought on by a disorder within the spleen itself, while secondary hypersplenism is caused by a variety of other diseases. Management and treatment should therefore be administered taking into account the specific etiology and be individualized for each patient. Available treatment options include non-surgical and surgical methods.
|
| 81 |
+
|
| 82 |
+
Surgical outcome following splenectomy is usually satisfactory; however, total splenectomy should be avoided if possible.
|
| 83 |
+
|
| 84 |
+
Continuous basic and clinical studies will advance our understanding of the underlying mechanisms of the development of hypersplenism, and provide better management strategies for the treatment of patients with hypersplenism.
|
| 85 |
+
|
| 86 |
+
## Acknowledgements
|
| 87 |
+
|
| 88 |
+
This review was supported by the Special Fund for International Cooperation Projects from the Science and Technology Foundation of Hainan Province, China (grant no. KJHZ2015-28).
|
| 89 |
+
|
| 90 |
+
## References
|
| 91 |
+
|
| 92 |
+
1. Kodama T, Takehara T, Hikita H, Shimizu S, Li W,
|
| 93 |
+
Miyagi T, Hosui A, Tatsumi T, Ishida H, Tadokoro S, et al: Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 138: 2487-2498, 2498.e1-2498.e7, 2010.
|
| 94 |
+
|
| 95 |
+
2. Hernandez-Gea V and Friedman SL: Platelets arrive at the scene of fibrosis……studies. J Hepatol 54: 1063-1065, 2011.
|
| 96 |
+
|
| 97 |
+
3. Djordjević J, Svorcan P, Vrinić D and Dapcević B: Splenomegaly and thrombocytopenia in patients with liver cirrhosis. Vojnosanit Pregl 67: 166-169, 2010 (In Serbian).
|
| 98 |
+
|
| 99 |
+
4. Lv Y, Han X, Gong X, Ma Q, Chang S, Wu H, Li Y and Deng J:
|
| 100 |
+
Grading of peripheral cytopenias caused by nonalcoholic cirrhotic portal hypertension and its clinical significance. Cell Biochem Biophys 71: 1141-1145, 2015.
|
| 101 |
+
|
| 102 |
+
5. Chauffard M: A'propos de la communication de M. Vaquez. Bull Soc mzed Hop Paris 24: 1201-1203, 1907.
|
| 103 |
+
|
| 104 |
+
6. Morawitz P and Denecked G: Erkrankungen der Milz. In:
|
| 105 |
+
Handbuch der inneren Medizin. Vol. 4. 2nd edition. von Bergmann G and Staehelin R (eds). Springer, Berlin, pp217-236, 1926 (In German).
|
| 106 |
+
|
| 107 |
+
7. Dameshek W: Hypersplenism. Bull NY Acad Med 31: 113-136, 1955.
|
| 108 |
+
|
| 109 |
+
8. Lv Y: Causes of peripheral blood cytopenias in patients with liver cirrhosis portal hypertension and clinical significances. Open J Endocr Metab Dis 4: 85-89, 2014. doi: 10.4236/ojemd.2014.44010.
|
| 110 |
+
|
| 111 |
+
9. Shah SH, Hayes PC, Allan PL, Nicoll J and Finlayson ND:
|
| 112 |
+
Measurement of spleen size and its relation to hypersplenism and portal hemodynamics in portal hypertension due to hepatic cirrhosis. Am J Gastroenterol 91: 2580-2583, 1996.
|
| 113 |
+
|
| 114 |
+
10. Aster RH: Pooling of platelets in the spleen: Role in the patho- genesis of 'hypersplenic' thrombocytopenia. J Clin Invest 45:
|
| 115 |
+
645-657, 1966.
|
| 116 |
+
|
| 117 |
+
11. Charrier S, Blundell M, Cédrone G, Louache F, Vainchenker W,
|
| 118 |
+
Thrasher AJ and Galy A: Wiskott-Aldrich syndrome protein- deficient hematopoietic cells can be efficiently mobilized by granulocyte colony-stimulating factor. Haematologica 98: 1300-1308, 2013.
|
| 119 |
+
|
| 120 |
+
12. Li ZF, Zhang Y, Gao J, Zhang PJ, Wang JX and Liu XG:
|
| 121 |
+
Expression and significance of Toll-like receptor 4 of splenic macrophage in patients with hypersplenism due to portal hypertension. Zhonghua Yi Xue Za Zhi 84: 1088-1091, 2004 (In Chinese).
|
| 122 |
+
|
| 123 |
+
13. Griffith RC and Janney CG: Hematopoiet system: bone marrow and blood, spleen, and lymph nodes. In: Anderson's Pathology. Kissane JM (ed). 9th edition. Mosby, St. Louis, MO, pp14081447, 1990.
|
| 124 |
+
|
| 125 |
+
14. Jiang A, Zhang S, Li Z, Liang R, Ren S, Li J, Pu Y and Yang J:
|
| 126 |
+
miR-615-3p promotes the phagocytic capacity of splenic macrophages by targeting ligand-dependent nuclear receptor corepressor in cirrhosis-related portal hypertension. Exp Biol Med (Maywood) 236: 672-680, 2011.
|
| 127 |
+
|
| 128 |
+
15. Ma S, Li A, Li Z, Zhang S, Jiang A, Zhang J, Zhou R and Dang S: Study of differential expression of cytokines between portal hypertensive hypersplenic tissue and normal splenic tissue by protein array. Chin Arch Gen Surg 6: 455-459, 2008 (In Chinese).
|
| 129 |
+
|
| 130 |
+
16. Eubank TD, Galloway M, Montague CM, Waldman WJ and Marsh CB: M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol 171: 2637-2643, 2003.
|
| 131 |
+
|
| 132 |
+
17. Ma J, Chen T, Mandelin J, Ceponis A, Miller NE, Hukkanen M,
|
| 133 |
+
Ma GF and Konttinen YT: Regulation of macrophage activation. Cell Mol Life Sci 60: 2334-2346, 2003.
|
| 134 |
+
|
| 135 |
+
18. Yamashita U and Kuroda E: Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 22: 105-114, 2002.
|
| 136 |
+
|
| 137 |
+
19. Vulcano M, Albanesi C, Stoppacciaro A, Bagnati R, D'Amico G,
|
| 138 |
+
Struyf S, Transidico P, Bonecchi R, Del Prete A, Allavena P, et al: Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J Immunol 31: 812-822, 2001.
|
| 139 |
+
|
| 140 |
+
20. Lin SD, Kawakami T, Ushio A, Sato A, Sato S, Iwai M, Endo R,
|
| 141 |
+
Takikawa Y and Suzuki K: Ratio of circulating follistatin and activin A reflects the severity of acute liver injury and prognosis in patients with acute liver failure. J Gastroenterol Hepatol 21: 374-380, 2006.
|
| 142 |
+
|
| 143 |
+
21. Brugger W, Möcklin W, Heimfeld S, Berenson RJ, MertelsmannR
|
| 144 |
+
and Kanz L: Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81: 2579-2584, 1993.
|
| 145 |
+
|
| 146 |
+
22. Yan F, Li W, Chen JT, Zeng YM, Guo YW, Zhang FR and Li ZF:
|
| 147 |
+
cDNA microarray-based screening of differentially expressed genes in macrophages in the spleen of patients with portal hypertension and hypersplenism. Nan Fang Yi Ke Da Xue Xue Bao 26:
|
| 148 |
+
1548-1551, 2006 (In Chinese).
|
| 149 |
+
|
| 150 |
+
23. Yamada M, Sato N, Taniyama C, Ohtani K, Arai K and Masai H: A 63-base pair DNA segment containing an Sp1 site but not a canonical E2F site can confer growth-dependent and E2F-mediated transcriptional stimulation of the human ASK gene encoding the regulatory subunit for human Cdc7-related kinase. J Biol Chem 277: 27668-27681, 2002.
|
| 151 |
+
|
| 152 |
+
24. Friedman LS: The risk of surgery in patients with liver disease.
|
| 153 |
+
|
| 154 |
+
Hepatology 29: 1617-1623, 1999.
|
| 155 |
+
|
| 156 |
+
25. Kajihara M, Kato S, Okazaki Y, Kawakami Y, Ishii H, Ikeda Y
|
| 157 |
+
and Kuwana M: A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. Hepatology 37: 1267-1276, 2003.
|
| 158 |
+
|
| 159 |
+
26. Pereira J, Accatino L, Alfaro J, Brahm J, Hidalgo P and Mezzano D: Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 50: 173-178, 1995.
|
| 160 |
+
|
| 161 |
+
27. Zucker ML, Hagedorn CH, Murphy CA, Stanley S, Reid KJ
|
| 162 |
+
and Skikne BS: Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction. Int J Lab Hematol 34: 525-532, 2012.
|
| 163 |
+
|
| 164 |
+
28. Eissa LA, Gad LS, Rabie AM and El-Gayar AM: Thrombopoietin level in patients with chronic liver diseases. Ann Hepatol 7: 235-244, 2008.
|
| 165 |
+
|
| 166 |
+
29. Dusheiko G: Thrombopoietin agonists for the treatment of thrombocytopenia in liver disease and hepatitis C. Clin Liver Dis 13: 487-501, 2009.
|
| 167 |
+
|
| 168 |
+
30. Sanjo A, Satoi J, Ohnishi A, Maruno J, Fukata M and Suzuki N:
|
| 169 |
+
Role of elevated platelet-associated immunoglobulin G and hypersplenism in thrombocytopenia of chronic liver diseases. J Gastroenterol Hepatol 18: 638-644, 2003.
|
| 170 |
+
|
| 171 |
+
31. Rios R, Sangro B, Herrero I, Quiroga J and Prieto J: The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 100: 1311-1316, 2005.
|
| 172 |
+
|
| 173 |
+
32. Lv YF, Li XQ, Gong XG, Xie XH, Han XY and Wang BC: Effect of surgery treatment on hypersplenism caused by cirrhotic portal hypertension. Minerva Chir 68: 409-413, 2013.
|
| 174 |
+
|
| 175 |
+
33. Jäger A and Kuchroo VK: Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand J Immunol 72: 173-184, 2010.
|
| 176 |
+
|
| 177 |
+
34. Stein SF and Harker LA: Kinetic and functional studies of platelets, fibrinogen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med 99: 217-230, 1982.
|
| 178 |
+
|
| 179 |
+
35. Ikura Y, Ohsawa M, Okada M, Iwai Y and Wakasa K: The significance of platelet consumption in the development of thrombocytopenia in patients with cirrhosis. Am J Med Sci 346: 199-203, 2013.
|
| 180 |
+
|
| 181 |
+
36. Kalambokis G and Tsianos EV: Endotoxaemia in the pathogenesis of cytopenias in liver cirrhosis. Could oral antibiotics raise blood counts? Med Hypotheses 76: 105-109, 2011.
|
| 182 |
+
|
| 183 |
+
37. Zuchini R, Huang CH, Tsai HW, Huang SC, Lin CP, Chen CY,
|
| 184 |
+
Lee GB and Lin XZ: Electromagnetic thermoablation to treat thrombocytopenia in cirrhotic and hypersplenic rats. J Gastroenterol Hepatol 25: 1578-1586, 2010.
|
| 185 |
+
|
| 186 |
+
38. Chernykh ER, Starostina NM, Paltsev AI, Leplina OY,
|
| 187 |
+
Shevela EY, Shipunov MV, Selihova YB, Kulagin AD, Lisukov IA, Nikonov SD, et al: Autologous bone marrow cells in the treatment of cirrhosis of the liver. Bull Exp Biol Med 144: 640-645, 2007.
|
| 188 |
+
|
| 189 |
+
39. Zhang W, Zhang S, Li ZF, Huang C, Ren S, Zhou R, Jiang A and Yang AN: Knockdown of PIK3R1 by shRNA inhibits the activity of the splenic macrophages associated with hypersplenism due to portal hypertension. Pathol Res Pract 206: 760-767, 2010.
|
| 190 |
+
|
| 191 |
+
40. Kenawi MM, el-Ghamrawi KA, Mohammad AA, Kenawi A
|
| 192 |
+
and el-Sadek AZ: Splenic irradiation for the treatment of hypersplenism from congestive splenomegaly. Br J Surg 84: 860-861, 1997.
|
| 193 |
+
|
| 194 |
+
41. Ismail E, Abdelmoety H, Elgerby MM and Abden H: Splenic irradiation in the treatment of hypersplenism from congestive splenomegaly. Life Sci J 9: 1121-1126, 2012.
|
| 195 |
+
|
| 196 |
+
42. Feng Kai, Ma K-S and Dong J-H: Changes of serum Tuftsin content among hypersplenism patients before and after radiofrequency ablation or splenectomy. Acta Academiae Medicinae Militaris Tertiae 28: 1983-1985, 2006 (In Chinese).
|
| 197 |
+
|
| 198 |
+
43. Spigos DG, Jonasson O, Mozes M and Capek V: Partial splenic embolization in the treatment of hypersplenism. AJR Am J Roentgenol 132: 777-782, 1979.
|
| 199 |
+
|
| 200 |
+
44. Sankararaman S, Velayuthan S, Vea R and Herbst J: Severe gastric variceal bleeding successfully treated by emergency splenic artery embolization. Pediatr Int 55: e42-e45, 2013.
|
| 201 |
+
|
| 202 |
+
45. He XH, Li WT, Peng WJ, Li GD, Wang SP and Xu LC: Total embolization of the main splenic artery as a supplemental treatment modality for hypersplenism. World J Gastroenterol 17: 2953-2957, 2011.
|
| 203 |
+
|
| 204 |
+
46. Krishnan SK, Hill A, Hillmen P, Arnold LM, Brooksbank GL,
|
| 205 |
+
Wood A, Scarsbrook A, Davies MH and Kelly RJ: Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab. Int J Hematol 98: 716-718, 2013.
|
| 206 |
+
|
| 207 |
+
47. N'Kontchou G, Seror O, Bourcier V, Mohand D, Ajavon Y,
|
| 208 |
+
Castera L, Grando-Lemaire V, Ganne-Carrie N, Sellier N, Trinchet JC, et al: Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients. Eur J Gastroenterol Hepatol 17: 179-184, 2005.
|
| 209 |
+
|
| 210 |
+
48. Kim H, Suh KS, Jeon YM, Park MS, Choi Y, Mori S, Hong G,
|
| 211 |
+
Lee HW, Yi NJ and Lee KW: Partial splenic artery embolization for thrombocytopenia and uncontrolled massive ascites after liver transplantation. Transplant Proc 44: 755-756, 2012.
|
| 212 |
+
|
| 213 |
+
49. Lv Y, Gong X, Xie X, Wang B, Yang Y and Li Y: Clinical study on the relationship between hematocytopenia and splenomegaly caused by cirrhotic portal hypertension. Cell Biochem Biophys 70: 355-360, 2014.
|
| 214 |
+
|
| 215 |
+
50. Yoshida D, Nagao Y, Tomikawa M, Kawanaka H, Akahoshi T,
|
| 216 |
+
Kinjo N, Uehara H, Hashimoto N, Hashizume M and Maehara Y:
|
| 217 |
+
Predictive factors for platelet count after laparoscopic splenectomy in cirrhotic patients. Hepatol Int 6: 657-661, 2012.
|
| 218 |
+
|
| 219 |
+
51. Ushitora Y, Tashiro H, Takahashi S, Amano H, Oshita A,
|
| 220 |
+
Kobayashi T, Chayama K and Ohdan H: Splenectomy in chronic hepatic disorders: portal vein thrombosis and improvement of liver function. Dig Surg 28: 9-14, 2011.
|
| 221 |
+
|
| 222 |
+
52. Zhan XL, Ji Y and Wang YD: Laparoscopic splenectomy for hypersplenism secondary to liver cirrhosis and portal hypertension. World J Gastroenterol 20: 5794-5800, 2014.
|
| 223 |
+
|
| 224 |
+
53. Tomikawa M, Akahoshi T, Sugimachi K, Ikeda Y, Yoshida K,
|
| 225 |
+
Tanabe Y, Kawanaka H, Takenaka K, Hashizume M and Maehara Y: Laparoscopic splenectomy may be a superior supportive intervention for cirrhotic patients with hypersplenism. J Gastroenterol Hepatol 25: 397-402, 2010.
|
| 226 |
+
|
| 227 |
+
54. Inagaki Y, Sugimoto K, Shiraki K, Tameda M, Kusagawa S,
|
| 228 |
+
Nojiri K, Ogura S, Yamamoto N, Takei Y, Ito M, et al: The long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis. Mol Med Rep 9: 487-492, 2014.
|
| 229 |
+
|
| 230 |
+
55. Ishigami M, Ishizu Y, Onishi Y, Kamei H, Kiuchi T, Itoh A,
|
| 231 |
+
Hirooka Y, Katano Y and Goto H: Long-term dynamics of hematological data and spleen volume in cirrhotic patients after liver transplantation-various dynamics depending on etiology. Springerplus 2: 374, 2013.
|
| 232 |
+
|
| 233 |
+
56. Chu HC, Hsieh CB, Hsu KF, Fan HL, Hsieh TY and Chen TW:
|
| 234 |
+
Simultaneous splenectomy during liver transplantation augments anti-viral therapy in patients infected with hepatitis C virus. Am J Surg 209: 180-186, 2015.
|
medical/md/PMC5228319.md
ADDED
|
@@ -0,0 +1,161 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# Facile Mechanical Shaking Method Is An Improved Isolation Approach For Islet Preparation And Transplantation
|
| 2 |
+
|
| 3 |
+
NINA YIN1*, TAO CHEN1*, YULING YU1, YONGMING HAN1, FEI YAN1, ZHOU ZHENG1 and ZEBIN CHEN2,3 1Department of Anatomy, College of Basic Medicine; 2Department of Acupuncture and Moxibustion, College of Acupuncture and Orthopedics; 3Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibustion, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China Received September 23, 2015; Accepted September 15, 2016
|
| 4 |
+
|
| 5 |
+
## Doi: 10.3892/Etm.2016.3844
|
| 6 |
+
|
| 7 |
+
Abstract. Successful islet isolation is crucial for islet transplantation and cell treatment for type 1 diabetes. Current isolation methods are able to obtain 500-1,000 islets per rat, which results in a waste of ≥50% of total islets. In the present study, a facile mechanical shaking method for improving islet yield (up to 1,500 per rat) was developed and summarized, which was demonstrated to be more effective than the existing well-established stationary method. The present results showed that isolated islets have a maximum yield of 1,326±152 when shaking for 15 min for the fully-cannulated pancreas. For both fully-cannulated and half-cannulated pancreas in the presence of rat DNAse inhibitor, the optimal shaking time was amended to 20 min with a further increased yield of 1,344±134 and 1,286±124 islets, respectively. Furthermore, the majority of the isolated islets were morphologically intact with a well‑defined surface and almost no central necrotic zone, which suggested that the condition of islets obtained via the mechanical shaking method was consistent with the stationary method. Islet size distribution was also calculated and it was demonstrated that islets from the stationary method exhibited the same size distribution as the non-cannulated group, which had more larger islets than the fully-cannulated and half-cannulated groups isolated via the shaking method. In addition, the results of glucose challenge showed that the refraction index of each group was >2.5, which indicated the well-preserved function of isolated islets. Furthermore, the transplanted islets exhibited a
|
| 8 |
+
*Contributed equally therapeutic effect after 1 day of transplantation; however, they failed to control blood glucose levels after ~7 days of transplantation. In conclusion, these results demonstrated that the facile mechanical shaking method may markedly improve the yield of rat islet isolation, and in *vitro* and in *vivo* investigation demonstrated the well-preserved function of isolated islets in the control of blood glucose. Therefore, the facile mechanical shaking method may be an alternative improved procedure to obtain higher islet yield for islet preparation and transplantation in the treatment of type 1 diabetes.
|
| 9 |
+
|
| 10 |
+
## Introduction
|
| 11 |
+
|
| 12 |
+
Diabetes mellitus is a clinical disorder of intermediary metabolism characterized by hyperglycemia and glycosuria due to the inadequate secretion and/or utilization of insulin, and previous investigation has demonstrated the potential of islet transplantation for the cure for type 1 diabetes with successful islet isolation and preparation (1). One crucial limitation of islets therapy in laboratory research and clinic application is the shortage of islets donations, which is due to the low efficiency of current islet isolation method (2,3). Therefore, high yielding islet isolation is a prerequisite of successful islet transplantation (4).
|
| 13 |
+
|
| 14 |
+
Over the past 40 years, various methods for the isolation of rat islets have been introduced. Isolation of rat pancreas islets was first described by Lacy and Kostianovsky (5), and various subsequent procedures have been reported for pancreatic islet isolation based on this technique (6). However, the majority of these methods were only able to obtain relatively low islet yields, which resulted in a large number of wasted rat islets (7). Following the application of all of these methods in our laboratory, it was demonstrated that the low isolation efficiency was predominantly due to the inadequate digestion of pancreas tissue. To improve the digestion efficiency, the rat pancreas was either perfused with enzyme solution or cut into pieces before digestion (8,9). However, the commonly used stationary method exhibited poor tissue/enzyme interaction and resulted in inadequate digestion (10,11). Islets were found to attach or become trapped in undigested tissue, which led to a decrease in isolation yield (12). The current well-established stationary method, which involves cannulation through the bile duct and Histopaque gradient centrifugation, is able to harvest 500‑1,000 islets from one rat, which is 50% of the total amount of a rat pancreas (13,14).
|
| 15 |
+
|
| 16 |
+
In the present study, a mechanical shaking method was established to solve the low efficiency of islet isolation and improve the islet yield. By applying continuous shaking during digestion, the pancreas tissue was adequately digested, which resulted in an improved isolation yield of up to 1,500 islets per rats (50% more than the well‑established stationary method). Notably, the majority of the isolated islets were morphologically intact with a well‑defined surface. Furthermore, optimization of the shaking conditions was studied and characterization of the islets demonstrated well-preserved function to control blood glucose in *vitro* and in *vivo*. This facile mechanical shaking method markedly improved the yield of islet isolation and is likely to aid islet preparation and transplantation for the treatment of type 1 diabetes.
|
| 17 |
+
|
| 18 |
+
## Materials And Methods
|
| 19 |
+
|
| 20 |
+
Animals. A total of 296 male Sprague-Dawley (SD) rats (8-12 weeks old), weighing 250-300 g, and 32 C57BL/6 mice (6-8 weeks old), weighing 20-22 g were purchased from the Laboratory Animal Services Center of Hubei University of Chinese Medicine (Wuhan, China). Animals were maintained in a controlled environment (room temperature, 20±1˚C; relative humidity, 55±15%; 12‑h light/dark cycle) and permitted ad *libitum* access to food and water throughout the experiment. All animals were treated in accordance with international ethical guidelines and the National Institutes of Health Guide concerning the Care and Use of Laboratory Animals. Facile mechanical shaking method. Male SD rats, weighing 250-300 g, were used. Following CO2 euthanasia, 8 ml M199/HEPES buffer digestion solution (Hyclone; GE Healthcare, Logan, UT, USA) supplemented with 0.1% Liberase (Roche Diagnostics, Indianapolis, IN, USA) was cannulated into the pancreas via the bile duct. The pancreas was subsequently transferred to a 50-ml centrifuge tube
|
| 21 |
+
(non-cannulated pancreas was cut into 1 mm2 pieces using surgical scissors) and maintained on ice for 30 min. Subsequently, the tube was placed on a rotary shaker (500 rpm; VWR Scientific, San Francisco, CA, USA) in a 37˚C incubator for 5‑35 min. Once all the tissue was digested and the suspension was homogeneous 4˚C PBS was added to terminate digestion and the sample was centrifuged twice in 4˚C PBS to remove Liberase (15 min at 500 x g),. The digested pancreas was filtered through a 450‑µm sieve (Sartorius AG, Goettingen, Germany) to remove large particles (mostly non-cannulated pancreas) and the digested pancreas was subsequently suspended in a Histopaque 1077/PBS media gradient (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany), and was centrifuged at ~1,000 x g for 30 min at room temperature. Islets trapped on the sieve were obtained by washing the sieve several times with PBS. All islets were purified by the selection of complete and live islets by hand under a light microscope for the following experiments under a light microscope (Thermo Fisher Scientific, Inc., Waltham, MA, USA).
|
| 22 |
+
|
| 23 |
+
Stationary method. Following cannulation, the pancreas was transferred to a centrifuge tube, maintained on ice for 30 min and subsequently incubated in a 37˚C water bath for digestion. Following incubation, the tube was shaken by hand to disrupt the pancreas until the suspension was homogeneous. Subsequently, 4˚C PBS was added to terminate digestion and drastic shaking was applied 40 times to completely disintegrate the large tissue particles. The remaining procedure was the same as the mechanical shaking method. Degrees of pancreas perfusion. To verify that the mechanical shaking method was suitable for the pancreas, cannulation was performed in three degrees, including fully-cannulated, half-cannulated and non-cannulated. In the fully-cannulated group, 8 ml media was applied and the pancreas was fully perfused; whereas in the half-cannulated group, 4 ml media was applied and the pancreas was just partially perfused. No media was cannulated into the pancreas in the non-cannulated group. Addition of inhibitor of caspase‑activated DNase (ICAD). Anti-rat ICAD was purchased from Medical and Biological Laboratories, Co., Ltd., (Nagoya, Japan) (15). A total of 1 µg/ml ICAD was added to the digestion media prior to shaking, and the formation of DNA-crosslinking was monitored, as previously described (16).
|
| 24 |
+
|
| 25 |
+
Islet culture. Isolated islets were cultured in a non-treated Petri dish with an islet density of 5 islets/cm2. The culture media was RPMI-1640 (Hyclone; GE Healthcare) supplemented with 2.8 mmol glucose, 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin (all Gibco; Thermo Fisher Scientific, Inc.) at 37˚C in humidified air containing 5% CO2 (17). Prior to each test, the islets were purified and complete and live islets were selected by hand under a light microscope for use in subsequent experiments.
|
| 26 |
+
|
| 27 |
+
Morphology and size of isolated islets. Following isolation, islet morphology was studied under a light microscope
|
| 28 |
+
(Thermo Fisher Scientific, Inc.). Islets in good condition are brown in color with a well‑identified surface and no necrotic zone in the center. For diameter distribution measurement, 200 islets were randomly chosen and analyzed under a dissec-tion microscope with a fluorescent illuminator equipped with an ocular micrometer with an accuracy of 25 µm. Glucose challenge. For the different isolation methods, 100 islets with a diameter of 100-200 µm were selected. Islets were pre-incubated for 1 h in 5 ml FBS-free RPMI-1640 medium containing low glucose (2.8 mmol) in a 6-well plate at 37˚C with 5% CO2. During the following 3 h, RPMI-1640 medium with 2.8, 28 and 2.8 mmol glucose was added consecutively at each hour, respectively. Following incubation, the medium was collected and stored at ‑20˚C for subsequent insulin concentration determination. Islet transplantation. Male C57BL/6 mice were utilized for transplantation. To establish insulin-dependent diabetic mice models, normal C57BL/6 mice were treated with 50 mg/kg streptozotocin (STZ; Sigma-Aldrich; Merck Millipore) via the tail veil for 5 consecutive days. The blood glucose levels of all the mice were retested prior to transplantation. Only mice with non-fasted blood glucose levels >300 mg/dl for 2 consecutive days were considered diabetic and underwent transplanta-tion. Mice were anesthetized using 3% isofluorane (AErrane; Baxter, Deerfield, IL, USA) in oxygen and maintained at the same rate throughout the procedure. Prior to transplantation, all islets were immersed in PBS three times to completely remove the culture media. A total of 500 islets were then suspended in 500 µl sterile PBS and transferred in a 1-ml syringe. The abdomens of the mice were shaved and sterilized using alcohol and the islets were subsequently injected into the abdominal cavity. The blood glucose levels of treated mice were monitored once every 2 days. A small drop of blood was collected from the tail vein using a lancet and tested using a commercial glucometer (Roche Diagnostics). Mice with blood glucose levels <200 mg/dl were considered normoglycemic. Monitoring continued until all mice had returned to a hyperglycemic state (blood glucose levels >250 mg/dl). Statistical analysis. All results are expressed as the mean ± standard deviation of data obtained from triplicate experiments. All analyses were performed using SPSS 17.0 statistical analysis software (SPSS, Inc., Chicago, IL, USA). Two-tailed Student's t-test was used for all statistical analyses, with P<0.05 considered to indicate a statistically significant difference.
|
| 29 |
+
|
| 30 |
+
## Results
|
| 31 |
+
|
| 32 |
+
Islet yield is improved by the facile mechanical shaking method. Fig. 1 demonstrates a comparison of islet yields from a single rat using the common stationary method and shaking methods. The results indicated that a higher yield of isolated islets was obtained with the facile mechanical shaking method (1,326±134), as compared with the common stationary method (906±128), which was an improvement of ~50% on the isolation yield. Fully cannulated treatment and the presence of ICAD contrib‑ utes to an increment of islet yield. To study how shaking time may affect the isolation yield, the pancreas was placed on the shaker for varying periods of time and the different cannulation situations were studied individually. For the fully-cannulated pancreas, as the shaking time increased, the isolation yield exhibited an increasing trend with a maximum yield of 1,346±137 when the shaking time was 15 min (Fig. 2A). When the shaking time increased further, the yield did not increase as expected; instead, a marked reduction was detected due to the formation of DNA-crosslinks. The half-cannulated pancreas exhibited a similar trend to the fully-cannulated pancreas, with a maximum yield of 1,293±135 islets when shaken for 15 min (Fig. 2B). However, the non-cannulated pancreas demonstrated a different trend, as the best shaking time was delayed to ~20 min, with a maximum yield of 365±62 islets
|
| 33 |
+
(Fig. 2C). This may be due to larger tissues requiring additional time to be digested. One phenomenon noted in all the groups was that further shaking following the maximum yield induced the formation of DNA-crosslinks, which decreased the isolation yield markedly.
|
| 34 |
+
|
| 35 |
+

|
| 36 |
+
|
| 37 |
+
To avoid the formation of DNA-crosslinks, ICAD was added to the digest media. Fig 3 shows the improvement of islet yield following the addition of ICAD. For both the fully cannulated and half-cannulated pancreas, the optimal shaking time was shifted to 20 min with a further increased yield of 1,344±134 and 1,286±124 islets (Fig. 3A and B). One crucial improvement was that, following the optimal shaking time, the yield gradually decreased over a longer period of time; therefore, the addition of ICAD made the shaking procedure more controllable. For the non-cannulated pancreas, the effect of ICAD addition was not obvious; the optimal shake time remained at 20 min with 423±92 islets (Fig. 3C). Shaking procedures retain the biological activity and func‑ tion of islets. Fresh islets were obtained following the shaking method. The majority of isolated islets were morphological intact with a well-defined surface, indicating the shaking procedure did not break the islets apart (Fig. 4). Almost none of the isolated islets exhibited a central necrotic zone, which suggested the islet condition in the shaking method group was consistent with the stationary method. Islets size distribution was also calculated and the findings indicated that the islets isolated via the stationary method has the same size distribution as the non-cannulated group, which had more larger islets than the fully-cannulated and half-cannulated groups subjected to the shaking method (Fig. 4).
|
| 38 |
+
|
| 39 |
+
Glucose challenge is an effective method for the study of islet functions in *vitro* prior to transplantation. The refraction index (high value/low value) represents insulin secretion ability via the islets' response to changes in blood glucose levels. As Fig 5 demonstrates, the refraction indices of all groups were >2.5, which indicated the well-preserved function of the isolated islets. Transplantation of isolated islets with mechanical shaking successfully decreases the increased blood glucose levels of diabetic mice. Transplanted islets exhibited therapeutic effects after 1 day of transplantation and all diabetic mice became normoglycemic (Fig. 6). All the groups exhibited the same trend at the initial stage, but failed to control blood glucose
|
| 40 |
+
|
| 41 |
+

|
| 42 |
+
|
| 43 |
+

|
| 44 |
+
|
| 45 |
+

|
| 46 |
+
|
| 47 |
+
level after ~7 days of transplantation. Foreign body reactions or an immune response to xenografts may result in the death of transplanted islets. The present results indicated that greater numbers of islets can be isolated with the facile mechanical shaking method, and these islets also exhibited the normal function of decreasing blood glucose levels.
|
| 48 |
+
|
| 49 |
+
## Discussion
|
| 50 |
+
|
| 51 |
+
The yield of islets isolation is crucial for islet transplantation in *vivo* (18). Though islets isolation methods have been extensively studied, the yield remains relatively low compared with the total islets isolated from a rat pancreas (19,20). In the
|
| 52 |
+
|
| 53 |
+

|
| 54 |
+
|
| 55 |
+

|
| 56 |
+
|
| 57 |
+
present study, a facile mechanical shaking method was established, which improved the isolation yield to up to 1,600 islets per rat. Moreover, the islets exhibited well-preserved function to control blood glucose in *vitro* and in *vivo*. The present results provide an improved alternative isolation approach for islet preparation and transplantation in diabetes treatment.
|
| 58 |
+
|
| 59 |
+
Cannulation through the bile duct is paramount for islets isolation due to more comprehensive interaction between the pancreas tissue and digest media. However, successful cannulation required good cutting off of the ampulla site and careful handling of the syringe, as a minor error may cause enzyme media leakage to the surrounding tissue or duodenum, leading to the half-cannulated state (8). When cannulation was not adequate, particularly when the pancreas was removed without cannulation, it was difficult to harvest a large number of islets via the stationary method. Furthermore, large sections of tissue were not well-digested when the stationary technique was utilized. By studying the islets yield following various shaking times, the optimal procedure for different cannulation situations was elucidated. In addition, the present findings also indicated that the optimal shaking time for the non-cannulated pancreas was relatively longer than with the fully and half cannulated pancreas, which may be explained by the increased time required by the enzyme to digest the larger sections of tissue. Notably, a singular optimal shaking time point was not elucidated, as the pancreas states prior to digestion varied each time. The key point demonstrated by the present findings was that digestion should be monitored until the majority of the large sections of tissue have been digested into tiny sections, which ensure that they are able to precipitate at the bottom like sand.
|
| 60 |
+
|
| 61 |
+
In the present study, only 500-800 islets were successfully isolated from one rat pancreas via the well-established stationary method. Following the stationary digestion process, numerous islets were found to be attached to large sections of tissue. By drastically shaking the tissue in the tube, some of the islets were detached from the tissue. However, violent shaking may also cause islets to disintegrate (21). To solve this problem, instead of shaking after digestion, a continuous shaking protocol was applied during enzyme digestion. The results demonstrated that the shaking method resulted in an islet yield that was ~2 times greater than that of the stationary method. We hypothesize that the following aspects may contribute to this higher yield of rat islets: i) The digested enzyme had more comprehensive interaction with the pancreas tissue in the tube when shaking was applied, which means the enzyme can digest deeper into the tissue and disintegrate it more effectively, resulting in much smaller tissue sections compared with the stationary method (22); or ii) shaking during digestion provided a continuous and relatively gentle shear force to those islets exposed in the media (23). Islets may gradually detach from the tissue instead of becoming trapped deep into the undigested tissue, thus they are able to maintain their morphological integration.
|
| 62 |
+
|
| 63 |
+
Notably, obvious differences were observed for the different situations in which digestion occurred, when shaking was conducted for too long a time period. For example, tiny tissue sections were further digested, causing cell rupture and DNA release (data not shown) (24). Tiny tissue sections may undergo DNA crosslinking and become flocculent, which results in the tissue being unable to precipitate to the bottom of the sample being treated, inducing a huge decrease in the isolation yield (25). However, the same phenomenon was not observed in the non-cannulated pancreas since the digestion efficiency was relatively lower and individual cells did not rupture before the large tissue sections had been digested. Flocculent tissue forms due to the release of DNA and caspase-activated DNase subsequently breaks the DNA, which then acts as a cross-linker, and islets becomes trapped in the cross-linked tissue. A previous study has shown that the addition of the ICAD may help to avoid the effect of broken DNA (26). Shaking in the presence of ICAD attenuated the formation of cross-linked tissue. During the full and half cannulation protocols that required a more controlled shaking time, the addition of ICAD had a marked effect in that there was no flocculent tissue formed even following extended shaking times and instead, the tissue was further digested. This not only made the shaking procedure easier to control but also further increased the islet yields in the cannulated groups. However, for the non-cannulated groups, the islet yield was lower even in the presence of ICAD since the tissue size was larger and the enzyme may not have been able to reach the central tissue to rupture individual cells. Quantity and quality are usually mutually exclusive.
|
| 64 |
+
|
| 65 |
+
During the isolation progress, analysis of islet size distribution was conducted to determine if the continuous shear force was able to break islets apart. The present results indicated that there was a slight difference between the stationary technique and the non-cannulated method, which experienced less shear force in shaking and resulted in more large islets. Under a light microscope, the differ-ences were difficult to recognize and islets from all methods were morphologically in good condition with a well‑defined surface. Furthermore, it should be noted that bigger islets are not necessarily better, as previous culture and transplantation studies found that larger islets had a large necrotic zone when beta cells in the center experienced a low oxygen transport rate (27,28). Glucose challenge was not only used to verify the viability of islets by studying the capability of islets to secret insulin response to various glucose levels, but it is also a critical in *vitro* experiment to predict the therapeutic efficiency of islets transplantation (29). The present results showed minimal differences between the islets isolated via the shaking and stationary methods, respectively, which have already been proven to exhibit good therapeutic efficiency when transplanted. The high reflection index indicated a sufficient amount of insulin would be secreted by islets isolated via the shaking method when blood glucose level raise. Islet transplantation has been demonstrated to be the most promising approach to elucidating a cure for type 1 diabetics and it may also be a direct way to verify the in *vivo* activity of isolated islets (30). The intraperitoneal cavity has been shown to be one of best transplantation sites, where nutrition and oxygen are abundant (31). Blood glucose levels exhibited the same trend for all the protocols, and xenograft islets were able to control the blood glucose levels of diabetic mice following transplantation. Viability persisted for approximately one week, which was consistent with the findings of previous studies (32,33).
|
| 66 |
+
|
| 67 |
+
The present study described a facile mechanical shaking method for the high isolation efficiency of rat islets. In the presence of rat ICAD, the isolation yield could reach as high as 1,600 islets per rat, which was 55% more than the current well-established stationary method. In *vitro* tests demonstrated that isolated islets were morphologically intact and had well-preserved function in response to blood glucose alterations, and the transplantation of isolated islets successfully reversed the blood glucose levels of diabetic mice for a week. With this facile mechanical shaking method, islet transplantation studies conducted with rats in the laboratory should be more effective. In addition, this method may be applied in human islet isolation and could potentially improve the efficiency of clinical islet therapy.
|
| 68 |
+
|
| 69 |
+
## References
|
| 70 |
+
|
| 71 |
+
1. Lakey JR, Burridge PW and Shapiro AM: Technical aspects of islet preparation and transplantation. Transpl Int 16: 613-632, 2003.
|
| 72 |
+
|
| 73 |
+
2. Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H,
|
| 74 |
+
Yonekawa Y, Yamada Y, Fukuda K, Tsukiyama K,
|
| 75 |
+
Suzuki H, et al: Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 365: 1642-1644, 2005.
|
| 76 |
+
|
| 77 |
+
3. Matsumoto S, Okitsu T, Iwanaga Y, Noguchi H, Nagata H,
|
| 78 |
+
Yonekawa Y, Yamada Y, Fukuda K, Shibata T, Kasai Y, et al:
|
| 79 |
+
Successful islet transplantation from nonheartbeating donor pancreata using modified Ricordi islet isolation method. Transplantation 82: 460-465, 2006.
|
| 80 |
+
|
| 81 |
+
4. Khan KM, Desai CS, Kalb B, Patel C, Grigsby BM, Jie T,
|
| 82 |
+
Gruessner RW and Rodriguez-Rilo H: MRI prediction of islet yield for autologous transplantation after total pancreatectomy for chronic pancreatitis. Dig Dis Sci 58: 1116-1124, 2013.
|
| 83 |
+
|
| 84 |
+
5. Lacy PE and Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16: 35-39, 1967.
|
| 85 |
+
|
| 86 |
+
6. Miyazaki J, Araki K, Yamato E, Ikegami H, Asano T, Shibasaki Y,
|
| 87 |
+
Oka Y and Yamamura K: Establishment of a pancreatic beta cell line that retains glucose-inducible insulin secretion: Special reference to expression of glucose transporter isoforms. Endocrinology 127: 126-132, 1990.
|
| 88 |
+
|
| 89 |
+
7. Sutherland DE, Radosevich DM, Bellin MD, Hering BJ,
|
| 90 |
+
Beilman GJ, Dunn TB, Chinnakotla S, Vickers SM, Bland B,
|
| 91 |
+
Balamurugan AN, et al: Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg 214: 409-424; discussion 424-426, 2012.
|
| 92 |
+
|
| 93 |
+
8. Li DS, Yuan YH, Tu HJ, Liang QL and Dai LJ: A protocol for islet isolation from mouse pancreas. Nat Protoc 4: 1649-1652, 2009.
|
| 94 |
+
|
| 95 |
+
9. Soltani SM, O'Brien TD, Loganathan G, Bellin MD, Anazawa T,
|
| 96 |
+
Tiwari M, Papas KK, Vickers SM, Kumaravel V, Hering BJ, et al:
|
| 97 |
+
Severely fibrotic pancreases from young patients with chronic pancreatitis: Evidence for a ductal origin of islet neogenesis. Acta Diabetol 50: 807-814, 2013.
|
| 98 |
+
|
| 99 |
+
10. Jin SM, Oh SH, Kim SK, Jung HS, Choi SH, Jang KT, Lee KT,
|
| 100 |
+
Kim JH, Lee MS, Lee MK and Kim KW: Diabetes-free survival in patients who underwent islet autotransplantation after 50% to 60% distal partial pancreatectomy for benign pancreatic tumors. Transplantation 95: 1396-1403, 2013.
|
| 101 |
+
|
| 102 |
+
11. Goto T, Tanioka Y, Sakai T, Terai S, Kamoda Y, Li S, Tanaka T,
|
| 103 |
+
TsujimuraT, Matsumoto I, FujinoY, et al: Application of the two-layer method on pancreas digestion results in improved islet yield and maintained viability of isolated islets. Transplantation 83: 754-758, 2007.
|
| 104 |
+
|
| 105 |
+
12. Machida T, Tanemura M, Ohmura Y, Tanida T, Wada H,
|
| 106 |
+
Kobayashi S, Marubashi S, Eguchi H, Ito T, Nagano H, et al:
|
| 107 |
+
Significant improvement in islet yield and survival with modified ET‑Kyoto solution: ET‑Kyoto/Neutrophil elastase inhibitor. Cell Transplant 22: 159-173, 2013.
|
| 108 |
+
|
| 109 |
+
13. Ito T, Chen D, Chang CW, Kenmochi T, Saito T, Suzuki S and Takemoto JY: Mesobiliverdin IXα enhances rat pancreatic islet yield and function. Front Pharmacol 4: 50, 2013.
|
| 110 |
+
|
| 111 |
+
14. de Haan BJ, Faas MM, Spijker H, van Willigen JW, de Haan A and de Vos P: Factors influencing isolation of functional pancreatic rat islets. Pancreas 29: e15-e22, 2004.
|
| 112 |
+
|
| 113 |
+
15. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 391: 43-50, 1998.
|
| 114 |
+
|
| 115 |
+
16. Zhang J and Xu M: Apoptotic DNA fragmentation and tissue homeostasis. Trends Cell Biol 12: 84-89, 2002.
|
| 116 |
+
|
| 117 |
+
17. Kim YH, Wee YM, Choi MY, Lim DG, Kim SC and Han DJ:
|
| 118 |
+
Interleukin (IL)-10 induced by CD11b(+) cells and IL-10-activated regulatory T cells play a role in immune modulation of mesenchymal stem cells in rat islet allografts. Mol Med 17: 697-708, 2011.
|
| 119 |
+
|
| 120 |
+
18. Najjar M, Manzoli V, Abreu M, Villa C, Martino MM, Molano RD, Torrente Y, Pileggi A, Inverardi L, Ricordi C, et al: Fibrin gels engineered with pro-angiogenic growth factors promote engraftment of pancreatic islets in extrahepatic sites in mice. Biotechnol Bioeng 112: 1916-1926, 2015.
|
| 121 |
+
|
| 122 |
+
19. Attia AA: Histological and electron microscopic studies of the effect of beta-carotene on the pancreas of streptozotocin (STZ)-induced diabetic rats. Pak J Biol Sci 12: 301-314. 2009.
|
| 123 |
+
|
| 124 |
+
20. Chen Y, Hong F, Chen H, Fan RF, Zhang XL, Zhang Y and Zhu JX: Distinctive expression and cellular distribution of dopamine receptors in the pancreatic islets of rats. Cell Tissue Res 357: 597-606, 2014.
|
| 125 |
+
|
| 126 |
+
21. Klaffschenkel RA, Waidmann M, Northoff H, Mahmoud AA
|
| 127 |
+
and Lembert N: PK11195, a specific ligand of the peripheral benzodiazepine receptor, may protect pancreatic beta-cells from cytokine-induced cell death. Artif Cells Blood Substit Immobil Biotechnol 40: 56-61, 2012.
|
| 128 |
+
|
| 129 |
+
22. Shimoda M, Noguchi H, Fujita Y, Takita M, Ikemoto T,
|
| 130 |
+
Chujo D, Naziruddin B, Levy MF, Kobayashi N, Grayburn PA
|
| 131 |
+
and Matsumoto S: Islet purification method using large bottles effectively achieves high islet yield from pig pancreas. Cell Transplantat 21: 501-508, 2012.
|
| 132 |
+
|
| 133 |
+
23. Silva PN, Green BJ, Altamentova SM and Rocheleau JV: A
|
| 134 |
+
microfluidic device designed to induce media flow throughout pancreatic islets while limiting shear-induced damage. Lab Chip 13: 4374-4384, 2013.
|
| 135 |
+
|
| 136 |
+
24. Itoh T, Takita M, SoRelle JA, Shimoda M, Sugimoto K,
|
| 137 |
+
Chujo D, Qin H, Naziruddin B, Levy MF and Matsumoto S: Correlation of released HMGB1 levels with the degree of islet damage in mice and humans and with the outcomes of islet transplantation in mice. Cell Transplant 21: 1371-1381, 2012.
|
| 138 |
+
|
| 139 |
+
25. Deans AJ and West SC: DNA interstrand crosslink repair and cancer. Nat Rev Cancer 11: 467-480, 2011.
|
| 140 |
+
|
| 141 |
+
26. Yamamoto-Tanaka M, Makino T, Motoyama A, Miyai M,
|
| 142 |
+
Tsuboi R and Hibino T: Multiple pathways are involved in DNA degradation during keratinocyte terminal differentiation. Cell Death Dis 5: e1181, 2014.
|
| 143 |
+
|
| 144 |
+
27. Barkai U, Weir GC, Colton CK, Ludwig B, Bornstein SR,
|
| 145 |
+
Brendel MD, Neufeld T, Bremer C, Leon A, Evron Y, et al: Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplantat 22: 1463-1476, 2013.
|
| 146 |
+
|
| 147 |
+
28. Henriksnäs J, Lau J, Zang G, Berggren PO, Köhler M and Carlsson PO: Markedly decreased blood perfusion of pancreatic islets transplanted intraportally into the liver: Disruption of islet integrity necessary for islet revascularization. Diabetes 61: 665-673, 2012.
|
| 148 |
+
|
| 149 |
+
29. Szkudelski T: Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the experimental model. Exp Biol Med
|
| 150 |
+
(Maywood) 237: 481-490, 2012.
|
| 151 |
+
|
| 152 |
+
30. Sakata N, Sumi S, Yoshimatsu G, Goto M, Egawa S and Unno M:
|
| 153 |
+
Encapsulated islets transplantation: Past, present and future. World J Gastrointest Pathophysiol 3: 19-26, 2012.
|
| 154 |
+
|
| 155 |
+
31. Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS and Shapiro AJ: Islet cell transplantation for the treatment of type 1 diabetes: Recent advances and future challenges. Diabetes Metab Syndr Obes 7: 211-23, 2014.
|
| 156 |
+
|
| 157 |
+
32. Caballero F, Siniakowicz K, Hollister-Lock J, Duran L, Katsuta H,
|
| 158 |
+
Yamada T, Lei J, Deng S, Westermark GT, Markmann J, et al: Birth and death of human β‑cells in pancreases from cadaver donors, autopsies, surgical specimens, and islets transplanted into mice. Cell Transplant 23: 139-151, 2014.
|
| 159 |
+
|
| 160 |
+
33. Yang SB, Lee HY, Young DM, Tien AC, Rowson-Baldwin A,
|
| 161 |
+
Shu YY, Jan YN and Jan LY: Rapamycin induces glucose intolerance in mice by reducing islet mass, insulin content and insulin sensitivity. J Mol Med (Berl) 90: 575-585, 2012.
|
medical/md/PMC5945097.md
ADDED
|
@@ -0,0 +1,180 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# The Glasgow Medical Journal.
|
| 2 |
+
|
| 3 |
+
No. II. August, 1904.
|
| 4 |
+
|
| 5 |
+
ORIGINAL ARTICLES.
|
| 6 |
+
|
| 7 |
+
CASE OF CHRONIC LYMPHATIC LEUKAEMIA.1 By JOHN WAIN MAN FINDLAY, M.D.,
|
| 8 |
+
Assistant Physician to the Glasgow Royal Infirmary, and Assistant to the Professor of Medicine in St. Mungo's College.
|
| 9 |
+
|
| 10 |
+
A. P., aged 60, first came under observation on 25th April r 1904, complaining of weakness and breathlessness of sixteen years' duration, and of pallor and enlargement of the lymphatic glands of two years' duration.
|
| 11 |
+
|
| 12 |
+
Past history.?In the year 1860, when 17 years of age, he joined the army, and very shortly thereafter contracted what he tells me was diagnosed as a hard chancre; at the same time he suffered from a suppurating bubo. He informs me that his chancre was cauterised. These complaints kept him in hospital for six weeks, and he asserts that he received no internal medication, local remedies alone being used. Towards the close of 1860, he was sent to India (Bombay Presidency),
|
| 13 |
+
and he remained there till 1866. He declares that the Bombay Presidency is noted for its non-malarious character. In 1862, he suffered from an acute orchitis, and in 1863 he had an attack of sunstroke. During the years 1866 to 1870, he was 1 Read at a meeting of the Glasgow Pathological and Clinical Society held on 9th May, 1904.
|
| 14 |
+
|
| 15 |
+
No. 2. F Vol. LXII.
|
| 16 |
+
|
| 17 |
+
stationed at home, and in 1870 he was again ordered to India.
|
| 18 |
+
|
| 19 |
+
His second period of Indian service was spent in the Bengal Presidency, where "fever and ague" were very prevalent, and in 1875 he was seized with " fever and ague," and was confined to hospital with the same for about six weeks.
|
| 20 |
+
|
| 21 |
+
In 1880, patient returned to this country, was discharged from the army, and took to clerking. His first winter in Glasgow started a bronchitis, which has hardly ever left him since, and in 1888 his bronchitis had become so chronic and troublesome that he was unable to go regularly to his work, and unfit to remain as a servant, so he became his own master and opened a small furniture shop. This venture gave him a lot of anxiety and worry, his health and strength kept on gradually failing, and in 1894 he gave up business altogether.
|
| 22 |
+
|
| 23 |
+
In 1895 a swelling appeared on the back of his head, and increased in size till it was larger than a duck's egg. This was diagnosed as a gumma, and he took medicine, containing mercury, for six months, by the end of which time, he declares, all his teeth were quite loose. During the first few weeks of treatment, the lump slowly diminished in size, and before the six months of treatment were up had disappeared without suppurating. In 1897, a gummatous(?) swelling appeared at the back of his neck, was poulticed for about a month with porridge and soda, and then " broke," discharging for about sixteen weeks. In 1898, he suffered from two similar swellings?one over the left mastoid process, the other just below the occipital protuberance?and these, under like treatment, ran much the same course as that in 1897. No sooner had the gummata in the neck healed than he developed " erysipelas" in the face, and this affection spread down the arms into his hands. He says that his face, arms, and hands, were red, cedematous, and greatly swollen at this time, and that leeting and crusting occurred in all these places. The eruption was very itchy, and persisted for a good many weeks. It seems highly probable that this was an eczematous condition. In 1899?when aged 56 years?a gummatous swelling made its appearance on the inner side of his right leg, just above the ankle, and this, after much assiduous poulticing with porridge and soda, occasionally intermitted for anything else that a neighbour might suggest,
|
| 24 |
+
" broke" in a great number of places, there being man}^ holes, he declares, just as though someone had gone over this part of his leg with a punch. This gumma discharged for many months, but did not confine him much to bed. When the leg was
|
| 25 |
+
" running,"
|
| 26 |
+
he noticed that the glands in the right groin got very large, tender, and painful. Though the pain and the tenderness went away when the leg healed up, the glands remained swollen, and have never varied in size since. While afflicted with his leg, he suffered from an eruption, which was dry and covered with thick white, almost silvery, scales on the sole of the right foot. [This eruption may have been a syphilitic psoriasis.]
|
| 27 |
+
During 1899, he drank large quantities of an infusion, which he made himself from sarsaparilla root, chiretta bark, and other " herbs."
|
| 28 |
+
Since 1899, he has had every few months an attack of what he calls " erysipelas." This affection starts as a redness over the bridge of his nose, and gradually spreads till the whole face is affected. It is intensely itchy, and his face swells up to such an extent that frequently his eyes become quite closed.
|
| 29 |
+
|
| 30 |
+
At these times, too, large blisters, the size of shillings, form on his face; he himself, or his wife, usually "jags" these blisters with a needle, which procedure allows a lot of " water" to escape. This eruption sometimes only takes a few hours to reach its height, but may take a day, and frequently he goes to bed all right and wakens in the morning with his face badly swollen. He always feels cold and shivery when this affection comes on, but never vomits, nor does he suffer from headache. When this trouble was fairly developed, it, as a rule, remained very bad for about three days, and then slowly faded away.
|
| 31 |
+
|
| 32 |
+
He has frequently suffered from a
|
| 33 |
+
" rash" on his buttocks, identical, his wife declares, to an eruption in the same locality which I diagnosed as herpes on 5th May. 1904.
|
| 34 |
+
|
| 35 |
+
History of present illness.?Though patient had been weak and very breathless for many years, he remained " well coloured
|
| 36 |
+
" until 1902?about two years ago?when his friends commenced to remark to him that he was getting very pale.
|
| 37 |
+
|
| 38 |
+
About much the same time he himself became conscious that he was losing weight, and that his lymphatic glands were swelling. First he noticed " lumps
|
| 39 |
+
" under his chin, and these grew till in the course of two or three weeks they attained the size of " plunkers," after which they got smaller till they became little larger than haricot beans. Then his attention was drawn to the fact that the glands at both sides of his neck were swelling. Next, he observed that the glands in the left axilla were enlarging, and he declares that these formed a mass the size of a tennis ball, and then slowly subsided. The glands in the right axilla became enlarged shortly after those in the left. As already mentioned, the glands in the right groin swelled up when the ulcers in his leg were discharging
|
| 40 |
+
(1899), and he does not think that they have varied in size since. He cannot say when the glands in the left groin became involved.
|
| 41 |
+
|
| 42 |
+
These glandular swellings in the neck and axillae all made their appearance within the course of three or four months, and during the last eighteen months he has frequently remarked considerable fluctuations in their size; they would swell up to a very noticeable extent in one situation and then go dowij again, only to become unduly prominent in some other region.
|
| 43 |
+
|
| 44 |
+
At different times he has noted the presence of enlarged glands in the infra-axillary regions, in the flanks, and even on the surface of his abdomen. There have never been any glandular tumours in the popliteal spaces or about his elbows. Never at any time were the glands painful or tender, but at times he suffered much from pains in his arms, especially about his elbows, and frequently he had muscular cramps and pains in his legs. He has never had headache, nor pain in his neck.
|
| 45 |
+
|
| 46 |
+
Only during the last year did he begin to notice that his face and eyelids were swollen in the morning, and that his feet and legs swelled after he had been out of bed for a short time.
|
| 47 |
+
|
| 48 |
+
He has never had any fainting fits or attacks of giddiness, and he has never suffered from palpitation; breathlessness, however, has been getting more marked all the time, and, lately, even speaking makes him very short of breath. His dyspnoea has practically kept him a prisoner in the house for the last six months.
|
| 49 |
+
|
| 50 |
+
During the first year after the glandular tumours appeared he very frequently had small bleedings from the nose, and for the last two years he has suffered every now and then from an obstruction of his nostrils?sometimes only one nostril?which is only relieved by the discharge of firm plugs of dried secretion, about the size of his little finger. Occasionally, during the last two years, he has coughed up a little blood.
|
| 51 |
+
|
| 52 |
+
He has never vomited blood, no more has he at any time observed blood in his urine or faeces, and he declares that his motions were never at any time abnormally dark in colour.
|
| 53 |
+
|
| 54 |
+
There have been no bleedings into or under the skin, and he has never suffered from any auditory or visual disturbances.
|
| 55 |
+
|
| 56 |
+
For several months past he has suffered from pain and tenderness over the lower half of the sternum. He has never had pain or tenderness in any of the other bones, if we except the pains in right elbow-joint already alluded to.
|
| 57 |
+
|
| 58 |
+
His appetite has been good throughout, and gastric and intestinal disturbances have been completely absent. He declares that he never sweats. Since the present illness commenced he always feels at his best in the morning.
|
| 59 |
+
|
| 60 |
+
Physical examination.?Patient's entire skin is remarkably pale, though when his temperature is elevated in the afternoon and evening, as happens not infrequently, there is a distinct malar flush. The conjunctivae and buccal mucous membrane show a marked degree of pallor. The face is swollen; the eyelids are "puffy," and pit on pressure. As he lies in bed there is no swelling of feet or legs. His limbs are thin, and his muscles are flabby and weak. There is not much sub-cutaneous fat.
|
| 61 |
+
|
| 62 |
+
Over the right side of the occipital bone, close to the lambdoidal suture, a depression, not involving the entire thickness of the bone, and admitting the points of two fingers, marks the site of the gummatous swelling that disappeared without suppuration under, treatment. Just below the occipital protuberance are several irregular puckered scars, and another scar exists over the left mastoid process?results of the gummata which suppurated. Over the lower third of the inner aspect of the right tibia is an irregularly, and deeply, pigmented area, dotted over with numerous round cicatrices, slightly depressed, with flat, pale, and silky surfaces, and varying in size from that of a split pea to a threepenny piece.
|
| 63 |
+
|
| 64 |
+
All the glands of the neck are enlarged; all are freely movable under the skin and over the deeper lying structures.
|
| 65 |
+
|
| 66 |
+
The majority resemble almonds, haricot beans, marbles, and small plums in shape and size, and no very large glandular masses are seen or felt. All the glands are soft, some are very soft, though not at all of that softness which suggests fluctuation. The submaxillary lymphatic glands, including the suprahyoid, the superficial cervical, the deep cervical, the mastoid, and the parotid 011 the right side are all involved.
|
| 67 |
+
|
| 68 |
+
A chain of glands is felt extending from the clavicle to the axilla on both sides, though more marked on the left. In the left axilla are several masses made up of numerous enlarged glands, somewhat adherent to one another, though not firmly matted together; here the largest mass equals in size that of a hen's egg. The right axilla contains many glandular masses as large as victoria plums, though none of the individual glands are so large as on the left side. Two isolated glands, the size of haricot beans, are present in the left infra-axillary region. No glands can be detected in the popliteal spaces or about the elbows. Both the oblique and vertical sets of 86 Leukaemia.
|
| 69 |
+
|
| 70 |
+
superficial inguinal glands are enlarged on both sides, as also are, I should say, the deep-seated inguinal glands, and large glandular masses can be traced along the course of the external iliac vessels. The glands are larger, more numerous, and somewhat harder in the right than in the left groin: the gumma which suppurated was in the right leg.
|
| 71 |
+
|
| 72 |
+
The tonsils are not at all-enlarged, and there is no excess of lymphoid tissue about the base of the tongue. The thyroid gland is not enlarged.
|
| 73 |
+
|
| 74 |
+
An examination of the chest reveals the presence of chronic bronchitis and emphysema. No dulness suggesting enlarge-ment of the mediastinal lymphatic glands or thymus can be made out, and there is no difference in the quality of the respiratory murmur on the two sides. He has a very trouble-some cough, and copious muco-purulent expectoration.
|
| 75 |
+
|
| 76 |
+
Some dilated venules are present about his cheeks. The external jugular veins are somewhat prominent, and a good many moderately dilated veins are seen over the upper part of the chest on its anterior aspect. The veins in his arms are also unduly prominent, and the superficial epigastric veins are moderately distended, the blood flowing normally, however, viz., from above downwards.
|
| 77 |
+
|
| 78 |
+
Heart.?Diffuse pulsation is seen and felt in the fifth left space, 3 inches from the middle line. Cardiac dulness is all but obliterated by emphysematous lungs. The heart sounds, though weak, are unaccompanied by murmurs, and there is no venous hum to be heard in the neck. The temporal arteries are hard and .tortuous, and the radial arteries are large, tortuous, and beaded with calcareous deposit. The pulse is regular and weak, and numbers from 84 to 96 per minute.
|
| 79 |
+
|
| 80 |
+
Abdomen.?Flatulent distension of the abdomen prevents me arriving at any conclusion as to the state of the abdominal lymphatic glands, apart from the external iliac already mentioned. There is no fluid in the peritoneal cavity. The spleen is moderately enlarged, measuring in length 6J inches; it reaches three finger breadths below the costal margin?
|
| 81 |
+
|
| 82 |
+
about 2J inches?and the splenic dulness begins above at the level of the tenth rib. The spleen does not feel unduly hard ;
|
| 83 |
+
no notch is detected. The liver is also enlarged, and is displaced downwards to a slight extent; in the middle line its vertical measurement is 3J inches, in the nipple line 6 inches, and in the axillary line 7 inches. Owing to the exceeding softness of the liver, its lower edge is palpated with difficulty. No enlargement of the kidneys can be detected. Urine, on standing, shows a considerable deposit of pale pink urates; a faint haze of albumen is present, but no blood and no sugar.
|
| 84 |
+
|
| 85 |
+
On microscopic examination a few hyaline casts are seen.
|
| 86 |
+
|
| 87 |
+
There are no signs to suggest disease of the nervous system.
|
| 88 |
+
|
| 89 |
+
The knee-jerks are active; plantar reflexes are present, and flexor in type. Pupils are slightly unequal, the right being the larger, but both contract actively to light and on accom-modation. Apart from pallor, an ophthalmoscopic examination reveals no abnormality. Hearing is quite good, taste is normal, but sense of smell is absent.
|
| 90 |
+
|
| 91 |
+
An irregular pyrexia is present; the morning temperature ranges between 97? and 98? F., and the evening record between 99? and 103? F.
|
| 92 |
+
|
| 93 |
+
Blood examinations (25th April, 1904, 415 p.m.)?
|
| 94 |
+
|
| 95 |
+
Red corpuscles, ...... 1,175,000 White ? 152,500 Ratio of white to red, about 1 in 7.
|
| 96 |
+
|
| 97 |
+
| 95 | per cent. |
|
| 98 |
+
|------|-------------|
|
| 99 |
+
| 1-9 | ?) |
|
| 100 |
+
| 2'5 | ? |
|
| 101 |
+
| 0*2 | ? |
|
| 102 |
+
| 0-1 | ? |
|
| 103 |
+
|
| 104 |
+
Differential count?
|
| 105 |
+
|
| 106 |
+
Small lymphocytes, Large ? ...
|
| 107 |
+
|
| 108 |
+
Polymorphonuclear neutrophiles, .
|
| 109 |
+
|
| 110 |
+
Transitional forms, Myelocytes, .....
|
| 111 |
+
|
| 112 |
+
1st May, 1904 (3*30 p.m.)?
|
| 113 |
+
|
| 114 |
+
Red corpuscles, ...... 1,343,600 White 334,800 Ratio of white to red, about 1 in 4.
|
| 115 |
+
|
| 116 |
+
Haemoglobin, ..... 25*5 per cent.
|
| 117 |
+
|
| 118 |
+
? . . , 25*5 per cent haemoglobin .. n Colour index, ?t ?, =
|
| 119 |
+
' practically unity.
|
| 120 |
+
|
| 121 |
+
26 per cent red corpuscles r j j Differential count (by Dr. Leonard Findlay)?
|
| 122 |
+
|
| 123 |
+
Small lymphocytes, ..... 96 per cent.
|
| 124 |
+
|
| 125 |
+
Large ? ..... 2 ?
|
| 126 |
+
|
| 127 |
+
Polymorphonuclear neutrophiles, . . 2 ?
|
| 128 |
+
|
| 129 |
+
Transitional forms, ..... 0 ,,
|
| 130 |
+
Myelocytes, ...... 0 ?
|
| 131 |
+
|
| 132 |
+
8th May, 190^ (3*30 p.m.)-
|
| 133 |
+
Red corpuscles, ...... 1,424,000 White 568,660 Ratio of white to red, about 1 in 2*5.
|
| 134 |
+
|
| 135 |
+
Haemoglobin, j ..... 30 per cent.
|
| 136 |
+
|
| 137 |
+
i -i 30 per cent haemoglobin Ak , Aak Colour index, -r-6 r~ = 1*05 .-. + 0*05 ' 28'4 per cent red corpuscles The small lymphocytes vary greatly in their affinity for nuclear stains, and show considerable differences in size.
|
| 138 |
+
|
| 139 |
+
Somewhat frequently it is difficult to determine whether a particular lymphocyte should be classed as large or small, but I have only counted as large lymphocytes those cells about which there could be no doubt whatever. In some films, numerous deformed or tattered and poorly-staining lympho-cytes of large size?degeneration forms (?)?were seen.
|
| 140 |
+
|
| 141 |
+
Mitosis was not once observed. Eosinophilic cells are very scanty; none were seen while the differential counts were being made. Though the red corpuscles vary in size and in their affinity for stains, it cannot be said that poikilocytosis exists. A few nucleated red corpuscles, both normoblasts and megaloblasts, were detected in the films prepared on 8th May.
|
| 142 |
+
|
| 143 |
+
Remarks.?The great rarity of this condition is my excuse for reporting this case, which would seem to be quite a typical example of chronic lymphatic leukaemia or chronic lymphsemia.
|
| 144 |
+
|
| 145 |
+
That it is not Hodgkin's disease is shown by the great increase in the number of white blood corpuscles; and the fact that this increase is due to a lymphocytosis distinguishes this case from one of spleno-medullary leukaemia. A lymphocytosis may be met with in lymphosarcoma, but never to the extent that obtains in this patient; besides, the widespread involvement of the lymphatic glands would of itself exclude such a diagnosis.
|
| 146 |
+
|
| 147 |
+
The presence of small lymphocytes to the extent of 95 per cent, and the scantiness of the other white cells, are quite in accord with the usual findings.
|
| 148 |
+
|
| 149 |
+
The number of red cells in this case is decidedly low.
|
| 150 |
+
|
| 151 |
+
Thus, Cabot1 gives, as the average of seven of his cases, 2,900,000, though in this are included counts of 912,000 and 700,000; and Osier 2 gives 2,294,000 as the average of red cells in his series; Muir, however,3 declares that the red corpuscles may be diminished to such an extent that they number only 1,000,000 or even less, and Rosenfeld4 reports a case where the red cells were only 1,210,300.
|
| 152 |
+
|
| 153 |
+
The number of white cells in this case is fairly high, and the ratio of white to red corpuscles?1 to 7, 1 to 4, and 1 to 25?might be described as extreme. Thus, Monro1 mentions the average findings as 140,000 whites, with a ratio to the reds of 1 in 20; Cabot2 gives an average of 59,000 white, with a ratio to the reds of 1 in 48?in one of Cabot's cases, however, the whites numbered 1,480,000, with a ratio to reds of 1 to 2; Osier3 gives the average of whites as 144,800, and the average ratio as 1 to 16?a ratio of 1 to 10 Osier regards as extreme; Muir4 declares that the ratio may be as high as 1 in 3 or even higher, and that the total number of leucocytes does not often reach 1,000,000.
|
| 154 |
+
|
| 155 |
+
Though chronic lymphaemia is most common in middle adult life, it is by no means unknown for it to develop in men at the age of my patient.
|
| 156 |
+
|
| 157 |
+
It is interesting to note that this man has suffered from two of the recognised remote causes of leukaemia, viz., malaria and syphilis : his syphilis, moreover, has been practically untreated.
|
| 158 |
+
|
| 159 |
+
In view of the fact that Jonathan Hutchinson 5 quotes a case with twenty-two years' complete freedom from recognised symptoms as an illustration of the long latency of syphilis, it is worth while drawing attention to the fact that this man enjoyed a still longer period of latency, viz., thirty-five years.
|
| 160 |
+
|
| 161 |
+
Attention may be directed to the circumstance that this man has suffered from pain and tenderness over the sternum for several months. Though frequently mentioned by writers of " manuals
|
| 162 |
+
" and " systems
|
| 163 |
+
" of medicine, it is rare to come across these symptoms in reading reports of cases, and, according to Muir,0 they would appear to be quite exceptional in this malady.
|
| 164 |
+
|
| 165 |
+
Though the glandular enlargement is considerable, pressure symptoms are almost absent, a fact that becomes quite ex-plicable when we note that matting of the glands only exists in the axillae, and even there but to a slight extent. The marked fluctuation in the size of the glands is quite in harmony with the descriptions of this disease. The duration
|
| 166 |
+
?about two years?of such considerable and widespread glandular enlargement would, however, appear to be some-what exceptional, since Muir7 states that enlargement of the lymphatic glands, when at all marked, usually occurs either late in the disease or in cases which run a rapid course.
|
| 167 |
+
|
| 168 |
+
It seems to me a very remarkable fact that, with such a severe degree of anaemia, haemic murmurs should be entirely absent.
|
| 169 |
+
|
| 170 |
+
As regards the skin disease that this man has suffered from so frequently, it is difficult, not having seen it, to express an opinion. It may be that his own diagnosis of " erysipelas
|
| 171 |
+
"
|
| 172 |
+
is perfectly correct, or it may be that this skin affection is what Liveing1 would call " spurious erysipelas." The suddenness with which it develops, and its intensely itchy and burning character are, however, very suggestive of an urticaria, and it corresponds somewhat closely to the " urticaria oedematosa" and " urticaria bullosa" as described by Crocker.2 Crocker suggests that many cases termed " urticaria bullosa" are really "dermatitis herpetiformis," and it may be that such, or pemphigus, is the condition here. The eruption that occurs on the buttocks is herpes. I cannot find that leukaemic patients have any special tendency to diseases of the skin, so the pronounced liability on this man's part to suffer from skin affections must probably be regarded as accidental rather than dependent in any way upon the leukaemia itself; a view, moreover, which is supported by the fact that he suffered from these skin troubles for at least a year before his lymphatic glands became enlarged.
|
| 173 |
+
|
| 174 |
+
From 26th April to 2nd May he has been taking 15 m. of Fowler's solution per diem, and from 3rd to 9th May, 22 5 m.
|
| 175 |
+
|
| 176 |
+
He undoubtedly feels better, and is not nearly so breathless since treatment was commenced, and the red corpuscles and haemoglobin, so far, show a slight but steady increase. On the other hand, the white corpuscles have undergone a very considerable augmentation. At the present time, however, it is impossible to say how much these variations in reds and whites are due to the arsenic and how much to the fluctuations which are recognised to occur in this disease.
|
| 177 |
+
|
| 178 |
+
1 Handbook of Skin Diseases, 1887, p. 100.
|
| 179 |
+
|
| 180 |
+
2 Diseases of the Skin, third edition, 1903, pp. 100, 101.
|
medical/md/PMC6438152.md
ADDED
|
@@ -0,0 +1,291 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# Chemical 
|
| 2 |
+
|
| 3 |
+
EDGE ARTICLE Hankum Park and Seung Bum Park Label-free target identifi cation reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent
|
| 4 |
+
|
| 5 |
+

|
| 6 |
+
|
| 7 |
+
**View Journal | View Issue**
|
| 8 |
+
|
| 9 |
+

|
| 10 |
+
|
| 11 |
+
|
| 12 |
+
Cite this: Chem. Sci., 2019, 10, 3449 All publication charges for this article have been paid for by the Royal Society of Chemistry
|
| 13 |
+
|
| 14 |
+
# Label-Free Target Identification Reveals Oxidative Dna Damage As The Mechanism Of A Selective Cytotoxic Agent†
|
| 15 |
+
|
| 16 |
+
## Hankum Park A And Seung Bum Park *Ab
|
| 17 |
+
|
| 18 |
+
Phenotypic screening can not only identify promising first-in-class drug candidates, but can also reveal potential therapeutic targets or neomorphic functions of known proteins. In this study, we identified target proteins of SB2001, a cytotoxic agent that acts specifically against HeLa human cervical cancer cells. Because SB2001 lacks chemical modification sites, label-free target identification methods including thermal stability shift-based fluorescence difference in two-dimensional gel electrophoresis (TS-FITGE) and thermal proteome profiling (TPP) were applied to characterize its mechanism of action. Owing to their differences, the two label-free target identification methods uncovered complementary target candidates. Candidates from both methods were prioritized according to their selective lethality upon the knockdown of those genes in HeLa cells, compared to CaSki cells which were used as a negative control cell line from the human cervix. LTA4H was identified only by TS-FITGE, but not by TPP, because only one isoform was stabilized by SB2001. Furthermore, it was implied that a noncanonical function of LTA4H was involved in the SB2001 activity. MTH1 was identified by both TS-FITGE
|
| 19 |
+
and TPP, and SB2001 inhibited the function of MTH1 in hydrolyzing oxidized nucleotides. Compared to CaSki cells, HeLa cells displayed downregulated DNA mismatch repair pathways, which made HeLa cells more susceptible to the oxidative stress caused by SB2001, resulting in increased 8-oxoG concentrations, DNA damage, and subsequent cell death.
|
| 20 |
+
|
| 21 |
+
Received 7th December 2018 Accepted 9th February 2019 DOI: 10.1039/c8sc05465g rsc.li/chemical-science
|
| 22 |
+
|
| 23 |
+
## Introduction
|
| 24 |
+
|
| 25 |
+
Phenotype-based chemical screening has contributed signicantly to the discovery of rst-in-class molecular entities with novel mechanisms of action.1 Phenotypic screening is an empirical and discovery-driven approach for identifying new bioactive compounds that modulate a specic cellular outcome of interest, rather than exploring a particular hypothesis-driven molecular target.2 The unbiased nature of phenotypic screening allows the discovery of novel proteins with therapeutic potential, disease-relevant pathways, unrevealed functions of proteins, or polypharmacology with multiple targets.3–7 Therefore, the identication of target proteins that bind to the bioactive compound is a crucial and decisive component of the phenotype-based drug discovery process.8 Conventional chemical proteomics methods for affinitybased target identication require functional chemical handles to immobilize the bioactive compound on a solid support.8 It is essential to know the structure–activity relationship (SAR) of bioactive compounds and their synthetic accessibility for the preparation of probe molecules; this has been a major obstacle in identifying the targets of bioactive natural compounds and synthetic compounds without functional handles.9 Therefore, label-free target identication is an important technique for the compounds with tight SARs. Cellular thermal shi assay
|
| 26 |
+
(CETSA) was the rst reported label-free method for verifying the physical engagement of bioactive compounds with target proteins in live cells.10 CETSA is based on the principle that the thermal denaturation curve of a particular protein may shi upon the binding of a bioactive compound. To expand the CETSA principle for an unbiased proteome-wide target identication method, thermal proteome proling (TPP)11 and thermal stability shi-based uorescence difference in twodimensional gel electrophoresis (TS-FITGE)12 were developed
|
| 27 |
+
(Fig. 1). TPP uses quantitative mass spectrometry with isobaric mass reporter-tagged peptides, whereas TS-FITGE utilizes a 2dimensional (2D) gel electrophoresis with different uorescence-tagged proteins. Although it has been proven that the thermal stability shi can identify target proteins in live cells, its applications remain limited.11–16 In this study, we used phenotypic screening to identify target proteins of a human cervical cancer HeLa cell-specic cytotoxic compound, SB2001 (Fig. 2a). Because any chemical
|
| 28 |
+
|
| 29 |
+

|
| 30 |
+
|
| 31 |
+
|
| 32 |
+
modications neutralized the function and HeLa cell-selectivity of SB2001, label-free target identication methods such as TPP
|
| 33 |
+
and TS-FITGE were the only available approaches for target identication. These methods were found to be complementary in terms of the number of total proteins and isoform coverage.
|
| 34 |
+
|
| 35 |
+
Functional experiments to conrm the candidates revealed leukotriene A4 hydrolase (LTA4H) and MutT homolog 1 (MTH1)
|
| 36 |
+
as target proteins. Protein expression proling revealed that mismatch repair (MMR) proteins were downregulated in HeLa cells, causing them to be susceptible to oxidative stress. Consequently, HeLa cells could not eliminate the increased concentration of oxidized nucleotides caused by the action of SB2001, which resulted in oxidative DNA damage and apoptosis.
|
| 37 |
+
|
| 38 |
+
## Results Discovery Of Sb2001 As A Hela-Specic Cytotoxic Agent
|
| 39 |
+
|
| 40 |
+
Phenotypic screening was conducted using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to assess the potential anticancer activity of the in-house chemical library containing heterobiaryl pyrazolo[3,4-b]pyridine moieties17 constructed by privileged substructure-based diversity-oriented synthesis (pDOS).18 Interestingly, SB2001 (Fig. 2a)
|
| 41 |
+
showed cytotoxicity specically against HeLa cells with a concentration for 50% maximal inhibition of cell growth
|
| 42 |
+
(GI50) value of 228 nM, but not against CaSki cells and the other eleven cell lines originating from either normal or cancerous tissues (Fig. 2b, cytotoxicity data of SB2001 toward other cell lines are not shown in this manuscript and will be published separately19). Although we attempted to functionalize the active compound for an affinity-based pull-down method, the SAR investigation indicated that minor modications to the original structure of SB2001 attenuated either its potency or its selectivity.19 Therefore, we decided to identify the target proteins of SB2001 using label-free methods based on the principle of thermal stability shi upon drug engagement.
|
| 43 |
+
|
| 44 |
+
## Label-Free Target Identication Using Ts-Fitge And Tpp
|
| 45 |
+
|
| 46 |
+
TS-FITGE and TPP share the same basic principle, which is that the binding of a protein to a drug may cause a shi in its thermal denaturation curve. In both TS-FITGE and TPP, the live cells were heat-denatured at various temperature points in the presence or absence of a specic drug. Thereaer, the heattreated cells were lysed, and the soluble fractions of cell lysates were collected by centrifugation. However, TS-FITGE and TPP
|
| 47 |
+
differ in several aspects, including the labeling method (uorescence dyes vs. isobaric mass tags, respectively), the separation of the analytes (2D gel electrophoresis vs. liquid chromatography, respectively), data acquisition (uorescence scanning vs. tandem mass spectrometry, respectively), quantication (of proteoforms vs. peptides, respectively), and proteomic proling (Fig. 1). These differences mean that the two labelfree techniques can be complementary.
|
| 48 |
+
|
| 49 |
+
During TS-FITGE, two different uorescent dyes were added to the soluble protein fraction at each temperature: Cy3 dyes were added to the DMSO-treated group, and Cy5 dyes were added to the drug-treated group. The Cy3- and Cy5-tagged proteomes from the same temperature were then mixed, and the labeled proteins were separated by 2D gel electrophoresis according to the isoelectric point and molecular weight of each proteoform. For inter-gel spot localization and quantication, the proteome of the lowest temperature was tagged with Cy2 and spiked into each gel as an internal standard. Importantly, we used Cy2, Cy3, and Cy5 dyes with almost identical mass and charge to minimize spot separation in 2D gel electrophoresis.12 The ratio of Cy5 to Cy3 uorescence intensity of each proteoform spot was quantied, and their distributions at each temperature were plotted using a box plot. Outliers in each box
|
| 50 |
+
|
| 51 |
+

|
| 52 |
+
|
| 53 |
+
plot were considered as differentially stabilized proteins, indicating binding of the target protein to the drug.
|
| 54 |
+
|
| 55 |
+
In the TPP, on the other hand, the soluble proteins from heat-denatured cells were digested into peptides, followed by the chemical conjugation of 10-plex isobaric mass tags to the peptide at each temperature. The tagged peptides, from ten different temperature points, were pooled and then separated by reverse-phase liquid chromatography according to their hydrophobicity. Using tandem mass spectrometry, each peptide was identied, and its abundance at each temperature was quantied based on its reporter ions. The melting curves of the proteins were inferred from those of their component peptides, and the melting temperatures (Tm) of the proteins in the DMSOand drug-treated groups were calculated separately. Proteins with signicant changes in Tm were considered as target proteins. Although quantitative proteomics using liquid chromatography-tandem mass spectrometry has become a state-ofthe-art technology due to its high throughput and high proteome coverage,20 TS-FITGE remains crucial for target identication, in that it can analyze different proteoforms including protein isoforms and various post-translational modications
|
| 56 |
+
(PTMs).21
|
| 57 |
+
|
| 58 |
+
## Selection And Prioritization Of Target Candidates
|
| 59 |
+
|
| 60 |
+
As shown in Fig. S1,† the global melting proteomes (meltomes)
|
| 61 |
+
in the absence or presence of SB2001 were revealed using both TS-FITGE and TPP. Target candidates with a signicant thermal stability shi were independently chosen from the results of TSFITGE and TPP: seven proteins (LTA4H, MTH1, ALDH2, PGAM1, ALDH1B1, SDHA, and ECH1) from TS-FITGE, and seven proteins (MTH1, MTRR, ERLIN2, DIS3, ERLIN1, CASP7, and ECH1) from TPP (Fig. 2c and S2†). Even though the thermal stability shi indicates the target engagement, the intensity of the thermal stability shi does not necessarily correlate with the relevance of the protein's function to its phenotype because each protein is diverse in terms of structure, innate thermal stability, and binding sites. Therefore, we prioritized the candidates not according to the intensity of the thermal shi but based on their functional relevance. As SB2001 caused selective cytotoxicity against HeLa cells, we compared the changes in viability aer knocking down each candidate gene using small interfering RNA (siRNA) in HeLa versus CaSki cells
|
| 62 |
+
(Fig. S3a†). CaSki cells were chosen as a negative control cell line, as both CaSki and HeLa cells originated from human papilloma virus-infected cervical cancer patients22 while SB2001 showed specic cytotoxicity only in HeLa cells but not in CaSki cells (Fig. 2b). As shown in Fig. 2c, we prioritized target candidates according to their selective lethality upon gene knockdown of each candidate protein in HeLa cells over CaSki cells, which phenocopied the HeLa cell-specic cytotoxicity of SB2001, for further functional validation.
|
| 63 |
+
|
| 64 |
+
## Target Validation Of Lta4H
|
| 65 |
+
|
| 66 |
+
The spot with the highest Cy5/Cy3 ratio in the 55 C gel (Fig. 3a, b and S1a†) showed temperature-dependent thermal stabilization in the presence of SB2001. In-gel digestion and mass
|
| 67 |
+
|
| 68 |
+
|
| 69 |
+

|
| 70 |
+
|
| 71 |
+
|
| 72 |
+
spectrometry analysis revealed this spot to be LTA4H, and the genetic knockdown of LTA4H substantially increased lethality in HeLa cells compared to that in CaSki cells (Fig. 2c). As LTA4H
|
| 73 |
+
was not selected by TPP, we manually inspected the melting curve of LTA4H from the TPP data. As shown in Fig. 3c, LTA4H
|
| 74 |
+
was excluded from the candidate list because its Tm shi was relatively small—0.48 and 0.52 C in the duplicate experiments.
|
| 75 |
+
|
| 76 |
+
CETSA with the LTA4H antibody revealed a marginal shi in its melting curve, consistent with the TPP data (Fig. 3d). However, this was inconsistent with the results of TS-FITGE, where LTA4H showed the most prominent red spot. Through western blot analysis of the 2D gel, we found that LTA4H had more than two isoforms with identical molecular weight (Fig. 3e), as has been previously reported.23,24 Interestingly, only one spot (lled triangle in Fig. 3e) exhibited thermal stabilization by SB2001. Consequently, the single LTA4H isoform that was isolated by TS-FITGE showed signicant thermal stabilization, but the overall thermal shi of LTA4H in TPP was marginal because the melting curve included all different LTA4H isoforms owing to the bottom-up analytic nature of shotgun proteomics.21 As the LTA4H antibody detected other LTA4H isoforms as well, CETSA
|
| 77 |
+
also showed a marginal difference in the melting curve. To conrm that LTA4H was the protein stabilized by SB2001, we conducted TS-FITGE with a known LTA4H inhibitor, SC57461A.25 As shown in Fig. 3f, SC-57461A clearly stabilized the same LTA4H spot as SB2001 did. On the other hand, SB2024, an inactive analogue of SB2001 (Fig. S4†), did not induce thermal stabilization of LTA4H in TS-FITGE (Fig. S5a and S5b†) and TPP
|
| 78 |
+
(Fig. S5c†).
|
| 79 |
+
|
| 80 |
+
It is known that LTA4H is a bifunctional enzyme that acts as both an epoxide hydrolase and aminopeptidase, and its catalytic sites for those two functions overlap.26 Therefore, we performed in vitro enzymatic assays to investigate whether SB2001 mimics the activity of SC-57461A, which blocks both the hydrolase and peptidase activity of LTA4H.25 However, SB2001 inhibited neither the hydrolase activity nor the aminopeptidase activity of LTA4H (Fig. 3g and h). On the other hand, the viability of HeLa cells was not affected by SC-57461A (Fig. 3i).
|
| 81 |
+
|
| 82 |
+
In spite of the contradictory activity with the known inhibitor, surface plasmon resonance (SPR) assay conrmed that SB2001 showed one-to-one binding kinetics to LTA4H with a KD
|
| 83 |
+
value of 2.7 mM while SB2024 hardly showed a binding sensorgram (Fig. 3j and S5d†). Next, we constructed a dose–
|
| 84 |
+
response curve of SB2001 aer the genetic knockdown of LTA4H to validate whether LTA4H was functionally related to the cytotoxic activity of SB2001. Compared to the negative control siRNA, the genetic knockdown of LTA4H signicantly sensitized the activity of SB2001 by increasing its potency
|
| 85 |
+
(Fig. 3k). Taken together, our results showed that the binding of SB2001 to LTA4H is functionally related to its HeLa cell-specic cytotoxicity, but the canonical function of LTA4H was not inhibited by SB2001, suggesting that LTA4H might have a yet undiscovered function. It is worth mentioning that the relatively low KD value in SPR assay compared to the GI50 value of HeLa cells implied that other target proteins might also be involved in the SB2001 activity.
|
| 86 |
+
|
| 87 |
+
## Target Validation Of Mth1
|
| 88 |
+
|
| 89 |
+
Another promising target candidate in TS-FITGE was found
|
| 90 |
+
|
| 91 |
+

|
| 92 |
+
|
| 93 |
+

|
| 94 |
+
|
| 95 |
+
using immobilized pH gradient gel strips spanning pH 4–7
|
| 96 |
+
(Fig. S1b†). The red spot "a", indicated by a triangle in Fig. 4a, had an outlying Cy5/Cy3 ratio in the 52 C gel (Fig. 4b) and was identied as MTH1 (also known as 7,8-dihydro-8-oxoguanine triphosphatase, NUDT1). The red spot "b", indicated by an arrow in Fig. 4a, had the highest Cy5/Cy3 ratio (Fig. 4b), but the spot also appeared red in the 37 C gel; therefore it was thought not to be the target protein stabilized by SB2001. The thermal stabilization of MTH1 was also identied by TPP (Fig. 4c). One melting curve (DMSO_2 in Fig. 4c) had a distinct shape and bottom value from the others; in addition, the comparison between SB2001 and SB2024, a negative control compound (Fig. S2†), supported that SB2001 induced the repetitive thermal stabilization of MTH1 compared to DMSO_1, SB2024_1, and SB2024_2 (Fig. S6a†). Therefore, we excluded the DMSO_2 curve as an outlier shape caused by low coverage of quantied peptides due to the limited running and scanning time for tandem mass analysis. CESTA with the MTH1 antibody conrmed the thermal stabilization of MTH1 upon treatment with SB2001 compared to DMSO and SB2024 (Fig. 4d and S6b†).
|
| 97 |
+
|
| 98 |
+
The isothermal dose–response curve showed a dose-dependent stabilization of MTH1 by SB2001 at 52 C (Fig. 4e).
|
| 99 |
+
|
| 100 |
+
MTH1 is a sanitizing enzyme that catalyzes the hydrolysis of oxidized nucleotides to protect DNA from oxidative stress.27,28 SB2001 strongly inhibited the in vitro enzymatic activity of
|
| 101 |
+
|
| 102 |
+
|
| 103 |
+

|
| 104 |
+
|
| 105 |
+
MTH1 toward its substrates, 8-oxo-dGTP and 2-OH-dATP
|
| 106 |
+
(Fig. 4f), indicating that SB2001 inhibits the canonical function of MTH1, as the other MTH1 inhibitors such as TH287 (ref. 29)
|
| 107 |
+
and (S)-crizotinib30 do (Fig. S7a–S7c†). In the Lineweaver–Burk plot with various concentrations of 8-oxo-dGTP, KM increased while Vmax remained constant upon treatment of SB2001
|
| 108 |
+
(Fig. S8†). These data indicate that SB2001 competes with the substrate to act as a competitive inhibitor such as TH287. The knockdown of MTH1 in HeLa cells also altered the cytotoxic potency of SB2001 by increasing the GI50 value (Fig. 4g),
|
| 109 |
+
providing further evidence that the biological effect of SB2001 is associated with MTH1. Thus, we performed SPR analysis to biophysically conrm the direct binding of SB2001 to the puried MTH1 protein; the SPR sensorgram clearly showed oneto-one binding kinetics, as well as a concentration-dependent increase in response units (Fig. 4h). The negative control compound SB2024 neither inhibited in vitro enzymatic assay
|
| 110 |
+
(Fig. S6c†) nor showed the binding events in SPR analysis
|
| 111 |
+
(Fig. S6d†).
|
| 112 |
+
|
| 113 |
+
## Origin Of The Selective Cytotoxicity Of Sb2001 Toward Hela Cells
|
| 114 |
+
|
| 115 |
+
Although we revealed that SB2001 inhibits the cellular function of MTH1, the reason for the selective cytotoxicity of SB2001 was still unclear because its function is rather general in many cellular systems. First, we investigated whether the binding of SB2001 to MTH1 would be impaired in CaSki cells. However, the thermal stability of MTH1 was also stabilized upon treatment with SB2001 in CaSki cells (Fig. 5a). Next, we checked whether the expression levels of MTH1 would be signicantly higher in HeLa cells to stimulate the differential activity of SB2001. However, through a global protein expression proling analysis between HeLa and CaSki cells obtained using quantitative proteomics, we found that MTH1 had nearly identical expression patterns in HeLa and CaSki cells (Fig. 5b). We then attempted to identify other differentially expressed proteins between HeLa and CaSki cells. Gene set enrichment analysis indicated that the expression of proteins involved in the DNA
|
| 116 |
+
mismatch repair (MMR) pathway, including MSH2, MSH3, MSH6, RFC, PCNA, Pold, and LigI, was consistently downregulated in HeLa cells (Fig. 5c and S9†). The correlation between the downregulated expression of MMR proteins and functional MMR-deciency was shown in a previous proteomics study with colorectal tumor cells.31 The DNA MMR pathway primarily repairs base mismatches and insertion/deletion loops through recognizing replication errors, excising the errors, resynthesizing the nucleotides, and ligating the gap.32 8-Oxoguanine (8-oxoG), an oxidized form of guanine, can pair with both cytosine and adenine, allowing it to cause G:C to T:A
|
| 117 |
+
transversions.33 In addition, there has been emerging evidence that MMR also plays important roles in the response to oxidative DNA damage by removing oxidized nucleotides such as 8oxoG from DNA.34 Thus, it is possible that the downregulation of MMR proteins in HeLa cells makes them more susceptible to oxidative stress. As shown in Fig. 5d, HeLa cells were more vulnerable than CaSki cells to the oxidant KBrO3, supporting this hypothesis. Furthermore, when HeLa cells were co-treated with SB2001 and an antioxidant, N-acetylcysteine, to compensate for the oxidative stress, the cytotoxicity of SB2001 in HeLa cells was signicantly neutralized in a dose-dependent manner
|
| 118 |
+
(Fig. 5e). Therefore, we propose that SB2001 selectively kills HeLa cells through the inhibition of MTH1 and the subsequent increases in cellular oxidative stress and oxidized nucleotides; this can be compensated for by MMR pathways in CaSki cells, but not in HeLa cells. The effect of MMR proteins on the HeLa cell-specic cytotoxicity of SB2001 was also supported by the knockdown of each MMR gene in HeLa cells; silencing of each gene resulted in an increased potency of SB2001 (Fig. 5f and S3b†).
|
| 119 |
+
|
| 120 |
+
## Biological Evaluation Of The Proposed Mechanism-Of-Action Of Sb2001
|
| 121 |
+
|
| 122 |
+
Once MTH1 is inhibited, the concentration of oxidized nucleotides increases, and these oxidized nucleotides are incorporated into DNA.35 When we measured the concentration of 8oxoG in HeLa and CaSki cells by avidin-Alexa Fluor 488 imaging,36 the basal concentration of 8-oxoG was higher in MMR-downregulated HeLa cells than in CaSki cells (Fig. 6a),
|
| 123 |
+
which is consistent with previous reports.37 Treatment of the strong oxidant KBrO3 elevated the cellular concentration of 8oxoG signicantly in HeLa cells, but only slightly in CaSki cells, while treatment with SB2001 increased cellular 8-oxoG in HeLa cells exclusively (Fig. 6a). The levels of 8-oxoG were correlated with cell viability upon treatment with SB2001 (Fig. 2b) and KBrO3 (Fig. 5d). This result was consistent with a previous study showing that the increase in 8-oxoG was the key determinant for cytotoxicity by MTH1 inhibition.38 Indeed, the suggested relationship between MTH1 inhibition and MMR was also supported by Bignami et al.,
|
| 124 |
+
37,39 who clearly showed that the expression of human MTH1 in MMR-defective mouse embryonic broblasts reduced the cellular 8-oxoG concentration, mutation rate, and genetic instability.
|
| 125 |
+
|
| 126 |
+
The increased incorporation of oxidized nucleotides into DNA causes DNA damage, which can be assessed by single-cell gel electrophoresis, also known as a comet assay.40 8-OxoG DNA
|
| 127 |
+
glycosylase 1 (OGG1) excises 8-oxoG bases in DNA, and the induced strand breaks cause DNA relaxation and migration in the gel electrophoresis, allowing measurement of the extent of lesion-specic DNA damage. The treatment of live cells with hydrogen peroxide for 5 min increased DNA damage and the migration length in both HeLa and CaSki cells (Fig. 6b).
|
| 128 |
+
|
| 129 |
+
However, a 2-day treatment of SB2001 increased DNA damage only in HeLa cells. The comet assay data clearly supported our nding that long-term treatment with SB2001 induces oxidative DNA damage only in HeLa cells but not in CaSki cells—where the oxidative stress could be attenuated by the MMR pathwaycompared to the acute treatment of an indiscriminate oxidant, hydrogen peroxide. As DNA damage accumulates, ataxia-telangiectasia mutated (ATM) kinase autophosphorylates and phosphorylates its downstream substrate, p53.41 Immunoblotting of these markers clearly showed that ATM and p53 were selectively activated in HeLa cells upon treatment with SB2001 (Fig. 6c). Consequently, caspase-3 and poly(ADP-ribose) polymerase
|
| 130 |
+
(PARP) were cleaved only in HeLa cells (Fig. 6c), which corresponded to the observed initial phenotype, the selective apoptosis of HeLa cells by SB2001 (Fig. 2b).
|
| 131 |
+
|
| 132 |
+
## Discussion
|
| 133 |
+
|
| 134 |
+
Although both TS-FITGE and TPP are based on thermal stability shi induced by drug engagement, they differ in several technical aspects. We utilized both techniques to compensate for the weakness of each of them and to increase the success rate of
|
| 135 |
+
|
| 136 |
+
|
| 137 |
+

|
| 138 |
+
|
| 139 |
+

|
| 140 |
+
|
| 141 |
+

|
| 142 |
+
label-free target identication. TPP, which uses state-of-the-art quantitative mass spectrometry, could identify and quantify thousands of proteins nearly simultaneously. Even though TSFITGE could visualize only a thousand protein spots in a 2D gel, protein isoforms, including different PTMs, could be separated based on their isoelectric points and molecular weights.
|
| 143 |
+
|
| 144 |
+
LTA4H was a good example of the different characteristics of TPP and TS-FITGE. LTA4H showed only a marginal Tm shi in TPP, but one isoform of LTA4H had a signicant thermal shi in TS-FITGE. Therefore, TS-FITGE illustrated its potential to identify relevant target proteins when a compound modulates their specic proteoforms. Moreover, the identication of LTA4H as a target protein demonstrated the merits of phenotypic screening. Phenotypic screening improves the likelihood of nding novel drug targets or new functions of known proteins. Historically, the aminopeptidase activity had been considered as a non-canonical function of LTA4H until the endogenous substrate and physiological relevance of the aminopeptidase function was discovered.42 It is now recognized that both functions play important roles in the regulation of inammation. Throughout this study, we assumed that LTA4H might have an undiscovered function regulating inammation-mediated oxidative DNA damage, which is probably mediated by leukotrienes. Indeed, previous studies showed that leukotriene C4 (LTC4), another metabolic product of LTA4, is a major mediator of stress-induced oxidative DNA damage, and antagonizing the LTC4 receptor abolished oxidative DNA damage and cell death.43 Our uorescence imaging data illustrated that cellular oxidative DNA damage was induced by the knockdown of LTA4H as well as MTH1 (Fig. S10†). It is worth mentioning that the cellular level of 8oxoG was signicantly higher in the case of SB2001 treatment than the knockdown case of either LTA4H or MTH1. The increased HeLa-selective cytotoxicity upon dual knockdown of LTA4H and MTH1, compared to their single knockdown, might support the dual modulation of SB2001 toward LTA4H
|
| 145 |
+
and MTH1 (Fig. S11a†). We also observed that the conventional LTA4H inhibitor (SC-57461A) in combination with the MTH1 inhibitor (TH287) did not mimic the efficacy of SB2001
|
| 146 |
+
(Fig. S11b†), indicating that the canonical LTA4H function is not involved in HeLa cell-specic cytotoxicity. Collectively, through the potential neomorphic function of LTA4H, the dual modulation of LTA4H and MTH1 might exhibit the effects of SB2001 on oxidative DNA damage in HeLa cells.
|
| 147 |
+
|
| 148 |
+
Synthetic lethality has been exploited to improve the therapeutic index of anticancer therapies by inhibiting one gene in cancer cells where another gene is specically mutated in the tumor, but normal in healthy cells.44 MMR
|
| 149 |
+
deciency has been identied as an important determinant of synthetic lethality.45–47 The mechanism of SB2001 seemed analogous to the synthetic lethality in that target inhibition by SB2001 was only lethal in HeLa cells where MMR proteins were consistently downregulated. Actually, SB2001 showed mild cytotoxicity in CaSki cells aer the knockdown of MSH2, MSH6, PMS2, or EXO1 (Fig. S12 and S3c†). We assume that SB2001 did not exhibit its full efficacy because not just single gene but a group of MMR genes are upregulated in CaSki cells.
|
| 150 |
+
|
| 151 |
+
Taken together, these results suggest that as the cellular level of 8-oxoG increased upon treatment with SB2001, the oxidative stress exceeded the capacity limit of MMR in HeLa cells, resulting in apoptosis, rather than DNA repair. We inferred that the compound could be suitable to treat MMR-downregulated HeLa cells specically, while not damaging other tissues with an undamaged MMR system. Indeed, SB2001 exhibited selective in vivo efficacy in the mice xenograed with MMR-downregulated HeLa cells but not in C33A, another cervical cancer cell.19 Interestingly, SB2001 exhibited differential behavior compared to the typical MTH1 inhibitors, (S)-crizotinib29 and TH287 (ref. 30) (Fig. S7a†). Although these molecules inhibited the in vitro MTH1 activity (Fig. S7b†), (S)-crizotinib and TH287 did not potently and selectively kill HeLa cells (Fig. S7d and S7e†). Additionally, while SB2001 decreased MSH2 and MSH6 expression levels exclusively in HeLa cells, (S)-crizotinib and TH287 did not differentially downregulated either MSH2 or MSH6 between HeLa and CaSki cells (Fig. S7f†). Therefore, SB2001 has a different mechanism from the typical MTH1 inhibitors via dual inhibition of LTA4H and MTH1 along with downregulated MMR in cellular systems.
|
| 152 |
+
|
| 153 |
+
## Conclusions
|
| 154 |
+
|
| 155 |
+
In conclusion, we identied target proteins and the mechanism of action of SB2001, a HeLa cell-specic cytotoxic agent discovered in a cell viability assay. Both TS-FITGE and TPP were used for target identication in a label-free manner because SB2001 has a tight SAR without any available modication sites.
|
| 156 |
+
|
| 157 |
+
LTA4H was identied only by TS-FITGE, as only one of its isoforms showed signicant thermal stabilization. Knockdown of LTA4H phenocopied the selective cytotoxicity of SB2001; functional validation suggested that a non-canonical function of LTA4H might be involved in the SB2001 activity. Both TS-FITGE
|
| 158 |
+
and TPP identied MTH1 as a target protein candidate, and the function of MTH1, the hydrolysis of oxidized nucleotides, was inhibited by SB2001. Protein expression proling revealed that proteins in the MMR pathway were downregulated in HeLa cells, causing them to become more vulnerable to oxidative stress and subsequent DNA damage. As a result, SB2001 was selectively cytotoxic to HeLa cells due to the increased levels of 8-oxoG, which led to DNA damage and apoptosis (Fig. 6d). This study demonstrates the merits of phenotypic screening followed by label-free target identication, as a potential neomorphic function of LTA4H related to oxidative DNA damage was implied, and polypharmacological application related to oxidative DNA damage involving LTA4H and MTH1 was suggested.
|
| 159 |
+
|
| 160 |
+
## Data Availability Statement
|
| 161 |
+
|
| 162 |
+
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identier PXD009903.
|
| 163 |
+
|
| 164 |
+
## Conflicts Of Interest
|
| 165 |
+
|
| 166 |
+
There are no conicts to declare.
|
| 167 |
+
|
| 168 |
+
## Acknowledgements
|
| 169 |
+
|
| 170 |
+
This work was supported by the Creative Research Initiative Grant (2014R1A3A2030423) and Bio & Medical Technology Development Program (2012M3A9C4048780) through the National Research Foundation of Korea (NRF) funded by the Korean Government (Ministry of Science & ICT). We appreciate Dr Sanghee Lee and Dr Heejun Kim, former members of our laboratory, for the early stage discovery of SB2001 and its chemical synthesis, respectively. We also thank Dr Jin Young Kim at the Korea Basic Science Institute for providing access to the Orbitrap Fusion Lumos mass spectrometer.
|
| 171 |
+
|
| 172 |
+
## Notes And References
|
| 173 |
+
|
| 174 |
+
1 D. C. Swinney and J. Anthony, Nat. Rev. Drug Discovery, 2011, 10, 507–519.
|
| 175 |
+
|
| 176 |
+
2 B. K. Wagner, Expert Opin. Drug Discovery, 2016, 11, 121–125.
|
| 177 |
+
|
| 178 |
+
3 M. Schenone, V. Dancik, B. K. Wagner and P. A. Clemons, Nat. Chem. Biol., 2013, 9, 232–240.
|
| 179 |
+
|
| 180 |
+
4 J. G. Moffat, F. Vincent, J. A. Lee, J. Eder and M. Prunotto, Nat. Rev. Drug Discovery, 2017, 16, 531–543.
|
| 181 |
+
|
| 182 |
+
5 T. Ito, H. Ando, T. Suzuki, T. Ogura, K. Hotta, Y. Imamura, Y. Yamaguchi and H. Handa, Science, 2010, 327, 1345–1350.
|
| 183 |
+
|
| 184 |
+
6 L. de Waal, T. A. Lewis, M. G. Rees, A. Tsherniak, X. Wu, P. S. Choi, L. Gechijian, C. Hartigan, P. W. Faloon, M. J. Hickey, N. Tolliday, S. A. Carr, P. A. Clemons, B. Munoz, B. K. Wagner, A. F. Shamji, A. N. Koehler, M. Schenone, A. B. Burgin, S. L. Schreiber, H. Greulich and M. Meyerson, Nat. Chem. Biol., 2016, 12, 102–108.
|
| 185 |
+
|
| 186 |
+
7 M. Prior, C. Chiruta, A. Currais, J. Goldberg, J. Ramsey, R. Dargusch, P. A. Maher and D. Schubert, ACS Chem.
|
| 187 |
+
|
| 188 |
+
Neurosci., 2014, 5, 503–513.
|
| 189 |
+
|
| 190 |
+
8 S. Ziegler, V. Pries, C. Hedberg and H. Waldmann, Angew.
|
| 191 |
+
|
| 192 |
+
Chem., Int. Ed. Engl., 2013, 52, 2744–2792.
|
| 193 |
+
|
| 194 |
+
9 L. Laraia and H. Waldmann, Drug Discovery Today: Technol.,
|
| 195 |
+
2017, 23, 75–82.
|
| 196 |
+
|
| 197 |
+
10 D. Martinez Molina, R. Jafari, M. Ignatushchenko, T. Seki, E. A. Larsson, C. Dan, L. Sreekumar, Y. Cao and P. Nordlund, Science, 2013, 341, 84–87.
|
| 198 |
+
|
| 199 |
+
11 M. M. Savitski, F. B. Reinhard, H. Franken, T. Werner, M. F. Savitski, D. Eberhard, D. Martinez Molina, R. Jafari, R. B. Dovega, S. Klaeger, B. Kuster, P. Nordlund, M. Bantscheff and G. Drewes, Science, 2014, 346, 1255784.
|
| 200 |
+
|
| 201 |
+
12 H. Park, J. Ha, J. Y. Koo, J. Park and S. B. Park, Chem. Sci.,
|
| 202 |
+
2017, 8, 1127–1133.
|
| 203 |
+
|
| 204 |
+
13 F. B. M. Reinhard, D. Eberhard, T. Werner, H. Franken, D. Childs, C. Doce, M. F. Savitski, W. Huber, M. Bantscheff, M. M. Savitski and G. Drewes, Nat. Methods, 2015, 12, 1129–1131.
|
| 205 |
+
|
| 206 |
+
14 K. V. M. Huber, K. M. Olek, A. C. Muller, C. S. H. Tan, K. L. Bennett, J. Colinge and G. Superti-Furga, Nat.
|
| 207 |
+
|
| 208 |
+
Methods, 2015, 12, 1055–1057.
|
| 209 |
+
|
| 210 |
+
15 I. Becher, T. Werner, C. Doce, E. A. Zaal, I. Togel, C. A. Khan, A. Rueger, M. Muelbaier, E. Salzer, C. R. Berkers, P. F. Fitzpatrick, M. Bantscheff and M. M. Savitski, Nat.
|
| 211 |
+
|
| 212 |
+
Chem. Biol., 2016, 12, 908–910.
|
| 213 |
+
|
| 214 |
+
16 M. Kitagawa, P.-J. Liao, K. H. Lee, J. Wong, S. C. Shang, N. Minami, O. Sampetrean, H. Saya, D. Lingyun, N. Prabhu, G. K. Diam, R. Sobota, A. Larsson, P. Nordlund, F. McCormick, S. Ghosh, D. M. Epstein, B. W. Dymock and S. H. Lee, Nat. Commun., 2017, 8, 2200.
|
| 215 |
+
|
| 216 |
+
17 S. Lee and S. B. Park, Org. Lett., 2009, 11, 5214–5217.
|
| 217 |
+
|
| 218 |
+
18 J. Kim, H. Kim and S. B. Park, J. Am. Chem. Soc., 2014, 136, 14629–14638.
|
| 219 |
+
|
| 220 |
+
19 S. Lee, W. Cho and S. B. Park, manuscript in preparation.
|
| 221 |
+
|
| 222 |
+
20 J. R. Yates, J. Am. Chem. Soc., 2013, 135, 1629–1640.
|
| 223 |
+
|
| 224 |
+
21 R. Aebersold, J. N. Agar, I. J. Amster, M. S. Baker, C. R. Bertozzi, E. S. Boja, C. E. Costello, B. F. Cravatt, C. Fenselau, B. A. Garcia, Y. Ge, J. Gunawardena, R. C. Hendrickson, P. J. Hergenrother, C. G. Huber, A. R. Ivanov, O. N. Jensen, M. C. Jewett, N. L. Kelleher, L. L. Kiessling, N. J. Krogan, M. R. Larsen, J. A. Loo, R. R. Ogorzalek Loo, E. Lundberg, M. J. MacCoss, P. Mallick, V. K. Mootha, M. Mrksich, T. W. Muir, S. M. Patrie, J. J. Pesavento, S. J. Pitteri, H. Rodriguez, A. Saghatelian, W. Sandoval, H. Schluter, S. Sechi, ¨
|
| 225 |
+
S. A. Slavoff, L. M. Smith, M. P. Snyder, P. M. Thomas, M. Uhl´en, J. E. Van Eyk, M. Vidal, D. R. Walt, F. M. White, E. R. Williams, T. Wohlschlager, V. H. Wysocki, N. A. Yates, N. L. Young and B. Zhang, Nat. Chem. Biol.,
|
| 226 |
+
2018, 14, 206–214.
|
| 227 |
+
|
| 228 |
+
22 K.-H. Lee, E.-K. Yim, C.-J. Kim, S.-E. Namkoong, S.-J. Um and J.-S. Park, Gynecol. Oncol., 2005, 98, 45–53.
|
| 229 |
+
|
| 230 |
+
23 B. Odlander, H.-E. Claesson, T. Bergman, O. R˚admark, H. J¨ornvall and J. Z. Haeggstr¨om, Arch. Biochem. Biophys.,
|
| 231 |
+
1991, 287, 167–174.
|
| 232 |
+
|
| 233 |
+
24 H. Bito, N. Ohishi, I. Miki, M. Minami, T. Tanabe, T. Shimizu and Y. Seyama, J. Biochem., 1989, 105, 261–264.
|
| 234 |
+
|
| 235 |
+
25 L. J. Askonas, J. F. Kachur, D. Villani-Price, C.-D. D. Liang, M. A. Russell and W. G. Smith, J. Pharmacol. Exp. Ther.,
|
| 236 |
+
2002, 300, 577–582.
|
| 237 |
+
|
| 238 |
+
26 S. Numao, F. Hasler, C. Laguerre, H. Srinivas, N. Wack, P. J¨ager, A. Schmid, A. Osmont, P. R¨othlisberger, J. Houguenade, C. Bergsdorf, J. Dawson, N. Carte, A. Hofmann, C. Markert, L. Hardaker, A. Billich, R. M. Wolf, C. A. Penno, B. Bollbuck, W. Miltz and T. A. R¨ohn, Sci. Rep., 2017, 7, 13591.
|
| 239 |
+
|
| 240 |
+
27 K. Sakumi, M. Furuichi, T. Tsuzuki, T. Kakuma, S. Kawabata, H. Maki and M. Sekiguchi, J. Biol. Chem., 1993, 268, 23524–
|
| 241 |
+
23530.
|
| 242 |
+
|
| 243 |
+
28 K. Fujikawa, H. Kamiya, H. Yakushiji, Y. Fujii, Y. Nakabeppu and H. Kasai, J. Biol. Chem., 1999, 274, 18201–18205.
|
| 244 |
+
|
| 245 |
+
29 K. V. M. Huber, E. Salah, B. Radic, M. Gridling, J. M. Elkins, A. Stukalov, A. S. Jemth, C. Gokturk, K. Sanjiv, K. Stromberg, T. Pham, U. W. Berglund, J. Colinge, K. L. Bennett, J. I. Loizou, T. Helleday, S. Knapp and G. Superti-Furga, Nature, 2014, 508, 222–227.
|
| 246 |
+
|
| 247 |
+
30 H. Gad, T. Koolmeister, A.-S. Jemth, S. Eshtad, S. A. Jacques, C. E. Strom, L. M. Svensson, N. Schultz, T. Lundback,
|
| 248 |
+
|
| 249 |
+
B. O. Einarsdottir, A. Saleh, C. Gokturk, P. Baranczewski, R. Svensson, R. P. A. Berntsson, R. Gustafsson, K. Stromberg, K. Sanjiv, M.-C. Jacques-Cordonnier, M. Desroses, A.-L. Gustavsson, R. Olofsson, F. Johansson, E. J. Homan, O. Loseva, L. Brautigam, L. Johansson, A. Hoglund, A. Hagenkort, T. Pham, M. Altun, F. Z. Gaugaz, S. Vikingsson, B. Evers, M. Henriksson, K. S. A. Vallin, O. A. Wallner, L. G. J. Hammarstrom, E. Wiita, I. Almlof, C. Kalderen, H. Axelsson, T. Djureinovic, J. C. Puigvert, M. Haggblad, F. Jeppsson, U. Martens, C. Lundin, B. Lundgren, I. Granelli, A. J. Jensen, P. Artursson, J. A. Nilsson, P. Stenmark, M. Scobie, U. W. Berglund and T. Helleday, Nature, 2014, 508, 215–221.
|
| 250 |
+
|
| 251 |
+
31 P. J. Halvey, X. Wang, J. Wang, A. A. Bhat, P. Dhawan, M. Li, B. Zhang, D. C. Liebler and R. J. C. Slebos, Cancer Res., 2014, 74, 387–397.
|
| 252 |
+
|
| 253 |
+
32 G.-M. Li, Cell Res., 2007, 18, 85–98.
|
| 254 |
+
|
| 255 |
+
33 K. C. Cheng, D. S. Cahill, H. Kasai, S. Nishimura and L. A. Loeb, J. Biol. Chem., 1992, 267, 166–172.
|
| 256 |
+
|
| 257 |
+
34 G. Bridge, S. Rashid and S. Martin, Cancers, 2014, 6, 1597–
|
| 258 |
+
1614.
|
| 259 |
+
|
| 260 |
+
35 H. Maki and M. Sekiguchi, Nature, 1992, 355, 273–275.
|
| 261 |
+
|
| 262 |
+
36 L. Struthers, R. Patel, J. Clark and S. Thomas, Anal. Biochem.,
|
| 263 |
+
1998, 255, 20–31.
|
| 264 |
+
|
| 265 |
+
37 C. Colussi, E. Parlanti, P. Degan, G. Aquilina, D. Barnes, P. Macpherson, P. Karran, M. Crescenzi, E. Dogliotti and M. Bignami, Curr. Biol., 2002, 12, 912–918.
|
| 266 |
+
|
| 267 |
+
38 U. Warpman Berglund, K. Sanjiv, H. Gad, C. Kalder´en, T. Koolmeister, T. Pham, C. Gokturk, R. Jafari, G. Maddalo, B. Seashore-Ludlow, A. Chernobrovkin, A. Manoilov, I. S. Pateras, A. Rasti, A. S. Jemth, I. Alml¨of, O. Loseva, T. Visnes, B. O. Einarsdottir, F. Z. Gaugaz, A. Saleh, B. Platzack, O. A. Wallner, K. S. A. Vallin, M. Henriksson, P. Wakchaure, S. Borhade, P. Herr, Y. Kallberg, P. Baranczewski, E. J. Homan, E. Wiita, V. Nagpal, T. Meijer, N. Schipper, S. G. Rudd, L. Br¨autigam, A. Lindqvist, A. Filppula, T. C. Lee, P. Artursson, J. A. Nilsson, V. G. Gorgoulis, J. Lehti¨o, R. A. Zubarev, M. Scobie and T. Helleday, Ann. Oncol.,
|
| 268 |
+
2016, 27, 2275–2283.
|
| 269 |
+
|
| 270 |
+
39 M. T. Russo, M. F. Blasi, F. Chiera, P. Fortini, P. Degan, P. Macpherson, M. Furuichi, Y. Nakabeppu, P. Karran, G. Aquilina and M. Bignami, Mol. Cell. Biol., 2004, 24, 465–
|
| 271 |
+
474.
|
| 272 |
+
|
| 273 |
+
40 P. L. Olive and J. P. Banath, Nat. Protoc., 2006, 1, 23–29.
|
| 274 |
+
|
| 275 |
+
41 A. Mar´echal and L. Zou, Cold Spring Harbor Perspect. Biol.,
|
| 276 |
+
2013, 5, a012716.
|
| 277 |
+
|
| 278 |
+
42 R. J. Snelgrove, P. L. Jackson, M. T. Hardison, B. D. Noerager, A. Kinloch, A. Gaggar, S. Shastry, S. M. Rowe, Y. M. Shim, T. Hussell and J. E. Blalock, Science, 2010, 330, 90–94.
|
| 279 |
+
|
| 280 |
+
43 E. Dvash, M. Har-Tal, S. Barak, O. Meir and M. Rubinstein, Nat. Commun., 2015, 6, 10112.
|
| 281 |
+
|
| 282 |
+
44 W. G. Kaelin Jr, Nat. Rev. Cancer, 2005, 5, 689–698.
|
| 283 |
+
|
| 284 |
+
45 S. A. Martin, A. McCarthy, L. J. Barber, D. J. Burgess, S. Parry, C. J. Lord and A. Ashworth, EMBO Mol. Med., 2009, 1, 323–
|
| 285 |
+
337.
|
| 286 |
+
|
| 287 |
+
46 M. Hewish, S. A. Martin, R. Elliott, D. Cunningham, C. J. Lord and A. Ashworth, Br. J. Cancer, 2013, 108, 983–992.
|
| 288 |
+
|
| 289 |
+
47 S. A. Martin, M. Hewish, D. Sims, C. J. Lord and A. Ashworth, Cancer Res., 2011, 71, 1836–1848.
|
| 290 |
+
|
| 291 |
+
|
medical/md/PMC6764476.md
ADDED
|
@@ -0,0 +1,28 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
|
| 2 |
+
|
| 3 |
+

|
| 4 |
+
|
| 5 |
+
POSTER \#10
|
| 6 |
+
|
| 7 |
+
# Adherence Of Patients To Oral Oncolytic And Neurologic Specialty Medications Provided By A Specialty Pharmacy
|
| 8 |
+
|
| 9 |
+
Binita Bhusal, Kiona Oleru, Veronica Arikian, Ryan Jaster, Marc Stranz and Justin Lindhorst
|
| 10 |
+
|
| 11 |
+
## Abstract
|
| 12 |
+
|
| 13 |
+
Background: Specialty medications (SP-D) are high cost prescription medications designed for the treatment of complex chronic conditions, i.e. cancer and neurological diseases. Such medications require special handling and shipping, administration, and patient education. To achieve the desired treatment outcomes, including minimizing adverse events, medication adherence is key. There are barriers to poor medication adherence, some of which include high cost, poor understanding of disease and associated therapy, psychological status, forgetfulness, complex dosing regimens, and side-effects.
|
| 14 |
+
|
| 15 |
+
The consequences of non-adherence include increased healthcare resource consumption and poor disease treatment outcomes, e.g. increased relapse, decreased survival time, and/or lack of patient satisfaction. Specialty pharmacy provided medication therapy management (SPMTM) can be important to achieving acceptable medication adherence and, therefore, better treatment outcomes. The specialty pharmacy is a community pharmacy focused on dispensing and providing clinical services pertaining to SP-D. It has pharmacy permits in 50 states as well as in Washington DC, Puerto Rico, and the US Virgin Islands. It is accredited by URAC and ACHC as a specialty pharmacy. Some of the key services provided by specialty pharmacy are: oncology, neurology, autoimmune disease, analgesia (non-controlled drug), investigational drugs, and other SP-D to treat rare/ultra-rare conditions.
|
| 16 |
+
|
| 17 |
+
Aims: The primary objective of the study was to measure the adherence rate to the oncology and neurology SP-D dispensed by the specialty pharmacy. The secondary objective of this study is to compare the quality-of-life (QoL) of patients who voluntarily participated in the SPMTM program at the program's start of care (SOC) assessment (before the SP-D had been started) and at the follow-up (FU) assessment (after SP-D had been started).
|
| 18 |
+
|
| 19 |
+
Methods: A retrospective, observational study of patient reported outcomes (PRO) was conducted at a specialty pharmacy among patients diagnosed with various forms of cancers and neurological issues who had prescriptions filled for SP-D from January 1, 2018 to December 31,2018. Patient education by the pharmacist was offered as part of the SPMTM program throughout patient participation in the program. Each patient was offered medication therapy assessment at SOC and 7 days prior to each refill dispense, using a proprietary clinical assessment instrument designed to capture patient reported data via telephonic interview with patients or their caregivers. Embedded in the assessment instruments were two QoL PRO metrics: (1) Number of days work/school missed; and (2) How have you been feeling? (1–10 scale, where 1 was feeling terrible and 10 was feeling wonderful). The means of the SOC (BEFORE SP drug state) and the F-U (AFTER SP drug state) data were captured monthly and annualized. The annualized means were compared, using the Mann-Whitney U-value (M-WU) twotailed statistic to test for a statistically significantdifference between the annualized means of the respective QoL measures at the p < 0.05 level of significance. In addition, the overall mean of the Proportion of Days Covered (PDC) was calculated, using the URAC PDC formula. Results: The total number of unique patients was 39,567, and the average number of dispenses per unique patient was two. The number of unique patients who voluntarily participated in the SPMTM
|
| 20 |
+
program and received clinical assessments was 33,243 (84%); 6,331 (16%) patients declined to participate in the SPMTM program. The number of patients who completed only the SOC assessment was 19,946 (60%); the number of patients who participated in only F-U assessment was 3,324 (10%); and the number of patients who participated in both assessments was 4,322 (13%). The overall mean annual Proportion of Days Covered (PDC) was 0.962 (96.2%). The medication adherence rate is 20.25%
|
| 21 |
+
higher as compared to the industry standard adherence rate of 80%. The mean Days of work/school missed QoL metric at SOC was 0.16 days and it was 0.02 days after F-U assessment. The annualized mean difference in work/school days missed demonstrated an improvement between before and after receiving SP-D, and SPMTM was 0.14 days. The Mann-Whitney U-value (M-WU) was determined to be 4, which had a calculated p ¼ 0.0001, and the M-WU value at the p < 0.05 level was 37. The How have you been feeling QoL metric annualized mean at SOC assessment was 7, and the annualized mean at refill assessment was 7.46. The total improvement in feeling is 0.46 higher on the 10-point scale. Therefore, patients reported improvement in how they felt after taking SP-D and participating in the SPMTM program. The M-WU value is 4, and calculated p ¼ 0.0001. The critical value of M-WU at p < 0.05 is 37.
|
| 22 |
+
|
| 23 |
+
Conclusions: From this 1-year study it was determined that: (1) the annualized PDC adherence rate of 0.96 was 20.25% higher than the industry standard of 0.8; (2) the Number of days work missed QoL was less after starting on a SP-D with SPMTM; and (3) the How patients feel QoL metric demonstrated that patients felt better after starting SP-D with SPMTM. The improved adherence rate was associated with taking the SP-D while participating in the SPMTM. The encouraging findings of this study suggest that additional larger studies should be conducted.
|
| 24 |
+
|
| 25 |
+
## Keywords
|
| 26 |
+
|
| 27 |
+
Adherence; MTM; PRO; QoL; assessments PRESENTER
|
| 28 |
+
Royce Burruss royce.burruss@biomatrixsprx.com
|
medical/md/PMC6910871.md
ADDED
|
@@ -0,0 +1,133 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
Follicular Helper T Cells Are Major Human Immunodeficiency Virus-2 Reservoirs and Support Productive Infection
|
| 2 |
+
|
| 3 |
+
## Ana Godinho-Santos, Russell B. Foxall,A Ana V. Antão,B **Bárbara Tavares,** Tiago Ferreira,C Ana Serra-Caetano, Paula Matoso,D **And Ana E. Sousa**
|
| 4 |
+
|
| 5 |
+
Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Portugal Follicular helper T cells (Tfh), CD4 lymphocytes critical for efficient antibody responses, have been shown to be key human immunodeficiency virus (HIV)-1 reservoirs. Human immunodeficiency virus-2 infection represents a unique naturally occurring model for investigating Tfh role in HIV/acquired immune deficiency syndrome, given its slow rate of CD4 decline, low to undetectable viremia, and high neutralizing antibody titers throughout the disease course. In this study, we investigated, for the first time, Tfh susceptibility to HIV-2 infection by combining in vitro infection of tonsillar Tfh with the ex vivo study of circulating Tfh from HIV-2-infected patients. We reveal that Tfh support productive HIV-2 infection and are preferential viral targets in HIV-2-infected individuals.
|
| 6 |
+
|
| 7 |
+
Keywords. follicular helper T cells; HIV-2; HIV/AIDS;
|
| 8 |
+
Tfh; viral reservoirs.
|
| 9 |
+
|
| 10 |
+
Life-long antiretroviral therapy (ART) is currently required to control viral replication in the 36 million people with human immunodeficiency virus (HIV). A better understanding of the establishment and maintenance of the persistent HIV reservoirs is critical to identify strategies to prevent viral rebound soon after ART interruption.
|
| 11 |
+
|
| 12 |
+
Follicular helper T cells (Tfh), CD4 T cells specialized in B-cell help
|
| 13 |
+
|
| 14 |
+

|
| 15 |
+
|
| 16 |
+

|
| 17 |
+
|
| 18 |
+
 and thus essential for durable antibody (Ab) responses, have been shown to be key HIV-1 reservoirs [1]. Follicular helper T cell biology and activation state may facilitate HIV infection within the germinal centers, which can be viewed as HIV sanctuaries even in individuals receiving ART [1, 2]. Although various studies have addressed the role of Tfh in HIV/acquired immune deficiency syndrome (AIDS),
|
| 19 |
+
there are important gaps concerning the relationship between the dynamics of Tfh viral reservoirs and its impact on development of neutralizing Abs (nAbs). Human immunodeficiency virus-2, a naturally occurring attenuated form of HIV/AIDS, provides a unique model to investigate the interplay between Tfh and HIV. Human immunodeficiency virus-2 infection is associated with the establishment of disseminated reservoirs similarly to HIV-1 [3]. Notwithstanding this, HIV-2-infected patients feature the following: (1) low to undetectable plasma viral load in the absence of ART [3, 4]; (2) slow rate of CD4 decline with reduced impact on the survival of infected adults [4]; (3) progressive immune activation directly associated with the degree of CD4 decline [4]; and (4) high titers of nAbs throughout the disease course [5]. There are limited data on the impact of HIV-2 on Tfh. In this study, we investigated, for the first time, the ability of Tfh to support HIV-2 infection in vitro and ex vivo through the study of purified circulating Tfh (cTfh) from HIV-2-infected individuals.
|
| 20 |
+
|
| 21 |
+
## Methods Human Samples
|
| 22 |
+
|
| 23 |
+
Tonsil specimens were obtained through routine pediatric tonsillectomy at Centro Hospitalar Universitário Lisboa Norte
|
| 24 |
+
([CHULN] Lisbon, Portugal). Human immunodeficiency virus-2-infected patients were under follow-up at Clinica Universitária de Doenças Infecciosas of CHULN. The study was conducted under the approval of the Ethical Boards of the CHULN/Faculdade de Medicina da Universidade de Lisboa.
|
| 25 |
+
|
| 26 |
+
Samples were collected after written informed consent from each participant or their legal representatives.
|
| 27 |
+
|
| 28 |
+
## Cell Isolation
|
| 29 |
+
|
| 30 |
+
Tonsillar mononuclear cells were recovered through tissue dispersion, isolated via Ficoll-Paque Plus (GE Healthcare) density gradient separation, and subsequently magnetically enriched (untouched Human CD4 T Cell Isolation Kit, MojoSort; BioLegend). Follicular helper T cells were then isolated from these cells as illustrated in Figure 1A (purity >98%; FACSAria high-speed cell sorter; BD Biosciences). Peripheral blood mononuclear cells, isolated by Ficoll-Paque Plus, were magnetically enriched for CD4 T cells (untouched Human CD4 T cell Enrichment kit; Stem Cell Technologies) and subsequently sort-purified (purity >98%; FACSAria) as illustrated in Figure 2A.
|
| 31 |
+
|
| 32 |
+

|
| 33 |
+
|
| 34 |
+
In Vitro Infections The following primary isolates were used as previously described [6]: CCR5- (R5-) tropic HIV-2, 60415K, subtype A;
|
| 35 |
+
CXCR4- (X4-) tropic HIV-2, 20.04, subtype A; and HIV-1 R5-tropic, 92US660, subtype B; HIV-1 X4-tropic, 92HT599, subtype B. All obtained from NIH AIDS Reagent Program, except 20.04 (provided by Nuno Taveira, Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Portugal). Sorted Tfh (2.5 × 105) were infected with primary isolates (1.6 ng reverse transcriptase [RT]/106 cells), washed after 3 hours with phosphate-buffered saline, and cultured (2.5 × 106 cells/mL) at 37°C/5% CO2 in Roswell Park Memorial Institute 1640 medium with 10% fetal bovine serum, 2 mM L-glutamine, 50 U/mL penicillin-streptomycin, 50 µg/mL gentamicin
|
| 36 |
+
|
| 37 |
+

|
| 38 |
+
|
| 39 |
+
(Gibco/Invitrogen) plus 3 µg/mL Polybrene (Sigma) in 96-well plates (Costar). After 24 hours, 5 × 104 cells were collected for deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) extraction, and the remaining cells were stimulated with immobilized anti-CD3 (α-CD3i, 1 μg/mL; eBioscience) and soluble anti-CD28 (α-CD28s, 1 μg/mL; eBioscience) in 96-well plates. Both cells and supernatants were collected after 48 hours and stored at −80°C.
|
| 40 |
+
|
| 41 |
+
## Quantification Of Cell-Associated Human Immunodeficiency Virus Deoxyribonucleic Acid And Gag Messenger Ribonucleic Acid By Real- Time Polymerase Chain Reaction
|
| 42 |
+
|
| 43 |
+
Total DNA and RNA were extracted from cell pellets of in vitroinfected Tfh and sort-purified blood CD4 T-cell subsets, using AllPrep DNA/RNA Micro kit (QIAGEN) and ZR-Duet DNA/
|
| 44 |
+
RNA MiniPrep kit (Zymo Research), respectively. For gag messenger RNA (mRNA) quantification, 80 ng of total RNA was used to synthesize complementary DNA using oligo(dT)20 and SuperScript III RT (Invitrogen). Real-time polymerase chain reaction (PCR) was performed with ABI 7500 Fast Real-Time PCR System (Applied Biosystems) using TaqMan gene expression master mix (Applied Biosystems); primers and probes used are described in Supplementary Table 1. Positive controls were generated as previously described [6].
|
| 45 |
+
|
| 46 |
+
## Viral Infectivity Assay
|
| 47 |
+
|
| 48 |
+
TZM-bl cells, carrying β-galactosidase gene under HIV-1 long terminal repeat control, were infected with supernatants harvested from in vitro-infected Tfh, in duplicates. Cells were lysed after 40 hours to evaluate Tat-inducible β-galactosidase expression by chlorophenolred-β-d-galactopyranoside colorimetric assay (CPRG; Roche). The background absorbance of lysed uninfected cells was subtracted from results.
|
| 49 |
+
|
| 50 |
+
## Statistical Analysis
|
| 51 |
+
|
| 52 |
+
Wilcoxon matched-pairs signed rank test or the Friedman test with Dunn's multiple-comparison posttest were performed using GraphPad Prism (v6.01) software. P < .05 were considered significant.
|
| 53 |
+
|
| 54 |
+
## Results
|
| 55 |
+
|
| 56 |
+
To assess their susceptibility to HIV-2 infection, we sort-purified Tfh from human tonsillar tissue based on CXCR5, PD-1, and ICOS expression (Figure 1A) and challenged them with HIV-2 and HIV-1 primary isolates with selective CCR5 or CXCR4 coreceptor usage, using RT activity to normalize the viral input. We found that HIV-2 were able to infect Tfh, irrespectively of coreceptor usage as shown by total HIV DNA levels measured after 24 hours of infection (Figure 1B). As anticipated, Tfh were susceptible to HIV-1 in our in vitro system, independently of their tropism, which is in agreement with previous reports [1, 7, 8]. Moreover, as expected given the higher expression of CXCR4 compared with CCR5 on Tfh, HIV-1 X4-tropic virus yielded increased copies of gag than its R5-tropic counterpart (Figure 1B). It is interesting to note that, in contrast with the pattern observed for HIV-1, CXCR4 usage was not associated with higher total HIV-2 DNA in the case of HIV-2 primary isolates (Figure 1B). The levels of HIV-1 X4-tropic virus were also significantly higher than those obtained with either R5or X4-tropic HIV-2 (Figure 1B).
|
| 57 |
+
|
| 58 |
+
We next investigated the levels of viral transcription in HIV2-infected Tfh by quantifying viral gag mRNA upon 24 hours of infection. As shown in Figure 1C, both R5- and X4-tropic HIV-2 viruses generated gag mRNA transcripts, demonstrating ongoing viral transcription in HIV-2-infected Tfh. It is interesting to note that, in the case of HIV-2-infected Tfh, there was a significant direct correlation between the levels of total HIV DNA and gag mRNA, which was not observed in the case of HIV-1 infection (Figure 1D).
|
| 59 |
+
|
| 60 |
+
To evaluate whether Tfh can support productive HIV-2 infection, we quantified the amount of viral production upon T-cell receptor (TCR) activation with α-CD3i/α-CD28s after 24 hours of infection. We observed an increase of cell-associated total viral DNA levels in both R5- and X4-tropic HIV-2 isolates after 48 hours of stimulation (Figure 1E), which suggests that Tfh support productive HIV-2 infection irrespectively of coreceptor usage. As expected, we also observed a comparable increase for both HIV-1 primary isolates. To provide further evidence of productive infection, supernatants from TCR-stimulated HIV-infected Tfh were collected and evaluated for their infectivity using the TZM-bl reporter cell line. The results indicated that the newly produced virions released by HIV-2-infected Tfh are infectious (Figure 1F).
|
| 61 |
+
|
| 62 |
+
Hence, Tfh are indeed able to support productive HIV-2 infection.
|
| 63 |
+
|
| 64 |
+
To confirm that in vitro Tfh susceptibility is recapitulated in vivo, we assessed whether Tfh isolated from HIV-2-infected individuals harbored HIV-2. CD4 T-cell subsets were purified from the peripheral blood of 6 ART-naive HIV-2-infected individuals, all females, median age 60, 3 "Caucasians," with undetectable viremia (less than 40 copies viral RNA/mL), preserved CD4 T-cell counts (median 882 cells/µL) and no history of opportunistic infections. Total HIV DNA was quantified in cTfh, defined as CD45RAnegCXCR5+ cells (Figure 2A), and compared with the levels measured in sorted naive (CCR7+CD45RA+), central memory (CCR7+CD45RAnegCXCR5neg), and effector memory ([EM] CCR7negCD45RAnegCXCR5neg) CD4 T-cell subsets (Figure 2B). We found that HIV-2 can infect Tfh in vivo, and, in addition, that blood Tfh showed the highest median levels of total HIV DNA, which were significantly different from the EM subset (Figure 2B). Of note, this reservoir was effectively controlled, because these patients featured no detectable viremia in the absence of ART. Therefore, our data support that Tfh are a major HIV-2 reservoir in vivo.
|
| 65 |
+
|
| 66 |
+
## Discussion
|
| 67 |
+
|
| 68 |
+
This first study addressing the ability of HIV-2 to infect Tfh revealed that HIV-2 infects purified tonsillar Tfh in vitro and identified peripheral blood Tfh as a key viral reservoir in HIV2-infected patients. Human immunodeficiency virus-2 primary isolates infected tonsillar Tfh irrespective of their tropism as attested by cell-associated HIV DNA and gag mRNA levels.
|
| 69 |
+
|
| 70 |
+
Follicular helper T cells are thought to be mainly infected at the stage of Tfh precursors, which express high levels of CCR5 [8]. Nonetheless, we showed that differentiated Tfh are susceptible to R5-tropic viruses, confirming that low levels of CCR5 are enough for efficient HIV-1 and HIV-2 infection. Of note, these results were obtained in the absence of extrinsic cell activation. Although polybrene was used to increase infection efficiency [9], this method does not affect cell activation or viability, and viral entry mechanisms were not the focus of this work. Our data on HIV-1 infection are in agreement with previous studies revealing high permissiveness of Tfh to HIV-1 [1, 10, 11]. X4-tropic HIV-1 generated higher amounts of total HIV DNA
|
| 71 |
+
than R5-tropic HIV-1, a typical pattern of coreceptor dependency that was not observed in HIV-2 primary isolates. It has been previously reported that HIV-2 cytopathicity in human lymphoid tissue is coreceptor dependent and comparable to that of HIV-1 [6]. Further studies using smaller viral inputs and a range of HIV-2 primary isolates are required to evaluate the underlying mechanisms.
|
| 72 |
+
|
| 73 |
+
Our results indicate that HIV-2 cannot only complete the early phase of the replication cycle until integration, but it can also undergo viral transcription in Tfh. It is interesting to note that a stronger correlation was observed between the levels of total HIV DNA and gag mRNA in HIV-2-infected Tfh than in those infected by HIV-1, which might suggest a distinct regulation of viral transcription. It is notable that the structure of HIV-2 transactivation region (TAR) differs from that of the HIV-1 TAR stem loop, being much longer and folded into a fork motif [12], providing a possible explanation for the changes in the transcription of partially spliced and unspliced viral transcripts upon Tat-TAR interaction. Because tonsillar Tfh, unlike peripheral CD4 T cells, support infection without exogenous stimulation, these cells represent a very relevant model to study latency and viral transcription.
|
| 74 |
+
|
| 75 |
+
Follicular helper T cells supported productive HIV-2 infection, as demonstrated by the increase in cell-associated viral DNA levels after TCR stimulation and the release of infectious virions into culture, as evaluated by the TZM-bl reporter cell line. Of note, this reporter system was not optimized to allow a quantitative evaluation of viral production, precluding the investigation of any possible posttranscriptional control, a phenomenon we previously observed in in vitro-infected thymocytes [6].
|
| 76 |
+
|
| 77 |
+
It could be argued that Tfh derived from inflamed tonsillar tissue may favor HIV infection. Nevertheless, our data obtained in peripheral blood Tfh from HIV-2-infected patients support Tfh susceptibility to HIV-2, and, importantly, showed that Tfh are a major HIV-2 reservoir in vivo. Follicular helper T cells have been identified as prime targets for HIV-1 infection [13]. Accordingly, we observed higher levels of cell-associated viral HIV-2 DNA in Tfh when compared with CD4 effector memory cells. It is notable that these patients featured no detectable viremia in the absence of ART and had preserved blood CD4 T-cell counts, indicating that HIV-2 infection is being naturally controlled regardless of disseminated viral reservoirs. The control of ongoing HIV-2 replication in these patients is likely due to particular host-pathogen interactions, because it has been shown that HIV-2 can efficiently replicate in vitro [6]. In support of a role for Tfh in this interplay, HIV-2 infection is associated with sustained titers of nAbs [5], irrespective of disease stage, which we have also shown to be accompanied by progressive memory B-cell depletion [14]. It is remarkable that a relatively preserved cTfh ability to provide adequate B-cell help has been documented in HIV-1 elite controllers in comparison to chronic HIV-1-infected individuals [15]. Future studies are required to better understand how Tfh infection impacts B-cell help in HIV-2-infected patients, which will ultimately provide insights into nAb responses.
|
| 78 |
+
|
| 79 |
+
## Conclusions
|
| 80 |
+
|
| 81 |
+
Our results, taken together, show that Tfh support productive HIV-2 infection and represent a key HIV-2 reservoir. Thus, HIV-2 infection of Tfh provides a unique model to identify host factors playing a role in the natural control of HIV-2 replication and to further investigate the generation of HIV nAbs.
|
| 82 |
+
|
| 83 |
+
## Supplementary Data
|
| 84 |
+
|
| 85 |
+
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
|
| 86 |
+
|
| 87 |
+
Supplementary Table 1. Primers and probes used for quantification of total human immunodeficiency virus (HIV) deoxyribonucleic acid (DNA) and gag messenger ribonucleic acid (mRNA) by quantitative real-time polymerase chain reaction (PCR).
|
| 88 |
+
|
| 89 |
+
## Notes
|
| 90 |
+
|
| 91 |
+
Acknowledgments. We sincerely thank the ENT and Infectious Diseases Departments of Hospital de Santa Maria/ CHULN/Lisboa Portugal and all the patients, children, and their parents for their collaboration. We thank the team members of Flow Cytometry Unit and Biosafety Level 3 facilities at Instituto de Medicina Molecular João Lobo Antunes (Lisboa, Portugal) for technical assistance.
|
| 92 |
+
|
| 93 |
+
Financial support. This work was funded by the following grants: PTDC/MED-IMU/30474/2017 - project cofunded by FEDER LISBOA-01-0145-FEDER-030474, through Programa Operacional Regional de Lisboa, do PORTUGAL 2020, and Fundação para a Ciência e a Tecnologia; Gilead Genesis; UID/BIM/50005/2019, project funded by Fundação para a Ciência e a Tecnologia (FCT)/Ministério da Ciência, Tecnologia e Ensino Superior through Fundos do Orçamento de Estado; and partially supported by ONEIDA project (LISBOA-010145-FEDER-016417) co-funded by "Fundos Europeus Estruturais e de Investimento" from "Programa Operacional Regional Lisboa 2020" and by national funds from FCT. A. G.-S., R. B. F., A. V. A., and P. M. received fellowships co-funded by FCT and FEDER.
|
| 94 |
+
|
| 95 |
+
Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.
|
| 96 |
+
|
| 97 |
+
## References
|
| 98 |
+
|
| 99 |
+
1. Perreau M, Savoye AL, De Crignis E, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med **2013**; 210:143–56.
|
| 100 |
+
|
| 101 |
+
2. Fukazawa Y, Lum R, Okoye AA, et al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med **2015**; 21:132–9.
|
| 102 |
+
|
| 103 |
+
3. Soares RS, Tendeiro R, Foxall RB, et al. Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patients. J Virol **2011**; 85:2429–38.
|
| 104 |
+
|
| 105 |
+
4. Sousa AE, Carneiro J, Meier-Schellersheim M,
|
| 106 |
+
Grossman Z, Victorino RM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J
|
| 107 |
+
Immunol **2002**; 169:3400–6.
|
| 108 |
+
|
| 109 |
+
5. Makvandi-Nejad S, Rowland-Jones S. How does the humoral response to HIV-2 infection differ from HIV-1 and can this explain the distinct natural history of infection with these two human retroviruses? Immunol Lett **2015**; 163:69–75.
|
| 110 |
+
|
| 111 |
+
6. Nunes-Cabaço H, Matoso P, Foxall RB, et al. Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes. J Virol **2015**; 89:2201–8.
|
| 112 |
+
|
| 113 |
+
7. Pallikkuth S, Sharkey M, Babic DZ, et al. Peripheral T follicular helper cells are the major HIV reservoir within central memory CD4 T cells in peripheral blood from chronically HIV-infected individuals on combination antiretroviral therapy. J Virol **2015**; 90:2718–2728.
|
| 114 |
+
|
| 115 |
+
8. Xu Y, Phetsouphanh C, Suzuki K, et al. HIV-1 and SIV predominantly use CCR5 expressed on a precursor population to establish infection in T follicular helper cells. Front Immunol **2017**; 8:1–15.
|
| 116 |
+
|
| 117 |
+
9. Davis HE, Morgan JR, Yarmush ML. Polybrene increases retrovirus gene transfer efficiency by enhancing receptorindependent virus adsorption on target cell membranes.
|
| 118 |
+
|
| 119 |
+
Biophys Chem **2002**; 97:159–72.
|
| 120 |
+
|
| 121 |
+
10. Kohler SL, Pham MN, Folkvord JM, et al. Germinal center T follicular helper cells are highly permissive to HIV-1 and alter their phenotype during virus replication. J Immunol 2016; 196:2711–22.
|
| 122 |
+
|
| 123 |
+
11. Boswell KL, Paris R, Boritz E, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV infection. PLoS Pathog **2014**; 10:e1003853.
|
| 124 |
+
|
| 125 |
+
12. Berkhout B. Structural features in TAR RNA of human and simian immunodeficiency viruses: a phylogenetic analysis.
|
| 126 |
+
|
| 127 |
+
Nucleic Acids Res **1992**; 20:27–31.
|
| 128 |
+
|
| 129 |
+
13. Lindqvist M, Lunzen J van, Soghoian DZ, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest **2012**; 122:3271–80.
|
| 130 |
+
|
| 131 |
+
14. Rocha C, Duarte J, Borrego P, et al. Potency of HIV-2specific antibodies increase in direct association with loss of memory B cells. AIDS **2017**; 31:2431–3.
|
| 132 |
+
|
| 133 |
+
15. Cubas RA, Mudd JC, Savoye AL, et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med **2013**; 19:494–9.
|
medical/md/PMC6917096.md
ADDED
|
@@ -0,0 +1,363 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
|
| 2 |
+
|
| 3 |
+

|
| 4 |
+
|
| 5 |
+
# Nonlinear Optical Corneal Crosslinking, Mechanical Stiffening, And Corneal Flattening Using Amplified Femtosecond Pulses
|
| 6 |
+
|
| 7 |
+
Samantha Bradford1,*, Eric Mikula1,*, Sun Woong Kim1,2, Yilu Xie1, Tibor Juhasz1, Donald J. Brown1, and James V. Jester1 1 University of California, Irvine, Department of Ophthalmology and Biomedical Engineering, Irvine, CA, USA
|
| 8 |
+
2 Yonsei University, Wonju College of Medicine, Department of Ophthalmology, Wonju, South Korea Correspondence: James V. Jester, University of California, Irvine, Gavin Herbert Eye Institute, 843 Health Sciences Rd, Hewitt Hall, Room 2036, Irvine, CA 92697-4390, USA.
|
| 9 |
+
|
| 10 |
+
e-mail: jjester@uci.edu Received: 18 July 2019 Accepted: 6 October 2019 Published: 16 December 2019 Keywords: cornea; crosslinking; femtosecond laser; myopia; keratoconus; nonlinear Citation: Bradford S, Mikula E, Kim SW, Xie Y, Juhasz T, Brown DJ, Jester JV. Nonlinear optical corneal crosslinking, mechanical stiffening, and corneal flattening using amplified femtosecond pulses. Trans Vis Sci Tech. 2019;8(6):35, https://doi.org/
|
| 11 |
+
10.1167/tvst.8.6.35 Copyright 2019 The Authors Purpose: We have shown that nonlinear optical corneal crosslinking (NLO CXL) and stiffening can be achieved in ex vivo rabbit corneas using an 80-MHz, 760-nm femtosecond (FS) laser, however the required power was beyond the American National Standard Institute limit. The purpose of this study was to test the efficacy of amplified FS pulses to perform CXL to reduce power by increasing pulse energy. Methods: A variable numerical aperture laser scanning delivery system was coupled to a 1030-nm laser with a noncollinear optical parametric amplifier to generate 760 nm, 50 to 150 kHz amplified FS pulses with 79.5-lm axial and 2.9-lm lateral twophoton focal volume. Ex vivo rabbit corneas received NLO CXL, and effectiveness was assessed by measuring collagen autofluorescence (CAF) and mechanical stiffening.
|
| 12 |
+
|
| 13 |
+
NLO CXL was also performed in 14 live rabbits, and changes in corneal topography were measured using an Orbscan.
|
| 14 |
+
|
| 15 |
+
Results: Amplified pulses (0.3 lJ) generated significant CAF that increased logarithmically with decreasing scan speed; achieving equivalent CAF to UVA CXL at 15.5 mm/s. Indentation testing detected a 62% increase in stiffness compared to control, and corneal topography measurements revealed a significant decrease of 1.0 6 0.8 diopter by 1 month (P , 0.05).
|
| 16 |
+
|
| 17 |
+
Conclusions: These results show that NLO CXL using amplified pulses can produce corneal collagen CXL comparable to UVA CXL.
|
| 18 |
+
|
| 19 |
+
Translational Relevance: NLO CXL using amplified pulses can produce corneal CXL
|
| 20 |
+
comparable to UVA CXL, suggesting a potential clinical application in which NLO CXL
|
| 21 |
+
can be used to perform personalized crosslinking for treatment of refractive errors and keratoconus.
|
| 22 |
+
|
| 23 |
+
## Introduction
|
| 24 |
+
|
| 25 |
+
Myopia is the most common refractive error and is estimated to affect 1.6 billion people worldwide, with a prevalence of 33% in the United States and up to 80% to 90% in East Asian young adults.1,2 Since its introduction nearly 30 years ago, laser-assisted in situ keratomileusis (LASIK) has become the standard of care for surgical correction of refractive errors.3 The procedure entails cutting a corneal flap and ablating the stroma underneath with an excimer laser, thus modifying corneal curvature to better focus light back onto the retina. Despite high patient satisfaction rates of LASIK (.95%),4 many patients, such as those with thin corneas, suspected keratoconus, or those with mild refractive errors, are not ideal candidates for the procedure. Specifically, in patients with low refractive error (62 diopters), the risks associated with cutting the LASIK flap may outweigh the benefits of a successful surgery. These patients can typically function day to day uncorrected, opting to wear glasses only during certain activities such as driving. This creates an unmet medical need for a noninvasive, safer procedure for the correction of low refractive errors.
|
| 26 |
+
|
| 27 |
+
In recent years, a number of technologies have emerged with the potential to address the issue of a safer, less-invasive refractive surgery for low refractive errors by avoiding cutting of a flap. The first technology in this category, ultraviolet A (UVA)
|
| 28 |
+
corneal collagen crosslinking (CXL), was initially developed in the early 2000s as a treatment for keratoconus, but it has been increasingly investigated as a refractive procedure.5,6 UVA CXL uses UVA
|
| 29 |
+
light to photoactivate riboflavin (previously imbibed into the stroma via eye drops), thus generating an excited triplet state of riboflavin, free oxygen radicals, and subsequent crosslinking of collagen fibrils. With respect to keratoconus, the goal of CXL is to halt the progression of the disease by strengthening the cornea. In regard to potential refractive CXL, the goal is to selectively alter the biomechanical properties of the corneal stroma via collagen crosslinks, thereby changing the topography of the cornea and correcting vision.
|
| 30 |
+
|
| 31 |
+
While UVA CXL is the most commonly used method to achieve corneal CXL, the use of femtosecond (FS) lasers has also gained interest in recent years. Wozniak et al.7 utilized blue (480 nm) FS pulses to induce a refractive index change in corneal tissue, while Wang et al.8 reported corneal CXL without riboflavin using infrared pulses. The nature of these two methods, however, is not directly based on the original UVA CXL methodology, and therefore explanations of the principles underlying these techniques are not fully understood. Our group has previously used an 80 MHz FS laser oscillator tuned to 760 nm to crosslink corneal collagen via nonlinear two-photon excitation of riboflavin, a technique referred to as nonlinear optical collagen crosslinking
|
| 32 |
+
(NLO CXL).9–11 NLO CXL uses two photons of near infrared FS laser light (with a combined energy of one UVA photon) to excite riboflavin, thus generating oxygen free radicals and subsequent collagen crosslinking, similar to UVA CXL. However, this technique is distinctly different from UVA CXL in that the excitation of riboflavin, and thus crosslinking, only occurs in the well-defined and specifically chosen two-photon focal volume of the laser delivery objective. The location of the focal volume can be arbitrarily scanned with micrometer precision to achieve a crosslinking area of any geometry and depth within the cornea. While we achieved corneal CXL and mechanical stiffening on par with UVA
|
| 33 |
+
CXL, these studies used a high repetition rate (80 MHz) low-pulse energy (10 nJ) laser requiring a high average power (~800 mW), well above the American National Standards Institute (ANSI) limit of 46.1 mW.12 To address this issue and reduce the average power exposure to a clinically acceptable level, this study explored using regeneratively amplified FS laser pulses (microjoule pulse energy) at low repetition rates (kilohertz) to precisely crosslink corneal collagen while remaining under the ANSI limit of 46.1 mW. By increasing pulse energy from 10 nJ to 1 lJ, it was expected that the average total energy could be proportionally reduced from 800 to 8 mW. This was verified in ex vivo eyes after treatment with a 5 kHz amplified FS laser using the presence of collagen autofluorescence (CAF) as an indicator that CXL had occurred.
|
| 34 |
+
|
| 35 |
+
Following preliminary experiments using 1-lJ
|
| 36 |
+
pulse energies, a custom noncollinear optical parametric amplifier (NOPA) was designed and built to deliver 760 nm amplified FS laser pulses at repetition rates of 50 to 150 kHz. Amplified NLO CXL was performed in ex vivo rabbit eyes, after which collagen autofluorescence and mechanical stiffness measurements were performed. Crosslinking experiments were also carried out in live rabbits, and topography was measured to assess refractive outcomes of amplified NLO CXL.
|
| 37 |
+
|
| 38 |
+
## Methods Proof Of Concept
|
| 39 |
+
|
| 40 |
+
Prior to building a custom amplified NLO CXL
|
| 41 |
+
system, the question of whether NLO CXL was even possible using amplified FS pulses was determined by examining CAF within ex vivo rabbit eyes treated by coupling our delivery optics with an amplifier system
|
| 42 |
+
(Legend-F Titanium Sapphire Regenerative Amplifier; Coherent, Inc., Santa Clara, CA). This 5-kHz, 130-
|
| 43 |
+
FS, 800-nm laser light was directed through an optical parametric amplifier (OPA) (Opera-LE-F OPA; Coherent, Inc.) to produce 1520-nm laser light that was then frequency doubled using a beta barium borate (BBO) crystal to produce a 760-nm beam with 1-lJ pulse energy. FS pulses were then focused into our previously described delivery device that uses a patented, low numerical aperture focusing system to generate enlarged two-photon volumes of 2 to 3 lm in diameter and 100 lm in axial length, as previously described.10,11 Using the 5-kHz repetition rate, ex vivo rabbit
|
| 44 |
+
|
| 45 |
+

|
| 46 |
+
|
| 47 |
+
corneas were raster scanned over a 4-mm-diameter area at a scan speed of 15 mm/s to produce single pulse, 2- to 3-lm-diameter CAF spots with a 3-lm spot separation using a total power of only 5 mW.
|
| 48 |
+
|
| 49 |
+
Corneas were then removed from the eye and fixed in 2% paraformaldehyde (PFA) in PBS, pH 7.2, overnight prior to two-photon detection of corneal CAF using a multiphoton confocal microscope (Zeiss 510; Carl Zeiss, Jena, Germany) and FS laser
|
| 50 |
+
(Chameleon; Coherent, Inc.) as previously described.10,11,13 Briefly, the presence of CAF was detected using 760-nm FS laser light to induce twophoton excited blue light 400- to 450-nm CAF from crosslinked regions of the cornea. CAF was examined within both vibratome cross sections and whole mount corneas viewed en face or parallel to the corneal surface (Fig. 1). Similar tissue preparation and imaging were performed for detection of CAF in later studies. The presence of CAF within these samples was used as justification for building a more stable system with a higher repetition rate, able to crosslink at faster speeds.
|
| 51 |
+
|
| 52 |
+
## Amplified Fs Laser And Delivery
|
| 53 |
+
|
| 54 |
+
Though commercially available FS oscillators are broadly tunable and can readily deliver 760-nm FS laser pulses, commercial turnkey amplified FS laser systems are not available at this wavelength. However, photons of different wavelengths can be generated from an FS laser source using nonlinear processes in an OPA. In this study, we used a commercially available amplified FS laser operating at 1030 nm
|
| 55 |
+
(One Five Origami; NKT Photonics, Birkerod, Denmark), with a variable repetition rate (50–150 kHz),
|
| 56 |
+
318-FS pulse duration, and 4-W average power as the laser source for a lab-built NOPA. The NOPA
|
| 57 |
+
generated variable microjoule pulses of 760-nm FS
|
| 58 |
+
light, which were then aligned into the beam delivery/
|
| 59 |
+
scanning device from our previous study10 and then into the eye. An overview of the entire system is presented in Figure 2. In general, a NOPA is a device capable of converting a pump photon of a specific wavelength into two photons of longer wavelengths, termed signal and idler. The wavelengths of the signal and idler can be continuously tuned as long as the requirement of energy conservation is met. The NOPA built for this study contains three stages:
|
| 60 |
+
supercontinuum generation, formation of the pump beam, and parametric conversion.
|
| 61 |
+
|
| 62 |
+
## Stage 1: Supercontinuum Generation
|
| 63 |
+
|
| 64 |
+
Approximately 10% of the output of the 1030-nm laser source is picked off by a beam splitter and focused onto a 200-lm-thick sapphire plate (Fig. 2, stage 1). Acting as a nonlinear medium, this spectrally broadens the original laser pulse via self-phase modulation, creating supercontinuum radiation that appears like white light to the eye. Centered at 1030 nm, the supercontinuum radiation contains spectral components from 500 to 1500 nm. The output is wellformed and smoothly varying, making it a suitable source to serve as the ''seed'' pulse for the OPA. The white light is passed through two water cuvettes, adding group velocity dispersion to the supercontinuum and ultimately reducing the bandwidth of the 760-nm OPA output to 12 nm.
|
| 65 |
+
|
| 66 |
+
## Stage 2: Pump Formation
|
| 67 |
+
|
| 68 |
+
After the 10% beam splitter, the remaining 1030nm source beam is sent to a 2-mm-thick BBO crystal for frequency doubling (Fig. 2, Stage 2). The 2-mm BBO is responsible for converting the source from 1030 to 515 nm, which can then be used to generate the two longer wavelength photons in the visible spectrum. BBO is used due to its large second-order susceptibility, v2, as well as its high damage threshold.
|
| 69 |
+
|
| 70 |
+
## Stage 3: Parametric Conversion
|
| 71 |
+
|
| 72 |
+
After frequency doubling in stage 2, the 515-nm radiation is sent to a second 400-lm-thick BBO
|
| 73 |
+
crystal (Fig. 2, stage 3) for parametric conversion.
|
| 74 |
+
|
| 75 |
+
After passing through the second BBO crystal, the 515-nm light produces a parametric ring of visible radiation. As the crystal angle is varied, color separation can be observed within the ring. The proper crystal angle is determined by finding the angle
|
| 76 |
+
|
| 77 |
+

|
| 78 |
+
|
| 79 |
+
that minimizes color separation. Once this angle is found, the supercontinuum seed from stage 1 is spatially overlapped with the 515-nm pump in the second BBO crystal and directionally overlapped with the parametric ring. After this is accomplished, the translation stage shown in Figure 2 (delay 1) is adjusted to ensure proper temporal overlap between the seed pulse and the 515-nm pump pulse. When both the seed and pump pulses are aligned spatially, directionally, and temporally, the parametric ring of radiation collapses into a beam that takes on the properties of the original pump beam. Owing to the fact that the supercontinuum seed is chirped, wavelength tuning can be accomplished by altering the timing of the seed relative to the pump pulse by adjusting delay 2 (Fig. 2). For this study, the center wavelength of the NOPA was adjusted to 760 nm with a full width at half maximum (FWHM) bandwidth of 12 nm, as measured by a spectrometer (Thorlabs, Newton, NJ). The pulse duration of the newly formed 760-nm beam was measured using a lab-built autocorrelator and found to be ~700 FS. The beam is then passed twice through an SF10 ultrafast laser dispersion compensation prism pair (DCP 1 and 2), which has the effect of compressing the pulse and thus controlling pulse duration. After compression, the pulse duration was measured to be ~400 FS.
|
| 80 |
+
|
| 81 |
+
## Laser Delivery
|
| 82 |
+
|
| 83 |
+
Upon leaving the pulse compressor, the beam passes through a half wave plate (k/2) and polarizing beam cube that function as a continuously variable beam attenuator. The rest of the beam delivery optics are identical to those used in our previous study.10 Briefly, the beam passes through a variable expanding telescope before entering a series of galvo steering mirrors that together scan the beam in a preprogrammed raster pattern at a preprogrammed speed.
|
| 84 |
+
|
| 85 |
+
The beam then passes through a second expanding telescope before being directed down into the objective and through the applanation glass and into the cornea. The effective numerical aperture of the delivery system used in this study was 0.12, which would theoretically result in a focal volume with axial and lateral dimensions of 79.5 and 2.9 lm, respectively, as calculated using Zipfel's equations.14
|
| 86 |
+
|
| 87 |
+
## Amplified Nlo Cxl In The Ex Vivo Rabbit Cornea
|
| 88 |
+
|
| 89 |
+
After confirming crosslinking using amplified FS
|
| 90 |
+
pulses was possible, it was necessary to determine the amount of amplified FS pulse energy needed to achieve corneal crosslinking at levels equal to standard UVA CXL. The amount of energy deposi-
|
| 91 |
+
Table 1. Scan Speed and Total Energy
|
| 92 |
+
|
| 93 |
+
| 5-lm Line Spacinga | 2-lm Line Spacinga | | | | |
|
| 94 |
+
|-----------------------------------------------------------------------------------------------------------------------|----------------------|---------------|-----------|-----------|-------|
|
| 95 |
+
| Scan | Group | | | | |
|
| 96 |
+
| Speed, mm/s | Size, n | Treatment | Total | Treatment | Total |
|
| 97 |
+
| Duration, min | Energy, J | Duration, min | Energy, J | | |
|
| 98 |
+
| 100 | 3 | 0.53 | 0.96 | 1.33 | 2.4 |
|
| 99 |
+
| 80 | 3 | 0.67 | 1.2 | 1.67 | 3.0 |
|
| 100 |
+
| 60 | 3 | 0.89 | 1.6 | 2.22 | 4.0 |
|
| 101 |
+
| 40 | 3 | 1.33 | 2.4 | 3.33 | 6.0 |
|
| 102 |
+
| 30 | 4 | 1.64 | 2.96 | 4.11 | 7.4 |
|
| 103 |
+
| 20 | 6 | 2.66 | 4.8 | 6.66 | 12.0 |
|
| 104 |
+
| 10 | 3 | 4.93 | 8.88 | 12.33 | 22.2 |
|
| 105 |
+
| 5 | 4 | 9.86 | 17.76 | 24.66 | 44.4 |
|
| 106 |
+
| UVA CXL | NA | NA | NA | 30 | 5.4 |
|
| 107 |
+
| a Line separations of 5 lm were used for CAF analysis, whereas 2-lm separations were used for mechanical testing. All | | | | | |
|
| 108 |
+
|
| 109 |
+
tion was controlled by varying the scan speed of the laser beam and thus the amount of laser pulses per unit area along the scan line. Previously, our group, as well as others, has used CAF as a metric to assess the degree of collagen crosslinking.9–11,15–17 The same method was used in this study, with CAF being compared against our previously published CAF data using standard UVA CXL.13 After a suitable scan speed was determined, we performed mechanical testing to determine the effect of amplified NLO
|
| 110 |
+
CXL on tissue stiffness.
|
| 111 |
+
|
| 112 |
+
## Scan Speed Versus Caf
|
| 113 |
+
|
| 114 |
+
A total of 29 rabbit eyes were shipped overnight on ice (Pel-Freez Biologicals, Rogers, AR); experiments were performed the same day as delivery. The epithelium was mechanically removed in the central 8 mm of the cornea with a Tooke knife. The corneas were then imbibed with riboflavin via eye drops containing 0.5% riboflavin-5-phospate and 20% high fraction dextran, molecular weight 450 to 650 kDa (Sigma-Aldrich Corp., St. Louis, MO) in PBS
|
| 115 |
+
solution once every 2 minutes for 30 minutes. Next, the eyes underwent amplified NLO CXL in the central 4 mm of the cornea. Treatment groups were defined by the scan speed of the laser beam, ranging from 5 to 100 mm/s. The beam was scanned in a single plane in a raster pattern as described previously, with a line separation of 5 lm to shorten the scanning time required for this portion of the study.10,11 The depth of focus was set for 50 lm below the contact glass so as to include the entire focal volume within the tissue. The pulse energy and average power were set to 0.3 lJ
|
| 116 |
+
and 30 mW, respectively, at 50- to 100-kHz pulse repetition frequency, well beneath the ANSI limit of 46.1 mW. The parameters for each treatment group as well as each group size are outlined in Table 1. Each group had at least three eyes (n ¼ 3). The treatment times reported in this table were calculated for line separations of both 2 and 5 lm, since the 5-lm separation used for CAF evaluation was later reduced to 2 lm for mechanical measurements and in vivo treatments. The values for standard UVA CXL are also provided for reference. After treatment, corneas were prepared for CAF measurements.
|
| 117 |
+
|
| 118 |
+
CAF was measured per the protocol in our previous studies, taking care to faithfully replicate the measurements via laser power and microscope settings to allow for reliable comparison.10 Briefly, after amplified NLO CXL, corneas were excised from the globe and fixed overnight in 2% PFA (Mallinckrodit Baker, Inc., Phillipsburg, NJ) in PBS at 48C. The corneas were then sectioned into 250-lm-thick slices perpendicular to the axis of crosslinking using a vibratome (Campden Instruments, Loughborough, England). The samples were then imaged for blue CAF using a microscope (Zeiss LSM 510; Carl Zeiss)
|
| 119 |
+
and a Coherent FS laser as an excitation source. The samples were excited at 760 nm while the CAF signal was collected between 400 and 450 nm using a bandpass filter.
|
| 120 |
+
|
| 121 |
+
The images were exported to image analysis software (Metamorph; Molecular Devices, Sunnyvale, CA), and three 100 3 100 pixel areas within both the central anterior crosslinked region and the background region were identified. The average intensities within both regions were then subtracted.
|
| 122 |
+
|
| 123 |
+
To compensate for the fact that line separation was
|
| 124 |
+
|
| 125 |
+

|
| 126 |
+
|
| 127 |
+
not continuous in the NLO CXL treatment, resulting in dark areas between the scan lines (Fig. 3) that would make the CAF data noncomparable to previous UVA CXL CAF data, a percentage of crosslinked area was calculated from the NLO CXL samples using the FWHM values of a line scan inserted across NLO CXL CAF images. This percentage was used as a multiplication factor to convert previously reported UVA CXL CAF data.13
|
| 128 |
+
|
| 129 |
+
## Amplified Nlo Cxl And Corneal Stiffness
|
| 130 |
+
|
| 131 |
+
Based on the results from scan speed experiments, a speed of 20 mm/s was chosen for the stiffness experiments as this speed resulted in CAF comparable to that of UVA CXL and still had reasonable procedure time when the line separation was reduced back to 2 lm. The total crosslinking time for this speed was approximately 6.66 minutes (Table 1). Mechanical measurements were conducted on corneas that underwent amplified NLO CXL (seven eyes) as well as control eyes (seven eyes). Three of the seven NLO CXL eyes were excluded because CAF analysis revealed the treatment region was outside the measured area. Two of the seven control eyes were excluded because their mechanical measurements were measured more than two standard deviations above the mean, indicating they were either old corneas or had become dehydrated during testing. The method used to measure mechanical stiffness was needle microindentation and followed our previously published protocol.10,18 Briefly, a 5 3 5-mm region was excised around the pupil to ensure the crosslinked region was present in the sample. Care was taken to maintain the corneal thickness between 400 and 450 lm to minimize the effect of hydration on elasticity. Next, the sample was placed under a 1-mm-diameter flat tip force transducer probe that was attached to a z-axis motorized controller. The probe was lowered carefully until contact was made with the sample. Once this start position was determined, the force transducer tip was advanced into the sample to 10%
|
| 132 |
+
of the sample thickness for 10 cycles as preconditioning to determine the stress–strain relationship. An elasticity value was calculated based on the peak force value of the 10th cycle using the equations outlined by Hayes et al.10,19,20
|
| 133 |
+
|
| 134 |
+
## Live Rabbit Model
|
| 135 |
+
|
| 136 |
+
A total of 14 New Zealand albino rabbits under 6 months old were used in this study. They were divided into two groups, five killed 2 weeks after treatment and nine after 2 months. All animals were treated according to the ARVO statement on the use of animals in vision research, and experiments were approved by the IACUC of the University of California, Irvine. The right eye of each rabbit underwent amplified NLO CXL whereas the left eye served as a control. Both eyes of the short-term group (2 weeks) were examined using in vivo confocal microscopy through focusing (CMTF) imaging to study cellular activity just prior to death and to measure the corneal thickness and haze within the stroma after treatment.13 For the long-term group (2 months), the corneal topography was measured in both right and left eyes using a topographer (Orbscan IIz; Bausch and Lomb, Rochester, NY) 1 week prior to treatment (baseline) and 1, 2, 4, and 8 weeks post treatment. The topography measurements were performed by an ophthalmologist (SWK) with previous experience in topography measurements in the rabbit. Gaze fixation was achieved for these measurements by holding the anesthetized animal while adjusting the machine
|
| 137 |
+
|
| 138 |
+

|
| 139 |
+
|
| 140 |
+
to take the measurement. A minimum of three complete scans were made for each eye at each time point, Before all CMTF or topography procedures, animals were anesthetized using a subcutaneous injection of 30 to 50 mg/kg ketamine hydrochloride
|
| 141 |
+
(Hospira, Irvine, CA) and 5 to 10 mg/kg xylazine (Akorn, Lake Forrest, IL). The effect of the procedure was measured by calculating the difference in refractive power, using a minimum of three measurements per exam, between the right and left eye at each time point (DD).
|
| 142 |
+
|
| 143 |
+
For amplified NLO CXL, sedated animals received a drop of topical ophthalmic 0.5% tetracaine hydrochloride (Alcon, Ft. Worth, TX) to prevent pain. The methods for epithelial removal and stromal riboflavin delivery were identical to those used in the ex vivo experiments described above. The right eyes then underwent amplified NLO CXL in the central 4 mm with a 2-lm line separation using a pulse energy and average power of 0.3 lJ and 30 mW at a laser scan speed of 20 mm/s. After treatment, the rabbits received a subcutaneous 0.1 mL injection of buprenorphine hydrochloride (Reckitt Benckiser Healthcare Ltd., Slough, UK) for pain. For 3 days following the procedure, each rabbit received an antibiotic eye drop, 0.3% gentamicin sulfate (Allergan, Inc., Irvine, CA),
|
| 144 |
+
three times daily in the treated eye to prevent infection.
|
| 145 |
+
|
| 146 |
+
After either 2 weeks (five rabbits) or 8 weeks (nine rabbits) post treatment, animals were euthanized via an intravenous injection (Euthanasia III; Vedco, Inc., St.
|
| 147 |
+
|
| 148 |
+
Joseph, MO) into the marginal ear vein after the last topography measurement. Immediately after death, corneas were fixed in situ under 20 mm Hg pressure via perfusion of 2% PFA to maintain the in vivo collagen structure, as described in previous studies.13 The corneas were then excised and prepared for CAF
|
| 149 |
+
measurements in the same manner as described above for ex vivo eyes to confirm the presence of crosslinking. After CAF was examined, sections were stained with phalloidin (1:100) and ethidium homodimer (2 lL/mL)
|
| 150 |
+
for fluorescent imaging of cellular structures as described in previous studies.13
|
| 151 |
+
|
| 152 |
+
## Statistics
|
| 153 |
+
|
| 154 |
+
Statistical analysis was performed using the TukeyKramer method for a multiple comparison, 1-way or repeated measures analysis of variance in statistical software (MatLab; Mathworks, Natick, MA).
|
| 155 |
+
|
| 156 |
+
Groups were considered to have a statistically significant difference with a P value of less than 0.05. In all figures, error bars represent standard deviation.
|
| 157 |
+
|
| 158 |
+
## Results Ex Vivo Amplified Nlo Cxl Scan Speed Versus Caf Intensity
|
| 159 |
+
|
| 160 |
+
Examples of CAF images used for measurements are shown in Figure 3. The measured CAF intensities corresponding to each treatment speed are graphed in Figure 4. CAF intensity was scaled downward logarithmically with increasing scan speed and fit to the equation y ¼ -375.1ln(x) þ 1806.6 with an R2 ¼
|
| 161 |
+
0.9814. Using the FWHM values from a line scan perpendicular through the crosslinked area of NLO
|
| 162 |
+
CXL CAF images, the percentage of crosslinked area was measured to be 61.4%. Using Zipfel's equations,14 a comparable theoretical value of 58% was calculated.
|
| 163 |
+
|
| 164 |
+
UVA CXL CAF values reported in a previous study
|
| 165 |
+
(1267 6 181)13 were converted to 777.9 6 111.1, using this percentage to compensate for the spacing between scan lines in NLO CXL CAF images.
|
| 166 |
+
|
| 167 |
+
Namely, only 61.4% of the UVA CXL CAF was considered. Using this value, amplified NLO CXL reached a comparable CAF intensity to UVA CXL at a speed of 15.5 mm/s.
|
| 168 |
+
|
| 169 |
+
## Corneal Stiffness
|
| 170 |
+
|
| 171 |
+
The indentation elasticity values of corneas treated using amplified NLO CXL were measured to be 84.3 6 5.9 kPa (n ¼ 4), 1.62 times larger than control values that averaged 52.2 6 8.6 kPa (n ¼ 5). After
|
| 172 |
+
|
| 173 |
+

|
| 174 |
+
|
| 175 |
+
statistical analysis, this difference was found to be statistically significant (P , 0.05). A comparison of these two values is provided in the graph in Figure 5.
|
| 176 |
+
|
| 177 |
+
## In Vivo Amplified Nlo Cxl
|
| 178 |
+
|
| 179 |
+
Clinical observation of the corneas 48 hours after treatment revealed very little irritation of the tissue.
|
| 180 |
+
|
| 181 |
+
No significant redness, swelling, or visible haze was observed, as can be seen in Figure 6A. Figure 6B and 6C show a cross-sectional CMTF image and a 178-lm deep plane image within a cornea at 2 weeks. The scattering seen in Figure 6B and the spindle-shaped cell bodies seen in Figure 6C indicate cellular migration within the treated region at 2 weeks. CMTF imaging within the short-term group also revealed a significantly thicker epithelium (42.4 6 1.5 vs. 36.1 6 1.8 lm), an unchanged stromal thickness (315.6 6 23.7 vs. 310.6 6 19.2 lm), and significantly increased haze (3148.1 6 622 vs. 1303.1 6 527) in the treated eye compared to control. Figure 6D shows CAF taken within a vibratome section after 2 weeks of healing. A consistent 110-lm-thick band of CAF
|
| 182 |
+
can be seen 90 lm below the surface of the epithelium.
|
| 183 |
+
|
| 184 |
+
Furthermore, cellular staining using phalloidin and ethidium homodimer (Fig. 6E) revealed the presence of keratocytes within the treated region of all samples. This is noticeably different from the completely acellular region seen in samples treated with UVA
|
| 185 |
+
CXL in previously reported studies.13 In the long-term group, corneal flattening was measured as the diopter difference (DD) of the central 3 mm between the right and left eye (R-L) of each rabbit prior to treatment and at the intervals listed previously. For this reason, a negative value indicates flattening of the treated eye. Corneal flattening was also measured as the DD of each cornea compared to baseline (DR or DL, respectively). Measurements of two rabbits were excluded because CAF could not be detected in the treated eye after sacrifice. Our previous studies have shown that CAF is unchanged even after 3 months of healing,13 so the lack of any CAF was considered indicative of a lack of CXL.
|
| 186 |
+
|
| 187 |
+
There are various reasons this error may have occurred. For example, the pupil may have been misaligned during treatment, or the rabbit may have slipped during the treatment. In either case, the treatment would not have been located in the center of the cornea and therefore was not measured in the correct location in subsequent testing. Example topography measurements of both control and treated eyes, before and after treatment, are shown in Figure 7. The average DD, DR, and DL from the seven remaining rabbits are graphed in Figure 8 and listed individually in Table 2. With the exception of week 2 (P ¼ 0.018), all time points showed significant flattening compared to baseline. Additionally, all DR
|
| 188 |
+
measurements were significantly less than DL measurements, indicating the treated cornea was flattening at a faster rate. With the exception of one rabbit that showed a central acellular region, samples in
|
| 189 |
+
|
| 190 |
+

|
| 191 |
+
|
| 192 |
+

|
| 193 |
+
|
| 194 |
+

|
| 195 |
+
|
| 196 |
+

|
| 197 |
+
|
| 198 |
+
which CAF was detected after 2 months showed increased cellular density throughout the crosslinked region compared to those at 2 weeks, as shown in Figure 9.
|
| 199 |
+
|
| 200 |
+
## Discussion
|
| 201 |
+
|
| 202 |
+
Our previous method of NLO CXL using nonamplified FS pulses was able to produce successful crosslinking. With that system we were able to quickly scan a crosslinked volume into corneal tissue, which produced an increased corneal stiffness and blue CAF, but the average power required to do this was Table 2. Corneal Flattening
|
| 203 |
+
|
| 204 |
+
| Time Point, wk | | | | | |
|
| 205 |
+
|--------------------------------------------------------------|-----|-----|-----|-----|-----|
|
| 206 |
+
| 0 | 1 | 2 | 4 | 8 | |
|
| 207 |
+
| Totala Mean | 0.1 | 1.4 | 0.8 | 1.0 | 1.2 |
|
| 208 |
+
| SD | 0.3 | 1.0 | 0.8 | 0.7 | 0.7 |
|
| 209 |
+
| DRa Mean | 0 | 2.7b | 2.8b | 3.7b | 5.1b |
|
| 210 |
+
| SD | 0 | 1.1 | 0.8 | 0.7 | 1.2 |
|
| 211 |
+
| DLa Mean | 0 | 1.2 | 1.9 | 2.6 | 3.8 |
|
| 212 |
+
| SD | 0 | 0.4 | 0.7 | 1.1 | 0.9 |
|
| 213 |
+
| a Total refers to the DD (R-L) at each time point, DR refers | | | | | |
|
| 214 |
+
|
| 215 |
+
more than 17 times the ANSI limit (800 mW
|
| 216 |
+
compared to the 46.1 mW limit).10,11 By utilizing amplified FS pulses, we were able to design a new system that produces crosslinking using a much lower average power, remaining under the ANSI limit. This study explored the effects of amplified NLO CXL in both ex vivo and in vivo models. To our knowledge, it is the first report using amplified FS pulses for photodynamic therapy that does not involve optical breakdown.
|
| 217 |
+
|
| 218 |
+
During ex vivo experiments, it was discovered that the laser scanning speed is logarithmically related to the resulting CAF intensity. A speed of 15.5 mm/s was found to have CAF comparable to traditional UVA CXL. For this reason, the closest, easily attainable speed (20 mm/s) was used for all other experiments.
|
| 219 |
+
|
| 220 |
+
We have also shown in this study that amplified NLO
|
| 221 |
+
CXL is still capable of producing a significant increase in mechanical stiffness of corneal tissue: 1.6 times stiffer than control.
|
| 222 |
+
|
| 223 |
+
Many other studies have explored the in vivo effects of UVA CXL and found marked effects on corneal structure, specifically a flattening of at least 1 diopter lasting a year or longer.21–25 This has increased the interest for use of corneal crosslinking to treat low refractive errors. Like UVA CXL, NLO CXL was a treatment originally designed to re-
|
| 224 |
+
|
| 225 |
+

|
| 226 |
+
|
| 227 |
+
strengthen corneas weakened by ectatic disease. This study showed that it is possible to achieve flattening with amplified NLO CXL as well, broadening the scope of this treatment to treat low refractive errors as well as corneal ectasia. Unlike UVA CXL, amplified NLO CXL has the ability to treat the cornea in a precise and customizable pattern at any depth within the cornea. For example, 50 lm below the surface was used in this study, with respect to the contact glass.
|
| 228 |
+
|
| 229 |
+
With this ability it could theoretically be possible to customize corneal CXL based on individual corneal topography. Also, if riboflavin could be imbibed into the stroma without removing the epithelium, it would be possible to crosslink below the intact epithelial layer without damaging those cells during crosslinking, resulting in a more effective and less painful procedure. This study also showed repopulation of the central CXL region of treatment by keratocytes as early as 2 weeks post treatment. Our previous study has shown that this repopulation is not attained following UVA CXL out to 3 months post CXL,13 although others have noted earlier repopulation.26–28 One remaining mystery left unanswered by this study is a physical explanation of why amplified FS pulses are able to produce CXL so much more efficiently than nonamplified pulses. Previous studies using nonamplified pulses had required 800 mW, 10 nJ per pulse, to produce both CAF and increased stiffening.10,11 In these studies, the scanning speed and repetition rate were set in such a way that more than 45,000 pulses overlapped at any arbitrary volume within the treatment area. Since each individual pulse is 10 nJ, each volume would then encounter more than 450 lJ over the course of the entire treatment. As expected, no more than 8 mW of total power was needed to produce CAF using 1 lJ pulses. It had been assumed that several hundred of these pulses would need to be overlapped, but unexpectedly, the CAF
|
| 230 |
+
spots seen in Figure 1 were created using a single pulse totaling 1 lJ, well below what was required using nonamplified pulses.
|
| 231 |
+
|
| 232 |
+
One explanation for this difference is the fluorescence lifetime of riboflavin compared to the timing of the pulses. Once a molecule of riboflavin has absorbed photons, the time it requires to pass into the excited triplet state is on the order of nanoseconds, and the half-life of the excited triplet state is around 15 ls. Any additional excitation within this half-life may be absorbed, sending the molecule back to an excited singlet state24 and interrupting the production of free radicals entirely.
|
| 233 |
+
|
| 234 |
+
The nonamplified pulse system used in our previous studies had a repetition rate of 80 MHz, or 10 ns between pulses. This is much shorter than the halflife of the riboflavin triplet state and leaves little time for the production of oxygen free radicals. We suspect that much of the energy spent using an 80-
|
| 235 |
+
MHz oscillator may have been wasted sending riboflavin molecules back and forth between excited singlet and triplet states without ever creating free radicals. The system used in this report had a pulse separation of 10 to 20 ls within the half-life of the riboflavin triplet state, thus creating far more energy-efficient CXL. Future experiments will be needed to test this theory.
|
| 236 |
+
|
| 237 |
+
One limitation of this study concerns measurements of corneal flattening and effects following NLO CXL. As has been noted previously, young rabbits (,6 months) as used in this study are not fully grown and show an age-related corneal flattening as well as thickening throughout their life.29 To account for potential age-related flattening, which does not stabilize until 8 months of age,30 each treated eye was compared to the contralateral control eye.
|
| 238 |
+
|
| 239 |
+
Another limitation of this study is the reduced measure of stiffening as compared to previous iterations of this device. While this generation of NLO CXL (using amplified pulses) was able to produce a significant 1.6 times increase in corneal elasticity, previous versions (using nonamplified pulses) and UVA CXL produced a 2.6 and 2.9 times increase, respectively, compared to control using the same indentation testing technique and equipment.10 On its face, this difference may seem to indicate a reduced stiffening effect with amplified NLO CXL when compared to nonamplified NLO CXL or UVA
|
| 240 |
+
CXL, but this is likely not the case for many reasons. First, amplified NLO CXL was able to induce CAF intensity levels equal to and above UVA CXL,
|
| 241 |
+
which, according to previous studies, implies increased stiffening.11 If amplified NLO CXL had actually produced a lower stiffening effect than did UVA CXL, it would be expected that CAF values would also be lower. Also, as stated previously, the CAF values measured in this study equaled those of previous UVA CXL studies at a speed of 15.5 mm/s.
|
| 242 |
+
|
| 243 |
+
Despite this, a speed of 20 mm/s was used for convenience, which could account for a small portion of the difference. Finally, the CXL volume was both thinner (approximately half) and positioned deeper than for previous studies.10,13 In all previous studies, mechanical measurements were performed on samples that had a CXL volume positioned exactly at the surface of the stroma. This places the indentation needle directly in contact with the treated area. As illustrated in Figures 3, 6, and 9, the CXL volume in this study was positioned deeper into the stroma, leaving a volume of untreated tissue above. Because the indentation needle was not directly in contact with treated area during testing, the results were slightly dampened. If the speed, thickness, and depth could be adjusted to match previous reports, it is likely the results would be higher than reported in this study.
|
| 244 |
+
|
| 245 |
+
## Conclusion
|
| 246 |
+
|
| 247 |
+
This study details both the development and testing of a modified NLO CXL technique. By utilizing amplified FS pulses, this technique was able to achieve both ex vivo and in vivo corneal CXL on par with nonamplified NLO CXL and traditional UVA CXL.
|
| 248 |
+
|
| 249 |
+
## Acknowledgments
|
| 250 |
+
|
| 251 |
+
Supported by National Institutes of Health (NIH)
|
| 252 |
+
EY024600, Research to Prevent Blindness, Inc. (RPB
|
| 253 |
+
203478), and Proof of Product Grant Program (UCI,
|
| 254 |
+
445043-19954).
|
| 255 |
+
|
| 256 |
+
Disclosure: S. Bradford, None; E. Mikula, None; S.W. Kim, None; Y. Xie, None; T. Juhasz, Nonlinear Optical Photodynamic Therapy (NLO-PDT) of the Cornea. US Patent Application No.12/523,058 (P);
|
| 257 |
+
D.J. Brown, Nonlinear Optical Photodynamic Therapy (NLO-PDT) of the Cornea. US Patent Application No.12/523,058 (P); J.V. Jester, Nonlinear Optical Photodynamic Therapy (NLO-PDT) of the Cornea. US Patent Application No.12/523,058 (P)
|
| 258 |
+
*Samantha Bradford and Eric Mikula contributed equally to this manuscript.
|
| 259 |
+
|
| 260 |
+
## References
|
| 261 |
+
|
| 262 |
+
1. Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT.
|
| 263 |
+
|
| 264 |
+
Epidemiology of myopia. Asia Pac J Ophthalmol (Phila). 2016;5:386–393.
|
| 265 |
+
|
| 266 |
+
2. Vitale S, Ellwein L, Cotch MF, Ferris FL III,
|
| 267 |
+
Sperduto R. Prevalence of refractive error in the United States, 1999–2004. Arch Ophthalmol. 2008;126:1111–1119.
|
| 268 |
+
3. Reinstein DZ, Archer TJ, Gobbe M. The history of LASIK. J Refract Surg. 2012;28:291–298.
|
| 269 |
+
|
| 270 |
+
4. Solomon KD, Ferna´ndez de Castro LE, Sandoval HP, et al. LASIK world literature review: quality of life and patient satisfaction. Ophthalmology.
|
| 271 |
+
|
| 272 |
+
2009;116:691–701.
|
| 273 |
+
|
| 274 |
+
5. Wollensak G, Spoerl E, Seiler T. Riboflavin/
|
| 275 |
+
ultraviolet-A–induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135:620–627.
|
| 276 |
+
|
| 277 |
+
6. Lim WK, Soh ZD, Choi HKY, Theng JTS.
|
| 278 |
+
|
| 279 |
+
Epithelium-on photorefractive intrastromal cross-linking (PiXL) for reduction of low myopia.
|
| 280 |
+
|
| 281 |
+
Clin Ophthalmol. 2017;11:1205–1211.
|
| 282 |
+
|
| 283 |
+
7. Wozniak KT, Gearhart SM, Savage DE, Ellis JD,
|
| 284 |
+
Knox WH, Huxlin KR. Comparable change in stromal refractive index of cat and human corneas following blue-IRIS. J Biomed Opt.
|
| 285 |
+
|
| 286 |
+
2017;22:55007.
|
| 287 |
+
|
| 288 |
+
8. Chao Wang MF, Guanxiong M, Zyablitskaya M,
|
| 289 |
+
Vukelic S. Femtosecond laser crosslinking of the cornea for non-invasive vision correction. Nat Photonics. 2018;12:416–422.
|
| 290 |
+
|
| 291 |
+
9. Chai D, Juhasz T, Brown DJ, Jester JV.
|
| 292 |
+
|
| 293 |
+
Nonlinear optical collagen cross-linking and mechanical stiffening: a possible photodynamic therapeutic approach to treating corneal ectasia. J Biomed Opt. 2013;18:038003.
|
| 294 |
+
|
| 295 |
+
10. Bradford SM, Mikula ER, Chai D, Brown DJ,
|
| 296 |
+
Juhasz T, Jester JV. Custom built nonlinear optical crosslinking (NLO CXL) device capable of producing mechanical stiffening in ex vivo rabbit corneas. Biomed Opt Express. 2017;8:4788–
|
| 297 |
+
4797.
|
| 298 |
+
|
| 299 |
+
11. Bradford SM, Brown DJ, Juhasz T, Mikula E,
|
| 300 |
+
Jester JV. Nonlinear optical corneal collagen crosslinking of ex vivo rabbit eyes. J Cataract Refract Surg. 2016;42:1660–1665.
|
| 301 |
+
|
| 302 |
+
12. Delori FC, Webb RH, Sliney DH; American National Standards Institute. Maximum permissible exposures for ocular safety (ANSI 2000),
|
| 303 |
+
with emphasis on ophthalmic devices. J Opt Soc Am A Opt Image Sci Vis. 2007;24:1250–1265.
|
| 304 |
+
|
| 305 |
+
13. Bradford SM, Mikula ER, Juhasz T, Brown DJ,
|
| 306 |
+
Jester JV. Collagen fiber crimping following in vivo UVA-induced corneal crosslinking. Exp Eye Res. 2018;177:173–180.
|
| 307 |
+
|
| 308 |
+
14. Zipfel WR, Williams RM, Webb WW. Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol. 2003;21:1369–1377.
|
| 309 |
+
|
| 310 |
+
15. Chai D, Gaster RN, Roizenblatt R, Juhasz T,
|
| 311 |
+
Brown DJ, Jester JV. Quantitative assessment of UVA-riboflavin corneal cross-linking using nonlinear optical microscopy. Invest Ophthalmol Vis Sci. 2011;52:4231.
|
| 312 |
+
|
| 313 |
+
16. Steven P, Hovakimyan M, Guthoff RF,
|
| 314 |
+
Hu¨ttmann G, Stachs O. Imaging corneal crosslinking by autofluorescence 2-photon microscopy, second harmonic generation, and fluorescence lifetime measurements. J Cataract Refract Surg. 2010;36:2150–2159.
|
| 315 |
+
|
| 316 |
+
17. Franco W, Ortega-Martinez A, Zhu H, Wang R,
|
| 317 |
+
Irene E, Kochevar IE. Fluorescence spectroscopy of collagen crosslinking: non-invasive and in-situ evaluation of corneal stiffness. In: Larin KV,
|
| 318 |
+
Sampson DD, eds. Optical Elastography and Tissue Biomechanics II, Vol. 9327. Bellingham, WA: SPIE; 2015.
|
| 319 |
+
|
| 320 |
+
18. Chai D, Gaster RN, Roizenblatt R, Juhasz T,
|
| 321 |
+
Brown DJ, Jester JV. Quantitative assessment of UVA-riboflavin corneal cross-linking using nonlinear optical microscopy. Invest Ophthalmol Vis Sci. 2011;52:4231–4238.
|
| 322 |
+
|
| 323 |
+
19. Hayes WC, Keer LM, Herrmann G, Mockros LF. A mathematical analysis for indentation tests of articular cartilage. J Biomech. 1972;5:541–551.
|
| 324 |
+
|
| 325 |
+
20. Levental I, Levental KR, Klein EA, et al. A
|
| 326 |
+
simple indentation device for measuring micrometer-scale tissue stiffness. J Phys Condens Matter.
|
| 327 |
+
|
| 328 |
+
2010;22:194120.
|
| 329 |
+
|
| 330 |
+
21. Hersh PS, Stulting RD, Muller D, Durrie DS,
|
| 331 |
+
Rajpal RK; United States Crosslinking Study Group. United States multicenter clinical trial of corneal collagen crosslinking for keratoconus treatment. Ophthalmology. 2017;124:1475–1484.
|
| 332 |
+
|
| 333 |
+
22. Kanellopoulos AJ, Asimellis G. Combined laser in situ keratomileusis and prophylactic highfluence corneal collagen crosslinking for high myopia: two-year safety and efficacy. J Cataract Refract Surg. 2015;41:1426–1433.
|
| 334 |
+
|
| 335 |
+
23. De Bernardo M, Capasso L, Lanza M, et al.,
|
| 336 |
+
Long-term results of corneal collagen crosslinking for progressive keratoconus. J Optom. 2015;8:
|
| 337 |
+
180–186.
|
| 338 |
+
|
| 339 |
+
24. Elling M, Kersten-Gomez I, Dick HB. Photorefractive intrastromal corneal crosslinking for the treatment of myopic refractive errors: sixmonth interim findings. J Cataract Refract Surg.
|
| 340 |
+
|
| 341 |
+
2017;43:789–795.
|
| 342 |
+
|
| 343 |
+
25. Vinciguerra P, Albe` E, Trazza S, Seiler T, Epstein D. Intraoperative and postoperative effects of corneal collagen cross-linking on progressive keratoconus. Arch Ophthalmol. 2009;127:1258–
|
| 344 |
+
1265.
|
| 345 |
+
|
| 346 |
+
26. Kozobolis V, Gkika M, Sideroudi H, et al. Effect of riboflavin/UVA collagen cross-linking on central cornea, limbus and intraocular pressure.
|
| 347 |
+
|
| 348 |
+
Experimental study in rabbit eyes. Acta Medica (Hradec Kralove). 2016;59:91–96.
|
| 349 |
+
|
| 350 |
+
27. Kruger A, Hovakimyan M, Ram´ırez Ojeda DF,
|
| 351 |
+
et al. Combined nonlinear and femtosecond confocal laser-scanning microscopy of rabbit corneas after photochemical cross-linking. Invest Ophthalmol Vis Sci. 2011;52:4247–4255.
|
| 352 |
+
|
| 353 |
+
28. Wollensak G, Iomdina E, Dittert DD, Herbst H.
|
| 354 |
+
|
| 355 |
+
Wound healing in the rabbit cornea after corneal collagen cross-linking with riboflavin and UVA.
|
| 356 |
+
|
| 357 |
+
Cornea. 2007;26:600–605.
|
| 358 |
+
|
| 359 |
+
29. Doughty MJ. The cornea and corneal endothelium in the aged rabbit. Optom Vis Sci. 1994;71:
|
| 360 |
+
809–818.
|
| 361 |
+
|
| 362 |
+
30. Riau AK, Tan NY, Angunawela RI, Htoon HM,
|
| 363 |
+
Chaurasia SS, Mehta JS. Reproducibility and age-related changes of ocular parametric measurements in rabbits. BMC Vet Res. 2012;8:138.
|
medical/md/PMC7308133.md
ADDED
|
@@ -0,0 +1,235 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
Open Access Full Text Article
|
| 2 |
+
|
| 3 |
+
# Original Research The Effect Of Cyp2C9 Genotype Variants In Type 2 Diabetes On The Pharmacological Effectiveness Of Sulfonylureas, Diabetic Retinopathy, And Nephropathy
|
| 4 |
+
|
| 5 |
+
This article was published in the following Dove Press journal: Vascular Health and Risk Management Meisam Saberi1 Zahra Ramazani1 Homeira Rashidi2 Alihossein Saberi3 1Department of Medical Chemistry, School of Pharmacy, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 2Diabetic Research Center, Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran; 3Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran Aim: Type 2 diabetes (T2D), as a major cause of morbidity and mortality, is predicted to have a prevalence of 629 million by 2045. As diabetic patients show considerable interindividual variation in response to antidiabetic treatment, this study aimed to investigate the gene polymorphism of cytochrome P450 as well as the effectiveness and safety of glibenclamide and gliclazide for different genotypes of CYP2C9. Besides, the chronic side effects of T2D including retinal microvasculature complications or retinopathy and renal dysfunction due to nephropathy in different genotypes were considered.
|
| 6 |
+
|
| 7 |
+
Patients and Methods: The participants including 80 T2D patients treated with glibenclamide or gliclazide were recruited from university hospitals of Ahvaz Jundishpur University of Medical Sciences, Ahvaz, in the southwest of Iran. Blood samples were collected from the patients at 2.5h after the morning dose of glibenclamide and 12h after the last dose of gliclazide. Genotyping from the extracted DNA was, then, performed using PCR-RFLP. The plasma level of glibenclamide and gliclazide was, in turn, measured by the reverse-phase high-pressure liquid chromatography.
|
| 8 |
+
|
| 9 |
+
Results: The results showed that the wild-type allele, i.e., CYP2C9*1, occurred in the highest frequency (0.8), while the frequency rates of the mutant allele, i.e., CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively. Moreover, no significant association was found between any of the genotypes as well as the clinical and biochemical characteristics of the patients. The findings also showed that the plasma level of sulfonylureas (i.e., glibenclamide and gliclazide) was the highest in the patients with the CYP2C9*3 allele. It was also found that 75.9% of the patients with variant genotypes had experienced hypoglycemia events. Furthermore, in the absence of wild type allele, a significant increase was observed in retinopathy (p=0.039) and nephropathy (p=0.05).
|
| 10 |
+
|
| 11 |
+
Conclusion: The findings can provide guidelines for the optimal management of the treatment protocols with sulfonylurea intended to control the T2D complications.
|
| 12 |
+
|
| 13 |
+
Keywords: CYP2C9, glibenclamide, gliclazide, retinopathy, nephropathy
|
| 14 |
+
|
| 15 |
+
## Introduction
|
| 16 |
+
|
| 17 |
+
Type 2 diabetes (T2D), as a metabolic disorder characterized by hyperglycemia, is reported to have a prevalence of 629 million by 2045.1 Genetic factors are, in turn, supposed to contribute to great inter-individual variation in response to antidiabetic treatment. Indeed, the importance of pharmacogenetics to reinforce therapeutic outcomes is widely acknowledged. Among others, sulfonylureas, as a group of antidiabetic drugs, are most widely used for the treatments of patients with T2D.2 In effect, the sulfonylurea receptor functions as a part of the ATP-dependent potassium channel in the beta cells of the pancreas (K-ATP).3 This way, channel function is inhibited due to the binding of the receptor to sulfonylurea. This, in turn, alters the resting potential of the cell, resulting in calcium influx and the stimulation of insulin secretion.
|
| 18 |
+
|
| 19 |
+
The net effect occurs when the beta cell response increases in both stimulants of glucose and non-glucose (e.g., amino acids), and insulin secrets at higher levels at all blood glucose concentrations. Having similar characteristics in their structure, glibenclamide and gliclazide, as the second generation sulfonylureas, are prescribed in much lower doses than the previous generation of sulfonylureas. However, the effectiveness of different sulfonylureas in lowering blood glucose concentration is reported to be the same.2 Although sulfonylureas are usually welltolerated, they usually have serious side effects including hypoglycemia which is more common in the long-acting version of such drugs.4–6 Sulfonylurea is known to be metabolized by cytochrome P450, which is encoded by the CYP2C9 gene. Several studies have already reported medical evidence suggesting that in patients with CYP2C9*2 and CYP2C9*3 variant alleles, the metabolism of the substrate is significantly slower than that in the wild-type allele.7–10 For instance, in a Go-DART study by Zhou et al11, it was shown that sulfonylureas were metabolized mainly by the cytochrome P450 2C9 (15). Two CYP2C9* and CYP2C *3 genotypes were, indeed, found to be associated with impaired substrate metabolism. Furthermore, many reports have demonstrated that at least one variant allele causes a significant decrease in CYP2C9 activity, requiring dose adjustment for sulfonylureas.12–15 Therefore, CYP2C9 gene polymorphism is likely to affect the metabolism and the adverse drug reaction (ADR) of glibenclamide and gliclazide.
|
| 20 |
+
|
| 21 |
+
Diabetic retinopathy, a retinal vascular disorder, occurs as a complication of diabetes mellitus and causes blindness in diabetic patients. In effect, the associated vision loss results from several mechanisms, including neovascularization, macular edema, and retinal capillary nonperfusion.16 Likewise, a few studies have shown that diabetic retinopathy is influenced by CYP2C9 variants.17 Epoxyeicosatrienoic acids (EETs) produced by CYP2C8 and CYP2C9, which are hydrolyzed to dihydroxyeicosatrienoic acids (DHETs) by epoxide hydrolase, are known to play an important role in the diabetic retinopathy.18 Therefore, CYP2C9 genetic polymorphism is also likely to affect retinopathy, considering that renal dysfunction has been reported in patients with T2D. The severity and onset of nephropathy maybe thus influenced by genetic variants.
|
| 22 |
+
|
| 23 |
+
This study was, thus, intended to analyze the frequency of CYP2C9 genotypes in T2 diabetic patients, and also investigate the metabolism as well as safety (ADR) of glibenclamide and gliclazide in patients with different CYP2C9 genotypes to predict their response to sulfonylureas. Also, this study examined whether the CYP2C9 polymorphisms were associated with the risk of diabetic retinopathy and diabetic nephropathy.
|
| 24 |
+
|
| 25 |
+
## Patients And Methods Patient Selection And Clinical Study Design
|
| 26 |
+
|
| 27 |
+
Iranian patients with T2D who had received medical treatment with sulfonylureas (i.e., glibenclamide or gliclazide) at Golestan and Imam Khomeini Hospitals were recruited for this study. The participants included 80 T2D male and female patients who had to take 10 mg Glibenclamide and 160 mg Gliclazide for more than 3 months. Blood samples were collected from the patients at 2.5 h after the morning dose of glibenclamide15 and 12h after the last dose of gliclazide, corresponding to the time for the peak drug concentration.19 The plasma samples collected were used to estimate the levels of sulfonylureas, and the buffy coat fraction was used for DNA extraction and genotyping of variant alleles. The plasma levels of glibenclamide and gliclazide were, then, estimated by reverse-phase high-pressure liquid chromatography.20,21 The DNA was extracted from the buffy coat using the salting-out extraction procedure. The variant alleles CYP2C9*2 and *3 were genotyped by PCR– restriction fragment length polymorphism (RLFP).22 Fasting blood glucose (FBS), HbA1c, blood urea nitrogen (BUN), creatinine (Cr), microalbuminuria, LDL (Low-density lipoprotein), HDL (High-density lipoprotein), total cholesterol and retinopathy data were collected from the patients' medical records.
|
| 28 |
+
|
| 29 |
+
Nephropathy was, in turn, achieved by using an NKF KDOQI.
|
| 30 |
+
|
| 31 |
+
GUIDELINES.23 The cause of chronic kidney disease, glomerular filtration rate (GFR) and albuminuria, collectively referred to as CGA staging, was checked according to the guidelines. The GFR ≥ 90mL/min/1.73m2 (G1) was considered as normal or high GFR, while GFR≤ 15 (G5) was described as kidney failure. There are several categories between G1 and G5 (i.e., G2, G3a, G3b, and G4) meaning mildly to severely decreased as GFR. Increasing albuminuria from less than 30mg/g to more than 300mg/g was, in turn, categorized as A1 to A3 (normal to severely increased). We described the risk of nephropathy using the combination of GFR decreasing and albuminuria increasing ranges. For instance, the patients with GFR<15 mL/min/1.73m2 and albuminuria more than 300mg/g (G5-A3) were considered at very high risk for nephropathy.
|
| 32 |
+
|
| 33 |
+
This study was approved by the Medical Ethics Committee at Ahvaz Jundishapur University of Medical Sciences, Iran. Informed written consent was obtained from the patients after they were introduced to the research objectives and the procedure used.
|
| 34 |
+
|
| 35 |
+
## Statistical Analysis
|
| 36 |
+
|
| 37 |
+
In the statistical analysis performed, all quantitative data were presented as mean ± standard deviation (SD), and the comparison between different genotype groups was conducted using an independent t-test and ANOVA test. The chi-square test was, in turn, used to compare the genotype and allelic frequency distribution of CYP2C9, as well as the distribution of sulfonylureas plasma level, ADRs (hypoglycemia), and the retinopathy and nephropathy between the genotype groups.
|
| 38 |
+
|
| 39 |
+
## Results
|
| 40 |
+
|
| 41 |
+
A total of 80 patients with T2D were genotyped by PCRRFLP method described previously (Table 1). The compound heterozygous genotypes were scored according to the Seng et al paper.22 In CYP2C9*1/CYP2C9*2 genotype, AvaII
|
| 42 |
+
digestion produced 296b + 79bp and 375bp, while Kpn1 digestion created 105bp. In turn, in CYP2C9*1/CYP2C9*3 genotype, AvaII digestion produced 375bp and 296bp + 79bp, while Kpn1 digestion produced 85bp + 20bp. Likewise, in the CYP2C9*2/CYP2C9*3 genotype, AvaII digestion produced 375bp and 296bp + 79 bp, while Kpn1 digestion produced 105bp fragments.
|
| 43 |
+
|
| 44 |
+
The genotype and allelic frequencies obtained were consistent with those of Hardy-Weinberg Equilibrium.
|
| 45 |
+
|
| 46 |
+
Indeed, CYP2C9*1 (wild type) was the predominant allele and occurred in high frequency in this study (0.8). Besides, the frequency of mutant alleles, CYP2C9*2 and CYP2C9*3, were 0.15 and 0.05, respectively.
|
| 47 |
+
|
| 48 |
+
The results also showed that there were 51 patients with CYP2C9*1/*1 genotype (63.57%), and CYP2C9*1/*2 (22.5%) was found to be the second most frequent genotype. Also, the percentage rates of the observed CYP2C9*1/*3 and CYP2C9*2/*3 genotypes were 10 and 2.5, respectively. Moreover, only one patient was observed with the CYP2C9*2/*3 compound heterozygous genotype. Though none of the patients was a homozygous mutant genotype for the CYP2C9*3 allele, two patients with CYP2C9*2 allele were found to be a homozygous mutant.
|
| 49 |
+
|
| 50 |
+
The demographic information and biochemical characteristics of the patients are summarized in Table 1. The parameters such as age, gender, duration of diabetes, FBS, HbA1c, BUN, TG, LDL, HDL, and total cholesterol were compared in different genotypes. The findings showed that there was no significant correlation between any of the genotypes as well as the clinical and biochemical characteristics of the patients. It was also found that 55 patients, out of 80 patients, underwent concomitant treatment with two drugs, namely sulfonylureas (glibenclamide or gliclazide) and metformin, 16 patients with three drugs (i.e.,
|
| 51 |
+
metformin, sulfonylureas, and another antidiabetic drug),
|
| 52 |
+
Table 1 The Demographic and Biochemical Factors in Different Genotypes of CYP2C9
|
| 53 |
+
|
| 54 |
+
Age (years) 58 54 56 51 53 N/A Gender (M/F) 18/33 9/9 1/7 0/2 0/1 N/A Duration of diabetes (years) 10 8 11 11 6 0.318 FBS(mg/dl) 185 202 196 109 162 0.666 HbA1c (%) 8.3 8 8.4 6.6 8.5 0.711 BUN 14 15 18 12 9 0.387 Creatinine 0.92 0.95 1.1 0.8 0.8 0.238 TG 156 176 260 260 115 0.316 LDL 96 100 132 125 63 0.157 HDL 44 51 39 40 33 0.177 Total cholesterol 167 173 193 181 119 0.498
|
| 55 |
+
|
| 56 |
+
CYP2C9*1/*1 (n=51)
|
| 57 |
+
|
| 58 |
+
CYP2C9*1/*2 (n=18)
|
| 59 |
+
|
| 60 |
+
CYP2C9*1/*3 (n=8)
|
| 61 |
+
|
| 62 |
+
CYP2C9*2/*2 (n=2)
|
| 63 |
+
|
| 64 |
+
CYP2C9*2/*3 (n=1)
|
| 65 |
+
|
| 66 |
+
p-value
|
| 67 |
+
|
| 68 |
+
9 patients with monotherapy, 5 patients with gliclazide, and other 4 patients with glibenclamide.
|
| 69 |
+
|
| 70 |
+
To examine the effects of CYP2C9 genotypes on the plasma level of sulfonylureas, the drug concentration was investigated using HPLC 2.5 hours after glibenclamide and 12 hours after gliclazide administration. The results showed that a relatively higher plasma level of sulfonylureas was observed in the CYP2C9*3 allele in comparison to those of other alleles. Besides, it was found that there was no steadystate in the plasma level of the drugs in patients with wild-type alleles (Table 2). Furthermore, the distributions of various alleles in two groups of patients, namely, steady-state and nonsteady-state, were significantly different (p=0.001).
|
| 71 |
+
|
| 72 |
+
Additionally, the occurrence of hypoglycemic ADRs to sulfonylureas was compared between the wild-type and variant genotypes. The results showed that 75.9% of the patients with variant genotypes had experienced hypoglycemia status, whereas this was not observed in the wild-type genotypes. Overall, these data showed that hypoglycemia status increased significantly in the patients with variant genotypes. The retinopathy was, in turn, checked in all samples, and a significant association was identified between the duration of diabetes and retinopathy (p=0.002).
|
| 73 |
+
|
| 74 |
+
To investigate the association between the variant genotypes and retinopathy, we initially checked the average duration of diabetes between various genotypes. As the findings showed, no significant difference was observed
|
| 75 |
+
(p=0.318). However, the association between the different genotypes and retinopathy was found to be significant
|
| 76 |
+
(p=0.039). In the patients with CYP2C9*1/*3 genotype 50%, while in CYP2C9*2/*2 and *2/*3 genotypes, 100% of the patients were affected by retinopathy (Figure 1).
|
| 77 |
+
|
| 78 |
+
In turn, to evaluate the impact of the duration of diabetes on the renal function, the correlation between nephropathy and the duration of diabetes was investigated. As the results showed, no significant correlation was found (p=0.404).
|
| 79 |
+
|
| 80 |
+
However, patients with variant genotypes were found to be significantly affected by nephropathy (p=0.05). Besides, 50% of the patients with CYP2C9*1/*3 and 67% of the patients with CYP2C9*2/*2 and CYP2C9*2/*3 genotypes were identified to be affected (Figure 2).
|
| 81 |
+
|
| 82 |
+
## Discussion
|
| 83 |
+
|
| 84 |
+
This study was, initially, intended to investigate the frequency of variant genotypes in 80 patients with T2D.
|
| 85 |
+
|
| 86 |
+
Then, the effect of variant genotypes of CYP2C9 on responses to sulfonylureas including glibenclamide and gliclazide was examined. The association between hypoglycemic ADRs and variant genotypes in T2 diabetics who were treated with sulfonylureas (glibenclamide or gliclazide) was also sought. Finally, the influence of variant genotypes on diabetic nephropathy and retinopathy was studied.
|
| 87 |
+
|
| 88 |
+
Investigating the prevalence of different CYP2C9 genotypes, it was found that the wild-type allele (CYP2C9*1)
|
| 89 |
+
was the highest. This result is similar to the allelic frequency reported in the study conducted by Ataby et al in the north of Iran, involving patients from Turkman and Fars ethnic groups.24 Similarly, several other studies showed that the most prevalent allele of CYP2C9*1 was the wild-type allele.9,2536 Also, it was reported that the second most prevalent allele was the CYP2C9*2 allele (15 %), which is consistent with the previous reports in Caucasian populations.37 However, the lowest frequency of this allele was observed in the Africans (0.46%), East Asians (0.56%) and Native Americans (1.25%).37 CYP2C9*3 allele in our study was found to be 5%, similar to the allelic frequency observed in Ataby for Turkman and Fars ethnic groups.24 In contrast, CYP2C9*3 showed the highest frequency among the South Asians (11.7%).37 Moreover, the frequency of the CYP2C9*3/*3 homozygous genotype was not identified in our study as well as in the Caucasian ethnic groups,38,39 whereas it was detected frequently in the Malay and Indian ethnic groups.22 Overall, these data show that the allelic frequency of the Iranian ethnic groups is similar to that of the Caucasian population.
|
| 90 |
+
|
| 91 |
+
Table 2 Plasma Level of Glybenclamid and Glyclaside as Well as the Number of Patients Reached Steady State in Different Genotype of CYP2C9
|
| 92 |
+
|
| 93 |
+
| CYP2C9*1/*1 | CYP2C9*1/*2 | CYP2C9*1/*3 | CYP2C9*2/*2 | CYP2C9*2/*3 | |
|
| 94 |
+
|--------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------|---------------|---------------|--------|
|
| 95 |
+
| Plasma level of glibenclamide (µg/mL) | 0.0053 | 0.1695 | 0.8072 | 0.6990 | N/A |
|
| 96 |
+
| Plasma level of gliclazide (µg/mL) | 0.0427 | 0.2213 | 2.4696 | 0.4790 | 2.4620 |
|
| 97 |
+
| Steady state (# cases) | 0 | 4 | 7 | 1 | 1* |
|
| 98 |
+
| Non-steady state (# cases) | 51 | 14 | 1 | 1 | 0 |
|
| 99 |
+
| Note: *The distributions of various alleles in two groups of patient, i.e., steady-state and non-steady-state, were significantly different (p=0.001). | | | | | |
|
| 100 |
+
|
| 101 |
+

|
| 102 |
+
|
| 103 |
+
Figure 1 Association of retinopathy and different genotypes of CYP2C9.
|
| 104 |
+
|
| 105 |
+

|
| 106 |
+
|
| 107 |
+
To find out the different responses of glibenclamide treatment in the patients with various CYP2C9 genotypes, the plasma level of glibenclamide in T2 diabetic patients with CYP2C9*1/*1, CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, and CYP2C9*2/*3 genotypes was measured 2.5 hours after the treatment. The plasma concentration of gliclazide was also measured for the same genotypes 12 hours after the treatment. Given that the peak of plasma concentration in the previous studies reached a maximum of 2 hours after the glibenclamide treatment,15 the plasma level was measured 2.5 hours after the administration in our study. However, as gliclazide remains in plasma for a longer time, the measurement was, thus, done 12 hours after the administration.
|
| 108 |
+
|
| 109 |
+
Consistent with the previous studies, the highest plasma level of glibenclamide was observed in the CYP2C9*1/*3 (0.8µg/mL). Moreover, the plasma level of gliclazide was higher not only in the CYP2C9*1/*3 genotype but also in CYP2C9*2/*3 genotypes (2.46µg/mL). In contrast, the lowest level of glibenclamide and gliclazide concentration in the plasma was observed in the wild-type CYP2C9*1/
|
| 110 |
+
*1 genotype. Therefore, this result implies that the elimination of plasma glibenclamide and gliclazide in patients with CYP2C9*1/*3 may be slower than that in patients with CYP2C9*1/*1. This, in turn, indicates that the higher concentration of glibenclamide and gliclazide may cause stronger pharmacological effects. Moreover, it was found that the plasma concentration of glibenclamide and gliclazide in other variant genotypes, namely CYP2C9*1/
|
| 111 |
+
*2 and CYP2C9*2/*2 was higher than that in the wildtype genotype (Table 2). However, the plasma level of gliclazide in CYP2C9*2/*2 was similar to that in the wildtype CYP2C9*1/*1 genotypes. Overall, these data showed that in the patients with wild-type genotypes, the elimination of glibenclamide and gliclazide was likely to be faster than that invariant genotypes, as a lower concentration of such drugs is needed for the patients with wild-type genotypes.
|
| 112 |
+
|
| 113 |
+
The association of variant genotypes with hypoglycemic ADRs in T2 diabetic patients treated with the sulfonylureas glibenclamide or gliclazide was, in turn, investigated. The results showed that the presence of variant genotypes predisposes sulfonylurea-treated patients to hypoglycemia. It was found that in individuals with variant genotypes (CYP2C9*1/*2, CYP2C9*1/*3, CYP2C9*2/*2, CYP2C9*2/*3) when treated with sulfonylureas, the risk of suffering a hypoglycemic event significantly increased. Similarly, in a study with a limited number of patients (i.e., 20 patients), Holstein et al reported that CYP2C9*2/*3 and CYP2C9*1/*3 genotypes correlated with severe hypoglycemia.40 By contrast, in the study conducted by Surendiran et al, there was no significant difference in the occurrence or severity of hypoglycemia.41 Accordingly, since hypoglycemia can significantly cause morbidity and mortality, the treatment protocol for diabetes should be geared to the patients' individual needs to reduce the occurrence of hypoglycemic episodes. It is suggested that, particularly at the beginning of the treatment by sulfonylurea, genotype analysis is likely to prevent overdose in patients with CYP2C9 genotypes, causing lower activity.42 In effect, identifying the genotype of the patient might help the physician adjust the regimen protocol accordingly, and therefore reduce the possibility of the patient's experiencing a hypoglycemic event. This approach to CYP2C9 genotyping of patients before the treatment by glimepiride has already been adopted in Korea and Russia.43,44 Our data also provide evidence supporting the use of such an approach.
|
| 114 |
+
|
| 115 |
+
## Limitations
|
| 116 |
+
|
| 117 |
+
There are several limitations to consider in this study, including the small sample size, compared to Go-DART
|
| 118 |
+
trials11 studies, limiting the generalizability of the findings.
|
| 119 |
+
|
| 120 |
+
Indeed, despite registering180 patients for the research purpose, we could only include data from 82 patients in the final analysis as some of the patients did not cooperate to be compatible with our inclusion criteria. However, the association of plasma level of sulfonylurea with CYP2C9 genotypes was statistically significant (p-value less than 0.05). Moreover, future studies using large mega studies seem necessary to confirm our findings.
|
| 121 |
+
|
| 122 |
+
To the best of our knowledge, this may be the first study on the impact of CYP2C9 genotype variants on retinopathy in patients with T2D. The data showed that in the absence of wild-type alleles, all patients were affected by retinopathy, while the presence of wild-type allele delayed the microvascular complications (Figure 1). However, it is not clear how CYP2C9 variant alleles (*2 and *3) influenced the retinal microvasculatures, but a few studies have reported the influence of CYP2C9 and their products, namely the epoxyeicosatrienoic acids (EETs), in the hypoxia-induced VEGF production and pathologic retinal angiogenesis.45 Also, comparing the risk of nephropathy in the patients with different CYP2C9 alleles, based on the marked increase in microalbuminuria and the decrease observed in the glomerular filtration rate (GFR), 66.7% of the patients with CYp2C9*2/*2 and CYP2C9*2/*3 genotypes were identified to be affected by nephropathy (Figure 2). It seems that the presence of wild-type alleles (*1/*1, *1/*2 and *1/*3) protected the normal function of the kidney in patients with T2D. However, the precise mechanism of CYP2C9 in diabetic retinopathy and nephropathy is still unclear.
|
| 123 |
+
|
| 124 |
+
It is concluded that the genotype analysis of CYP2C9 in patients with T2D can provide guidelines for the optimal management of the treatment protocol with sulfonylurea by physicians so that they can make sound decisions to regulate the treatment protocol accordingly before the initiation of sulfonylurea therapy, and thus prevent the hypoglycemic events.
|
| 125 |
+
|
| 126 |
+
## Ethics Approval And Consent To Participate
|
| 127 |
+
|
| 128 |
+
In this clinical experimental study, all peripheral blood samples were collected and used by the ethical rules con-firmed by the ethics committee of Ahvaz Jundishapur University of Medical Sciences (Code no: IR.AJUMS. REC.139.221). Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by the authors. Written informed consent was also obtained from all patients. Data were anonymously and confidentially retrieved with compliance with the Declaration of Helsinki.
|
| 129 |
+
|
| 130 |
+
## Acknowledgments
|
| 131 |
+
|
| 132 |
+
We thank the patients and nurses in diabetic specific clinics at Imam Khomeini and Golestan Hospitals affiliated to Ahvaz Jundishpur University of Medical Sciences, Ahvaz, Iran for their contribution to the research. The study was supported by the grant provided by the Deputy of Research Affairs at Ahvaz Jundishpur University of Medical Sciences.
|
| 133 |
+
|
| 134 |
+
## Author Contributions
|
| 135 |
+
|
| 136 |
+
All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
|
| 137 |
+
|
| 138 |
+
## Disclosure
|
| 139 |
+
|
| 140 |
+
The authors declare no conflicts of interest.
|
| 141 |
+
|
| 142 |
+
## References
|
| 143 |
+
|
| 144 |
+
1. Federation ID, editor. IDF Diabetes Atlas Update Poster. Brussels, Belgium: International Diabetes Federation; 20152015.
|
| 145 |
+
|
| 146 |
+
2. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non—insulin-department diabetes mellitus. Arch Intern Med.
|
| 147 |
+
|
| 148 |
+
1997;157(8):836–848. doi:10.1001/archinte.1997.00440290014001 3. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP IV. Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268(5209):423. doi:10.1126/science.7716547 4. Tessier D, Dawson K, Tetrault J, Bravo G, Meneilly G.
|
| 149 |
+
|
| 150 |
+
Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med. 1994;11(10):974–980. doi:10.1111/j.1464-5491.1994.tb00256.x 5. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17
|
| 151 |
+
(6):467–473. doi:10.1002/dmrr.235 6. Gangji AS, Cukierman T, Gerstein HC, Goldsmith CH, Clase CM.
|
| 152 |
+
|
| 153 |
+
A systematic review and meta-analysis of hypoglycemia and cardiovascular events. Diabetes Care. 2007;30(2):389–394. doi:10.2337/dc061789 7. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
|
| 154 |
+
|
| 155 |
+
Pharmacogenet Genomics. 2002;12(3):251–263. doi:10.1097/0000 8571-200204000-00010 8. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M,
|
| 156 |
+
Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenet Genomics. 2000;10
|
| 157 |
+
(2):95–104. doi:10.1097/00008571-200003000-00001 9. Sullivan-Klose TH, Ghanayem BI, Bell DA, et al. The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism.
|
| 158 |
+
|
| 159 |
+
Pharmacogenet Genomics. 1996;6(4):341–349. doi:10.1097/00008 571-199608000-00007 10. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
|
| 160 |
+
|
| 161 |
+
Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4ʹ-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenet Genomics.
|
| 162 |
+
|
| 163 |
+
1997;7(2):103–113. doi:10.1097/00008571-199704000-00003 11. Zhou K, Donelly L, Burch L, et al. Loss–off-functionCYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a go-DARTS study. Clin Pharmacol Ther. 2010;87(1):52–56.
|
| 164 |
+
|
| 165 |
+
doi:10.1038/clpt.2009.176 12. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenet Genomics.
|
| 166 |
+
|
| 167 |
+
2002;12(2):101–109. doi:10.1097/00008571-200203000-00004 13. Shon J-H, Yoon Y-R, Kim K-A, et al. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenet Genomics. 2002;12
|
| 168 |
+
(2):111–119. doi:10.1097/00008571-200203000-00005 14. Suzuki K, Yanagawa T, Shibasaki T, Kaniwa N, Hasegawa R, Tohkin M.
|
| 169 |
+
|
| 170 |
+
Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. Diabetes Res Clin Pract. 2006;72(2):148–154. doi:10.1016/j.diabres.2005.09.019 15. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ,
|
| 171 |
+
Kivistö KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther. 2002;72
|
| 172 |
+
(3):326–332. doi:10.1067/mcp.2002.127495 16. American Academy of Ophthalmology. Preferred Practice Pattern:
|
| 173 |
+
Diabetic Retinopathy. September 20; 2014; San Francisco, Calif: American Academy of Ophthalmology.
|
| 174 |
+
|
| 175 |
+
17. Capozzi ME, McCollum GW, Penn JS. The role of cytochrome P450 epoxygenases in retinal angiogenesis cytochrome P450 epoxygenases.
|
| 176 |
+
|
| 177 |
+
Invest Ophthalmol Vis Sci. 2014;55(7):4253–4260. doi:10.1167/iovs.1414216 18. Suzuki S, Oguro A, Osada-Oka M, Funae Y, Imaoka S.
|
| 178 |
+
|
| 179 |
+
Epoxyeicosatrienoic acids and/or their metabolites promote hypoxic response of cells. J Pharmacol Sci. 2008;108(1):79–88. doi:10.1254/
|
| 180 |
+
jphs.08122FP
|
| 181 |
+
19. Shao H, Ren X, Liu N, et al. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther.
|
| 182 |
+
|
| 183 |
+
2010;35(3):351–360. doi:10.1111/j.1365-2710.2009.01134.x 20. Rajendran S, Philip B, Gopinath R, Suresh B. RP-HPLC method for the estimation of glibenclamide in human serum. Indian J Pharm Sci. 2007;69(6):796. doi:10.4103/0250-474X.39436 21. Venkatesh P, Harisudhan T, Choudhury H, Mullangi R, Srinivas NR.
|
| 184 |
+
|
| 185 |
+
Simultaneous estimation of six anti-diabetic drugs—glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomed Chromatogr. 2006;20(10):1043–1048. doi:10.1002/bmc.635 22. Seng KC, Gin GG, Sangkar JV, Phipps ME. Frequency of cytochrome P450 2C9 (CYP2C9) alleles in three ethnic groups in Malaysia. Asia Pac J Mol Biol Biotechnol. 2003;11(2):83–91.
|
| 186 |
+
|
| 187 |
+
23. Levey AS, Coresh J, Balk E, et al. National kidney foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137–147.
|
| 188 |
+
|
| 189 |
+
doi:10.7326/0003-4819-139-2-200307150-00013 24. Ataby OA, Tabari RG, Mansourian AR, Samai NM, Marjani A.
|
| 190 |
+
|
| 191 |
+
Genetic polymorphism of cytochrome P450 2C9 (CYP2C9) in two ethnic groups in Iran. Am J Biomed Sci. 2013;5(3):177–187.
|
| 192 |
+
|
| 193 |
+
doi:10.5099/aj130300177 25. Wang S-L, Huang J-D, Lai M-D, Tsai -J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.
|
| 194 |
+
|
| 195 |
+
Pharmacogenet Genomics. 1995;5(1):37–42. doi:10.1097/00008571199502000-00004 26. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus.
|
| 196 |
+
|
| 197 |
+
Pharmacogenet Genomics. 1996;6(5):429–439. doi:10.1097/000 08571-199610000-00007 27. Nasu K, Kubot T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenet Genomics.
|
| 198 |
+
|
| 199 |
+
1997;7(5):405–409. doi:10.1097/00008571-199710000-00011 28. Ackermann E, Cascorbi I, Sachse C, Brockmoller J, Mrozikiewiza P,
|
| 200 |
+
Roots I. Frequencies and the allelic linkage of CYP2C9 mutations in a German population and the detection of a C/T mutation in intron 2. Eur J Clin Pharmacol. 1997;52:A71.
|
| 201 |
+
|
| 202 |
+
29. Kimura M, Ieiri I, Mamiya K, Urae A, Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. Ther Drug Monit. 1998;20(3):243–247.
|
| 203 |
+
|
| 204 |
+
doi:10.1097/00007691-199806000-00001 30. Yasar Ü, Eliasson E, Dahl M-L, Johansson I, Ingelman-Sundberg M,
|
| 205 |
+
Sjöqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun. 1999;254(3):628–631. doi:10.1006/bbrc.1998.9992 31. Brockmöller J, Bauer S, Sachse C, et al. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999;48(3):409–415.
|
| 206 |
+
|
| 207 |
+
doi:10.1046/j.1365-2125.1999.00012.x 32. Gaedigk A. Interethnic differences of drug-metabolizing enzymes.
|
| 208 |
+
|
| 209 |
+
Int J Clin Pharmacol Ther. 2000;38(2):61–68. doi:10.5414/CPP38061 33. Kim J, Gaedigk A, Leeder J, Kearns G, Bertino J. Cyp2c9 mutant alleles frequencies in a rural us Caucasian population. Clin Pharmacol Ther. 2000;67(2):120.
|
| 210 |
+
|
| 211 |
+
34. Choo E, Dresser G, Stein C, et al. Identification of a new CYP2C9 variant in African-Americans. Clin Pharmacol Ther. 2000;67(2):169.
|
| 212 |
+
|
| 213 |
+
35. Jittikoon J, Mahasirimongkol S, Charoenyingwattana A, et al.
|
| 214 |
+
|
| 215 |
+
Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations.
|
| 216 |
+
|
| 217 |
+
J Hum Genet. 2016;61(2):119–127. doi:10.1038/jhg.2015.115 36. Villegas-Torres B, Sánchez-Girón F, Jaramillo-Villafuerte K,
|
| 218 |
+
Soberón X, Gonzalez-Covarrubias V. Genotype frequencies of VKORC1 and CYP2C9 in native and Mestizo populations from Mexico, potential impact for coumarin dosing. Gene. 2015;558
|
| 219 |
+
(2):235–240. doi:10.1016/j.gene.2014.12.068 37. Céspedes-Garro C, Fricke-Galindo I, Naranjo MEG, et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015;11
|
| 220 |
+
(12):1893–1905. doi:10.1517/17425255.2015.1111871 38. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353
|
| 221 |
+
(9154):717–719. doi:10.1016/S0140-6736(98)04474-2 39. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M,
|
| 222 |
+
Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol. 2001;79(10):841–847. doi:10.1139/y01-065 40. Holstein A, Plaschke A, Ptak M, et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol.
|
| 223 |
+
|
| 224 |
+
2005;60(1):103–106. doi:10.1111/j.1365-2125.2005.02379.x 41. Surendiran A, Pradhan S, Agrawal A, et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur J Clin Pharmacol. 2011;67(8):797–801.
|
| 225 |
+
|
| 226 |
+
doi:10.1007/s00228-011-1013-8 42. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J.
|
| 227 |
+
|
| 228 |
+
Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clin Pharmacokinet. 2005;44(12):1209–1225. doi:10.2165/00003088200544120-00002 43. Kim YM, Yoo SH, Kang RY, et al. Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. Am J Health Syst Pharm. 2007;64(2):166–175. doi:10.2146/ajhp050490 44. Mosikian A, Dolgorukova A, Zalevskaya A. Possible approaches to CYP2C9-guided prescription of sulfonylureas in Russia.
|
| 229 |
+
|
| 230 |
+
Pharmacogenomics. 2016;17(18):2115–2126. doi:10.2217/pgs-20160121 45. Tacconelli S, Patrignani P. Inside epoxyeicosatrienoic acids and cardiovascular disease. Front Pharmacol. 2014;5:239. doi:10.3389/
|
| 231 |
+
fphar.2014.00239 Vascular Health and Risk Management Dovepress Publish your work in this journal Vascular Health and Risk Management is an international, peerreviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peerreview system, which is all easy to use. Visit http://www.dovepress.
|
| 232 |
+
|
| 233 |
+
com/testimonials.php to read real quotes from published authors.
|
| 234 |
+
|
| 235 |
+
Submit your manuscript here: https://www.dovepress.com/vascular-health-and-risk-management-journal
|
medical/md/PMC7776074.md
ADDED
|
@@ -0,0 +1,48 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
Graph 3 - Surgical site infection: rate with and without post-discharge surveillance.
|
| 2 |
+
|
| 3 |
+

|
| 4 |
+
|
| 5 |
+
Disclosures. **All Authors**: No reported disclosures
|
| 6 |
+
|
| 7 |
+
## 892. Meningitis After Ventricular Shunt Operations: Multicenter Study To Identify Etiology, Incidence And Risk Factors
|
| 8 |
+
|
| 9 |
+
LUCCA G. GIAROLA, Medical Student1; Handerson Dias Duarte de Carvalho, Medical Student2; Braulio Roberto Gonçalves Marinho Couto, n/a1; Carlos Ernesto Ferreira Starling, n/a3; 1Centro Universitário de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil; 2Centro Universitário de Belo Horizonte - UniBH, Belo Horizonte, Minas Gerais, Brazil; 3Lifecenter Hospital, Belo Horizonte, Minas Gerais, Brazil Session: P-42. HAI: Surgical Site Infections Background. A Ventriculoperitoneal shunt is the main treatment for communicating hydrocephalus. Surgical site infection associated with the shunt device is the most common complication and an expressive cause of morbidity and mortality of the treatment.
|
| 10 |
+
|
| 11 |
+
The objective of our study is to answer three questions: a)What is the risk of meningitis after ventricular shunt operations? b) What are the risk factors for meningitis? c)
|
| 12 |
+
What are the main microorganisms causing meningitis?
|
| 13 |
+
|
| 14 |
+
Methods. A retrospective cohort study assessed meningitis and risk factors in patients undergoing ventricular shunt operations between 2015/Jul and 2018/Jun from 12 hospitals at Belo Horizonte, Brazil. Data were gathered by standardized methods defined by the National Healthcare Safety Network (NHSN)/CDC procedure-associated protocols for routine SSI surveillance. Sample size = 926.
|
| 15 |
+
|
| 16 |
+
26 variables were evaluated by univariate and multivariate analysis (logistic regression).
|
| 17 |
+
|
| 18 |
+
Results. 71 patients were diagnosed with meningitis which represent a risk of 7.7% (C.I.95%= 6.1%; 9.6%). From the 26 variables, three were acknoleged as risk factors: age < two years old (OR = 3.20; p < 0.001), preoperative hospital length of stay
|
| 19 |
+
> four days (OR = 2.02; p = 0.007) and more than one surgical procedure (OR = 3.23; p = 0.043). Patients two or more years old, who had surgery four days after hospital admission, had increased risk of meningitis from 4% to 6% (p = 0.140). If a patient < two years had surgery four days post hospital admission, the risk is increased from 9% to 18% (p = 0.026). 71 meningitis = > 45 (63%) the etiologic agent identified: Staphylococcus aureus (33%), *Staphylococcus epidermidis* (22%), *Acinetobacter sp* (7%), Enterococcus sp (7%), *Pseudomonas sp* (7%), and other (18%). Hospital length of stay in non-infected patients (days): mean = 21 (sd = 28), median = 9; hospital stay in infected patients: mean = 34 (sd = 37), median = 27 (p=0.025). Mortality rate in patients without infection was 10% while hospital death of infected patients was 13% (p=0.544).
|
| 20 |
+
|
| 21 |
+
Conclusion. Two intrinsic risk factors for meningitis post ventricular shunt, age under two years old and multiple surgeries, and one extrinsic risk factor, preoperative length of hospital stay, were identified. Incidence of meningitis post VP shunt decreases with urgent surgical treatment.
|
| 22 |
+
|
| 23 |
+
Disclosures. **All Authors**: No reported disclosures
|
| 24 |
+
|
| 25 |
+
## 893. Occurrence'S Prediction Of Surgical Site Infection In Limb Amputation
|
| 26 |
+
|
| 27 |
+
Surgery Flávio Henrique Batista de Souza, n/a1; Braulio Roberto Gonçalves Marinho Co uto, n/a1; Felipe Leandro Andrade da Conceição, n/a1; Gabriel Henrique Silves tre da Silva, n/a1; Igor Gonçalves Dias, n/a2; Rafael Vieira Magno Rigueira, n/a2; Gustavo Maciel Pimenta, n/a2; Maurilio B. Martins, n/a2; Júlio César O. Mendes, n/a2; Guilherme Brangioni Januário, n/a2; Rayane Thamires Oliveira, n/a2; Laura Ferraz de Vasconcelos, n/a2; Laís L. de Araújo, n/a2; Ana Clara Resende Rodrigues, n/a2; Camila Morais Oliveira E Silva, n/a2; Eduarda Viana De Souza, n/a2; Júlia Faria Melo, n/a2; Maria Cláudia Assunção De Sá, n/a2; Walquíria Magalhães Silva, n/a2; Beatriz Izabel de Souza Alves, n/a2; Débora Mendes Resende, n/a2; Guilherme Prata Borges A., n/a2; Gustavo Ryan Martins Santos, n/a2; João Paulo Silva Santos Xavier, n/a2; Lucas de Paula Lacerda, n/a2; Maria Júlia Santos e Silva, n/a2; 1Centro Universitário de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil; 2Centro Universitário de Belo Horizonte UNIBH, Belo Horizonte, Minas Gerais, Brazil Session: P-42. HAI: Surgical Site Infections Background. A research was conducted between July 2016 and June 2018 in five hospitals in Belo Horizonte, a city of 3,000,000 inhabitants, focused on surgical site infection (SSI) in patients undergoing limb amputation surgery procedure. The main objective is to statistically evaluate such incidences and enable a study of the prediction power of SSI through MLPs (Multilayer Perceptron), a pattern recognition algorithm.
|
| 28 |
+
|
| 29 |
+
Methods. Data were collected on SSI by the Hospital Infection Control Committees (CCIH) of the hospitals involved. The information was forwarded to the NOIS (Nosocomial Infection Study) Project. After data collection, three procedures were performed: a treatment of the database collected for the use of intact samples; a statistical analysis on the profile of the hospitals collected and; an assessment of the predictive power of five types of MLP (Backpropagation Standard, Momentum, Resilient Propagation, Weight Decay, and Quick Propagation) for SSI prediction. MLPs were tested with 3, 5, 7, and 10 hidden layer neurons and a database split for the resampling process (65% or 75% for testing, 35% or 25% for validation). They were compared by measuring AUC (Area Under the Curve - ranging from 0 to 1) presented for each of the configurations.
|
| 30 |
+
|
| 31 |
+
Results. From 969 data, only 507 were intact for analysis. Statistically: in 12.45%
|
| 32 |
+
there was an incidence of global infection and that in 10.67% of the cases were SSI
|
| 33 |
+
(among which, 94.6% had to be hospitalized for more than 10 days); patients were hospitalized on average 21 days (from 0 to 141 days); the average duration is 78 minutes
|
| 34 |
+
(maximum 360 minutes); 53 deaths (a 16.98% death rate in case of SSI). A maximum prediction power of 0.688 was found.
|
| 35 |
+
|
| 36 |
+
Conclusion. Despite the loss rate of almost 40% of the database samples due to the presence of noise, it was obtained a relevant sampling to evaluate the profile the hospitals. For the predictive process, although some configurations reached 0.688, which makes promising the use of the automated SSI monitoring framework for patients undergoing limb amputation surgery. To optimize data collection and enable other hospitals to use the SSI prediction tool (available in www.sacihweb.com), two mobile application were developed: one for monitoring the patient in the hospital and the other for post-hospital discharge monitoring.
|
| 37 |
+
|
| 38 |
+
Disclosures. **All Authors**: No reported disclosures
|
| 39 |
+
|
| 40 |
+
## 894. Patient And Surgery Characteristics On Wound Complication And Surgical Site Infection In Sarcoma Patients Undergoing Hemipelvectomy
|
| 41 |
+
|
| 42 |
+
Ju Hee Katzman, MD1; Steven Sun, n/a1; David Joyce, MD2; John Greene, MD2; 1University of South Florida, Tampa, Florida; 2Moffitt Cancer Center, Tampa, Florida Session: P-42. HAI: Surgical Site Infections Background. Hemipelvectomy is associated with a significant risk of wound complications, including infections, bleeding and injuries to nearby neurovascular structures as well as the gastrointestinal and genitourinary tract. This study aimed to determine the patient characteristics and approach to treatment that could affect the occurrence of surgical site infection or wound complications in sarcoma patients undergone hemipelvectomy.
|
| 43 |
+
|
| 44 |
+
Methods. We conducted a retrospective analysis of 33 adult patients who underwent hemipelvectomy at Moffitt Cancer Center, Tampa, FL, from 2008 to 2016. We used Chi-square (Exact Fisher) test to investigate the association between wound complication and categorical variables. We used a T-test to evaluate the difference in numerical variables for outcomes.
|
| 45 |
+
|
| 46 |
+
Results. Out of 33 patients, 12 (36.4%) patients experienced wound complications after hemipelvectomy (Table 1). The average age of patients with wound complications was 63.3 3 (57.1±15.4) years old, significantly higher than that of patients without wound complications (p=0.004). Without adjustment, the use of computer navigation had a lower wound complication rate (p=0.027). Patients with wound complications had longer hospital length of stay (14.8 vs. 7.0 days, p=0.016). Among patients with surgical site infection (Table 2), there were no patients' characteristics or surgical characteristics associated with this outcome.
|
| 47 |
+
|
| 48 |
+
Five (15%) patients developed surgical site infection and they had longer hospital stay (19.4 vs. 8.1 days, p=0.001). The organisms identified from wound cultures include methicillin-resistant *Staphylococcus aureus*, viridans Streptococcus, Peptostreptococcus asaccharolyticus, Enterobacter cloacae, Pseudomonas aeruginosa, *Candida albicans*. The organisms in late infections (more than 6 months since surgery), included above organisms plus *Stenotrophomonas maltophilia* and Achromobacter xylosidans.
|
medical/md/PMC8562246.md
ADDED
|
@@ -0,0 +1,410 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
|
| 2 |
+
|
| 3 |
+

|
| 4 |
+
|
| 5 |
+

|
| 6 |
+
|
| 7 |
+

|
| 8 |
+
|
| 9 |
+
Instant activation of TRP channels by NH4
|
| 10 |
+
|
| 11 |
+

|
| 12 |
+
|
| 13 |
+
þ promotes neuronal bursting and glutamate spikes in CA1 neurons Saju Balakrishnan, Sergej L. Mironov *
|
| 14 |
+
Institute of Neuro- and Sensory Physiology, Georg-August-University, Humboldtallee 23, 37073, G€ottingen, Germany ARTICLE INFO
|
| 15 |
+
|
| 16 |
+
| Keywords: Hippocampus Mouse Glutamate imaging Bursting ASIC TRPC1 TRPV1 channels |
|
| 17 |
+
|------------------------------------------------------------------------------------|
|
| 18 |
+
|
| 19 |
+
Ammonia (NH4 þ) is a by-product of cell metabolism and may elicit subcellular effects with specific physiological responses. Chronic effects have been implicated in several neurological diseases and attributed to persistent elevation in blood ammonia levels transferred to the brain. In previous studies the activities of neurons and astrocytes have been examined at ammonia concentrations an order of magnitude higher than measured in the blood. The effects developed within several minutes. Here we focused upon acute responses of neurons to ammonia and whether they may occur at much lower doses. To this end, we combined patch-clamp in CA1 neurons with glutamate imaging in hippocampal slices. Particular attention was paid to the Rett syndrome that has been originally attributed to hyperammonemia. We compared the responses in the wild-type (WT) and model Rett mice (MECP2-null, RTT) to ammonia doses from 0.3 mM on. In both preparations NH4 þ promptly depolarized neurons and increased the ambient glutamate. The bursting activity emerged in WT and it was augmented in RTT. Searching for subcellular mechanisms we examined possible modulation of ion channels by ammonia. We did not find any changes in HCN- and Ca2þ currents, which substantially contribute to the bursting activity. The non-selective cation channels were markedly potentiated by ammonia. ASIC channels had a major contribution to the augmentation of neuronal activity by ammonia. Interestingly, their general blocker amiloride (100 μM)
|
| 20 |
+
moderately excited CA1 cells akin to NH4 þ. In its presence subsequent ammonia effects were markedly compromised. Blockade of TRPC1 channels partially occluded NH4 þ effects. ASIC and TRPC1 blockers decreased the amplitude of excitatory postsynaptic currents (EPSC) and neuronal bursts, congruent with a postsynaptic location of the channels. Inhibition of TRPV1 channels potentiated the responses to NH4 þ. EPSC amplitudes did not change, but the frequency decreased, indicating presynaptic effects. All extracellular NH4 þ actions were observed at concentrations as low as 0.3 mM and the neurons reacted immediately after ammonia arrived the slice. We propose that a brief augmentation of neuronal activity by NH4 þ may occur either spontaneously during arousal or induced by inhalation of smelling salts.
|
| 21 |
+
|
| 22 |
+
| ABSTRACT |
|
| 23 |
+
|------------|
|
| 24 |
+
|
| 25 |
+
## 1. Introduction
|
| 26 |
+
|
| 27 |
+
Ammonia (NH4 þ) is the main end product of the metabolism of amino acids in the body. Previously, most attention has been attracted to its toxic actions. Millimolar concentrations of NH4 þ are known to induce various pathological disorders within the brain (Cagnon & Braissant, 2007). The toxicity is often observed during hepatic encephalopathy, when brain NH4 þ is elevated through circulation. Symptoms such as lethargy and epilepsy are already observed at 0.5 - l.0 mM blood ammonia levels (Yamamoto et al., 2013). Severe CNS disturbances, such as coma, require brain concentrations between 2.5 and 5 mM (Szerb &
|
| 28 |
+
Butterworth, 1992). The blood ammonia may not match CNS levels, however. Many biochemical reactions can either produce NH4 þ or utilize it as a substrate that could potentially induce fast and big local ammonia changes within the brain. The considerations have been recently cast into a hypothesis treating brain ammonia as a potential neurotoxic factor in Alzheimer's (Seiler, 2002; Adlimoghaddam et al., 2016). Changes in ammonia levels due to the intracellular metabolism of amino acids is thought to proceed mostly in the glia, which perhaps explains why the majority of studies have been focused upon astrocytes (Bachmann, 2002; Rose et al., 2005; Marcaggi & Coles, 2001; Rangroo Thrane et al., 2013; Halpin et al., 2014; Schroeter et al., 2015; Oja et al., 2017). The long-term actions of ammonia documented in these studies appealed to various mechanisms e. g. a disturbed equilibrium between glutamate and
|
| 29 |
+
* Corresponding author.
|
| 30 |
+
|
| 31 |
+
E-mail address: smirono@gwdg.de (S.L. Mironov).
|
| 32 |
+
|
| 33 |
+
https://doi.org/10.1016/j.crphys.2020.05.002 Received 5 March 2020; Received in revised form 11 May 2020; Accepted 24 May 2020 2665-9441/© 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
|
| 34 |
+
|
| 35 |
+
|
| 36 |
+
glutamine and induction of glia swelling; Ca-mediated efflux of glutamate from astrocytes; impairment of mitochondrial function with production of reactive oxygen species, including NO. All these effects rely upon specific signaling cascades that could match a considerable delay in onset and overlong duration of responses (from several minutes to hours). A suggested attribution of NH4 þ effects to astrocytes nonetheless requires understanding whether and how ammonia can directly modify the properties of neurons.
|
| 37 |
+
|
| 38 |
+
Previous studies in hippocampus (reviewed in (Szerb & Butterworth, 1992)) indicated modulation of neuronal and synaptic activities by ammonia, albeit at supramillimolar concentrations and chronic challenges. The effects are mostly inhibitory and attributed to slow depolarization by ammonia, promoting inactivation of sodium conductance.
|
| 39 |
+
|
| 40 |
+
The data cannot explain immediate stimulating action of ammonia vapors, whose inhalation was used historically for arousal after fainting.
|
| 41 |
+
|
| 42 |
+
Such sudden increases in neuronal activity should be mediated by specific mechanisms that are still elusive but may help to clarify the welldocumented both positive and toxic effects of hyperammonemia. The data about subcellular targets of NH4 þ are scarce. It is known that ammonia directly activates acid-sensitive ion channels (ASIC), (Mironov
|
| 43 |
+
& Lux, 1993; Pidoplichko & Dani, 2006) and transient receptor potential
|
| 44 |
+
(TRP) channels TRPV1 and TRPC1 (Dhaka et al., 2009; Saffarzadeh et al.,
|
| 45 |
+
2016). However, the use of cultured cells limits a functional significance of these studies.
|
| 46 |
+
|
| 47 |
+
We aimed to examine acute ammonia effects in the intact neuronal tissue. To this end, we monitored the activity of hippocampal CA1 neurons using the whole-cell patch-clamp technique and measured ambient glutamate with fluorescent sensor iGluSnFr targeted to the membrane of neurons or astrocytes. As in the previous studies (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018), we routinely compared the responses in slices from the wild-type
|
| 48 |
+
(WT) mice and animals carrying the Rett Syndrome (RTT) deficiency.
|
| 49 |
+
|
| 50 |
+
The rationale was to seek for possible differences in responses to NH4 þ in RTT and WT to ammonia, because the Rett Syndrome has been originally attributed to hyperammonemia (Rett, 1966). A direct connection in patients was examined in only one study (Campos-Castello et al., 1988 - ) and no significant changes in blood ammonia in RTT patients have been found. The question remains, because ammonia levels in blood and the brain do not mirror each other (Marcaggi & Coles, 2001).
|
| 51 |
+
|
| 52 |
+
Rett Syndrome is a neurodevelopmental disorder that causes improper maturation of the synapses due to the loss of function of methyl-CpG binding protein 2, MeCP2 (Moretti & Zoghbi, 2006). The hyperexcitability in RTT is thought to stem from excitation/inhibition imbalance (Zhang et al., 2008) and related to abnormal glutamate handling (Johnston et al., 2014). We indeed measured elevated ambient glutamate levels in RTT (Balakrishnan & Mironov, 2018a). This apparently set conditions to produce regenerative glutamate spikes that were typical in RTT hippocampus, and virtually absent in WT (Balakrishnan &
|
| 53 |
+
Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018). Glutamate spikes in WT readily emerged only after activation of metabotropic glutamate receptors (mGluR) (Balakrishnan &
|
| 54 |
+
Mironov, 2018).
|
| 55 |
+
|
| 56 |
+
We here report that NH4 þ excites CA1 neurons, elevates ambient glutamate, enhances bursting activity and induces glutamate spikes in WT. The effects in RTT are similar but have bigger amplitudes and longer durations. Importantly, we consistently observed the effects already at 0.3 mM NH4 þ, an order of magnitude lower than used in other studies
|
| 57 |
+
(Cagnon & Braissant, 2007; Szerb & Butterworth, 1992; Bachmann, 2002; Oja et al., 2017). Patch-clamp studies revealed no modifications of voltage-sensitive HCN- and Ca2þ channels after ammonia. To find an explanation of increased excitability by ammonia we turned to non-selective ASIC, TRPC1 and TRPV1 channels. They were activated by NH4 þ and correspondingly modulated neuronal and synaptic properties.
|
| 58 |
+
|
| 59 |
+
Their concerted actions converge to transiently enhance neuronal and glutamate activities after brief ammonia surges. Because glutamatergic neurons endorse the biggest population within the brain, similar responses to NH4 þ may be expected to occur elsewhere, adding a broader implication to the presented findings.
|
| 60 |
+
|
| 61 |
+
## 2. Methods
|
| 62 |
+
|
| 63 |
+
All experimental procedures used are essentially the same as employed in previous studies (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018) and only briefly recapitulated below.
|
| 64 |
+
|
| 65 |
+
## 2.1. Preparation And Solutions
|
| 66 |
+
|
| 67 |
+
All mouse experiments were approved by the local authority, the Lower Saxony State Office for Consumer Protection and Food Safety
|
| 68 |
+
(Nieders€achsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit) and performed in accordance with the issued guidelines and regulations. For removal of tissues, animals were deeply anaesthetized and rapidly killed by cervical dislocation. All experiments were performed using the mouse model for Rett Syndrome (further RTT);
|
| 69 |
+
strain B6.129P2(C)– MeCP2tm1-1Bird (Guy et al., 2001) from the Jackson Laboratory (Bar Harbor, ME, USA). After preparation all mice were routinely genotyped to confirm the wild-type (WT) and MECP2-null
|
| 70 |
+
(RTT) mice.
|
| 71 |
+
|
| 72 |
+
Transverse hippocampal slices were prepared at postnatal day P3 and placed on the support membranes (Millicell-CM Inserts, PICMORG50; Millipore). Slices for experiments were virally transduced with glutamate sensor (Marvin et al., 2013) that was targeted to neurons (AAV5.hSyn.iGluSnFr.WPRE.SV40) or astrocytes (AAV5.GFAP.iGluSnFr.WPRE.SV40). The constructs were from Penn Vector Core, Department of Pathology and Laboratory Medicine; U. Pennsylvania. Transduction was done two days after plating slices and the experiments were performed from P7 on, after expression of the sensor reached the steady state. The probes targeted to the glia and neurons reported similar changes in all experimental protocols used, see also (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018).
|
| 73 |
+
|
| 74 |
+
Because the sensors are expressed in the plasma membranes of neurons or astrocytes and exposed to the thin extracellular space (<100 nm wide),
|
| 75 |
+
they should sense the same ambient glutamate. The data obtained with the two sensors were therefore pooled together for analysis.
|
| 76 |
+
|
| 77 |
+
In the experiments, the support membrane with the attached slice was placed in the recording chamber. It was continuously superfused at 34 C
|
| 78 |
+
with artificial cerebrospinal fluid (ACSF) contained (in mM): 138 NaCl, 5 KCl, 1.5 CaCl2, 1 MgCl2, 30 HEPES, 1 NaH2PO4, 10 glucose, and pH 7.4, adjusted with NaOH. In the experiments with NHþ4 elevated above 1 mM, Naþ levels were correspondingly lowered to maintain osmolality.
|
| 79 |
+
|
| 80 |
+
All salts and other common substances were from Sigma (Deisenhofer, Germany). The agonists and antagonists for channels and receptors were from Tocris Bioscience (Bristol, UK) and Alomone Labs (Israel). The stock solutions of drugs were made either in DMSO or ACSF and diluted at least by 1000-fold for applications.
|
| 81 |
+
|
| 82 |
+
## 2.2. Imaging
|
| 83 |
+
|
| 84 |
+
The cells were viewed under a 40 objective (Achroplan, N. A. 0.95)
|
| 85 |
+
in a Zeiss Axioscope equipped with a monochromatic light source
|
| 86 |
+
(CAIRN, UK). Images from a cooled CCD camera (ANDOR) were digitized
|
| 87 |
+
(256256 pixels at 12 bit resolution) and collected with ANDOR software. Metamoph (Princeton Instruments) was used for analysis. In glutamate imaging the cells were illuminated at 470 nm and the emission was collected at 525 10 nm. Glutamate levels were obtained from relative increases in fluorescence ΔF/Fo as described (Balakrishnan &
|
| 88 |
+
Mironov, 2018a). A typical experimental configuration is depicted in the inset in Fig. 1.
|
| 89 |
+
|
| 90 |
+
|
| 91 |
+
|
| 92 |
+

|
| 93 |
+
|
| 94 |
+
## 2.3. Patch-Clamp
|
| 95 |
+
|
| 96 |
+
Recording electrodes were pulled from borosilicate glass (WPI,
|
| 97 |
+
Berlin, Germany) and had resistances of 2–3 MΩ. In current-clamp recordings the pipettes were filled with a solution containing 110 mM Kþ-gluconate, 5 mM KCl, 50 mM HEPES, 0.005 mM EGTA,
|
| 98 |
+
4 mM MgSO4, 4 mM ATP, 0.2 mM GTP, 9 mM phosphocreatine, at pH
|
| 99 |
+
7.4 adjusted with KOH. In recording HCN and Ca2þ currents, we used a Csþ based solution containing 92 mM CsMeSO4, 43 mM CsCl, 5 mM
|
| 100 |
+
TEA-Cl, 0.4 mM EGTA, 1 mM MgCl2, 10 mM HEPES, 4 mM ATP,
|
| 101 |
+
0.4 mM GTP, at pH 7.4 adjusted with CsOH. The osmolality was 290 5 mosm.
|
| 102 |
+
|
| 103 |
+
Patch-clamp signals were recorded with an EPC-9 (HEKA, Germany)
|
| 104 |
+
amplifier. HCN and Ca2þ currents were evoked by voltage steps to 110 and 40 mV for 300 ms, respectively, from a holding potential of 70 mV (close to the resting potential measured in CA1 neurons). Although HCN currents might be better evoked from a holding potential which is more positive than 60 mV to assure their complete deactivation (Mironov et al., 2000), we have chosen 70 mV as a holding potential on the following grounds: At 50 mV, the Ca2þ conductance is small, but cannot be neglected (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018). The persistent Ca2þ current can steadily elevate intracellular calcium and produce unwanted side effects.
|
| 105 |
+
|
| 106 |
+
Activation of HCN channels achieves 95% at 110 mV (Balakrishnan &
|
| 107 |
+
Mironov, 2018b; Mironov et al., 2000) and we avoided bigger hyperpolarization steps to keep neurons viable.
|
| 108 |
+
|
| 109 |
+
The analysis of spontaneous postsynaptic potentials (sEPSC) was performed as described previously (Mironov & Langohr, 2007). In brief summary, we calculated the first two moments mn ¼ RI
|
| 110 |
+
n(t)dt of the continuous 10 s-long-recordings of the current I(t) at 70 mV with bursting periods excluded. The mean amplitude (A) and frequency of synaptic currents (f) were determined as A ¼ 4τm2/m1 and f ¼ m2/4τm1, where τ is a decay constant of the mean EPSC, obtained from single non-overlapping EPSCs showing the fast rise time.
|
| 111 |
+
|
| 112 |
+
Fig. 1. NH4 þ transiently increases ambient glutamate and neuronal bursting in CA1 neurons. A and B show the effects of NH4 þ in slices prepared from wild-type (WT) and model Rett animals (RTT) as indicated. Each column presents the three panels containing the two traces showing the changes in ambient glutamate (blue) and voltage trajectories
|
| 113 |
+
(black) measured simultaneously. Mean [Glu] traces were obtained from 12 regions of interest encircled the cells expressing glutamate sensor iGluSnFr (see Methods). Average traces are overlaid onto grey background showing SEM. The slice was transduced with neuronal glutamate sensor and CA1 neuron was selected to patch. The inset in the middle shows the experimental configuration. The internal solution contained Alexa 588 to visualize the neuron with dendritic tree (red). We consistently observed the repetitive glutamate spikes in naïve slices from RTT
|
| 114 |
+
animals (B). Application of NH4 þ for 30 s at 0.3–10 mM (as indicated) induced stereotypic effects consisted of brief augmentation of activity with subsequent depression. The glutamate spikes coincided with burst discharges in neurons (presented as black and grey traces in respective panels). In naïve slices from WT animals (A) repetitive glutamate spikes were absent and emerged with NH4 þ addition. The responses were similar but had smaller amplitude. During washout and slow recovery ambient glutamate levels slightly elevated that was followed by appearance of glutamate spikes in WT. The mean data are summarized in Fig. 2.
|
| 115 |
+
|
| 116 |
+
## 2.4. Statistics
|
| 117 |
+
|
| 118 |
+
Approximately equal numbers of neurons were measured in parallel, both for the wild-type and MeCP2-null mice, and analyzed blinded to genotype. Each test in this study was repeated with at least four different preparations and the mean data in imaging were obtained by analyzing responses for >12 cells present in the image field. The mean traces in time-lapse experiments that present sample responses are overlaid upon thick grey areas showing SEM obtained from single traces. Means SEM
|
| 119 |
+
were compared by using Student's t test, with p < 0.05 being the criterion for statistical significance. The results of independent experiments were compared with a Mann-Whitney-U-test.
|
| 120 |
+
|
| 121 |
+
## 3. Results
|
| 122 |
+
|
| 123 |
+
Brief application of ammonia to the hippocampal slices readily increased ambient glutamate and potentiated bursting activity. The responses in CA1 area were stereotypical in the preparations from both wild-type and RTT animals (Fig. 1). They were observed already at 0.3 mM NH4 þ and showed saturation at 10 mM NH4 þ as summarized in Fig. 2. At 30 mM NH4 þ the effects were essentially the same as at 10 mM
|
| 124 |
+
NH4 þ (n ¼ 3, for both WT and RTT, data not shown). For all concentrations tested, NH4 þ induced a transient increase in ambient glutamate and neuronal activity, shown in Fig. 1 by the blue and black/grey traces, respectively. The repetitive glutamate spikes are tightly related to the bursting activity in RTT preparations (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018) and both activities slices were potentiated by NH4 þ (Fig. 1B). In the majority of naïve WT slices the rhythmic activity was absent and NH4 þ induced transient appearance of glutamate spikes and bursts (Fig. 1A). Wash-out of ammonia produced slight depolarization that paralleled the increase in ambient glutamate, and regenerative glutamate transients established.
|
| 125 |
+
|
| 126 |
+
The effects remind of the appearance of rhythmic activity in WT slices after stimuli that elevated ambient glutamate (Balakrishnan & Mironov,
|
| 127 |
+
|
| 128 |
+

|
| 129 |
+
|
| 130 |
+
2018). The analysis of NH4 þ effects in WT and RTT are summarized in Fig. 2 with statistical significance indicated.
|
| 131 |
+
|
| 132 |
+
Depolarization and concomitant enhancement of neuronal excitability implies the activation of some cation channels that mediate inward current. The first candidates to examine are the voltage-sensitive Ca2þ (ICa) and hyperpolarization-activated currents (IHCN), which contribute to the bursting activity. The channels have different characteristics in WT and RTT CA1 neurons (Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018); and we asked whether they can be modulated by NH4 þ. ICa and IHCN currents characteristics before and after NH4 þ applications showed no significant differences (Fig. 3). In these experiments we concerned possible modulation of ICa and IHCN by intracellular pH (pHi) as reported in (Mironov &
|
| 133 |
+
Lux, 1991; Zong et al., 2001), respectively. Intracellular alkalinization develops within several minutes (Mironov & Lux, 1991). The absence of changes in the ICa and IHCN currents after NH4 þ for 30 s applications indicates an exclusively extracellular target in our experiments.
|
| 134 |
+
|
| 135 |
+
We next tested the non-selective channels that can generate the inward current we sought. The first choice was acid-sensitive ion channels
|
| 136 |
+
(ASIC) that are activated by NH4 þ (Mironov & Lux, 1993; Pidoplichko &
|
| 137 |
+
Dani, 2006). Unexpectedly, a general ASIC blocker, amiloride, produced responses akin to NH4 þ (Fig. 4A, the two traces on the left). After brief initial potentiation, the glutamate spikes and neuronal bursts diminished, but persisted (group summary of effects of amiloride and other TRP
|
| 138 |
+
blockers is presented in Fig. 5). The addition of NH4 þ in the presence of amiloride (Fig. 4A, on the right) elicited much smaller responses compared to the 'control' responses (Fig. 1) indicating a substantial blockade of ASIC channels by amiloride. This dichotomous action can be explained by the results of Adams et al. (1999) who showed that amiloride can act as an agonist and antagonist of ASIC channels. This feature should be taken into account in possible clinical applications, because the drug may produce a weak stimulating effect opposite to a presumed inhibitory action. Amiloride also decreased the amplitude of spontaneous excitatory postsynaptic currents (EPSC) and synaptic drives (a correlate of neuronal bursts) (Fig. 4B). No significant changes in frequency of EPSCs was observed (Fig. 5A), indicating only postsynaptic effects.
|
| 139 |
+
|
| 140 |
+
Several TRP channels can be modulated by NH4 þ (Dhaka et al., 2009; Saffarzadeh et al., 2016). TRPC1 channel blocker, 20 μM SKF96365
|
| 141 |
+
(1-[2-(4-Methoxyphenyl)-2-[3-(4-methoxyphenyl) propoxy] ethyl-1-
|
| 142 |
+
H-imidazole hydrochloride) significantly decreased the amplitude and frequency of glutamate spikes and neuronal bursts (Fig. 6A; Fig. 5B).
|
| 143 |
+
|
| 144 |
+
1 mM NH4 þ induced transient potentiation of activity (Fig. 6A, on the right), significantly smaller than the control responses (Fig. 1). SKF
|
| 145 |
+
decreased the amplitudes of EPSC and synaptic drives, and the EPSC frequency was unchanged (Fig. 5B). The mean EPSCs after SKF became 30% smaller (the two traces in Fig. 6B on the right). The decay time was not significantly changed (3.6 0.4 vs. 3.8 0.3 ms after SKF, p > 0.1)
|
| 146 |
+
which indicates unchanged electrotonic length i. e. the active TRPC1 channels postsynaptically located in the spines but not within the dendritic shaft.
|
| 147 |
+
|
| 148 |
+
Fig. 2. Changes in ambient glutamate and depolarization by NH4 þ in CA1 neurons in the slices from wild-type and RTT animals. All data were obtained from experiments made in different fresh
|
| 149 |
+
(naive) preparations from RTT and WT animals as indicated. Group summary presents mean data SEM
|
| 150 |
+
from experiments whose number is indicated in the first row. The differences from the baseline (first three rows) are significant at p < 0.1 (*), p < 0.05 (**), and p < 0.01 (***) (Student's t test). Note that the amplitude of responses showed saturation with increasing þ concentration. Estimation of EC50 from mean data at three different concentration gave 2.4 (WT) and 2.6 mM (RTT), respectively. The data obtained in WT and RTT at 0.3 and 1 mM NH4 þ are significantly different at P < 0.01. The differences between the means for 1 and 10 mM NH4 þ are different at P < 0.1 (P
|
| 151 |
+
estimates were obtained using Mann-Whitney-U-test).
|
| 152 |
+
|
| 153 |
+
|
| 154 |
+
(4-(3-Chloro-2-pyridinyl)-N-[4-(1, 1-dimethylethyl) phenyl]-1piperazinecarboxamide). It has a high potency (IC50 ¼ 35 nM) (Jardín et al., 2017) and 1 μM BCTC fully blocked TRPV1 channels in DRG cells
|
| 155 |
+
(Kitamura et al., 2018) and inhibited TRPV1 channels expressed in HEK293t cells at 100 nM by 98% (Leffler et al., 2008). In our experiments 20 μM BCPC reliably increased the amplitude and frequency of neuronal bursts and related glutamate transients in RTT. Subsequent application of 1 mM NH4 þ produced bigger effects than in the control (Fig. 8A on the right vs. Fig. 1B, group summary in Fig. 5D). In the presence of BCTC the frequency of EPSC increased and the amplitudes of spontaneous and mean EPSC did not change (Figs. 5 and 6B), which indicates a presynaptic target.
|
| 156 |
+
|
| 157 |
+

|
| 158 |
+
|
| 159 |
+
þ does not modulate voltage-sensitive Ca2þ (ICa) and hyperpolarization-activated (IHCN)
|
| 160 |
+
channels. Whole-cell voltage-clamp experiments were made in CA1 neurons from WT and RTT animals as indicated. A - Sample ICa traces were measured for 300 ms-long voltage steps from 70 to 50 mV before and 30 s after application of 1 mM NH4 þ. B - Sample IHCN traces were obtained in the same cells with voltage steps from 70 to 110 mV. The histograms on the right present group summary. The Student's t test in all cases gave p > 0.1 that indicated not significant (n.s.) differences. ICa currents in WT were yet distinctly bigger (111 7 vs. 191 12 pA) and IHCN currents were significantly smaller in RTT
|
| 161 |
+
(121 8 vs. 81 6 pA). For both sets of data P < 0.1 (the Mann-Whitney-U-test).
|
| 162 |
+
TRPC1 channels can cross-talk to metabotropic glutamate receptors
|
| 163 |
+
|
| 164 |
+

|
| 165 |
+
|
| 166 |
+
(mGluR). This signaling pathway is important in CA1 (Balakrishnan &
|
| 167 |
+
Mironov, 2018) and other neurons (Lepannetier et al., 2018). Stimulation of mGluR1/5 with DHPG ((S)-3,5-Dihydroxyphenylglycine) in slices from WT animals induced regenerative glutamate spikes and neuronal bursts (Fig. 7A). The responses to NH4 þ after DHPG in WT became bigger than in naïve slices (compare Figs. 1A and 7A, group summary is given in Fig. 5D). EPSCs after DHPG became bigger and faster (Fig. 7B). This can be explained by the reduction of IHCN-mediated shunting in CA1 dendrites after mGluR1 stimulation (Balakrishnan & Mironov, 2018).
|
| 168 |
+
|
| 169 |
+
TRPV1 (vanilloid) channels contribute to NH4 þ effects in sensory neurons (Dhaka et al., 2009). We tested a specific blocker BCTC
|
| 170 |
+
Fig. 4. Amiloride modulates NH4
|
| 171 |
+
|
| 172 |
+

|
| 173 |
+
|
| 174 |
+
þ effects n RTT
|
| 175 |
+
slices. The recordings were made in RTT slices that showed spontaneous glutamate spikes related to AP
|
| 176 |
+
bursts in CA1 neurons. A - The two traces show changes in ambient glutamate (top) and the voltage trajectories in CA1 neuron (bottom). In this experiment 100 μM amiloride (a general blocker of ASIC
|
| 177 |
+
channels) was first applied to the bath and then 1 mM
|
| 178 |
+
NH4 þ was added. The recordings on the left show that amiloride alone acted akin NH4 þ (Fig. 1). The two insets in the middle present glutamate spikes and neuronal bursts before and after amiloride effect stabilized. The episodes in the continuous traces on the left were taken at time-points marked by asterisk and hash symbols. In the presence of amiloride a subsequent addition of NH4 þ elicited much smaller effects than in the control (compare the traces on the right and 'a standard response' in Fig. 1B). B - Spontaneous EPSCs. The synaptic drives are indicated by asterisks.
|
| 179 |
+
|
| 180 |
+
The recordings were made in the whole-cell voltageclamp mode at the holding potential 70 mV. Note small attenuation of amplitudes of EPCS and synaptic drives in the presence of amiloride. The mean data from respective experiments are summarized in Fig. 5.
|
| 181 |
+
|
| 182 |
+
Fig. 5. Effects of channel blockers on basal activity and NH4 þ responses in CA1 neurons. All data were obtained from experiments made in different fresh
|
| 183 |
+
(naive) preparations from RTT and WT animals as indicated. The effects of channel blockers were collected largely in RTT (blue bars), because the slices consistently demonstrated spontaneous glutamate transients. To establish them in WT slices we first activated mGluR1/5 with DHPG to establish the stable rhythmic activity (Balakrishnan & Mironov, 2018),
|
| 184 |
+
and then examined the response to NH4 þ as shown also in Fig. 7. Group summaries present mean data SEM from the experiments whose number is listed in each column at the top. In all tests, the mean intervals between glutamate spikes were close to interburst periods (p > 0.1, Student's t test). The effects of blockers showed significant differences at p < 0.1 (*), p < 0.05 (**), or were not significant (p > 0.1, n. s.)
|
| 185 |
+
(Student's t test) and are correspondingly marked in the histograms.
|
| 186 |
+
|
| 187 |
+
Current Research in Physiology 3 (2020) 20–29
|
| 188 |
+
|
| 189 |
+

|
| 190 |
+
|
| 191 |
+
4. Discussion
|
| 192 |
+
NH4 þ in the brain has a plethora of actions; all considered as pathological (Cagnon & Braissant, 2007; Yamamoto et al., 2013; Szerb &
|
| 193 |
+
Butterworth, 1992; Seiler, 2002; Adlimoghaddam et al., 2016; Bachmann, 2002; Rose et al., 2005; Marcaggi & Coles, 2001; Rangroo Thrane et al., 2013; Halpin et al., 2014; Schroeter et al., 2015; Oja et al., 2017). A seminal example is a hepatic encephalopathy that stems from elevation of ammonia levels in the body translated to the CNS, and causing hyperammonemia. The blood ammonia levels may not represent an actual value within the brain (Marcaggi & Coles, 2001). Neurons and
|
| 194 |
+
|
| 195 |
+

|
| 196 |
+
|
| 197 |
+
glia cells are metabolically active and various biochemical reactions can lead to large and fast regional variations in extracellular ammonia, sensed by specific subcellular entities, producing ultimate changes in the neuronal activity. We sought for mechanisms that may underlie direct ammonia actions on neurons. Chronic NH4 þ effects in the hippocampus have been studied before, with 'field' macroelectrodes or sharp microelectrodes (Szerb & Butterworth, 1992). We looked 'deeper' and applied patch-clamp in combination with glutamate imaging to monitor the activity of CA1 neurons. We focused upon immediate responses of neurons to low doses of ammonia, which have not been examined in detail.
|
| 198 |
+
|
| 199 |
+

|
| 200 |
+
|
| 201 |
+
Fig. 6. NH4 þ effects n RTT slices are diminished in the presence of TRPC1 channel blocker, SKF. The experimental paradigm was similar to that described in Fig. 4. Here also the results for RTT slices with spontaneous activity were used for presentation as they showed spontaneous activity. A - SKF suppressed the amplitude and frequency of glutamate spikes and AP bursts (left panel). The two episodes in the middle show sample activities at the expanded time-scale before and after DHPG. The right panel demonstrates a diminished effect of subsequent NH4 þ application in the presence of SKF. Spontaneous EPSCs and synaptic drives also had smaller amplitudes (B). The mean data from respective experiments are summarized in Fig. 5.
|
| 202 |
+
|
| 203 |
+
The traces obtained in the presence of SKF were brown-coded for comparison.
|
| 204 |
+
|
| 205 |
+
Specifically, we found that (a) as low as 0.3 mM NH4 þ depolarizes CA1 neurons; (b) ammonia transiently potentiates neuronal excitability as manifested by enhanced neuronal bursting and repetitive glutamate spikes; (c) the effects are mediated by postsynaptic ASIC and TRPC1 channels and presynaptic TRPV1 channels; (d) in slices from WT animals the responses were similar but distinctly weaker than in RTT (Figs. 1 and 2). Because the majority of CNS neurons are glutamatergic, the responses of CA1 neurons to ammonia may represent stereotypical reactions within the brain.
|
| 206 |
+
|
| 207 |
+
The fluorescent glutamate sensor iGluSnFr (Marvin et al., 2013) is expressed in the plasma membrane and senses interstitial glutamate Fig. 7. NH4 þ effects n WT slices after stimulation of mGluR1/5 with DHPG. A - 1 μM DHPG initiated transient appearance of glutamate spikes and neuronal bursts in WT preparation, and, after several minutes wash-out a robust spontaneous activity appeared, in line with previous findings (Balakrishnan & Mironov, 2018). The episodes of activity before and after DHPG
|
| 208 |
+
are extracted from continuous traces at times indicated by asterisk and hash symbols and shown in the middle at the expanded time-scale. The responses to NH4 þ then became distinctly bigger after treatment and resembled those recorded in naïve RTT slices (see Fig. 1B for comparison and mean data in Fig. 2). B –
|
| 209 |
+
Spontaneous EPSCs before and after DHPG. A synaptic drive (a correlate of neuronal burst) is marked by asterisk in the middle trace. Mean EPSCs are shown on the right. They became sharper and bigger after DHPG
|
| 210 |
+
that can be explained by diminution of IHCN-mediated shunting in dendrites (Balakrishnan & Mironov, 2018).
|
| 211 |
+
|
| 212 |
+

|
| 213 |
+
|
| 214 |
+
Fig. 8. Modulation of NH4 þ effects in RTT slices by TRPV1 channel blocker, BCTC. The experiments with BCTC were conducted in a similar way as presented in Figs. 4 and 6 for amiloride and SKF,
|
| 215 |
+
respectively. A - BCTC increased the amplitude and frequency of glutamate spikes and AP bursts (left panel) and potentiated subsequent response to NH4 þ
|
| 216 |
+
(right panel). B - Continuous traces show spontaneous EPSCs and include single synaptic drive (asterisk). BCTC increased EPSC amplitude and the frequency was unchanged (the statistics is given in Fig. 5). Mean EPSC on the right demonstrate some increase in the amplitude with the time-course unchanged, consistent with unaltered electrotonic conduction. The traces obtained in the presence of BCTC are violet-coded.
|
| 217 |
+
|
| 218 |
+
The mean data from respective experiments are summarized in Fig. 5.
|
| 219 |
+
|
| 220 |
+
changes from 0.1 μM to 1 mM as fast as 1 ms (Balakrishnan & Mironov, 2018a). Glutamate imaging unraveled a novel hallmark of RTT phenotype in hippocampus - regenerative glutamate spikes that are generated synchronously and tightly related to bursting activity in CA1 neurons
|
| 221 |
+
(Balakrishnan & Mironov, 2018a; Balakrishnan & Mironov, 2018b; Balakrishnan & Mironov, 2018). Such an activity pattern is presented in Figs. 1, 4, 6 and 8. Low NH4 þ doses elevated ambient glutamate both in RTT and WT. In RTT slices the spiking activity was enhanced. In naïve WT preparations ammonia induced the glutamate spikes for a short time that then subsided. After several minutes of wash-out repetitive transients reappeared and persisted. This reminds of previously observed effects in WT, where robust rhythmic glutamate spikes in WT are established after brief glutamate surges due to stimulation of mGluR1
|
| 222 |
+
(Balakrishnan & Mironov, 2018).
|
| 223 |
+
|
| 224 |
+
NH4 þ has a variety of effects upon the cells. For example, it is reported to exert long-term intracellular effects through various biochemical cascades in glia (Cagnon & Braissant, 2007; Bachmann, 2002; Rose et al., 2005; Marcaggi & Coles, 2001; Rangroo Thrane et al., 2013; Halpin et al., 2014; Schroeter et al., 2015; Oja et al., 2017). The data in these studies have been collected at 10-fold bigger concentrations of ammonia that were applied for up to 1 h. The most ubiquitous NH4 þ action is the ability to alkalinize intracellular pH that modifies the Ca2þ (Mironov &
|
| 225 |
+
Lux, 1991), HCN (Zong et al., 2001), and TRPV1 channels (Dhaka et al.,
|
| 226 |
+
2009). The changes in pHi develop within several minutes, even when 10 mM NH4 þ is applied (Mironov & Langohr, 2007). To assure that the NH4 þ effects in our experiments are extracellular, the duration of applications was set to a minimum (30 s) and 1 mM NH4 þ was used in most pharmacological experiments. The absence of distinct changes in ICa and IHCN (Fig. 2) speaks for solely extracellular ammonia actions under the conditions used.
|
| 227 |
+
|
| 228 |
+
Ammonia not only diffuses passively through the cell membranes in NH3 form but can also permeate through ion channels. For example, NHþ4 permeates around twice better than Naþ through TRPV3
|
| 229 |
+
(Schrapers et al., 2018) and nACh channels (Hille, 2001). In the cytoplasm, NHþ4 can give away the extra proton and acidify the cell interior.
|
| 230 |
+
|
| 231 |
+
The effects are dubbed as unconventional ammonia actions (Nagaraja &
|
| 232 |
+
Brookes, 1998; Burckhardt & Fromter, 1992 € ) but not confirmed in other studies (cf. (Marcaggi & Coles, 2001) for review). Let us estimate possible effects in our case. After application of 1 mM NHþ4 we measured the currents 48 4 pA (n ¼ 6, WT) and 52 6 pA (n ¼ 6, RTT). They are compatible with that mediated by TRPC1 channels after activation of mGluR1 with DHPG (Balakrishnan & Mironov, 2018). Given a spherical cell with 10 μm radius and intracellular volume of 4 pL, a 1 pA current will deliver 3 μM cations per second. The current through the non-specific channels (ASIC and TRPC1) is carried mostly by extracellular Naþ and it is in excess in ACSF. A partial current due to 1 mM NHþ4 would then be (PNH4. [NHþ4]/PNa. [Naþ]).50 pA ¼ 0.8 pA. This corresponds to the rate of NHþ4 delivery ~2 μM/s, which is close to the estimate ~3 μM/s (Marcaggi & Coles, 2001) for transport rate for ammonia within the brain. This predicts that ~0.1 mM NHþ4 could be accumulated in the cytoplasm during 30 s-long challenges to ammonia. Even if each NHþ4 ion gives a proton away; it will be readily captured by intrinsic cytoplasmic pH buffers whose capacity is much bigger (~10 mM). This upper estimate of possible effect of NHþ4 permeation indicate its marginal influence in our case. A conclusion is supported by the absence of changes in Ca2þ and HCN conductances, which should be depressed after presumable intracellular acidification by ammonia (Mironov & Lux, 1991; Zong et al., 2001).
|
| 233 |
+
|
| 234 |
+
Depolarization is an immediate response in neurons to NH4 þ. Seeking for appropriate subcellular candidates, we turned to non-specific cation channels, whose activation generates the inward current needed for depolarization. After blockade of TRPV1 channels, the activity of CA1 neurons and their responses to NH4 þ were potentiated. Only the EPSC
|
| 235 |
+
frequency was changed but not the amplitude (Fig. 8), therefore we tentatively ascribe the presynaptic actions of NH4 þ upstream. TRPV1 channels endow hippocampal interneurons (Saffarzadeh et al., 2016),
|
| 236 |
+
and therefore the removal of tonic inhibition of CA1 cells may explain a slight increase in excitability observed.
|
| 237 |
+
|
| 238 |
+
After blockade of ASIC (Fig. 4) and TRPC1 channels (Fig. 6), the glutamate spikes and neuronal bursts were suppressed and NH4 þ responses diminished. In both cases we identified the changes as postsynaptic, because the blockers decreased only the EPSC amplitude but not the frequency (Figs. 4B and Fig. 6B). The exact location of ASIC and TRPC1 channels is difficult to discern at present. Most likely the channels are active in dendritic spines and cell soma. We can exclude their location in dendritic shafts, because the time course of EPSC measured in the
|
| 239 |
+
|
| 240 |
+
presence of blockers was not altered. Would the channels contribute to the dendritic conductance, changes in shunting would then modify EPSC
|
| 241 |
+
kinetics; similar to what dendritic HCN channels do (Balakrishnan &
|
| 242 |
+
Mironov, 2018a).
|
| 243 |
+
|
| 244 |
+
TRPC1 channels often colocalize with mGluR and the cross-talk between them is implicated in modulation of synaptic plasticity (Lepannetier et al., 2018). We previously described an important role of mGluR1/5 in RTT (Balakrishnan & Mironov, 2018). NH4 þ effects in WT
|
| 245 |
+
were markedly potentiated after mGluR1/5 stimulation (Fig. 7). Metabotropic glutamate receptors are invoked in inborn systemic hyperammonemia (Schrapers et al., 2018). This, and the important role of mGluR in determining a neuronal phenotype in RTT, suggests that NH4 þ homeostasis can modulate a cross-talk between TRPC1 and mGluR1/5 and underlie significant aberrations during brain development.
|
| 246 |
+
|
| 247 |
+
The data add another piece of evidence to understanding possible origins of neuronal disturbances in RTT by first showing that ammonia strongly influences glutamate homeostasis. NH4 þ effects are both immediate and long-lasting (Fig. 1). Elevation of ammonia within the brain may represent another factor that contributes to intrinsic overexcitability in RTT, whose symptoms develop during CNS maturation. The blood ammonia levels in RTT were measured in only one study
|
| 248 |
+
(Campos-Castello et al., 1988 - ) and no significant changes were reported in 15 human patients. Perhaps it is premature to ultimately close the case and revive an original attribution of hyperammonemia to RTT (Rett, 1966). As argued in the Introduction backed by a recent literature (Seiler, 2002; Adlimoghaddam et al., 2016; Marcaggi & Coles, 2001), the local ammonia levels in the brain may not match those in blood plasma.
|
| 249 |
+
|
| 250 |
+
Production and utilization of ammonia in neurons and glia can experience fast modification in interstitial ammonia levels. Measurement of ammonia within the brain is a challenging task. The measurements show that NH4 þ modulates the activity of neurons within seconds.
|
| 251 |
+
|
| 252 |
+
Ion-sensitive microelectrodes may not resolve such fast transients that can be also extremely localized. The imaging may help but reliable fluorescent probes are not yet designed.
|
| 253 |
+
|
| 254 |
+
The effects of ammonia in RTT are distinctly stronger. This might be expected, because RTT neurons are more excitable and glutamate handling is less efficient (Balakrishnan & Mironov, 2018a; Balakrishnan
|
| 255 |
+
& Mironov, 2018b; Balakrishnan & Mironov, 2018). The inward currents generated by ASIC, TRPC1 and TRPV1 channels enhance depolarization drive to neurons and promote excitability. ASIC (Mironov & Lux, 1993)
|
| 256 |
+
and TRPC1 channels (Balakrishnan & Mironov, 2018) are also permeable to Ca2þ. Our data posit these non-selective cation channels as important determinants in neuronal excitability.
|
| 257 |
+
|
| 258 |
+
It is logical to propose that intrinsic vulnerability of neurons in RTT
|
| 259 |
+
and preponderance to epilepsy may be alleviated by respective blockers. A notion is supported by recent data about the role of ASIC and TRPC1 channels in the initiation and maintenance of seizures (Lepannetier et al., 2018). We must yet warn that a clinical usage of amiloride is to be made with caution, because this general ASIC channel blocker has also a weak stimulatory effect, similar to NH4 þ itself (Adams et al., 1999); see also Fig. 4 in this study.
|
| 260 |
+
|
| 261 |
+
The data were obtained in hippocampus but may have more broad implications, because glutamatergic neurons are abundant in CNS and may respond to NH4 þ in a similar way. Recent studies (Chepkova et al.,
|
| 262 |
+
2017; Yanovsky et al., 2012) documented the effects of ammonia in the histaminergic neurons in hypothalamus in relation to mGluR1, ASIC and TRPC channels. It is proposed that the excitation is mediated by glutamate and is important in the control of arousal. This may also involve immediate increase in excitability by ammonia, similar to that observed in this study.
|
| 263 |
+
|
| 264 |
+
The observed effects might explain such acute ammonia actions as the historical use of smelling salts to arouse fainting persons or utilized today by power lifters and other athletes to get a burst of adrenaline before high intensity activities. Smelling salts help to arouse consciousness because ammonia gas first irritates the nose and lungs, and may cause an inhalation reflex. This alters the pattern of breathing, resulting in improved respiratory flow rates and possibly alertness due to adrenaline-inducing boost. In this study we examined CA1 hippocampal neurons and described a novel effect of their instant excitation by ammonia. The results obtained previously in DRG (Mironov & Lux, 1993) and cortical neurons (Pidoplichko & Dani, 2006) tempt to speculate that immediate reaction to ammonia may be stereotypical for many neuronal types including olfactory and sympathetic neurons. When nasal mucosa is irritated, the olfactory cortex would receive an adequate excitatory signal and process it with appropriate functional response. Direct or indirect stimulation of the second neuron in sympathicus would also increase subsequent secretion of catecholamines and stimulation of adrenergic receptors. On the downside, excessive cellular depolarization by ammonia may lead to neurotoxic effects, possibly explaining the link between local cerebral hyperammonia and cell death in diseases such as hepatic encephalopathy or Alzheimer's.
|
| 265 |
+
|
| 266 |
+
## Author Contributions
|
| 267 |
+
|
| 268 |
+
S.L.M: Conceptualization, Methodology, Data evaluation, Figures; Writing and funding acquisition. SB: Methodology, Patch-clamp and Imaging, Validation.
|
| 269 |
+
|
| 270 |
+
## Funding
|
| 271 |
+
|
| 272 |
+
This project was funded by The Deutsche Forschungsgemeinschaft
|
| 273 |
+
(DFG) through CNMPB (Centre for Nanoscale Microscopy and Molecular Physiology of the Brain, Cluster of Excellence 171, DFG Research Center 103, Germany).
|
| 274 |
+
|
| 275 |
+
## Declaration Of Competing Interest
|
| 276 |
+
|
| 277 |
+
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
|
| 278 |
+
|
| 279 |
+
## Acknowledgements
|
| 280 |
+
|
| 281 |
+
We thank Nicole Hartelt for expert technical assistance. We also deeply appreciate the lab of Dr. Looger for sharing AAV-vector to express glutamate sensor in neurons and astrocytes.
|
| 282 |
+
|
| 283 |
+
## Appendix A. Supplementary Data
|
| 284 |
+
|
| 285 |
+
Supplementary data to this article can be found online at https
|
| 286 |
+
://doi.org/10.1016/j.crphys.2020.05.002.
|
| 287 |
+
|
| 288 |
+
## References
|
| 289 |
+
|
| 290 |
+
Adams, C.M., Snyder, P.M., Welsh, M.J., 1999. Paradoxical stimulation of a DEG/ENaC
|
| 291 |
+
channel by amiloride. J. Biol. Chem. 274, 15500–15504.
|
| 292 |
+
|
| 293 |
+
Adlimoghaddam, A., Sabbir, M.G., Albensi, B.C., 2016. Ammonia as a potential neurotoxic factor in Alzheimer's disease. Front. Mol. Neurosci. 9, 57.
|
| 294 |
+
|
| 295 |
+
Bachmann, C., 2002. Mechanisms of hyperammonemia. Clin. Chem. Lab. Med. 40, 653–662.
|
| 296 |
+
|
| 297 |
+
Balakrishnan, S., Mironov, S.L., 2018. CA1 neurons acquire Rett Syndrome phenotype after brief activation of glutamatergic receptors: specific Role of mGluR1/5. Front.
|
| 298 |
+
|
| 299 |
+
Cell. Neurosci. 12, 363–370.
|
| 300 |
+
|
| 301 |
+
Balakrishnan, S., Mironov, S.L., 2018a. Regenerative glutamate release in the hippocampus of Rett syndrome model mice. PloS One 13, e0202802.
|
| 302 |
+
|
| 303 |
+
Balakrishnan, S., Mironov, S.L., 2018b. Rescue of hyperexcitability in hippocampal CA1 neurons from Mecp2 (-/y) mouse through surface potential neutralization. PloS One 13, e0195094.
|
| 304 |
+
|
| 305 |
+
Burckhardt, B.C., Fromter, E., 1992. Pathways of NH € 3/NH4 þ permeation across Xenopus laevis oocyte cell membrane. Pflügers Archiv. 420, 83–86.
|
| 306 |
+
|
| 307 |
+
Cagnon, L., Braissant, O., 2007. Hyperammonemia-induced toxicity for the developing central nervous system. Brain Res. Rev. 56, 183–197.
|
| 308 |
+
|
| 309 |
+
|
| 310 |
+
Campos-Castello, J., Peral Guerra, M., Riviere G - omez, A., Oliete García, F., Herranz -
|
| 311 |
+
Tanarro, J., Toledano Barrero, M., Espinar Sierra, J., Cristobal Sassot, S., Lautre Ecenarro, M.J., Franco Carcedo, C., et al., 1988. Rett's syndrome: study of 15 cases.
|
| 312 |
+
|
| 313 |
+
An. Esp. Pediatr. 28, 286–292.
|
| 314 |
+
|
| 315 |
+
Chepkova, A.N., Sergeeva, O.A., Gorg, B., Haas, H.L., Kl € ocker, N., H € €aussinger, D., 2017.
|
| 316 |
+
|
| 317 |
+
Impaired novelty acquisition and synaptic plasticity in congenital hyperammonemia caused by hepatic glutamine synthetase deficiency. Sci. Rep. 7, 40190.
|
| 318 |
+
|
| 319 |
+
Dhaka, A., Uzzell, V., Dubin, A.E., Mathur, J., Petrus, M., Bandell, M., Patapoutian, A.,
|
| 320 |
+
2009. TRPV1 is activated by both acidic and basic pH. J. Neurosci. 29, 153–158.
|
| 321 |
+
|
| 322 |
+
Guy, J., Hendrich, B., Holmes, M., Martin, J.E., Bird, A., 2001. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat. Genet. 27, 322–326.
|
| 323 |
+
|
| 324 |
+
Halpin, L.E., Northrop, N.A., Yamamoto, B.K., 2014. Ammonia mediates methamphetamine-induced increases in glutamate and excitotoxicity.
|
| 325 |
+
|
| 326 |
+
Neuropsychopharmacology 39, 1031–1038.
|
| 327 |
+
|
| 328 |
+
Hille, B., 2001. Ion Channels of Excitable Membranes. Sinauer, Massachusetts.
|
| 329 |
+
|
| 330 |
+
Jardín, I., Lopez, J.J., Diez, R., S - -anchez-Collado, J., Cantonero, C., Albarr-an, L.,
|
| 331 |
+
Woodard, G.E., Redondo, P.C., Salido, G.M., Smani, T., Rosado, J.A., 2017. TRPs in pain sensation. Front. Physiol. 8, 392–401.
|
| 332 |
+
|
| 333 |
+
Johnston, M.V., Ammanuel, S., O'Driscoll, C., Wozniak, A., Naidu, S., Kadam, S.D., 2014.
|
| 334 |
+
|
| 335 |
+
Twenty-four hour quantitative-EEG and in-vivo glutamate biosensor detects activity and circadian rhythm dependent biomarkers of pathogenesis in Mecp2 null mice.
|
| 336 |
+
|
| 337 |
+
Front. Syst. Neurosci. 8, 118–126.
|
| 338 |
+
|
| 339 |
+
Kitamura, N., Nagami, E., Matsushita, Y., Kayano, T., Shibuya, I., 2018. Constitutive activity of transient receptor potential vanilloid type 1 triggers spontaneous firing in nerve growth factor-treated dorsal root ganglion neurons of rats. IBRO Rep. 5, 33–42.
|
| 340 |
+
|
| 341 |
+
Leffler, A., Fischer, M.J., Rehner, D., Kienel, S., Kistner, K., Sauer, S.K., Gavva, N.R.,
|
| 342 |
+
Reeh, P.W., Nau, C., 2008. The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J. Clin. Invest. 118, 763–776.
|
| 343 |
+
|
| 344 |
+
Lepannetier, S., Gualdani, R., Tempesta, S., Schakman, O., Seghers, F., Kreis, A., Yerna, X.,
|
| 345 |
+
Slimi, A., de Clippele, M., Tajeddine, N., Voets, T., Bon, R.S., Beech, D.J., Tissir, F., Gailly, P., 2018. Activation of TRPC1 channel by metabotropic glutamate receptor mGluR5 modulates synaptic plasticity and spatial working memory. Front. Cell.
|
| 346 |
+
|
| 347 |
+
Neurosci. 12, 318.
|
| 348 |
+
|
| 349 |
+
Marcaggi, P., Coles, J.A., 2001. Ammonium in nervous tissue: transport across cell membranes, fluxes from neurons to glial cells, and role in signalling. Prog. Neurobiol.
|
| 350 |
+
|
| 351 |
+
64, 157–183.
|
| 352 |
+
|
| 353 |
+
Marvin, J.S., Borghuis, B.G., Tian, L., Cichon, J., Harnett, M.T., Akerboom, J., Gordus, A.,
|
| 354 |
+
Renninger, S.L., Chen, T.W., Bargmann, C.I., Orger, M.B., Schreiter, E.R., Demb, J.B.,
|
| 355 |
+
Gan, W.B., Hires, S.A., Looger, L.L., 2013. An optimized fluorescent probe for visualizing glutamate neurotransmission. Nat. Methods 10, 162–170.
|
| 356 |
+
|
| 357 |
+
Mironov, S.L., Langohr, K., 2007. Modulation of synaptic and channel activities in the respiratory network of the mice by NO/cGMP signalling pathways. Brain Res. 1130, 73–82.
|
| 358 |
+
|
| 359 |
+
Mironov, S.L., Lux, H.D., 1991. Cytoplasmic alkalinization increases high-threshold calcium current in chick dorsal root ganglion neurones. Pflügers Archiv. 419, 138–143.
|
| 360 |
+
|
| 361 |
+
Mironov, S.L., Lux, H.D., 1993. NH4Cl-induced inward currents and cytoplasmic Ca2þ transients in chick sensory neurones. Neuroreport 4, 1055–1058.
|
| 362 |
+
|
| 363 |
+
Mironov, S.L., Langohr, K., Richter, D.W., 2000. Hyperpolarization-activated current, Ih, in inspiratory brainstem neurons and its inhibition by hypoxia. Eur. J. Neurosci. 12, 520–526.
|
| 364 |
+
|
| 365 |
+
Moretti, P., Zoghbi, H.Y., 2006. MeCP2 dysfunction in Rett syndrome and related disorders. Curr. Opin. Genet. Dev. 16, 276–281.
|
| 366 |
+
|
| 367 |
+
Nagaraja, T.N., Brookes, N., 1998. Intracellular acidification induced by passive and active transport of ammonium ions in astrocytes. Am. J. Physiol. 274, C883–C891.
|
| 368 |
+
|
| 369 |
+
Oja, S.S., Saransaari, P., Korpi, E.R., 2017. Neurotoxicity of ammonia. Neurochem. Res.
|
| 370 |
+
|
| 371 |
+
42, 713–720.
|
| 372 |
+
|
| 373 |
+
Pidoplichko, V.I., Dani, J.A., 2006. Acid-sensitive ionic channels in midbrain dopamine neurons are sensitive to ammonium, which may contribute to hyperammonemia damage. Proc. Natl. Acad. Sci. Unit. States Am. 103, 11376–11380.
|
| 374 |
+
|
| 375 |
+
Rangroo Thrane, V., Thrane, A., Wang, F., Cotrina, M.L., Smith, N.A., Chen, M., Xu, Q.,
|
| 376 |
+
Kang, N., Fujita, T., Nagelhus, E.A., Nedergaard, M., 2013. Ammonia triggers neuronal disinhibition and seizures by impairing astrocyte potassium buffering. Nat.
|
| 377 |
+
|
| 378 |
+
Med. 19, 1643–1648.
|
| 379 |
+
|
| 380 |
+
Rett, A., 1966. On a unusual brain atrophy syndrome in hyperammonemia in childhood.
|
| 381 |
+
|
| 382 |
+
Wien Med. Wochenschr. 116, 723–726.
|
| 383 |
+
|
| 384 |
+
Rose, C., Kresse, W., Kettenmann, H., 2005. Acute insult of ammonia leads to calciumdependent glutamate release from cultured astrocytes, an effect of pH. J. Biol. Chem.
|
| 385 |
+
|
| 386 |
+
280, 20937–20944.
|
| 387 |
+
|
| 388 |
+
Saffarzadeh, F., Eslamizade, M.J., Mousav, i SM., Abraki, S.B., Hadjighassem, M.R.,
|
| 389 |
+
Gorji, A., 2016. TRPV1 receptors augment basal synaptic transmission in CA1 and CA3 pyramidal neurons in epilepsy. Neuroscience 314, 170–178.
|
| 390 |
+
|
| 391 |
+
Schrapers, K.T., Sponder, G., Liebe, F., Liebe, H., Stumpff, F., 2018. The bovine TRPV3 as a pathway for the uptake of Naþ, Ca2þ, and NH4þ. PloS One 13, e0193519.
|
| 392 |
+
|
| 393 |
+
Schroeter, A., Wen, S., Molders, A., Erlenhardt, N., Stein, V., Kl € ocker, N., 2015. Depletion €
|
| 394 |
+
of the AMPAR reserve pool impairs synaptic plasticity in a model of hepatic encephalopathy. Mol. Cell. Neurosci. 68, 331–339.
|
| 395 |
+
|
| 396 |
+
Seiler, N., 2002. Ammonia and Alzheimer's disease. Neurochem. Int. 41, 189–207.
|
| 397 |
+
|
| 398 |
+
Szerb, J.C., Butterworth, R.F., 1992. Effect of ammonium ions on synaptic transmission in the mammalian central nervous system. Prog. Neurobiol. 39, 135–153.
|
| 399 |
+
|
| 400 |
+
Yamamoto, Y., Takahashi, Y., Imai, K., Mishima, N., Yazawa, R., Inoue, K., Itoh, K.,
|
| 401 |
+
Kagawa, Y., Inoue, Y., 2013. Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia 54, 983–989.
|
| 402 |
+
|
| 403 |
+
Yanovsky, Y., Zigman, J.M., Kernder, A., Bein, A., Sakata, I., Osborne-Lawrence, S.,
|
| 404 |
+
Haas, H.L., Sergeeva, O.A., 2012. Proton- and ammonium-sensing by histaminergic neurons controlling wakefulness. Front. Syst. Neurosci. 6, 23–31.
|
| 405 |
+
|
| 406 |
+
Zhang, L., He, J., Jugloff, D.G., Eubanks, J.H., 2008. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability.
|
| 407 |
+
|
| 408 |
+
Hippocampus 18, 294–309.
|
| 409 |
+
|
| 410 |
+
Zong, X., Stieber, J., Ludwig, A., Hofmann, F., Biel, M., 2001. A single histidine residue determines the pH sensitivity of the pacemaker channel HCN2. J. Biol. Chem. 276, 6313–6319.
|
medical/md/PMC8873605.md
ADDED
|
@@ -0,0 +1,485 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
# Original Research Intestinal Hif-2A Regulates Glp-1 Secretion Via Lipid Sensing In L-Cells
|
| 2 |
+
|
| 3 |
+
Raja Gopal Reddy Mooli,1 Dhanunjay Mukhi,1 Anil K. Pasupulati,1 Simon S. Evers,2 Ian J. Sipula,1 Michael Jurczak,1 Randy J. Seeley,2 Yatrik M. Shah,3,4 and Sadeesh K. Ramakrishnan1 1Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 2Department of Surgery, 3Department of Molecular and Integrative Physiology, 4Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan
|
| 4 |
+
|
| 5 |
+

|
| 6 |
+
|
| 7 |
+
## Summary
|
| 8 |
+
|
| 9 |
+
Activation of intestinal hypoxia-inducible factor signaling improves glucose homeostasis in a glucagon-like peptide-1–
|
| 10 |
+
dependent manner. We show that activation of intestinal hypoxia-inducible factor 2a signaling increases GLP-1 levels and attenuates diet-induced metabolic perturbations such as visceral adiposity, glucose intolerance, and hepatic steatosis.
|
| 11 |
+
|
| 12 |
+
BACKGROUND & AIMS: Compelling evidence shows that glucagon-like peptide-1 (GLP-1) has a profound effect in restoring normoglycemia in type 2 diabetic patients by increasing pancreatic insulin secretion. Although L-cells are the primary source of circulating GLP-1, the current therapies do not target L-cells to increase GLP-1 levels. Our study aimed to determine the molecular underpinnings of GLP-1 secretion as an impetus to identify new interventions to target endogenous L-cells.
|
| 13 |
+
|
| 14 |
+
METHODS: We used genetic mouse models of intestine-specific overexpression of hypoxia-inducible factor (HIF)-1a and HIF2a (VhlDIE), conditional overexpression of intestinal HIF-2a
|
| 15 |
+
(Hif-2aLSL;Vilin-Cre/ERT2), and intestine-specific HIF-2a knockout mice (Hif-2aDIE) to show that HIF signaling, especially HIF-2a, regulates GLP-1 secretion.
|
| 16 |
+
|
| 17 |
+
RESULTS: Our data show that intestinal HIF signaling improved glucose homeostasis in a GLP-1–dependent manner. Intestinal HIF potentiated GLP-1 secretion via the lipid sensor G-protein–coupled receptor (GPR)40 enriched in L-cells. We show that HIF-2a regulates GPR40 in L-cells and potentiates fatty acid–induced GLP-1 secretion via extracellular regulated kinase (ERK). Using a genetic model of intestine-specific overexpression of HIF-2a, we show that HIF-2a is sufficient to increase GLP-1 levels and attenuate diet-induced metabolic perturbations such as visceral adiposity, glucose intolerance, and hepatic steatosis. Lastly, we show that intestinal HIF-2a signaling acts as a priming mechanism crucial for postprandial lipidmediated GLP-1 secretion. Thus, disruption of intestinal HIF-2a decreases GLP-1 secretion. CONCLUSIONS: In summary, we show that intestinal HIF
|
| 18 |
+
signaling, particularly HIF-2a, regulates the lipid sensor GPR40, which is crucial for the lipid-mediated GLP-1 secretion, and suggest that HIF-2a is a potential target to induce endogenous GLP-1 secretion. (Cell Mol Gastroenterol Hepatol 2022;13:1057–1072; https://doi.org/10.1016/j.jcmgh.2021.12.004)
|
| 19 |
+
Keywords: GLP-1; L-Cells; HIF-2a; GPR40; Nutrient-Sensing.
|
| 20 |
+
|
| 21 |
+
The intestine plays a crucial yet complex role in integrating the nutrient inputs with central and peripheral metabolic homeostasis via gut-derived molecules.1 Among them, gut-derived hormone glucagon-like peptide-1 (GLP-1) inhibits food intake and glucagon secretion, promotes pancreatic insulin secretion, and restores glycemia.2–4 Thus, GLP-1–based therapies, which include GLP-1 agonists and inhibitors of GLP-1 degrading enzymes, have a profound effect in ameliorating hyperglycemia in type 2 diabetes. However, these therapies do not target endogenous GLP-1 production largely owing to the incomplete understanding of the molecular underpinnings of the GLP-1 secretory mechanisms.
|
| 22 |
+
|
| 23 |
+
GLP-1 is secreted from L-cells of the intestine in response to nutrients such as monosaccharides and lipids via distinct mechanisms. For instance, glucose and fructose stimulate GLP-1 secretion by depolarizing the L-cells, whereas lipids, especially long-chain fatty acids (LCFAs),
|
| 24 |
+
potently stimulate GLP-1 via G-protein–coupled receptor
|
| 25 |
+
(GPR)40 and GPR120 enriched in the L-cells.4–8 Compelling evidence has shown that inhibition of GPR40/120 signaling impairs GLP-1 secretion and induces glucose intolerance, suggesting a crucial role for intestinal lipid-sensing in metabolic homeostasis.9–11 However, the mechanisms that regulate L-cell lipid-sensing are not well understood.
|
| 26 |
+
|
| 27 |
+
Under physiological conditions, the epithelial cells adjacent to the lumen have significantly lower oxygen tension than the base of the crypts. Thus, a steep oxygen gradient exists within intestinal villi and along the intestinal tract and is crucial for intestinal homeostasis.12–14 The intestinal oxygen levels are regulated by blood circulation, oxygen perfusion, and the metabolic activity of the epithelia.15 For instance, intestinal blood circulation is decreased at fasting, and refeeding induces intestinal hyperemia.12,16 In addition, mucosa experiences a uniquely steep gradient because of its juxtaposition with the anoxic lumen of the gut. The disruption in the intestinal oxygen gradient results in barrier dysfunction and colonization of pathogens, leading to inflammatory diseases.17–19 Thus, intestinal oxygen levels are dynamically regulated by nutritional cues; however, its metabolic relevance remains to be elucidated.
|
| 28 |
+
|
| 29 |
+
The hypoxic response is mediated by the transcription factors hypoxia-inducible factor (HIF)-1a and HIF-2a.
|
| 30 |
+
|
| 31 |
+
20,21 Under normoxic conditions, HIF-a is hydroxylated at the proline residues by the prolyl hydroxylase domain (PHD)
|
| 32 |
+
enzymes using the available molecular oxygen. The E3 ubiquitin ligase von-Hippel Lindau (VHL) then binds the hydroxylated HIF-a and induces its degradation. Under hypoxic conditions, HIF-a is no longer hydroxylated by PHD,
|
| 33 |
+
resulting in its stabilization. HIF-a then heterodimerizes with the aryl hydrocarbon receptor nuclear translocator to induce the transcription of its target genes.21 HIF-1a and HIF-2a share several metabolic genes and also regulate a distinct set of genes. For instance, HIF-1a regulates glycolytic genes, whereas HIF-2a regulates the genes involved in lipid metabolism.20 Given that intestinal glucose and lipid metabolism regulate GLP-1 secretion,22,23 we hypothesized that intestinal HIF signaling could be involved in regulating GLP-1.
|
| 34 |
+
|
| 35 |
+
To date, intestinal HIF signaling has been investigated extensively in various diseases such as obesity, iron overload, inflammation, and cancer.24–26 We show a novel role of intestinal HIF, particularly HIF-2a, in inducing the expression of the L-cell lipid-sensor GPR40. Mechanistically, we identify that HIF-2a–GPR40 signaling promotes GLP-1 secretion via extracellular regulated kinase (ERK). We show that intestinal HIF-2a in mice increases GPR40 expression, increases GLP-1 levels, and improves glucose tolerance. We further show the physiological relevance of intestinal HIF-2a signaling in postprandial GLP-1 secretion and diet-induced metabolic syndrome. In summary, we provide empiric evidence that HIF-2a could be a novel target to induce endogenous GLP-1 secretion by enhancing L-cell lipid-sensing.
|
| 36 |
+
|
| 37 |
+
## Results Intestinal Hif Signaling Improved Glucose Homeostasis Via Incretin Glp-1
|
| 38 |
+
|
| 39 |
+
To determine if metabolic cues regulate intestinal hypoxia signaling, we assessed HIF-oxygen–dependent degradation (ODD) reporter mice that possess the ODD domain of HIF fused with luciferase, allowing visualization of HIF
|
| 40 |
+
stabilization (Figure 1A). We found that fasting stabilized HIF in the small intestines as shown by increased luciferase activity (Figure 1B). Moreover, protein levels of Hif-1a and Hif-2a (Figure 1C) and their target genes such as Dmt1, Dcytb, Glut1, and Pgk1 were increased significantly in the small intestines of fasted mice (Figure 1D), suggesting that metabolic cues activate HIF signaling in the intestine. To investigate whether intestinal hypoxia signaling has a metabolic role, we assessed mice with constitutive activation of intestinal-epithelial HIF generated by villinCre–mediated disruption of VHL (VhlDIE). Our data show that VhlDIE mice have lower body weight than wild-type littermate controls (Figure 1E). Although no difference in basal glucose levels was noticed, the intraperitoneal (IP)
|
| 41 |
+
glucose tolerance test showed better glucose disposal in VhlDIE mice (Figure 1F). Intriguingly, no difference in the Abbreviations used in this paper: a-LA, a-linolenic acid; cDNA, complementary DNA; DMEM, Dulbecco's modified Eagle medium; DMOG,
|
| 42 |
+
|
| 43 |
+

|
| 44 |
+
|
| 45 |
+

|
| 46 |
+
|
| 47 |
+

|
| 48 |
+
|
| 49 |
+
dimethyloxalyl glycine; ERK, Extracellular signal Regulated Kinase; GLP-1, glucagon-like peptide-1; GPR, G-protein–coupled receptor; GSK, GSK1120212; HFD, high-fat diet; HIF, hypoxia-inducible factor; IP, intraperitoneal; LCFA, long-chain fatty acid; MEK, Mitogenactivated Proetin Kinase; mRNA, messenger RNA; ODD, oxygen–
|
| 50 |
+
dependent degradation; PBS, phosphate-buffered saline; pERK,
|
| 51 |
+
Phospho Extracellular regulated kinase; PHD, prolyl hydroxylase domain; PKA, protein kinase A; qPCR, quantitative polymerase chain reaction; STC-1, Secretin tumor cell line-1; VCO2, carbon dioxide production; VHL, von-Hippel Lindau; VO2, oxygen consumption.
|
| 52 |
+
|
| 53 |
+
Most current article
|
| 54 |
+
© 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA
|
| 55 |
+
Institute. This is an open access article under the CC BY-NC-ND
|
| 56 |
+
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
|
| 57 |
+
|
| 58 |
+
2352-345X
|
| 59 |
+
https://doi.org/10.1016/j.jcmgh.2021.12.004
|
| 60 |
+
|
| 61 |
+

|
| 62 |
+
|
| 63 |
+
insulin tolerance test mice was observed (Figure 1G), suggesting that intestinal HIF signaling improves glucose homeostasis independent of insulin sensitivity.
|
| 64 |
+
|
| 65 |
+
The intestine regulates systemic glucose homeostasis partially via the incretin GLP-1, which enhances glucosestimulated insulin secretion from the pancreas.27,28 GLP1–secreting L-cells are mostly scattered in the distal parts of the intestine,29 where hypoxia is prevalent15; therefore, we assessed the possible role of intestinal HIF in regulating GLP-1. Remarkably, steady-state GLP-1 levels were increased significantly in male and female VhlDIE mice
|
| 66 |
+
(Figure 1H and I). However, ileal and pancreatic total GLP-1 levels were unchanged (Figure 1J and K). The insulinotropic effect of GLP-1 was observed when glucose was administered orally.4,30 Because GLP-1 is increased at a steady-state, we hypothesized that IP glucose would potentiate glucosestimulated insulin secretion in VhlDIE mice. Consistently, we found IP glucose challenge augmented first-phase insulin secretion in VhlDIE mice (Figure 1L). We then tested whether GLP-1 mediates the improvement in glucose homeostasis in VhlDIE mice. Administration of GLP-1 antagonists exendin 939 (Figure 1M) abolished the improvement in glucose tolerance in VhlDIE mice (Figure 1N), suggesting that intestinal HIF promotes systemic glucose homeostasis via GLP-1.
|
| 67 |
+
|
| 68 |
+
## Hif Induces Glp-1 By Augmenting Gpr40- Mediated Lipid Sensing
|
| 69 |
+
|
| 70 |
+
Because HIF-mediated transcriptional reprogramming promotes cellular differentiation,31,32 we assessed whether intestinal HIF induced L-cell differentiation. To this end, we performed immunostaining for GLP-1 in the small intestine, which showed no difference in the L-cell number between VhlDIE mice and littermate controls (Figure 2A). Quantitative polymerase chain reaction (qPCR) analysis in the small intestines of VhlDIE mice showed an increase in the messenger RNA (mRNA) levels of Pcsk1, which cleaves preproglucagon
|
| 71 |
+
(Gcg) to GLP-1 (Figure 2B). However, no difference in Gcg and ChgA mRNA levels were noted between the groups
|
| 72 |
+
(Figure 2B), suggesting that L-cell content is not increased in VhlDIE mice. An increase in GLP-1 without changes in Lcell number indicated a potential involvement of secretory mechanisms. GLP-1 is secreted in response to luminal nutrients such as carbohydrates, lipids, and proteins.4,6 Our data show that VhlDIE mice had increased mRNA levels of Glut1 (glucose metabolism), G-protein–coupled receptor
|
| 73 |
+
(Gpr)40, and Gpr120 (LCFA receptors). However, no difference in the amino acid sensor Gpr142 was observed (Figure 2C). Thus, we posited that enhanced enteroendocrine glucose or lipid response could have increased GLP-1 levels in VhlDIE mice. We gavaged VhlDIE mice with glucose to test our hypothesis, which did not elicit any significant GLP-1 response (Figure 2D). However, LCFA-rich corn oil increased GLP-1 secretion in VhlDIE mice
|
| 74 |
+
(Figure 2E), suggesting that intestinal HIF induces GLP-1 by augmenting L-cell lipid-sensing. LCFA stimulates GLP-1 secretion predominantly through GPR40, but not GPR120,33 and, therefore, we tested whether GPR40 mediates intestinal HIF regulation of GLP-1 (Figure 2F). Our data show that inhibition of GPR40 using a GPR40-specific antagonist, GW1100, did not affect GLP-1 levels in VhlF/F
|
| 75 |
+
mice. Remarkably, GW1100 significantly reduced GLP-1 in VhlDIE mice (Figure 2G). Moreover, inhibition of GPR40 abolished the improvement in glucose tolerance in VhlDIE
|
| 76 |
+
mice (Figure 2H), indicating that lipid sensing via GPR40 is necessary for HIF-mediated GLP-1 secretion and improvement in glucose homeostasis.
|
| 77 |
+
|
| 78 |
+
## Erk Is The Downstream Target Of Hif-2A–Gpr40 Signaling
|
| 79 |
+
|
| 80 |
+
Studies have shown that protein kinase A (PKA) mediates nutrient-stimulated GLP-1 secretion.34,35 However, we did not observe any induction in PKA signaling as assessed by phospho-PKA substrate levels in the small intestine of VhlDIE mice (Figure 2I). To identify the potential downstream mediators, we treated the enteroendocrine L-cell line (secretin tumor cell; STC-1) with u-3 fatty acid a-linolenic acid (a-LA), the potent inducer of GLP-1. Consistent with previous studies,7,36 a-LA induced pERK levels in STC1 cells (Figure 2J), and inhibition of ERK using the mitogen activated protein-extracellular regulated kinase (MEK–ERK)
|
| 81 |
+
inhibitor GSK1120212 (GSK) attenuated a-LA–induced GLP1 secretion (Figure 2K), suggesting that lipid sensing stimulates GLP-1 via ERK. When we assessed the small intestine of VhlDIE mice, we found increased levels of pERK
|
| 82 |
+
(Figure 2L), which was enhanced further in the ileal explants by a-LA treatment (Figure 2M). To determine whether HIF signaling regulates GLP-1 via ERK, we inhibited ERK using GSK (Figure 2N and O), which led to a significant reduction in GLP-1 levels in VhlDIE mice (Figure 2P). Further analysis showed that ERK inhibition did not affect Gpr40 mRNA levels in VhlDIE mice (Figure 2Q), suggesting that ERK
|
| 83 |
+
is downstream of GPR40 in HIF regulation of GLP-1 secretion.
|
| 84 |
+
|
| 85 |
+
## Intestinal Hif-2A Augments Lipid-Sensing And Glp-1 Secretion In L-Cells
|
| 86 |
+
|
| 87 |
+
HIF-1a and HIF-2a share several target genes and regulate a unique set of genes in a cell-specific manner.24,37 To characterize the isoform of HIF involved in lipid sensing, we transiently overexpressed HIF-1a or HIF-2a in STC-1 cells. HIF-1a overexpression did not significantly change Gpr40 and Gpr120 mRNA levels (Figure 3A and B). However, HIF-2a overexpression significantly induced both Gpr40 and Gpr120 mRNA levels (Figure 3C and D), with no change in the expression of Pcsk1, Gcg, and ChgA (Figure 3E). We then tested whether HIF-2a overexpression would augment aLAinduced GLP-1 secretion. Overexpression of HIF-2a does not affect GLP-1 levels or pERK levels in the absence of ligand
|
| 88 |
+
(Figure 3F and G). However, adding aLA significantly increased GLP-1 levels and pERK in STC-1 cells overexpressing HIF-2a (Figure 3G and H).
|
| 89 |
+
|
| 90 |
+
We then tested whether pharmacologic induction of HIF2a using dimethyloxalyl glycine (DMOG) would augment the expression of lipid-sensing genes and GLP-1 secretion.
|
| 91 |
+
|
| 92 |
+
DMOG-treated mice showed increased mRNA levels of HIF2a target genes and Gpr40 and Gpr120 in the small intestine
|
| 93 |
+
|
| 94 |
+

|
| 95 |
+
|
| 96 |
+
(Figure 3I). Furthermore, corn oil–stimulated GLP-1 secretion was potentiated in DMOG-treated mice (Figure 3J).
|
| 97 |
+
|
| 98 |
+
Collectively, our data suggest that HIF-2a promotes lipidmediated GLP-1 secretion in L-cells.
|
| 99 |
+
|
| 100 |
+
We then tested whether intestinal HIF-2a is sufficient to potentiate lipid sensing using mice with conditional overexpression of intestinal HIF-2a (Hif-2aLSL;Vilin-Cre/ERT2)
|
| 101 |
+
generated by crossing the mice with HIF-2a driven by Rosa 26 flanked by locus of X-over P (loxp)-stop-loxp sites (Hif2aLSL), with mice expressing tamoxifen-inducible Cre recombinase driven under villin promoter (Figure 3K–M).
|
| 102 |
+
|
| 103 |
+
Our data show that the temporal induction of HIF-2a increases the mRNA levels of Gpr40 and Gpr120 in the small intestine of Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 3N). Moreover, GLP-1 and pERK levels were increased in the intestines of Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 3O and P).
|
| 104 |
+
|
| 105 |
+
Thus, our data suggest that activation of intestinal HIF-2a is sufficient to induce lipid-sensing genes and GLP-1. We then assessed whether intestinal HIF-2a promotes metabolic homeostasis. A glucose tolerance test in chow-fed, tamoxifentreated Hif-2aLSL;Vilin-Cre/ERT2 mice showed improved glucose tolerance, albeit no difference in body weight (Figure 3Q and R), indicating that intestinal HIF-2a promotes glucose homeostasis.
|
| 106 |
+
|
| 107 |
+
## Intestinal Hif-2A Attenuates Diet-Induced Glucose Intolerance
|
| 108 |
+
|
| 109 |
+
We then assessed if activation of intestinal HIF-2a would ameliorate diet-induced glucose intolerance. To this end, Hif-2aLSL and Hif-2aLSL;Vilin-Cre/ERT2 mice were treated with tamoxifen to temporally activate HIF-2a and then fed with a 60% high-fat diet (HFD) for 24 weeks (Figure 4A). Hif-2aLSL;-
|
| 110 |
+
Vilin-Cre/ERT2 mice showed a significant decrease in body weight gain (Figure 4B), which was further evident from a significant reduction in fat mass along with an increase in lean mass
|
| 111 |
+
(Figure 4C). The weight differences were not attributed to any change in intestinal lipid absorption (Figure 4D). However, the cumulative food intake assessed for 3 days was significantly lower in Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 4E). Furthermore, the glucose tolerance test showed better glucose tolerance in Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 4F), independent of insulin sensitivity (Figure 4G). These metabolic effects were associated with increased serum and ileal GLP-1 levels in HFD
|
| 112 |
+
Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 4H and I). qPCR analysis in the small intestine showed a significant increase in Pcsk1 and Gcg, albeit no change in L-cell number (Figure 4J and K). Furthermore, mRNA levels of Gpr120 and Gpr40 and pERK were increased in the small intestines of HFD Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 4L and M). Thus, the data suggest that activation of intestinal HIF-2a ameliorates diet-induced glucose intolerance and increases GPR40 signaling and GLP-1 levels.
|
| 113 |
+
|
| 114 |
+
## Intestinal Hif-2A Protects Against Diet-Induced Obesity And Hepatic Steatosis
|
| 115 |
+
|
| 116 |
+
To determine if intestinal HIF-2a regulates energy homeostasis, we assessed Hif-2aLSL;Vilin-Cre/ERT2 mice using indirect calorimetry. We found no difference in energy expenditure in HFD Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 5A),
|
| 117 |
+
or in oxygen consumption (VO2) or carbon dioxide production (VCO2) (Figure 5B). Despite the lack of changes in VCO2 and VO2, we found a small but significant reduction in the ratio of VCO2 to VO2, or the respiratory exchange ratio, in Hif2aLSL;Vilin-Cre/ERT2 mice (Figure 5C), indicating increased relative utilization of fat compared with carbohydrate metabolism. Assessment of gonadal adipose tissue showed decreased adiposity and adipocyte size in Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 5D and E), which corroborated with increased lipolysis, as shown by increased phospho–hormone-sensitive lipase levels (Figure 5F). However, there was no change in adipose tissue inflammation (Figure 5G). Despite no difference in the liver weight (Figure 5H), we found a significant reduction in hepatic steatosis as shown by H&E analysis and lower hepatic triglyceride levels in HFD-fed Hif-2aLSL;Vilin-Cre/ERT2 mice (Figure 5I and J). qPCR analysis in the livers of Hif-2aLSL;Vilin-Cre/ERT2 mice showed a significant decrease in lipogenic genes such as Cd36, Fasn, Srebp1c, and Plin2
|
| 118 |
+
(Figure 5K). However, no difference in fatty acid oxidation and inflammatory genes was noted, except Acot1 and Tnfa
|
| 119 |
+
(Figure 5K). Thus, although the mechanism behind the increase in relative whole-body fat utilization could not be accounted for by changes in hepatic gene expression, our data suggest that an increased supply of fatty acids resulting from increased lipolysis (Figure 5F) contributed to the effect via a substrate-driven mechanism that would provide more fatty acids to the liver, heart, brown adipose tissue (BAT), and skeletal muscle for oxidation. Collectively, our data show that activation of intestinal HIF-2a attenuates visceral adiposity and hepatic steatosis.
|
| 120 |
+
|
| 121 |
+
Figure 2. (See previous page). Intestinal HIF promotes lipid-induced GLP-1 secretion via ERK. (A) Immunostaining for GLP-1 and L-cell number in the small intestine of VhlDIE mice. qPCR analysis for (B) enteroendocrine L-cell–specific genes and (C) nutrient-sensing/metabolism genes in the small intestines of VhlDIE mice. (D) Serum total GLP-1 levels assessed in VhlDIE
|
| 122 |
+
mice gavaged with glucose (2 g/kg body weight), and blood was collected after 30 minutes. (E) Serum total GLP-1 levels in VhlDIE mice gavaged with corn oil (20 mL/kg body weight), and blood was collected after 30 minutes. (F) Experimental schema showing VhlDIE mice gavaged with GPR40 antagonist GW1100 at 2.5 mg/kg body weight at the indicated time points. (G)
|
| 123 |
+
Serum total GLP-1 levels and (H) blood glucose excursion and area under curve (AUC) during intraperitoneal glucose tolerance test (ipGTT) in GW100-treated mice. (I) Western blot for phospho protein kinase A (pPKA) substrate in the small intestine of VhlDIE mice. (J) Western blot analysis in STC-1 cells treated with 50 mmol/L a-LA for 60 minutes. (K) Total GLP-1 in the media from STC-1 cells treated with 50 mmol/L a-LA for 60 minutes in the presence or absence of 0.5 mmol/L GSK. (L) Western blot analysis in ileal scrapes of VhlDIE mice. n ¼ 5–6 mice per group. (M) Western blot analysis in the ileal explants of VhlDIE mice treated with 50 mmol/L a-LA for 60 minutes. Western blot for pERK in GSK-treated (N) C57BL/6, (O) VhlDIE mice. (P) Serum total GLP-1 in fasted VhlDIE mice orally gavaged with GSK at 3 mg/kg body weight. (Q) qPCR analysis for lipid-sensing genes in ileal scrapes of VhlDIE mice orally gavaged with GSK. All data are presented as means ± SEM. *P - .05, **P - .01, and ***P - .001 as analyzed by 2-tailed Student t test or 1-way analysis of variance with Tukey correction. DAPI, 40,6-diamidino-2phenylindole; Veh, vehicle.
|
| 124 |
+
|
| 125 |
+

|
| 126 |
+
|
| 127 |
+
## Hif-2A Is An Essential Regulator Of Intestinal
|
| 128 |
+
|
| 129 |
+
Lipid Sensing and GLP-1 Secretion Based on our data that intestinal HIF signaling is induced by fasting (Figure 1A and B), we assessed whether metabolic cues regulate lipid-sensing genes via HIF-2a. qPCR
|
| 130 |
+
analysis showed that fasting significantly increases the mRNA levels of Gpr40 and Gpr120 in the small intestines
|
| 131 |
+
(Figure 6A). We show that acute inhibition of HIF-2a using the HIF-2a–specific inhibitor PT-2385 abolishes the fastingmediated induction of Gpr40 and Gpr120 mRNA (Figure 6B).
|
| 132 |
+
|
| 133 |
+
Moreover, PT-2385–treated mice showed attenuated corn oil–stimulated GLP-1 secretion (Figure 6C). Together, our data suggest that intestinal HIF-2a induced by fasting primes the intestine for optimal lipid-mediated GLP-1 secretion.
|
| 134 |
+
|
| 135 |
+
To further elucidate the essential role of HIF-2a in lipid sensing, we assessed mice with intestinal epithelial-specific knockout of HIF-2a (Hif-2aDIE). As expected, Gpr120 and
|
| 136 |
+
|
| 137 |
+

|
| 138 |
+
|
| 139 |
+
Gpr40 mRNA levels were reduced significantly in the small intestines of fasted Hif-2aDIE mice (Figure 6D); however, no difference was noted under the fed condition (Figure 6E).
|
| 140 |
+
|
| 141 |
+
Moreover, meal-stimulated GLP-1 secretion was attenuated significantly in Hif-2aDIE mice (Figure 6F), suggesting that HIF-2a signaling is an essential regulator of postprandial GLP-1 secretion. DMOG treatment induces both HIF-1a and HIF-2a, we therefore evaluated the specificity of the HIF
|
| 142 |
+
isoform involved in DMOG-mediated potentiation of GLP-1 secretion. To this end, we treated Hif-2aDIE mice with or without DMOG to assess corn oil–stimulated GLP-1 secretion. Our data show that DMOG failed to potentiate GLP-1 secretion in Hif-2aDIE mice (Figure 6G), indicating that DMOG promotes GLP-1 secretion via HIF-2a.
|
| 143 |
+
|
| 144 |
+
We previously reported that disruption of intestinal HIF-2a did not result in any difference in body weight or glucose homeostasis when fed on a chow diet.26 Consistently, body weight, glucose tolerance, and insulin tolerance were similar between 8-week-old Hif-2aF/F and Hif-2aDIE mice maintained on a chow diet (Figure 6H–J).
|
| 145 |
+
|
| 146 |
+
However, Hif-2aDIE mice develop mild but significant glucose intolerance and insulin resistance at 13 months, albeit with no difference in body weight (Figure 6K–M).
|
| 147 |
+
|
| 148 |
+
qPCR analysis in the small intestine showed an agedependent increase in the mRNA levels of Hif-2a, Gpr120, and Gpr40 (Figure 6N), which was abolished in Hif-2aDIE mice. Further analysis showed significantly lower levels of serum GLP-1 in Hif-2aDIE mice
|
| 149 |
+
|
| 150 |
+

|
| 151 |
+
|
| 152 |
+
(Figure 6O). Collectively, our data suggest that intestinal HIF-2a is essential for the intestinal expression of lipidsensing genes and GLP-1 levels, and disruption of intestinal HIF-2a leads to age-associated metabolic derangements.
|
| 153 |
+
|
| 154 |
+
## Discussion
|
| 155 |
+
|
| 156 |
+
For decades, it has been known that microvascular circulation decreases during fasting, contributing to low oxygen levels in the intestinal epithelia.15,16,38–41 Several studies have shown that the degree of hypoxia determines the tissue/cell response. For example, subtle and/or rapid changes in oxygen tension lead to a HIF response that promotes physiological adaptation to increase intestinal iron absorption via HIF-2a42 or promotes barrier function via HIF-1a.
|
| 157 |
+
|
| 158 |
+
19,43 However, chronic and robust HIF-2a activation integrates with inflammatory cues to induce colitis.44 Here, using a genetic model mimicking hypoxic induction, we show that intestinal HIF signaling improves glucose homeostasis, glucose-stimulated insulin secretion, and increases steady-state GLP-1 levels. Oral but not parenteral administration of nutrients is necessary to observe the glucoregulatory effects of GLP-1.45 However,
|
| 159 |
+
|
| 160 |
+

|
| 161 |
+
|
| 162 |
+
VhlDIE mice had lower glucose excursion in response to IP
|
| 163 |
+
glucose challenge, which is abolished by exendin 9-39.
|
| 164 |
+
|
| 165 |
+
Thus, we attribute the basal increase in GLP-1 to HIFmediated improvement in glucose homeostasis.
|
| 166 |
+
|
| 167 |
+
Intestinal release of GLP-1 could be induced by increasing L-cell content or augmenting GLP-1 secretion.4,46 We found that intestinal HIF potentiated GLP-1 secretion in response to lipids (LCFA), consistent with the increased intestinal expression of the lipid sensors GPR40 and GPR120. Ligandmediated activation of GPR40 and GPR120 have redundant functions in GLP-1 secretion.6,8 Our data that inhibition of GPR40 is sufficient to abrogate the HIF-mediated increase in GLP-1 indicates that intestinal HIF promotes GLP-1 predominantly through GPR40. Furthermore, we identified ERK as the downstream mediator of HIF–GPR40 regulation of GLP-1.
|
| 168 |
+
|
| 169 |
+
Thus, we propose a novel mechanism in which hypoxia signaling regulates metabolic homeostasis via GPR40mediated lipid sensing and GLP-1 secretion.
|
| 170 |
+
|
| 171 |
+
Our data show that HIF-2a but not HIF-1a induces GPR40 in L-cells. This observation is consistent with the differential role of HIF-1a and HIF-2a in regulating distinct sets of genes.47,48 HIF-2a expression did not affect the basal GLP-1 levels in L-cells, but potentiated the ligand-stimulated GLP-1 secretion. However, HIF-2a activation increased both basal and ligand-mediated GLP-1 secretion in vivo. Given that intestinal L-cells are exposed to luminal fatty acids,49 we attribute the increased basal GLP-1 levels to sensing of luminal lipids via GPR40.
|
| 172 |
+
|
| 173 |
+
Activation of intestinal HIF-2a attenuated dietinduced weight gain, glucose intolerance, and hepatic steatosis. These metabolic effects are associated with canonical GLP-1 functions such as decreased food intake, hepatic lipogenesis, and increased adipose tissue lipolysis. Thus, the metabolic effects in HIF-2a–activated mice could be attributed to increased GPR40–GLP-1 signaling and suggest intestinal HIF-2a prevents diet-induced metabolic perturbations. However, this observation contradicts our recent report that disruption of intestinal HIF-2a protects against diet-induced glucose intolerance and hepatic steatosis owing to a decrease in intestinal ceramide synthesis.26 Accumulating evidence supports the view that an obesity-associated increase in GLP-1 counteracts diet-induced glucose intolerance and hepatic steatosis via multiple mechanisms.50,51 We postulate that the paradox in our findings could be attributed to increased GLP-1 levels in HIF-2a–overexpressing mice.
|
| 174 |
+
|
| 175 |
+
Thus, our study highlights the complex role of intestinal HIF-2a in metabolic homeostasis, depending on the cell type of its activation. Whether GLP-1 released from Lcells counteracts ceramide synthesis in enterocytes via a paracrine effect needs further investigation.
|
| 176 |
+
|
| 177 |
+
Our study also provides empiric evidence that HIF-2a regulation of lipid sensing and GLP-1 is a physiologically relevant mechanism essential for postprandial GLP-1 secretion. We show that acute pharmacologic inhibition of HIF-2a attenuates fasting-mediated GPR40/120 expression, suggesting that HIF-2a primes the lipid-sensing mechanism to respond swiftly to dietary lipids. This concept is supported further by our observation that pharmacologic inhibition of HIF-2a abolishes postprandial GLP-1 secretion stimulated by lipids. We show that disruption of HIF-2a in the intestine reduces GPR40/120 expression and meal-stimulated GLP-1 secretion. Furthermore, a DMOG-mediated increase in GLP-1 is dependent on intact intestinal HIF-2a signaling. Despite an impairment in GLP-1 secretion, disruption of HIF-2a does not lead to any metabolic phenotype in young mice, consistent with our previous report.26 Remarkably, older intestinespecific HIF-2a knockout mice developed glucose and insulin intolerance, associated with decreased GPR40 and GLP-1 levels. Thus, we postulate that intestinal HIF-2a is crucial to protect against age-associated metabolic ailments, potentially via GLP-1 signaling.
|
| 178 |
+
|
| 179 |
+
## Conclusions
|
| 180 |
+
|
| 181 |
+
Compelling evidence shows that GLP-1–based therapies are superior in restoring normoglycemia in type 2 diabetic patients.52–54 However, no current treatments leverage the endogenous GLP-1 owing to an incomplete understanding of the GLP-1 secretory mechanisms. Our data provide a strong mechanistic insight into the role of HIF-2a in regulating GLP-1 secretion through lipid sensing. Given that DMOG potentiates GLP-1 secretion via intestinal HIF-2a and targeted delivery of PHD inhibitors to the intestine is feasible,55,56 our study provides a strong rationale for future investigations determining the pharmacologic targeting of intestinal HIF signaling in metabolic diseases. Further investigations using mouse models with L-cell specific HIF-2a gain- or loss-of-function studies also may unfold novel targets to stimulate endogenous GLP-1 production.
|
| 182 |
+
|
| 183 |
+
## Limitations
|
| 184 |
+
|
| 185 |
+
The intestinal-epithelial VHL knockout mice and DMOG
|
| 186 |
+
treatment assessed in this study induce both HIF-1a and HIF-2a. VHL also is known to elicit HIF-independent functions that could affect metabolic homeostasis. Furthermore, the villin Cre-mediated recombination induces HIF-2a in all intestinal epithelial cells. Therefore, studies with L-cell–-
|
| 187 |
+
specific HIF-2a gain- or loss-of-function will unravel novel targets to induce endogenous GLP-1 production.
|
| 188 |
+
|
| 189 |
+
## Methods
|
| 190 |
+
|
| 191 |
+
Animals Mice were housed up to 4 (males) or 5 per cage (females), kept under a 12-hour light/dark cycle, and maintained on respective regular chow (D12450J; Research Diets, New Brunswick, NJ), or HFD (60% kcal from fat, D12492; Research Diets). All mice were given free access to food and water. All experiments were performed using ageand sex-matched littermates, unless indicated in the figure legends. The generation and use of hypoxia reporter mice
|
| 192 |
+
(ODD domain-luc), VhlDIE, Hif-2aDIE, and Hif-2aLSL;Vilin-Cre/ERT2 were described previously.26,57 Littermate controls that do not express Cre recombinase were used as controls for all studies. The intestinal expression of HIF-2a was temporally induced in Hif-2aLSL;Vilin-Cre/ERT2 mice by IP injection of tamoxifen (20 mg/
|
| 193 |
+
kg body weight) dissolved in corn oil. Littermate controls (Hif2aLSL) mice also were injected with tamoxifen. For HFD
|
| 194 |
+
studies, Hif-2aLSL and Hif-2aLSL;Vilin-Cre/ERT2 mice were injected with tamoxifen and then started on 60% HFD. Tamoxifen was administered to the mice once a month during HFD feeding.
|
| 195 |
+
|
| 196 |
+
For IVIS imaging (Caliper Life Sciences, Hopkinton, MA), ODDLuc were fasted overnight and then injected with D-luciferin at 50 mg/kg body weight, and after 15 minutes the small intestine was excised and imaged using the IVIS 200 imaging system. All animal experiments were approved by the Animal Care and Use Committee at the University of Michigan and the University of Pittsburgh.
|
| 197 |
+
|
| 198 |
+
## In Vivo Glp-1 Secretion Studies
|
| 199 |
+
|
| 200 |
+
For corn oil–stimulated GLP-1 secretion, VhlF/F and VhlD1E
|
| 201 |
+
mice were fasted for 16 hours and challenged with a bolus of 20 mL/kg corn oil (Sigma-Aldrich, St. Louis, MO) administered by oral gavage. The blood was collected from the tail at 0 and 30 minutes after gavage. For MEK-ERK inhibition, GSK1120212 (Cayman Chemicals, Ann Arbor, MI) dissolved in dimethyl sulfoxide and diluted in phosphate-buffered saline (PBS) was administered by oral gavage at 3 mg/kg body weight and then mice were fasted immediately for 16 hours. Two hours before blood collection, another dose of GSK1120212 was provided. For GPR40 antagonism, GW1100 (Cayman Chemicals) dissolved in dimethyl sulfoxide and diluted in PBS were administered by oral gavage at 2.5 mg/kg body weight. Two hours before blood collection, mice again were administered with another dose of GW1100. For HIF-2a inhibitor studies, mice were treated with PT-2385 (MedChemExpress, Monmouth Junction, NJ) at 50 mg/kg body weight dissolved in 10% EtOHþ30% polyethylene glycol 400
|
| 202 |
+
(PEG400)þ60% microcrystalline tyrosine or vehicle alone and fasted immediately. For HIF activation studies, mice were treated with DMOG (MedChemExpress) at 10 mg/kg body weight dissolved in dimethyl sulfoxide (further diluted in PBS) or vehicle. Two hours before blood collection, mice were administered another dose of DMOG. For mixed-meal-
|
| 203 |
+
–induced GLP-1 secretion, mice were fasted overnight for 16 hours and challenged with a bolus of 2 g/kg glucose in Ensure Plus (Abbott Laboratories, Columbus, OH), administered by oral gavage. The blood was collected from the tail at 0 and 15 minutes after gavage. For all the assays measuring GLP-1, blood was collected in the tubes containing dipeptidyl peptidase IV (DPPIV) inhibitor Diprotein A (100 mmol/L), and serum was separated by centrifugation at 7500g for 10 minutes at 4C.
|
| 204 |
+
|
| 205 |
+
## Cell Culture, Transfection, And Glp-1 Secretion Assays
|
| 206 |
+
|
| 207 |
+
STC-1 cells (mouse intestinal neuroendocrine cells; ATCC, Manassas, VA) were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% fetal bovine serum.
|
| 208 |
+
|
| 209 |
+
Cells were maintained at 37C and 5% CO2. For transient expression studies, STC-1 cells at 60%–70% confluence were transfected with 5 mg empty vector or plasmids encoding HIF-1a complementary DNA (cDNA) or HIF-2a cDNA using Lipofectamine 3000 transfection reagent
|
| 210 |
+
(Thermofisher Scientific Waltham, MA). The cells were analyzed 48 hours after transfection. For the GLP-1 secretion assay, an equal number of cells were plated in 6-well plates and transfected with an empty vector or HIF-2a. After 48 hours, the cells were washed twice with Hanks balanced salt solution (Thermofisher Scientific) and treated with a-linolenic acid (50 mmol/L) in DMEM for 60 minutes at 37C in the presence of Diprotein A (100 mmol/L; Cayman Chemicals). For GLP-1 secretion with MEK inhibitor, cells were treated with a-linolenic acid (50 mmol/L) in the presence or absence of GSK1120212 (Cayman Chemicals) at 0.5 mmol/L and incubated for 60 minutes at 37C. Total GLP-1 was measured in the media using an enzyme-linked immunosorbent assay kit (Crystal Chem, IL).
|
| 211 |
+
|
| 212 |
+
## Rna Isolation And Real-Time Reversetranscription Pcr
|
| 213 |
+
|
| 214 |
+
Total RNA was extracted from the small intestine
|
| 215 |
+
(ileum), liver, and adipose tissue using TRIzol reagent
|
| 216 |
+
(Thermofisher Scientific) as per standard protocol. cDNA
|
| 217 |
+
was prepared with 1 mg total RNA using Moloney murine leukemia virus (Mu-MLV) reverse transcriptase (Promega, Madison, WI). The relative expression of genes was assessed with SYBR Green master mix (Radiant Molecular Tools, Fort Lauderdale, FL) using QuantStudio 3 Station qPCR machine
|
| 218 |
+
(Applied Biosystems, Foster City, CA). The relative expression of target genes was calculated using a comparative delta threshold cycles (DCT) method after normalizing to bactin. The primer sequences used were as follows: Ffar1 forward: 5'-AGGCGCTCTCCTCACACTC-3', reverse: 5'- CTAGCCACATTGGAGGCATT-3'; Ffar4 forward: 5'-
|
| 219 |
+
CCATCCCTCTAGTGCTCGTC-3', reverse: 5'-TGCGGAAGAGTCGGTAGTCT-3'; Gpr142 forward: 5'-TGCTGCCTACAGTCAATGGT-3', reverse: 5'-TGACGATATCTGAAGCCGTG3'; Glut1 forward: 5'-CAAGTCTGCATTGCCCATGAT-3',
|
| 220 |
+
reverse: 5'-CAAGTCTGCATTGCCCATGAT-3'; b-actin forward: 5'-TATTGGCAACGAGCGGTTCC-3', reverse: 5'-GGCATAGAGGTCTTTACGGATGT-3'; Hif-1a forward: 5'-
|
| 221 |
+
GGGTACAAGAAACCACCCAT-3', reverse: 5'-GAGGCTGTGTCGACTGAGAA-3'; Hif-2a forward: 5'-AGCTTCCTTCGGACACATAAG-3', reverse: 5'-GCTTTCAGGTACAAGTTATCCATTT-3';
|
| 222 |
+
DcytB forward: 5'-CATCCTCGCCATCATCTC-3', reverse: 5'- GGCATTGCCTCCATTTAGCTG-3'; Dmt1 forward: 5'-
|
| 223 |
+
TGTTTGATTGCATTGGGTCTG-3', reverse: 5'-CGCTCAGCAGGACTTTCGAG-3'; Pgk1 forward: 5'-CAAATTTGATGAGAATGCCAAGACT-3', reverse: 5'- TTCTTGCTGCTCTCAGTACCAC-3'; Gcg forward: 5'-GCTTATAATGCTGGTGCAAG-3', reverse: 5'-TTCATCTCATCAGGGTCCTC-3'; Ngn3 forward: 5'-
|
| 224 |
+
GCATGCACAACCTCAACTC-3', reverse: 5'-
|
| 225 |
+
TTTGTAAGTTTGGCGTCATC-3'; ChgA forward: 5'-GCAGGCTACAAAGCGATCCA-3', reverse: 5'-CTCTGTCTTTCCATCTCCATCCA-3'; Pcsk1 forward: 5'-
|
| 226 |
+
TCTGGTTGTCTGGACCTCTGAGT-3', reverse: 5'-CATCAAGCCTGCCCCATTCTTT-3'; Cd36 forward: 5'-
|
| 227 |
+
CCTGCAAATGTCAGAGGAAA-3', reverse: 5'-GCGACATGATTAATGGCACA-3'; Srebp1 forward: 5'-
|
| 228 |
+
TGGTTGTGATGAGCTGGAG-3', reverse: 5'-GGCTCTGGAACAGACACTGG-3'; Cpt1a forward: 5'-CCAGGCTACAGTGGGACATT-3', reverse: 5'-GAACTTGCCCATGTCCTTGT-3'; Acox1 forward: 5'-TCGAAGCCAGCGTTACGAG-3', reverse: 5'- ATCTCCGTCTGGGCGTAGG-3'; Fasn forward: 5'-
|
| 229 |
+
GTTGGCCCAGAACTCCTGTA-3', reverse: 5'- GTCGTCTGCCTCCAGAGC-3'; Pai1 forward: 5'-
|
| 230 |
+
ACGCCTGGTGCTGGTGAATGC-3', reverse: 5'-ACGGTGCTGCCATCAGACTTGTG-3'; Tnfa forward: 5'-AGGGTCTGGGCCATAGAACT-3', reverse: 5'-CCACCACGCTCTTCTGTCTAC-3';
|
| 231 |
+
Ccl2 forward: 5'-CTCACCTGCTGCTACTCATTC-3', reverse: 5'-
|
| 232 |
+
ACTACAGCTTCTTTGGGACAC-3'; Acot1 forward: 5'-ATGGCAGCAGCTCCAGACT-3', reverse: 5'-ATCTCCGTCTGGGCGTAGG-3'; Ppara forward: 5'-AGAGCCCCATCTGTCCTCTC-3',
|
| 233 |
+
reverse: 5'-ACTGGTAGTCTGCAAAACCAAA-3'; Plin2 forward:
|
| 234 |
+
5'-CTCAGGAGGAGCTGGAGATG-3', reverse: 5'-TCAATCAGGTGGACAGTGGA-3'; Scd1 forward: 5'-CAGCCGAGCCTTGTAAGTTC-3', reverse: 5'-
|
| 235 |
+
GCTCTACACCTGCCTCTTCG-3'; Cxcl1 forward: 5'-CTGCACCCAAACCGAAGTC-3', reverse: 5'-AGCTTCAGGGTCAAGGCAAG-3'; Il1b forward: 5'-AAGAGCTTCAGGCAGGCAGTATCA3', reverse: 5'-TGCAGCTGTCTAGGAACGTCA-3'; Mcp1 forward: 5'-AGCTCTCTCTTCCTCCACCA-3', reverse: 5'-
|
| 236 |
+
GGCGTTAACTGCATCTGGCT-3'.
|
| 237 |
+
|
| 238 |
+
## Western Blot
|
| 239 |
+
|
| 240 |
+
Total protein lysates for immunoblotting were prepared using radioimmunoprecipitation assay lysis buffer (0.5%
|
| 241 |
+
NP-40, 0.1% sodium deoxycholate, 150 mmol/L NaCl, 50 mmol/L Tris-Cl, pH 7.5) containing 1 mmol/L phenylmethylsulphonyl fluoride, protease inhibitor cocktail
|
| 242 |
+
(Sigma-Aldrich) and 2 mmol/L sodium orthovanadate.
|
| 243 |
+
|
| 244 |
+
Protein concentration was determined using a protein assay kit (Bio-Rad, Hercules, CA), and proteins were resolved on a 9% polyacrylamide gel and transferred onto nitrocellulose or polyvinylidene difluoride membranes (Bio-Rad).
|
| 245 |
+
|
| 246 |
+
Nonspecific binding was blocked using 3% skim milk, and membranes were incubated overnight at 4C with primary antibodies such as ERK, pERK (Cell Signaling Technology, Denvers, MA), HIF-2a (Novus Biologicals, Littleton, CO), and HIF-1a (Abcam, Waltham, MA). Secondary antibodies conjugated with DyLight (Cell Signaling Technology) were added to the membranes and visualized using the Odyssey CLx Imaging System (LI-COR, Lincoln, NE).
|
| 247 |
+
|
| 248 |
+
## Liver Triglyceride Assay
|
| 249 |
+
|
| 250 |
+
Liver triglycerides were quantified as described previously.58 Briefly, liver tissue was homogenized in chloroform:
|
| 251 |
+
methanol (2:1) and incubated for 60 minutes at room temperature on a shaker, followed by acidification with 1 mol/L H2SO4. The organic phase containing the lipids was collected by centrifugation at 2000g for 10 minutes. The triglycerides from the organic phase and serum were measured using colorimetric Infinity Triglyceride Reagent (Thermofisher Scientific). Tissue triglyceride levels were normalized to their respective weights.
|
| 252 |
+
|
| 253 |
+
## Ileal Explant Ex Vivo Studies
|
| 254 |
+
|
| 255 |
+
The ileum from VhlF/F and VhlD1E was excised and washed thoroughly in glucose-free Krebs-Ringer bicarbonate buffer
|
| 256 |
+
(138 mmol/L NaCl, 5.6 mmol/L KCl, 2.6 mmol/L CaCl2, 1.2 mmol/L MgCl2, 4.2 mmol/L NaHCO3, 1.2 mmol/L NaH2PO4, and 10 mmol/L HEPES; pH 7.4) and cut into small pieces. The ileal explants were weighed, transferred to DMEM/F12, and treated with a-linolenic acid (50 mmol/L) for 60 minutes at 37C. The whole-cell extract for Western analysis was prepared using radioimmunoprecipitation assay buffer.
|
| 257 |
+
|
| 258 |
+
## Tissue Histology And Immunofluorescence
|
| 259 |
+
|
| 260 |
+
Liver and white adipose tissue were fixed in 10%
|
| 261 |
+
PBS–buffered formalin (Thermofisher Scientific), embedded in paraffin, and 6 micron sections were prepared. H&E
|
| 262 |
+
staining was performed using the standard protocol. For immunofluorescence, antigen retrieval was performed using citrate buffer (pH 6), and the sections were blocked in 10%
|
| 263 |
+
goat serum in phosphate buffered saline Tween-20 (PBST) for 30 minutes at room temperature. Sections were incubated in primary antibody (GLP-1) overnight, followed by multiple washing with PBS. Sections then were probed with secondary antibody conjugated with Alexa Flour (Cell Signaling), and images were captured using a Nikon microscope (Nikon Instruments Inc. Melville, NY). The number of L-cells was counted manually.
|
| 264 |
+
|
| 265 |
+
Body Composition and Indirect Calorimetry Body fat and lean mass of conscious mice were determined by EchoMRI (EchoMRI, LLC, Houston, TX). The whole-body composition as a percentage of fat and lean mass were calculated for individual mice by dividing the tissue mass by body weight. Energy homeostasis was measured by indirect calorimetry using the Promethion Multiplexed Metabolic Cage System (Sable Systems, Las Vegas, NV).59 Mice were housed in individual chambers with free access to food and water. The first 24 hours were considered an acclimatization period, and mice were studied for 72 hours. Energy expenditure was normalized to lean body mass.
|
| 266 |
+
|
| 267 |
+
## Metabolic Tests
|
| 268 |
+
|
| 269 |
+
For intraperitoneal glucose tolerance test (ipGTT),
|
| 270 |
+
dextrose was injected at 1.5 g/kg body weight in overnight fasted mice. For intraperitoneal insulin tolerance test
|
| 271 |
+
(ipITT), insulin (Eli Lilly, Indianapolis, IN) was injected at 0.75 U/kg body weight in mice fasted for 6 hours. Glucose was measured from the tail vein blood at 0, 15, 30, 45, 60, and 120 minutes using a glucometer (Bayer, Parsippany, NJ). The area under the curve over 120 minutes was calculated using a standard formula. For GLP-1–receptor agonists, mice were injected intraperitoneally with either vehicle (PBS) or exendin 9-39 (Cayman Chemicals) 1 hour before glucose administration. For acute-phase, glucosestimulated insulin secretion, mice were anesthetized with avertin, and then glucose was administered intraperitoneally at 2 g/kg body weight and blood was collected by retroorbital bleeding. For the lipid tolerance test, corn oil (200 mL/mice) was gavaged to the mice, and serum was collected at the indicated time points.
|
| 272 |
+
|
| 273 |
+
## Tissue, Media, And Serum Glp-1 Assay
|
| 274 |
+
|
| 275 |
+
Small intestinal and pancreatic tissue was homogenized in 200 mL lysis buffer (50 mmol/L Tris HCl [pH 8 at 4C], 1 mmol/L EDTA, 10% glycerol [wt/vol], 0.02% Tween-20) supplemented with protease inhibitors and 100 mmol/L of Diprotein A. Total GLP-1 (Crystal Chem, Elk Grove Village, IL
|
| 276 |
+
and Meso Scale Discovery Rockville, MD) was measured in the tissue supernatant, media, and serum following the manufacturer's recommendation. Tissue GLP-1 levels were normalized to protein content.
|
| 277 |
+
|
| 278 |
+
## Statistical Analysis
|
| 279 |
+
|
| 280 |
+
All the data are represented as means ± SEM. Statistical analysis was performed using GraphPad Prism; version 8.1.2. (San Diego, CA). The statistical difference between the 2 groups was determined by using a 2-tailed Student t test. To compare more than 2 groups, 1-way analysis of variance followed by the Tukey multiple-comparisons test was applied. The differences between groups were considered statistically significant at P -
|
| 281 |
+
.05, and P values were calculated with a 95% CI. P values for the figures are indicated in the corresponding figure legends.
|
| 282 |
+
|
| 283 |
+
All in vitro experiments were performed at least 2 times.
|
| 284 |
+
|
| 285 |
+
## Data Access
|
| 286 |
+
|
| 287 |
+
All authors had access to all data and reviewed and approved the final manuscript.
|
| 288 |
+
|
| 289 |
+
## References
|
| 290 |
+
|
| 291 |
+
1. Sun EWL, Martin AM, Young RL, Keating DJ. The regulation of peripheral metabolism by gut-derived hormones. Front Endocrinol (Lausanne) 2018;9:754.
|
| 292 |
+
|
| 293 |
+
2. Krieger JP. Intestinal glucagon-like peptide-1 effects on food intake: physiological relevance and emerging mechanisms. Peptides 2020;131:170342.
|
| 294 |
+
|
| 295 |
+
3. Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014;15:181–187.
|
| 296 |
+
|
| 297 |
+
4. Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ,
|
| 298 |
+
Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF,
|
| 299 |
+
Holst JJ, Langhans W, Meier JJ, Nauck MA, PerezTilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, TangChristensen M, Woods SC, DiMarchi RD, Tschop MH.
|
| 300 |
+
|
| 301 |
+
Glucagon-like peptide 1 (GLP-1). Mol Metab 2019; 30:72–130.
|
| 302 |
+
|
| 303 |
+
5. Reimann F, Habib AM, Tolhurst G, Parker HE,
|
| 304 |
+
Rogers GJ, Gribble FM. Glucose sensing in L cells: a primary cell study. Cell Metab 2008;8:532–539.
|
| 305 |
+
|
| 306 |
+
6. Duca FA, Waise TMZ, Peppler WT, Lam TKT. The metabolic impact of small intestinal nutrient sensing. Nat Commun 2021;12:903.
|
| 307 |
+
|
| 308 |
+
7. Hirasawa A, Tsumaya K, Awaji T, Katsuma S,
|
| 309 |
+
Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120.
|
| 310 |
+
|
| 311 |
+
Nat Med 2005;11:90–94.
|
| 312 |
+
|
| 313 |
+
8. Ghislain J, Poitout V. Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges. Nat Rev Endocrinol 2021;17:162–175.
|
| 314 |
+
|
| 315 |
+
9. Syed I, Lee J, Moraes-Vieira PM, Donaldson CJ,
|
| 316 |
+
Sontheimer A, Aryal P, Wellenstein K, Kolar MJ, Nelson AT, Siegel D, Mokrosinski J, Farooqi IS, Zhao JJ,
|
| 317 |
+
Yore MM, Peroni OD, Saghatelian A, Kahn BB. Palmitic acid hydroxystearic acids activate GPR40, which is involved in their beneficial effects on glucose homeostasis. Cell Metab 2018;27:419–427 e4.
|
| 318 |
+
|
| 319 |
+
10. Paschoal VA, Walenta E, Talukdar S, Pessentheiner AR,
|
| 320 |
+
Osborn O, Hah N, Chi TJ, Tye GL, Armando AM, Evans RM, Chi NW, Quehenberger O, Olefsky JM, Oh DY. Positive reinforcing mechanisms between GPR120 and PPARgamma modulate insulin sensitivity.
|
| 321 |
+
|
| 322 |
+
Cell Metab 2020;31:1173–1188 e5.
|
| 323 |
+
|
| 324 |
+
11. Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M. Free fatty acid receptors in health and disease. Physiol Rev 2020;100:171–210.
|
| 325 |
+
|
| 326 |
+
12. Taylor CT, Colgan SP. Hypoxia and gastrointestinal disease. J Mol Med (Berl) 2007;85:1295–1300.
|
| 327 |
+
|
| 328 |
+
13. Fisher EM, Khan M, Salisbury R, Kuppusamy P. Noninvasive monitoring of small intestinal oxygen in a rat model of chronic mesenteric ischemia. Cell Biochem Biophys 2013;67:451–459.
|
| 329 |
+
|
| 330 |
+
14. Singhal R, Shah YM. Oxygen battle in the gut: hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine. J Biol Chem 2020; 295:10493–10505.
|
| 331 |
+
|
| 332 |
+
15. Zheng L, Kelly CJ, Colgan SP. Physiologic hypoxia and oxygen homeostasis in the healthy intestine. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol 2015;309:C350–C360.
|
| 333 |
+
|
| 334 |
+
16. Zeitouni NE, Chotikatum S, von Kockritz-Blickwede M,
|
| 335 |
+
Naim HY. The impact of hypoxia on intestinal epithelial cell functions: consequences for invasion by bacterial pathogens. Mol Cell Pediatr 2016;3:14.
|
| 336 |
+
|
| 337 |
+
17. Glover LE, Lee JS, Colgan SP. Oxygen metabolism and barrier regulation in the intestinal mucosa. J Clin Invest 2016;126:3680–3688.
|
| 338 |
+
|
| 339 |
+
18. Saeedi BJ, Kao DJ, Kitzenberg DA, Dobrinskikh E,
|
| 340 |
+
Schwisow KD, Masterson JC, Kendrick AA, Kelly CJ,
|
| 341 |
+
Bayless AJ, Kominsky DJ, Campbell EL, Kuhn KA,
|
| 342 |
+
Furuta GT, Colgan SP, Glover LE. HIF-dependent regulation of claudin-1 is central to intestinal epithelial tight junction integrity. Mol Biol Cell 2015;26:2252–2262.
|
| 343 |
+
|
| 344 |
+
19. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS,
|
| 345 |
+
Colgan SP, Haase VH. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J Clin Invest 2004;114:1098–1106.
|
| 346 |
+
|
| 347 |
+
20. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell 2012;148:399–408.
|
| 348 |
+
|
| 349 |
+
21. Gonzalez FJ, Xie C, Jiang C. The role of hypoxiainducible factors in metabolic diseases. Nat Rev Endocrinol 2018;15:21–32.
|
| 350 |
+
|
| 351 |
+
22. Bodnaruc AM, Prud'homme D, Blanchet R, Giroux I.
|
| 352 |
+
|
| 353 |
+
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a review. Nutr Metab (Lond) 2016;13:92.
|
| 354 |
+
|
| 355 |
+
23. Miyamoto J, Igarashi M, Watanabe K, Karaki SI,
|
| 356 |
+
Mukouyama H, Kishino S, Li X, Ichimura A, Irie J, Sugimoto Y, Mizutani T, Sugawara T, Miki T, Ogawa J, Drucker DJ, Arita M, Itoh H, Kimura I. Gut microbiota confers host resistance to obesity by metabolizing dietary polyunsaturated fatty acids. Nat Commun 2019; 10:4007.
|
| 357 |
+
|
| 358 |
+
24. Ramakrishnan SK, Shah YM. Role of intestinal HIF2alpha in health and disease. Annu Rev Physiol 2016; 78:301–325.
|
| 359 |
+
|
| 360 |
+
25. Singhal R, Mitta SR, Das NK, Kerk SA, Sajjakulnukit P,
|
| 361 |
+
Solanki S, Andren A, Kumar R, Olive KP, Banerjee R,
|
| 362 |
+
Lyssiotis CA, Shah YM. HIF-2alpha activation potentiates oxidative cell death in colorectal cancers by increasing cellular iron. J Clin Invest 2021;131:e143691.
|
| 363 |
+
|
| 364 |
+
26. Xie C, Yagai T, Luo Y, Liang X, Chen T, Wang Q,
|
| 365 |
+
Sun D, Zhao J, Ramakrishnan SK, Sun L, Jiang C,
|
| 366 |
+
Xue X, Tian Y, Krausz KW, Patterson AD, Shah YM,
|
| 367 |
+
Wu Y, Jiang C, Gonzalez FJ. Activation of intestinal hypoxia-inducible factor 2alpha during obesity contributes to hepatic steatosis. Nat Med 2017; 23:1298–1308.
|
| 368 |
+
|
| 369 |
+
27. Song Y, Koehler JA, Baggio LL, Powers AC,
|
| 370 |
+
Sandoval DA, Drucker DJ. Gut-proglucagon-derived peptides are essential for regulating glucose homeostasis in mice. Cell Metab 2019;30:976–986 e3.
|
| 371 |
+
|
| 372 |
+
28. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24–32.
|
| 373 |
+
|
| 374 |
+
29. Svendsen B, Pedersen J, Albrechtsen NJ, Hartmann B,
|
| 375 |
+
Torang S, Rehfeld JF, Poulsen SS, Holst JJ. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology 2015;156:847–857.
|
| 376 |
+
|
| 377 |
+
30. Christensen MB. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Dan Med J 2016;63:B5230.
|
| 378 |
+
|
| 379 |
+
31. Chan MC, Ilott NE, Schodel J, Sims D, Tumber A,
|
| 380 |
+
Lippl K, Mole DR, Pugh CW, Ratcliffe PJ, Ponting CP,
|
| 381 |
+
Schofield CJ. Tuning the transcriptional response to hypoxia by inhibiting hypoxia-inducible factor (HIF) prolyl and asparaginyl hydroxylases. J Biol Chem 2016; 291:20661–20673.
|
| 382 |
+
|
| 383 |
+
32. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465–472.
|
| 384 |
+
|
| 385 |
+
33. Xiong Y, Swaminath G, Cao Q, Yang L, Guo Q,
|
| 386 |
+
Salomonis H, Lu J, Houze JB, Dransfield PJ, Wang Y,
|
| 387 |
+
Liu JJ, Wong S, Schwandner R, Steger F, Baribault H,
|
| 388 |
+
Liu L, Coberly S, Miao L, Zhang J, Lin DC, Schwarz M.
|
| 389 |
+
|
| 390 |
+
Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol 2013;369:119–129.
|
| 391 |
+
|
| 392 |
+
34. Drucker DJ, Jin T, Asa SL, Young TA, Brubaker PL.
|
| 393 |
+
|
| 394 |
+
Activation of proglucagon gene transcription by protein kinase-A in a novel mouse enteroendocrine cell line. Mol Endocrinol 1994;8:1646–1655.
|
| 395 |
+
|
| 396 |
+
35. Knepel W, Chafitz J, Habener JF. Transcriptional activation of the rat glucagon gene by the cyclic AMPresponsive element in pancreatic islet cells. Mol Cell Biol 1990;10:6799–6804.
|
| 397 |
+
|
| 398 |
+
36. Chang E, Kim L, Choi JM, Park SE, Rhee EJ, Lee WY,
|
| 399 |
+
Oh KW, Park SW, Park DI, Park CY. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/
|
| 400 |
+
ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism 2015;64:633–641.
|
| 401 |
+
|
| 402 |
+
37. Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors–similar but not identical. Mol Cells 2010;29:435–442.
|
| 403 |
+
|
| 404 |
+
38. Kvietys PR, Pittman RP, Chou CC. Contribution of luminal concentration of nutrients and osmolality to postprandial intestinal hyperemia in dogs. Proc Soc Exp Biol Med 1976;152:659–663.
|
| 405 |
+
|
| 406 |
+
39. Jeays AD, Lawford PV, Gillott R, Spencer PA,
|
| 407 |
+
Bardhan KD, Hose DR. A framework for the modeling of gut blood flow regulation and postprandial hyperaemia.
|
| 408 |
+
|
| 409 |
+
World J Gastroenterol 2007;13:1393–1398.
|
| 410 |
+
|
| 411 |
+
40. Shepherd AP. Metabolic control of intestinal oxygenation and blood flow. Fed Proc 1982;41:2084–2089.
|
| 412 |
+
|
| 413 |
+
41. Matheson PJ, Wilson MA, Garrison RN. Regulation of intestinal blood flow. J Surg Res 2000;93:182–196.
|
| 414 |
+
|
| 415 |
+
42. Ramakrishnan SK, Anderson ER, Martin A, Centofanti B,
|
| 416 |
+
Shah YM. Maternal intestinal HIF-2alpha is necessary for sensing iron demands of lactation in mice. Proc Natl Acad Sci U S A 2015;112:E3738–E3747.
|
| 417 |
+
|
| 418 |
+
43. Xue X, Ramakrishnan S, Anderson E, Taylor M,
|
| 419 |
+
Zimmermann EM, Spence JR, Huang S, Greenson JK, Shah YM. Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 2013; 145:831–841.
|
| 420 |
+
|
| 421 |
+
44. Synnestvedt K, Furuta GT, Comerford KM, Louis N,
|
| 422 |
+
Karhausen J, Eltzschig HK, Hansen KR, Thompson LF,
|
| 423 |
+
Colgan SP. Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest 2002; 110:993–1002.
|
| 424 |
+
|
| 425 |
+
45. Lindgren O, Carr RD, Deacon CF, Holst JJ, Pacini G,
|
| 426 |
+
Mari A, Ahren B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011;96:
|
| 427 |
+
2519–2524.
|
| 428 |
+
|
| 429 |
+
46. Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism.
|
| 430 |
+
|
| 431 |
+
Nat Rev Endocrinol 2019;15:226–237.
|
| 432 |
+
|
| 433 |
+
47. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC.
|
| 434 |
+
|
| 435 |
+
Differential roles of hypoxia-inducible factor 1alpha (HIF1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361–9374.
|
| 436 |
+
|
| 437 |
+
48. Ratcliffe PJ. HIF-1 and HIF-2: working alone or together in hypoxia? J Clin Invest 2007;117:862–865.
|
| 438 |
+
|
| 439 |
+
49. Lu VB, Gribble FM, Reimann F. Nutrient-induced cellular mechanisms of gut hormone secretion. Nutrients 2021; 13:883.
|
| 440 |
+
|
| 441 |
+
50. Hira T, Pinyo J, Hara H. What is GLP-1 really doing in obesity? Trends Endocrinol Metab 2020;31:71–80.
|
| 442 |
+
|
| 443 |
+
51. Farhadipour M, Depoortere I. The function of gastrointestinal hormones in obesity-implications for the regulation of energy intake. Nutrients 2021;13:1839.
|
| 444 |
+
|
| 445 |
+
52. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes -
|
| 446 |
+
state-of-the-art. Mol Metab 2021;46:101102.
|
| 447 |
+
|
| 448 |
+
53. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012;8:728–742.
|
| 449 |
+
|
| 450 |
+
54. Brunton SA, Wysham CH. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgrad Med 2020;132(Suppl 2):3–14.
|
| 451 |
+
|
| 452 |
+
55. Tambuwala MM, Manresa MC, Cummins EP, Aversa V,
|
| 453 |
+
Coulter IS, Taylor CT. Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis.
|
| 454 |
+
|
| 455 |
+
J Control Release 2015;217:221–227.
|
| 456 |
+
|
| 457 |
+
56. Riopel M, Moon JS, Bandyopadhyay GK, You S, Lam K,
|
| 458 |
+
Liu X, Kisseleva T, Brenner D, Lee YS. Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2alpha-dependent mechanism. Mol Metab 2020;41:101039.
|
| 459 |
+
|
| 460 |
+
57. Ramakrishnan SK, Zhang H, Takahashi S, Centofanti B,
|
| 461 |
+
Periyasamy S, Weisz K, Chen Z, Uhler MD, Rui L,
|
| 462 |
+
Gonzalez FJ, Shah YM. HIF2alpha is an essential molecular brake for postprandial hepatic glucagon response independent of insulin signaling. Cell Metab 2016; 23:505–516.
|
| 463 |
+
|
| 464 |
+
58. Mooli RGR, Rodriguez J, Takahashi S, Solanki S,
|
| 465 |
+
Gonzalez FJ, Ramakrishnan SK, Shah YM. Hypoxia via ERK signaling inhibits hepatic PPARalpha to promote fatty liver. Cell Mol Gastroenterol Hepatol 2021; 12:585–597.
|
| 466 |
+
|
| 467 |
+
59. Mooli RGR, Mukhi D, Watt M, Edmunds L, Xie B,
|
| 468 |
+
Capooci J, Reslink M, Eze C, Mills A, Stolz DB, Jurczak M, Ramakrishnan SK. Sustained mitochondrial biogenesis is essential to maintain caloric restrictioninduced beige adipocytes. Metabolism 2020; 107:154225.
|
| 469 |
+
|
| 470 |
+
Received September 16, 2021. Accepted December 6, 2021. Correspondence Address correspondence to: Sadeesh K. Ramakrishnan, PhD, Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15237. e-mail: ramaks@pitt.edu; fax: (412) 648-3290. CRediT Authorship Contributions Raja Gopal Reddy Mooli (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Validation:
|
| 471 |
+
Equal; Visualization: Equal; Writing - original draft: Equal; Writing - review &
|
| 472 |
+
editing: Equal)
|
| 473 |
+
Dhanunjay Mukhi (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting)
|
| 474 |
+
Anil K. Pasupulati (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting)
|
| 475 |
+
Simon Evers (Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting)
|
| 476 |
+
Ian J. Sipula (Data curation: Supporting; Formal analysis: Supporting)
|
| 477 |
+
Michael Jurczak (Data curation: Supporting; Formal analysis: Supporting; Supervision: Supporting; Writing - review & editing: Supporting)
|
| 478 |
+
Randy J. Seeley (Funding acquisition: Supporting; Supervision: Supporting; Writing - review & editing: Supporting)
|
| 479 |
+
Yatrik M. Shah (Conceptualization: Supporting; Formal analysis: Supporting; Funding acquisition: Supporting; Investigation: Supporting; Supervision:
|
| 480 |
+
Supporting; Writing - review & editing: Supporting)
|
| 481 |
+
Sadeesh K. Ramakrishnan (Conceptualization: Lead; Data curation: Lead; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Supervision: Lead; Writing - original draft: Lead; Writing
|
| 482 |
+
- review & editing: Lead)
|
| 483 |
+
Conflicts of interest The authors disclose the following: Randy J. Seeley has received grants and personal fees from Novo Nordisk and Astra Zeneca; personal fees from Scohia, Fractyl, and ShouTi Pharma; and holds equity in Calibrate and Rewind. The remaining authors disclose no conflicts.
|
| 484 |
+
|
| 485 |
+
Funding This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases grant DK110537 (S.K.R.); National Institutes of Health grants CA148828, DK095201, and CA245546 (Y.M.S.), and DK117821, DK089503, and DK119188 (R.J.S.); and the Pittsburgh Foundation grant MR2020 109502 (M.J.).
|
medical/md_images/PMC10559360/0_image_4.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10559360/0_image_6.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10559360/15_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10645190/PMC10645190_meta.json
ADDED
|
@@ -0,0 +1,27 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
{
|
| 2 |
+
"languages": [
|
| 3 |
+
"en"
|
| 4 |
+
],
|
| 5 |
+
"filetype": "pdf",
|
| 6 |
+
"toc": [],
|
| 7 |
+
"pages": 5,
|
| 8 |
+
"ocr_stats": {
|
| 9 |
+
"ocr_pages": 2,
|
| 10 |
+
"ocr_failed": 0,
|
| 11 |
+
"ocr_success": 2,
|
| 12 |
+
"ocr_engine": "surya"
|
| 13 |
+
},
|
| 14 |
+
"block_stats": {
|
| 15 |
+
"header_footer": 0,
|
| 16 |
+
"code": 0,
|
| 17 |
+
"table": 0,
|
| 18 |
+
"equations": {
|
| 19 |
+
"successful_ocr": 0,
|
| 20 |
+
"unsuccessful_ocr": 0,
|
| 21 |
+
"equations": 0
|
| 22 |
+
}
|
| 23 |
+
},
|
| 24 |
+
"postprocess_stats": {
|
| 25 |
+
"edit": {}
|
| 26 |
+
}
|
| 27 |
+
}
|
medical/md_images/PMC10756843/0_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10756843/5_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10767772/2_image_1.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10772648/10_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10772648/7_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10790005/7_image_1.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10850403/0_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10850403/2_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC10850403/5_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2190190/12_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2212278/2_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2212278/4_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2212278/5_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2212278/6_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2886898/6_image_7.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC2886898/7_image_7.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3276052/1_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3321272/2_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3321272/2_image_1.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3341158/0_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3341158/1_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3341158/1_image_1.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3378941/PMC3378941.md
ADDED
|
@@ -0,0 +1,313 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
|
| 2 |
+
|
| 3 |
+

|
| 4 |
+
|
| 5 |
+
# A Descriptive Epidemiological Study On The Patterns Of Occupational Injuries In A Coastal Area And A Mountain Area In Southern China
|
| 6 |
+
|
| 7 |
+
Liping Li,1 Xiaojian Liu,1,2 Bernard C K Choi,1,3 Yaogui Lu,1 Min Yu4 To cite: Li L, Liu X, Choi BCK,
|
| 8 |
+
et al. A descriptive epidemiological study on the patterns of occupational injuries in a coastal area and a mountain area in Southern China. BMJ Open 2012;2:e000965.
|
| 9 |
+
|
| 10 |
+
doi:10.1136/
|
| 11 |
+
bmjopen-2012-000965
|
| 12 |
+
< Prepublication history for this paper is available online. To view these files please visit the journal online (http://
|
| 13 |
+
dx.doi.org/10.1136/
|
| 14 |
+
bmjopen-2012-000965).
|
| 15 |
+
|
| 16 |
+
Received 10 February 2012 Accepted 14 May 2012 This final article is available for use under the terms of the Creative Commons Attribution Non-Commercial 2.0 Licence; see http://bmjopen.bmj.com 1Injury Prevention Research Centre, Medical College of Shantou University, Shantou, China 2Shenzhen Centre for Disease Prevention and Control, Shenzhen, China 3Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada 4Zhejiang Provincial Centre for Disease Prevention and Control, Hangzhou, China Correspondence to Dr Bernard Choi; bernard.choi@utoronto.ca
|
| 17 |
+
|
| 18 |
+
## Abstract
|
| 19 |
+
|
| 20 |
+
Objectives: This study compared patterns of occupational injuries in two different areas, coastal (industrial) and mountain (agricultural), in Southern China to provide information for development of occupational injury prevention measures in China.
|
| 21 |
+
|
| 22 |
+
Design: Descriptive epidemiological study.
|
| 23 |
+
|
| 24 |
+
Setting: Data were obtained from the Hospital Injury Surveillance System based on hospital data collected from 1 April 2006 to 31 March 2008.
|
| 25 |
+
|
| 26 |
+
Participants: Cases of occupational injury, defined as injury that occurred when the activity indicated was work.
|
| 27 |
+
|
| 28 |
+
Outcome measures: Distribution and differences of patterns of occupational injuries between the two areas.
|
| 29 |
+
|
| 30 |
+
Results: Men were more likely than women to experience occupational injuries, and there was no difference in the two areas (p¼0.112). In the coastal area, occupational injury occurred more in the 21e30year age group, but in the mountain area, it was the 41e50-year age group (p<0.001). Occupational injuries in the two areas differed by location of hometown, education and occupation (all p<0.001).
|
| 31 |
+
|
| 32 |
+
Occupational injuries peaked differently in the month of the year in the two areas (p<0.001). Industrial and construction areas were the most frequent locations where occupational injuries occurred (p<0.001). Most occupational injuries were unintentional and not serious, and patients could go home after treatment. The two areas also differed in external causes and consequences of occupational injuries.
|
| 33 |
+
|
| 34 |
+
Conclusions: The differing patterns of occupational injuries in the coastal and mountain areas in Southern China suggest that different preventive measures should be developed. Results are relevant to other developing countries that have industrial and agricultural areas.
|
| 35 |
+
|
| 36 |
+
## Introduction
|
| 37 |
+
|
| 38 |
+
Occupational injury is a serious problem affecting the health of workers. The International Labour Organization (ILO) estimates that about 2.2 million people die globally
|
| 39 |
+
|
| 40 |
+
## Article Summary
|
| 41 |
+
|
| 42 |
+
Article focus
|
| 43 |
+
- Occupational injury is a serious problem causing 350 000 deaths and 270 million serious non-fatal injuries globally every year.
|
| 44 |
+
|
| 45 |
+
- This study is the first attempt in China to compare the characteristics and risk factors of occupational injuries in a coastal area (industrial)
|
| 46 |
+
and a mountain area (agricultural).
|
| 47 |
+
|
| 48 |
+
- Occupational injury patterns were found to differ in the two areas, in terms of location of hometown, education, occupation, month of the year, location of injuries, external causes and consequences.
|
| 49 |
+
|
| 50 |
+
Key messages
|
| 51 |
+
- Our findings provide important information for developing occupational injury prevention programmes in industrial and agricultural areas.
|
| 52 |
+
|
| 53 |
+
- Accumulation of occupational injury studies steadily builds the epidemiological information base on which to develop interventions.
|
| 54 |
+
|
| 55 |
+
- Identification of the local geographic patterns of occupational injuries helps to import existing proven interventions from other similar geographic areas.
|
| 56 |
+
|
| 57 |
+
Strengths and limitations of this study
|
| 58 |
+
- The Hospital Injury Surveillance System that we established in Southern China has started to produce useful data for occupational injury prevention.
|
| 59 |
+
|
| 60 |
+
- The system still lacks important useful information such as full occupational history, evaluation measures of data accuracy and completeness, and rate information.
|
| 61 |
+
|
| 62 |
+
every year from occupational injury and illness. Of this total, about 350 000 deaths are caused by fatal occupational injuries. The global workforce of 2.8 billion workers also experience about 270 million serious nonfatal injuries and 160 million work-related diseases.1 The total cost of occupational accidents and work-related diseases represents 4% of the gross national product or approximately US$1.36 trillion worldwide.2 Occupational injury is serious in China. According to the ILO, fatal occupational injuries in China accounts for 26% of the world total.1 In China, government and researchers have been taking steps to understand and prevent occupational injuries. Some research on occupational injuries has been published.3e7 To deal with missing data and underreporting, methodological research has been published on the use of the captureerecapture method.8 9 An injury surveillance system was set up in China to track the pattern of occupational injuries, and it has been effective in preventing injuries.10e12 The economy in China is more developed in the south than in the north, especially in the highly industrial coastal areas, which attract migrant workers from other provinces. As most of these migrant workers are young and inexperienced job seekers, a high level of occupational injuries have been reported and cannot be neglected.13 14 The patterns of occupational injuries differ between developed and developing countries.15 This suggests that their patterns could be different between the more developed (coastal) and less developed (mountain) areas in Southern China. The coastal area is highly industrialised, while the mountain area is mainly agricultural.
|
| 63 |
+
|
| 64 |
+
The coastal and mountain areas were chosen for the study because they represent the two major types of economic development in China. They are expected to lead to different types and patterns of occupational injuries. Our study is the first attempt in China to compare the characteristics and risk factors of occupational injuries in a coastal area and a mountain area in order to provide further understanding and a scientific basis for the prevention of occupational injuries in Southern China.
|
| 65 |
+
|
| 66 |
+
The study was based on the Hospital Injury Surveillance System we have established in Southern China.
|
| 67 |
+
|
| 68 |
+
## Methods Case Identification
|
| 69 |
+
|
| 70 |
+
Injury cases were defined as first-time visits to the hospital due to a particular injury, and the activity when the injury occurred was work.
|
| 71 |
+
|
| 72 |
+
## Data Collection
|
| 73 |
+
|
| 74 |
+
Injury surveillance was based on hospital data collected in two areas of Southern China, a coastal and a mountain area. Ethical approval was granted by the Shantou University research ethics review board. No patient consent form was required as the study was based on routine administrative data only. Data were collected from 1 April 2006 to 31 March 2008.
|
| 75 |
+
|
| 76 |
+
Hospital staff completed the injury report forms including patient demographics, date and time of admission, details about the injury cause and location, the injury intention and severity, diagnoses, treatment procedures, and discharge information. Every month, researchers collected the reporting forms. Data were entered into a database, and injury diagnosis and causes were coded by trained research staff using the 10th revision of International Classification Disease.
|
| 77 |
+
|
| 78 |
+
## Quality Control
|
| 79 |
+
|
| 80 |
+
Hospital staff who completed report forms were trained by researchers of the project. Every week, researchers reviewed the injury report forms to find problems and provide suggestions to improve. The data were entered into the research database by double keying to reduce error.
|
| 81 |
+
|
| 82 |
+
## Data Analysis
|
| 83 |
+
|
| 84 |
+
Data analysis involved use of SPSS V.15.0 for Windows
|
| 85 |
+
(SPSS Inc.). Descriptive statistics were used. c2 Analysis was used to compare differences between the mountain and coastal areas. A p<0.05 (two sided) was considered statistically significant.
|
| 86 |
+
|
| 87 |
+
## Results
|
| 88 |
+
|
| 89 |
+
Over the 2-year period, 8929 occupational injuries were identified, of which 7400 (82.88%) were men. The average age of the injured cases was 38.37 years (SD¼12.36). The age group 31e40 years experienced the most occupational injuries, accounting for 29.2% of the injured patients.
|
| 90 |
+
|
| 91 |
+
Sex and age differences between coastal and mountain
|
| 92 |
+
|
| 93 |
+

|
| 94 |
+
|
| 95 |
+
areas in cases of occupational injuries There was no sex difference. In the coastal area, there were 3230 male occupational injuries (81.86% of all cases) as compared with 5699 male occupational injuries in the mountain area (83.45%), with no statistically significant difference between the two areas (p¼0.112).
|
| 96 |
+
|
| 97 |
+
In the coastal area, the average age of injured patients was 32.10 years (SD¼11.34) as compared with 41.91 years (SD¼11.47) in the mountain area (p<0.001).
|
| 98 |
+
|
| 99 |
+
In the coastal area, occupational injuries peaked in the age group 21e30 years, whereas in the mountain area, the peak occurred in the age group 41e50 years
|
| 100 |
+
(p<0.001) (figure 1).
|
| 101 |
+
|
| 102 |
+
2
|
| 103 |
+
Differences between coastal and mountain areas in characteristics of cases of occupational injuries In the coastal area, injured cases were mostly from the local city (54.6%) and other provinces (39.9%), whereas in the mountain area, 88.4% were from the local city
|
| 104 |
+
(p<0.001) (table 1). The education of injured cases differed between the coastal and mountain areas
|
| 105 |
+
(p<0.001). In the coastal area, 59.0% of patients completed junior middle school and 19.0% completed primary school. In the mountain area, fewer injured patients had completed junior middle school
|
| 106 |
+
(43.9%) and more had completed primary school
|
| 107 |
+
(29.7%).
|
| 108 |
+
|
| 109 |
+
Occupations differed between injured cases in the two areas (p<0.001). In the coastal area, patients worked largely in production, transport and equipment operation (57.0%); professional and technical (14.5%) and commercial and service sector (11.0%). In the mountain area, injured patients worked mostly in production, transport and equipment operation (37.3%); agriculture, grazing, fishing and water conservancy (33.8%) and professional and technical (11.0%).
|
| 110 |
+
|
| 111 |
+
| Table 1 | Comparison of characteristics of cases of occupational injuries in a coastal area and a mountain area in Southern | | |
|
| 112 |
+
|-----------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|----------------------|---------|
|
| 113 |
+
| China, 2006e2008 Characteristics | Coastal area, N (%) | Mountain area, N (%) | p Value |
|
| 114 |
+
| Hometown Local city | 1732 (54.6) | 5038 (88.4) | 0.000 |
|
| 115 |
+
| Other cities in local province | 173 (5.5) | 188 (3.3) | |
|
| 116 |
+
| Other provinces | 1267 (39.9) | 473 (8.3) | |
|
| 117 |
+
| Education None | 77 (2.4) | 573 (10.15) | 0.000 |
|
| 118 |
+
| Primary school (years 1e6) | 605 (19.0) | 1690 (29.7) | |
|
| 119 |
+
| Junior middle school (years 7e9) | 1874 (59.0) | 2499 (43.9) | |
|
| 120 |
+
| Senior middle school (years 10e12) | 524 (16.5) | 828 (14.5) | |
|
| 121 |
+
| College | 77 (2.4) | 78 (1.4) | |
|
| 122 |
+
| University | 20 (0.6) | 26 (0.5) | |
|
| 123 |
+
| Occupation Professional and technical | 461 (14.5) | 628 (11.0) | 0.000 |
|
| 124 |
+
| Clerical | 134 (4.2) | 175 (3.1) | |
|
| 125 |
+
| Commercial and service sector | 350 (11.0) | 264 (4.6) | |
|
| 126 |
+
| Agriculture, grazing, fishing and water conservancy | 232 (7.3) | 1927 (33.8) | |
|
| 127 |
+
| Production, transport and equipment operation | 1817 (57.0) | 2127 (37.3) | |
|
| 128 |
+
| Others | 195 (6.1) | 578 (10.1) | |
|
| 129 |
+
| Location of accident Home | 41 (1.3) | 132 (2.3) | 0.000 |
|
| 130 |
+
| Public residential places | 124 (3.8) | 172 (3.0) | |
|
| 131 |
+
| (dormitory, old age home, prison, etc) School and public places | 55 (1.7) | 77 (1.4) | |
|
| 132 |
+
| Sports places | 4 (0.1) | 8 (0.1) | |
|
| 133 |
+
| Roads and streets | 167 (5.2) | 283 (5.0) | |
|
| 134 |
+
| Trade and service places (airport, bank, hotel, | 377 (11.7) | 321 (5.6) | |
|
| 135 |
+
| shop, office building, etc) Industry and construction places | 2282 (70.7) | 3804 (66.7) | |
|
| 136 |
+
| Farms and field | 45 (1.4) | 855 (15.0) | |
|
| 137 |
+
| Other places | 124 (3.8) | 35 (0.6) | |
|
| 138 |
+
| Unknown | 10 (0.3) | 12 (0.2) | |
|
| 139 |
+
| Intent Unintentional | 2812 (87.7) | 5403 (94.8) | 0.000 |
|
| 140 |
+
| Intentional (attack, violence) | 385 (12.0) | 287 (5.0) | |
|
| 141 |
+
| Suicide/unknown | 8 (0.2) | 9 (0.2) | |
|
| 142 |
+
| Severity Mild | 2247 (70.0) | 4681 (82.1) | 0.000 |
|
| 143 |
+
| Moderate | 781 (24.3) | 918 (16.1) | |
|
| 144 |
+
| Severe | 184 (5.7) | 100 (1.8) | |
|
| 145 |
+
| Outcome Going home after treatment | 2462 (77.5) | 5087 (89.3) | 0.000 |
|
| 146 |
+
| Observation, hospitalisation or transfer | 693 (21.8) | 575 (10.1) | |
|
| 147 |
+
| to another institution Death | 8 (0.3) | 8 (0.1) | |
|
| 148 |
+
| Unknown | 15 (0.5) | 29 (0.5) | |
|
| 149 |
+
|
| 150 |
+
3
|
| 151 |
+
|
| 152 |
+
Statistically significant differences between cases in the coastal and mountain areas were also found in location of accident, intent, severity and outcome (table 1). In the coastal area, the leading locations where occupational injury occurred were industry and construction places (70.7%), and trade and service places (11.7%), whereas in the mountain area, the predominant places were industry and construction places (66.7%), and farms and field
|
| 153 |
+
(15.0%) (p<0.001). Most occupational injuries were unintentional in both areas (87.7% in the coastal area and 94.8% in the mountain area) (p<0.001). Also different was severity of occupational injury (p<0.001). Most occupational injuries were mild and moderate in the two areas (70.0% and 24.3% in the coastal area and 82.1% and 16.1% in the mountain area, respectively). In the coastal area, most patients with occupational injuries could go home after treatment (77.5%) and some were kept for observation, hospitalisation or transfer (21.8%), whereas in the mountain area, 89.3% of patients could go home after treatment and 10.1% were kept for observation, hospitalisation or transfer (p<0.001). Eight fatalities occurred with occupational injuries in each of the two areas (table 1).
|
| 154 |
+
|
| 155 |
+
## Time Of Occurrence Of Occupational Injuries In The Coastal And Mountain Areas
|
| 156 |
+
|
| 157 |
+
With respect to month of the year, occupational injuries occurred every month but differed between coastal area and mountain area (p<0.001) (figure 2). There were two peaks in a year in the occurrence of occupational injuries in the two areas. May and November were the peak months in the coastal area and April and September in the mountain area. Occupational injures were low in February in the two areas.
|
| 158 |
+
|
| 159 |
+
With respect to day of the week, occupational injuries occurred more frequently towards beginning of the work week (Mondays and Tuesdays) (figure 3). Occupational injuries more likely occurred on weekdays (72.8% in the coastal area and 73.3% in the mountain area), with no significant difference between the two areas (p¼0.662).
|
| 160 |
+
|
| 161 |
+
With respect to time of the day on a 24 h clock, occurrence of injury differed between the two areas
|
| 162 |
+
|
| 163 |
+

|
| 164 |
+
|
| 165 |
+

|
| 166 |
+
|
| 167 |
+
(p<0.001). The peak times were 10:00 and 16:00 h in the coastal area and 9:00 and 15:00 h in the mountain area (figure 4). The external causes and consequences of occupational injuries in the coastal and mountain areas of Southern China The external cause codes of occupational injuries differed between the two areas. In the coastal area, the five leading external causes were contact with other and unspecified machinery (W31); being struck by or against other objects (W22); assault by bodily force (Y04); contact with a knife, sword or dagger (W26) and being struck by a thrown, projected or falling object (W20). In the mountain area, the five leading external causes were unspecified falls (W19); exposure to other and unspecified inanimate mechanical forces (W49); contact with a knife, sword or dagger (W26); contact with other and unspecified heat or hot substances (X19) and assault by a blunt object (Y00)
|
| 168 |
+
(table 2).
|
| 169 |
+
|
| 170 |
+
The consequence codes of occupational injuries differed between the two areas. Although the first leading consequence code was open wounds of the wrist or hand
|
| 171 |
+
(S61) in both areas, the other four leading consequence codes differed. In the coastal area, the second to fifth leading consequences were open wounds of the head
|
| 172 |
+
(S01), crushing injury of the wrist or hand (S67), superficial injury involving multiple body parts (T00) and open wound of the ankle or foot (S91). In the mountain area, they were superficial injury of the thorax (S20), superficial injury involving multiple body parts (T00), injury to the eye or orbit (S05) and open wound of the head (S01) (table 3).
|
| 173 |
+
|
| 174 |
+
## Discussion And Conclusions
|
| 175 |
+
|
| 176 |
+

|
| 177 |
+
|
| 178 |
+
Occupational injuries are related to industrial and economic growth, but they also represent a significant economic cost for the society.2 There are many migrant workers working in various factories and enterprises in Southern China, so occupational injuries are a particular issue and concern. This study, based on data from our Hospital Injury Surveillance System, explored and Figure 2 Distribution of occupational injuries by month of the year in a costal area and a mountain area in Southern China, 2006e2008.
|
| 179 |
+
|
| 180 |
+
4
|
| 181 |
+
Figure 4 Distribution of
|
| 182 |
+
|
| 183 |
+

|
| 184 |
+
|
| 185 |
+
occupational injuries by time of the day in a costal area and a mountain area in Southern China, 2006e2008.
|
| 186 |
+
|
| 187 |
+
compared patterns of occupational injuries in a coastal area and a mountain area in Southern China. Our study results have provided important information for formulating strategies and measures for the prevention of occupational injuries.
|
| 188 |
+
|
| 189 |
+
## Demographic Characteristics
|
| 190 |
+
|
| 191 |
+
Men are more likely to experience occupational injuries, particularly in the age group 20e40 years. These results were similar to other studies.12e14 16e18 We found that the injury cases in the coastal area were younger than those in the mountain area. This could be the result of more migrant workers in the coastal area, who are mostly young men.12 More than half of the patients with occupational injuries were from the local city. About one-third of the patients were from other provinces in the coastal area, a result similar to findings for occupational injuries in another study.14 Migrant workers constitute a big proportion of the working population in the coastal area.
|
| 192 |
+
|
| 193 |
+
Those who suffered occupational injuries had low educational levels; almost all had only primary or junior middle school education, again similar to other findings.13 14 The low education level likely leads to lack of knowledge about self-protection and increases the danger at work.
|
| 194 |
+
|
| 195 |
+
Time of occupational injuries Seasonal variation of occupational injuries has been demonstrated in the industries.4 5 14 Our study found that occupational injuries occurred the least often in February, which coincides with the Chinese national holiday of the Spring Festival when industries and factories are closed and many migrant workers go home for the holiday. The peak month of occupational injuries in the two areas, however, differed: May and November in the coastal area and April and September in the mountain area. Issues such as climate and type of industry will need further research.
|
| 196 |
+
|
| 197 |
+
Occupational injuries showed two peak times during the day in the two areas, with little difference between areas. The peak times (10:00 and 16:00 h in the coastal area and 9:00 and 15:00 h in the mountain area) were similar to findings elsewhere,12 19 which suggests that the dangerous time is at the beginning of the work shift when operation starts for the day and towards the end when attention span is low.
|
| 198 |
+
|
| 199 |
+
Occupational injuries occurred more frequently during beginning of the work week (Mondays and Tuesdays) in both the coastal and mountain areas, a result similar to the findings in Canada by Choi et al.20 However, the Friday peak observed in Canada was only found in the coastal area but not in the mountainous area.
|
| 200 |
+
|
| 201 |
+
| Table 2 | The five leading external causes with their code and percentage of occupational injuries in a coastal area and | |
|
| 202 |
+
|--------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|
|
| 203 |
+
| a mountain area in Southern China, 2006e2008 Rank Coastal area (%) | Mountain area (%) | |
|
| 204 |
+
| 1 | Contact with other and | Unspecified falls (W19) (34.0) |
|
| 205 |
+
| unspecified machinery (W31) (20.6) | | |
|
| 206 |
+
| 2 | Being struck by or against other and | Exposure to other and unspecified |
|
| 207 |
+
| unspecified objects (W22) (6.3) | inanimate mechanical forces (W49) (33.9) | |
|
| 208 |
+
| 3 | Assault by bodily force (Y04) (6.2) | Contact with a knife, sword or dagger (W26) (11.1) |
|
| 209 |
+
| 4 | Contact with a knife, sword or | Contact with other and unspecified |
|
| 210 |
+
| dagger (W26) (6.1) | heat or hot substances (X19) (3.7) | |
|
| 211 |
+
| 5 | Being struck by a thrown, | Assault by a blunt object (Y00) (3.1) |
|
| 212 |
+
| projected or falling object (W20) (5.9) | | |
|
| 213 |
+
|
| 214 |
+
| Table 3 | The five leading consequences with their code and percentage of occupational injuries in a coastal area and | |
|
| 215 |
+
|--------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|
|
| 216 |
+
| a mountain area in Southern China, 2006e2008 Rank Coastal area (%) | Mountain area (%) | |
|
| 217 |
+
| 1 | Open wound of the wrist or hand (S61) (23.5) | Open wound of the wrist or hand (S61) (9.8) |
|
| 218 |
+
| 2 | Open wound of the head (S01) (9.6) | Superficial injury of the thorax (S20) (6.9) |
|
| 219 |
+
| 3 | Crushing injury of the wrist or hand (S67) (8.3) | Superficial injury involving multiple body parts (T00) (6.3) |
|
| 220 |
+
| 4 | Superficial injury involving multiple body parts (T00) (4.7) | Injury to the eye or orbit (S05) (5.0) |
|
| 221 |
+
| 5 | Open wound of the ankle or foot (S91) (3.9) | Open wound of the head (S01) (5.0) |
|
| 222 |
+
|
| 223 |
+
## Injury Characteristics
|
| 224 |
+
|
| 225 |
+
In the coastal and mountain areas, the largest proportion of occupational injuries occurred in production, transport and equipment operations. This result is similar to other research.21 22 Construction industries probably present a major risk in this occupational category, and those injuries could be prevented or minimised by personal protective equipment. In the mountain area, almost one-third of the injured patients were farmers, and farms and field were in addition an important location for occupational injuries.
|
| 226 |
+
|
| 227 |
+
Most of the occupational injuries in both areas were unintentional and minor, and patients could go home after treatment. Again this is similar to results from Ma et al.
|
| 228 |
+
|
| 229 |
+
12 A lot of the research has focused on fatal occupational injuries. However, non-fatal injuries are more frequent and cause more disease burden1 and should not be neglected.
|
| 230 |
+
|
| 231 |
+
The leading external causes of occupational injuries in the two areas differed. The leading external cause in the coastal area was contact with other and unspecified machinery (20.6%). Research has showed that injury by machinery is the most frequent type of occupational injury.18 The leading external cause in the mountain area was falls (34.0%), which is similar to findings in other studies.16 23 Falls have been recognised as a major threat to the safety of individuals in industry and also in daily living.24 With respect to the consequences of injury, open wounds of the wrist and hand are the most frequent, which is similar to other findings in China5 12 and in other countries.16 The wrist and hand are the most used body parts at work and will need particular protection.
|
| 232 |
+
|
| 233 |
+
China has seen rapid economic growth in recent decades and the associated increase in occupational injuries. The main strength of our study is that it was the first in China to examine occupational injuries in a coastal area and a mountain area. The two areas were selected to represent the two major types of economies
|
| 234 |
+
(industrial and agricultural) in China, so that our findings are likely to be relevant to other parts of China.
|
| 235 |
+
|
| 236 |
+
Additionally, the study was a first attempt to use a routine administrative database (Hospital Injury Surveillance System) for the development of occupational injury prevention strategies. The database has built-in data quality control mechanisms.
|
| 237 |
+
|
| 238 |
+
There are limitations in the study. The Hospital Injury Surveillance System we used in this study targets all kinds of injuries, not just occupational injuries. Therefore, it lacks sufficient detailed information on the type and years of work and can only provide limited information for preventive measures at work. Also, while some quality control measures were put in place to promote accuracy in data collection, no quantitative information was available in the surveillance system to describe the accuracy (reliability and validity) of the case reports or completion rates. Furthermore, presentation of rate information within demographic and occupational subgroups would be desirable, but this information was not available in the surveillance system.
|
| 239 |
+
|
| 240 |
+
Our study does provide some important baseline information for improving worker safety in China. The differences in the patterns of occupational injuries observed in the coastal industrial area and a mountain agricultural area in Southern China provide good evidence for diversified prevention strategies in different areas and settings. Accumulation of descriptive studies of occupational injuries like ours steadily builds the epidemiological information base on which to develop interventions. Effective intervention approaches may already exist for many of the injuries observed. Identification of the local geographic patterns of occupational injuries helps to import proven interventions from other similar geographic areas.
|
| 241 |
+
|
| 242 |
+
Future work in China should focus on establishing a more comprehensive occupational injury surveillance system. This can be based on the Thai experience in the recording, notification, compilation and classification of occupational injuries, carried out by the ILO.25 Innovative injury prevention measures can also be generated from brainstorming sessions of experts, similar to the prioritising workshop conducted by the Pan American Health Organization.26 Results of this study are relevant to other developing countries that have more developed
|
| 243 |
+
(industrial) and less developed (agricultural) areas.
|
| 244 |
+
|
| 245 |
+
Acknowledgements We gratefully acknowledge the staff of the Injury Surveillance Project in Shantou and Changshan for data support. Contributors LL conceived the study. LL, XL and BC designed the protocol. LL, XL, YL and MY contributed to the data collection. YL and MY analysed the data. LL and BC wrote the first draft of the manuscript, and all authors contributed to the subsequent writing, critical review and revision of the manuscript. All authors contributed to the interpretation of the results and approved the final version.
|
| 246 |
+
|
| 247 |
+
Funding The study was funded by the National Natural Science Foundation of China (No. 30571613). Competing interests None. Ethics approval Ethics approval was provided by the Shantou University research ethics review board.
|
| 248 |
+
|
| 249 |
+
Provenance and peer review Not commissioned; externally peer reviewed.
|
| 250 |
+
|
| 251 |
+
Data sharing statement There are no additional unpublished data from the study available for data sharing.
|
| 252 |
+
|
| 253 |
+
REFERENCES
|
| 254 |
+
1. Takala J. Introductory Report: Decent WorkdSafe Work. Geneva:
|
| 255 |
+
International Labour Office, 2005:6e10.
|
| 256 |
+
|
| 257 |
+
2. Ha¨ma¨la¨inen P. The effect of globalization on occupational accidents.
|
| 258 |
+
|
| 259 |
+
Saf Sci 2009;47:733e42.
|
| 260 |
+
|
| 261 |
+
3. Xia ZL, Courtney TK, Sorock GS, et al. Fatal occupational injuries in a new development area in the People's Republic of China. J Occup Environ Med 2000;42:917e22.
|
| 262 |
+
|
| 263 |
+
4. Liu XR, Yang JG, Shen J, et al. Epidemiological study of occupational injuries in a new chemical industrial zone during the period of 1993w2002. Industry Health Occup Dis 2003;29:321e5.
|
| 264 |
+
|
| 265 |
+
5. Shi X, Ye D. An epidemiological survey on occupation injury in a non ferrous metal company, 1980w1999. Chin J Dis Control Prev 2004;8:543e5.
|
| 266 |
+
|
| 267 |
+
6. Liu J, Gao X, Xiaofeng L, et al. Epidemiological study on occupational injury in one port enterprise. Chinese J Public Health 2005;21:997.
|
| 268 |
+
|
| 269 |
+
7. Yue Q, Lan Y. Epidemiological study on occupational injury during 1995w2004 in an iron factory. Mod Prev Med 2006;33:2363e6.
|
| 270 |
+
|
| 271 |
+
8. Hu W, Zhou A. Application of Capture-mark-recapture method on investigating unreported occupational injury. Chin J Ind Med 2005;18:40e1.
|
| 272 |
+
|
| 273 |
+
9. Hu W. Research progress on epidemiological methods of occupational injuries. Foreign Med Sci (Section Hygiene) 2002;29:174e7.
|
| 274 |
+
|
| 275 |
+
10. Amell TK, Kumar S, Rosser BW. Ergonomics, loss management, and occupational and illness surveillance, Part 2: injury and illness incident profile. Sample data. Int J Ind Ergon 2002;29:199e210.
|
| 276 |
+
|
| 277 |
+
11. Perry MJ, Sun BX, Zhang HX, et al. Emergency department surveillance of occupational injuries in Shanghai's Putuo District, People's Republic of China. Ann Epidemiol 2005;15:351e7.
|
| 278 |
+
|
| 279 |
+
12. Ma W, Peng J, Liang X, et al. Analysis on epidemiological characteristics of occupational injury among workers in different economic regions in Guangdong province. South China J Prev Med 2007;33:5e8.
|
| 280 |
+
|
| 281 |
+
13. Peng J, Zhou H, Zhou H, et al. Epidemiologic characteristic of nonfatal occupational injuries in mental manufacturing industry. Chin J
|
| 282 |
+
Public Health 2007;23:329e30.
|
| 283 |
+
|
| 284 |
+
14. Chen RC, Wang MQ, Cui R, et al. Epidemiological characteristics of the Occupationally injured population in the Foreign Electron industry.
|
| 285 |
+
|
| 286 |
+
Occup Health 2008;24:1351e4.
|
| 287 |
+
|
| 288 |
+
15. Concha M, Nelson I, Fingerhut M, et al. The global burden due to occupational injury. Am J Ind Med 2005;48:470e81.
|
| 289 |
+
|
| 290 |
+
16. Roudsari S, Ghodsi M. Occupational injuries in Tehran. Injury 2005;36:33e9.
|
| 291 |
+
|
| 292 |
+
17. Lin YH, Chen CY, Luo JL. Gender and age distribution of occupational fatalities in Taiwan. Accid Anal Prev 2008;4:1604e10.
|
| 293 |
+
|
| 294 |
+
18. Ma J, Yu Y. Occupational safety research and influencing factors.
|
| 295 |
+
|
| 296 |
+
Occup Health 2007;23:59e60.
|
| 297 |
+
|
| 298 |
+
19. Shi X, Wang Y. The application of circular distribution test in the analysis of occupational injury. Chin J Dis Control Prev 2006;10:30e2.
|
| 299 |
+
|
| 300 |
+
20. Choi BCK, Levitsky M, Lloyd RD, et al. Patterns and risk factors for sprains and strains in Ontario, Canada, 1990: an analysis of the workplace health and safety agency data base. J Occup Envion Med 1996;38:379e89.
|
| 301 |
+
|
| 302 |
+
21. Ong CN, Phoon WO, Tan TC, et al. A study of work injuries in eight Asian countries. Ann Acad Med Singapore 1984;13:429e34.
|
| 303 |
+
|
| 304 |
+
22. Marika L, Henk M, Jorma L, et al. The Effectiveness of interventions for preventing injuries in the construction industry. Am J Prev Med 2008;35:77e84.
|
| 305 |
+
|
| 306 |
+
23. Noe R, Rocha J, Clavel C, et al. Occupational injuries identified by an emergency department based injury surveillance system in Nicaragua. Inj Prev 2004;10:227e32.
|
| 307 |
+
|
| 308 |
+
24. Yoon Y, Thurmon L. Nonfatal occupational injuries associated with slips and falls in the United States. Int J Ind Ergon 2006;36:83e92.
|
| 309 |
+
|
| 310 |
+
25. Choi BCK. Recording, notification, compilation, and classification of statistics of occupational accidents and diseases: the Thai experience. J Occup Envion Med 1996;38:1151e60.
|
| 311 |
+
|
| 312 |
+
26. Choi BCK, Eijkemans GM, Tennassee LM. Prioritization of occupational sentinel health events for workplace health and hazard surveillance: the Pan American Health Organization experience. J
|
| 313 |
+
Occup Envion Med 2001;43:147e57.
|
medical/md_images/PMC3378941/PMC3378941_meta.json
ADDED
|
@@ -0,0 +1,27 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
{
|
| 2 |
+
"languages": [
|
| 3 |
+
"en"
|
| 4 |
+
],
|
| 5 |
+
"filetype": "pdf",
|
| 6 |
+
"toc": [],
|
| 7 |
+
"pages": 7,
|
| 8 |
+
"ocr_stats": {
|
| 9 |
+
"ocr_pages": 0,
|
| 10 |
+
"ocr_failed": 0,
|
| 11 |
+
"ocr_success": 0,
|
| 12 |
+
"ocr_engine": "none"
|
| 13 |
+
},
|
| 14 |
+
"block_stats": {
|
| 15 |
+
"header_footer": 32,
|
| 16 |
+
"code": 0,
|
| 17 |
+
"table": 3,
|
| 18 |
+
"equations": {
|
| 19 |
+
"successful_ocr": 0,
|
| 20 |
+
"unsuccessful_ocr": 0,
|
| 21 |
+
"equations": 0
|
| 22 |
+
}
|
| 23 |
+
},
|
| 24 |
+
"postprocess_stats": {
|
| 25 |
+
"edit": {}
|
| 26 |
+
}
|
| 27 |
+
}
|
medical/md_images/PMC3426374/1_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3426374/PMC3426374_meta.json
ADDED
|
@@ -0,0 +1,27 @@
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 1 |
+
{
|
| 2 |
+
"languages": [
|
| 3 |
+
"en"
|
| 4 |
+
],
|
| 5 |
+
"filetype": "pdf",
|
| 6 |
+
"toc": [],
|
| 7 |
+
"pages": 2,
|
| 8 |
+
"ocr_stats": {
|
| 9 |
+
"ocr_pages": 0,
|
| 10 |
+
"ocr_failed": 0,
|
| 11 |
+
"ocr_success": 0,
|
| 12 |
+
"ocr_engine": "none"
|
| 13 |
+
},
|
| 14 |
+
"block_stats": {
|
| 15 |
+
"header_footer": 0,
|
| 16 |
+
"code": 0,
|
| 17 |
+
"table": 0,
|
| 18 |
+
"equations": {
|
| 19 |
+
"successful_ocr": 0,
|
| 20 |
+
"unsuccessful_ocr": 0,
|
| 21 |
+
"equations": 0
|
| 22 |
+
}
|
| 23 |
+
},
|
| 24 |
+
"postprocess_stats": {
|
| 25 |
+
"edit": {}
|
| 26 |
+
}
|
| 27 |
+
}
|
medical/md_images/PMC3777673/0_image_3.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3920570/0_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3920570/0_image_4.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC3942506/2_image_0.png
ADDED
|
Git LFS Details
|
medical/md_images/PMC4144211/0_image_0.png
ADDED
|
Git LFS Details
|